Cell entry and exit of porcine endogenous retrovirus A: receptors and release inhibitor by Mattiuzzo, G.
1 
 
 
 
Cell Entry and Exit of Porcine Endogenous 
Retrovirus A: Receptors and Release Inhibitor 
 
 
 
Giada Mattiuzzo 
 
 
 
 
Submitted to   
University College London  
For the degree of Doctor of Philosophy 
 
 
 
September 2009 
 
 
 
Wohl Virion Centre 
Windeyer Building 
University College London 
 
  2 
 
Declaration 
I, Giada Mattiuzzo, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this 
has been indicated in the thesis. 
  3 
 
Abstract 
Following the discovery that porcine endogenous retrovirus (PERV) can 
infect human cells, the potential risk of a zoonotic infection by PERV has 
been a major obstacle in the xenotransplantation field. The aim of this thesis 
is to gain a better understanding of PERV biology, so as to help assess and 
reduce the risk of PERV zoonosis. 
PERV subgroup A can enter human cells through two human PERV-A 
receptors (huPAR-1 and -2). To determine critical regions in the receptor for 
PERV-A infection, chimeric receptors between huPAR-2 and the non 
functional murine PAR (muPAR) have been analysed. A single amino acid 
difference (amino acid 109) was found responsible for the inability of muPAR 
to mediate PERV-A binding and infection. These results were then applied to 
the evaluation of PERV infection of non-human primates (NHP). NHP could 
represent an ideal animal model for assessing the risk of zoonosis following 
long-term exposure to porcine material. However, PERV does not infect NHP 
cells with the same efficiency as it does human cells. The data presented in 
this thesis suggests that in some NHP species the poor infectivity is due to 
mutation of the same critical amino acid (a.a.109) described for muPAR. 
However, African green monkey cells express two functional receptors and 
other mechanisms are likely to be responsible for the low susceptibility to 
PERV-A infection. 
Secondly, I evaluated the effect of a release inhibitor as a possible strategy 
to reduce PERV dissemination from pig cells. Human tetherin can inhibit 
retrovirus production from cells. I showed that overexpression of human and 
newly cloned porcine tetherin in pig cells can reduce the release of PERV. 
My data suggests that tetherin-expressing transgenic pigs could represent a 
safer donor in xenotransplantation.  
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Chapter 1 
1 INTRODUCTION 
 
1.1 Xenotransplantation 
The term ‘transplantation’ derives from the latin transplantare meaning ‘to 
plant again in another place’ (trans=across and plantare=to plant), and it is 
currently used in the medical field to indicate the transfer of cells, tissues and 
organs from a donor to a recipient. When donor and recipient belong to 
different species, it is referred as ‘xenotransplantation’ (from the greek xeno= 
foreign). The history of xenotransplantation can be dated back to the 
beginning of the sixteenth century, when attempts were made to treat human 
patients by using sheep, lamb and calf blood transfusions or tissue 
transplantation [reviewed in (Deschamps et al., 2005)]. A few organ 
transplantations were also conducted at the beginning of the 1900s [reviewed 
in (Taniguchi and Cooper, 1997)]. Unsurprisingly, all of these experiments 
were unsuccessful, mainly because the immunological bases of rejection 
were still unclear. In the second half of the twentieth century, the discovery of 
immunosuppressive drugs kindled the interest of the scientific community in 
xenotransplantation. In fact, it became possible to avoid xenograft rejection of 
an organ belonging to a closely related species. In 1964, Keith Reemtsma 
transplanted a chimpanzee kidney into a 23 year-old woman. The patient 
eventually died 9 months later for an acute electrolyte imbalance, but without 
evidence of rejection (Reemtsma et al., 1964). Furthermore, with the 
increased rate of success in human-to-human transplantation (namely 
allotransplantation) due to the arrival of immunosuppressive protocols, the 
gap between the number of organ transplantations performed every year and 
the waiting list of candidates is enlarging (Figure 1.1).  
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3) Animal donors can be bred in a ‘clean’/controlled environment and the 
organs screened for the presence of infectious agents before implantation.  
The US Food and Drug Administration (FDA) has produced guidelines for 
xenotransplantation regarding donor animal selection, the facilities where to 
farm them, health surveillance and the screening for pathogens 
(www.fda.gov/cber/gdlns/xenophs0101.htm). Although the most obvious 
choice of donor animal would seem to be a closely to humans related 
species, such as non-human primates (NHP), the animal source 
recommended by the FDA is swine. Among several reasons, the risk for 
transmission of infectious disease from pigs to humans is lower than with 
NHP. Moreover, pigs offer fewer ethical problems since they are currently 
farmed for food. They have a short gestation (3.5 months) and large litter (6-
14 piglets). Maintaining pigs in specific pathogen-free (SPF) conditions is 
relatively easy and economically affordable. It is also possible to produce 
genetically modified pigs in the laboratory (Brunetti et al., 2008; Dai et al., 
2002; Lai et al., 2002).  
Xenotransplantation is not yet a worldwide clinical reality because some 
obstacles still exist:  
1) Some porcine organs may not be physiologically compatible with a 
human recipient, especially those organs which perform complex 
biochemical and metabolic functions, such as kidney and liver 
(Hammer, 2002; Soin et al., 2001).  
2)  The immune rejection of the xenograft. Three types of reaction have 
been described [reviewed in (Yang and Sykes, 2007)]. Hyperacute 
rejection (HAR) and acute humoral xenograft rejection (AHXR) are 
antibody-mediated processes and occurred early after transplantation. 
If both HAR and AHXR have been prevented, the xenograft may still 
be subject to cell-mediated rejection.  
3) Although farming pigs in SPF conditions can reduce the risk of 
contamination by most known porcine pathogens, there are still safety 
issues posed by unknown pathogens and a certain type of viruses 19 
 
such as porcine endogenous retroviruses, which are part of the pig 
genome and therefore difficult to eliminate (Patience et al., 1997). 
Genetic engineering of the donor pigs can overcome most of the 
xenotransplantation-related problems described above. 
1.1.1  Genetically modified pigs 
HAR may occur within minutes after xenotransplantation and it is 
characterised by the destruction of the vascular endothelium of the donor 
organ. This process is triggered by natural antibodies present in humans 
directed against pig antigens in a complement-dependent way. The major 
antigen in pigs is the disaccharide residue galactose-α(1-3)-galactose (αGal) 
[reviewed in (Galili, 2001)]. The enzyme α1,3-galactosyltransferase that 
synthesises αGal is active in most mammalian species (including pigs) but 
not in humans, apes and Old World monkeys. These species have a high 
concentration of circulating anti-αGal antibodies in response to continuous 
antigenic exposure by the gastrointestinal bacterial flora (Galili et al., 1988). 
Several strategies have been exploited which involve development of 
transgenic or gene knockout pigs. Animals lacking both alleles of the gene for 
α1,3-galactosyltransferase have successfully been bred (Kolber-Simonds et 
al., 2004; Phelps et al., 2003). Their organs have been tested in a pig-to-
baboon transplantation, and HAR was avoided. The recipients lived up to 6 
months but then developed thrombotic microangiopathy and coagulation 
disregulation (Kuwaki et al., 2005; Tseng et al., 2005; Yamada et al., 2005). 
Although these results are encouraging, more has to be done to ultimately 
avoid xenograft rejection. The future direction of research includes the 
introduction of further genetic modifications in pigs. To specifically target 
microvascular thrombosis, transgenic pigs expressing anticoagulant or 
antiplatelet genes such as CD39, hirudin, or a transmembrane-anchored 
form of human tissue factor pathway inhibitor, or the knockout of fibrinogen-
like protein 2, can be employed [reviewed in (Ekser et al., 2009)]. To inhibit 
the complement-mediated immune response in the patients, pigs have been 
genetically modified to express human complement regulatory proteins 
(CRP) prolonging the xenograft survival from minutes to weeks: decay-20 
 
accelerating factor (DAF or CD55), CD59 and membrane cofactor protein, 
(CD46) (Adams et al., 2001; Bhatti et al., 1999; Cozzi et al., 2000; McCurry et 
al., 1995). 
All these strategies aimed at avoiding the immune response of recipient may 
increase the risk of the transfer of pathogens between species (section 1.2). 
Enveloped viruses budding from a host cells acquire and expose proteins 
present on the cell membrane. The lack of αGal in the donor animal cells will 
lead to the lack of this strong antigen in the viral particles, diminishing the 
immune response to the possible viruses harboured in the donor xenograft 
(Kim et al., 2007; Magre et al., 2004; Quinn et al., 2004). Furthermore, 
viruses budding from CPR-transgenic pigs would be protected, to some 
extent, from the complement-mediated lysis. In vitro studies conducted to 
explore this risk were not conclusive. Porcine endogenous retroviruses, 
budding from a CD59-expressing pig cell line, were neutralised by human 
serum, although CD59 was incorporated in the viral envelope (Takefman et 
al., 2002). However, in more recent studies, rhabdoviruses and retroviruses 
produced through a pig endothelial cell line expressing CD55 (Magre et al., 
2004) and PERV produced through cell lines engineered to express CD59 or 
CD55 (Hazama et al., 2005) were shown to be partially protected by 
complement-mediated inactivation. 
Due to the unpredictable risk posed by immune system-resistant transgenic 
pigs, more effort should be directed into increasing the safety of using the 
donor animals. 21 
 
1.2  Zoonosis in xenotranplantation 
Zoonosis (from greek zoon=animal and nosis=disease) is the transfer of an 
animal pathogen to a human host.  
Infectious disease agents have often co-evolved with their own host species 
in a harmless relationship. Microbes are adapted to their host and not 
genetically equipped for infecting a different species efficiently (species 
barrier). However, occasionally, events of cross-species infection may 
happen due to physical proximity of different species. In this instance, there 
are two possible scenarios: the infectious agent will die with, or within, the 
new host, or adapt and spread in the new species causing epidemic. In the 
past, the human population has been afflicted (and still is) by several 
zoonoses. Among the most notorious examples are typhus [reviewed in 
(Andersson and Andersson, 2000)], plague [reviewed in (Perry and 
Fetherston, 1997)], Dengue fever [reviewed in (Gubler, 1988)], West Nile 
virus encephalitis [reviewed in (Kramer et al., 2007)], avian influenza 
[reviewed in (Alexander and Brown, 2000; de Wit and Fouchier, 2008)], AIDS 
(Gao et al., 1999; Keele et al., 2006), Nipah virus encephalitis [(Chua et al., 
1999; Paton et al., 1999) and reviewed in (Chua, 2003)], new variant of 
Creutzfeldt-Jakob disease (Will et al., 1996), severe acute respiratory 
syndrome (SARS) (Drosten et al., 2003) and the recent pandemic swine 
influenza (Garten et al., 2009; Smith et al., 2009). 
A literature survey has revealed that the majority of sources of emerging and 
reemerging infections in humans are zoonotic pathogens and viruses are 
greatly overrepresented (Woolhouse and Gowtage-Sequeria, 2005). A 
possible explanation for this lies in the fast evolution rate of viruses which 
can therefore adapt to a new host with comparative ease (Drake and 
Holland, 1999). 
In xenotransplantation, the risk of zoonosis is increased because normal host 
defences such as skin and mucosal surface are bypassed when human and 
animal tissues are placed in close contact and the patient receiving the 
xenograft undergoes immunosuppressive treatment. A cross-species 
infection is not only a danger for the recipient of the xenograft, but can also 22 
 
lead to the development of a potential new epidemic in the human 
population. As pig is considered the most suitable candidate as donor 
species, porcine viruses represent a potential threat. They can be grouped 
into four categories: 1) exogenous acute viruses; 2) viruses able to establish 
a persistent infection in the infected cells; 3) endogenous retrovirus; 4) 
unknown viruses. Regarding the latest, the identification of uncharacterised 
viruses in pigs, may help to increase the safety of xenotransplantation. New 
techniques to screen the donor animal for known and unknown pathogens 
include DNA microarray (Palacios et al., 2007; Wang et al., 2002; Wang et 
al., 2003) and metagenomic surveys using high-throughput shotgun 
sequencing technology (Palacios et al., 2008). To improve the safety of an 
unpredictable risk, patients receiving porcine materials should be monitored 
in a life-long surveillance program, to promptly detect any unexplained 
posttransplantation illness (www.fda.gov/cber/gdlns/xenophs0101.htm). 
1.2.1  Porcine exogenous viruses 
Most known viruses belong to the exogenous acute group. They usually 
infect a cell, replicate, and kill it on their way out. Pigs are not always a 
natural reservoir of these viruses, but they may act as a vector to mediate the 
cross-species infection to humans. Some such examples include influenza 
virus (Castrucci et al., 1994; Ludwig et al., 1995), Nipah virus (Parashar et 
al., 2000) and the recently described Reston Ebola virus (Barrette et al., 
2009). The porcine exogenous viruses most relevant in xenotransplantation 
are described below. 
1) Swine Influenza viruses belong to the Orthomyxoviridae family, Influenza 
virus A genus. These enveloped viruses have a negative-sense single-
stranded RNA genome divided into eight segments (Klenk et al., 2004). Due 
to the segmented nature of its genome, new strains of Influenza virus may 
emerge by genetic reassortment of the RNA segments through infection of 
the same cells by two different strains (Brown et al., 1998; Webster et al., 
1995). Zoonotic infection of humans by swine influenza virus was first proven 
in 1976 by Smith and colleagues (Smith et al., 1976). Reassortment of avian 
and human influenza viruses in pigs was also detected (Castrucci et al., 23 
 
1994; Ludwig et al., 1995). It has been hypothesised that pandemic flu, in 
1918, was derived from a swine influenza virus (Taubenberger et al., 1997), 
but recent genetic analysis could not confirm this hypothesis [reviewed in 
(Reid et al., 2004)]. Nevertheless, the threat of a reassortment strain of 
Influenza virus from pigs that could potentially cause a pandemic still exists. 
Indeed, a pandemic swine flu has recently been described (Garten et al., 
2009; Smith et al., 2009). 
2) Another porcine virus able to cross the species barrier between pigs and 
humans is Nipah virus. This enveloped virus is a member of the 
Paramyxoviridae family, whose genome is a linear, negative-sense, single-
stranded RNA molecule (Rima et al., 2004). Bats are the natural reservoir of 
this virus (Chua et al., 2002; Reynes et al., 2005; Sendow et al., 2006). The 
first outbreak of viral encephalitis due to Nipah virus occurred in Malaysia 
and Singapore between 1998 and 1999, resulting in 276 cases of 
encephalitis with 106 deaths (Chua et al., 2000; Chua et al., 1999). During 
this outbreak, the mode of transmission was mainly pig-to-human with only 
8% of the infected individuals not having had direct contact with pigs 
(Parashar et al., 2000). In the following years, several outbreaks occurred in 
Asia, with a worsening in mortality, and other modes of transmission such as 
foodborne and human-to-human were identified (Gurley et al., 2007; Hsu et 
al., 2004; Luby et al., 2006). 
3) The family Filoviridae comprises filamentous enveloped viruses whose 
genome is a linear, negative-sense, single-stranded RNA molecule. Two 
genera belong to this family, Marburgvirus  and  Ebolavirus (Suzuki and 
Gojobori, 1997). Filoviruses are associated with acute fatal hemorrhagic 
disease in humans and non-human primates. Reston Ebolavirus has recently 
been identified in pigs from different farms in the Philippines (Barrette et al., 
2009). Although Reston Ebolavirus has not been associated with any 
diseases in humans (Morikawa et al., 2007), concern arose in that its 
passage through swine may allow the virus to become more pathogenic. In 
the xenotransplantation context, the unexpected discovery of Ebola virus in 
pigs showed how surveillance of the animal donor should be extended to a 24 
 
wide range of viruses, even those which are not normally associated with 
disease in pigs. 
4) Porcine rotaviruses are associated with gastroenteritis and diarrhoea in 
the human and swine population. They have a segmented double-stranded 
RNA genome enclosed in a core made of three protein layers (Holmes et al., 
2006). As for the previously described influenza virus, the 11 segments which 
form the rotavirus genome can rearrange in a superinfected cell, and new 
strains may emerge [reviewed in (Ramig, 1997)]. Cross-species infection by 
rotavirus has been documented: human rotavirus has been shown to infect 
pigs in vivo (Ward et al., 1996) and clinical studies have reported human 
infection by porcine rotavirus (Gabbay et al., 2008; Nguyen and Hildreth, 
2000). Furthermore, reassortment between human and porcine rotaviruses 
does occur (Li et al., 2008; Martella et al., 2008; Mascarenhas et al., 2007; 
Matthijnssens et al., 2008).  
Porcine exogenous viruses described above represent a possible risk in 
xenotransplantation. However, they cause an acute infection, easily 
recognised by clinical symptoms and diagnostic tests are available. 
Therefore, upon surveillance in SPF facilities for these viruses, a possible 
infection can be contained with ease. Instead, infection by other swine 
viruses may be not so easily recognisable, and special attention should be 
focussed on the following viruses. 
5) Members of the Parvoviridae family are non-enveloped, single-stranded, 
DNA viruses with a broad host range (Berns et al., 2004). Porcine parvovirus 
is the aetiological agent in the syndrome of reproductive failure in pigs, which 
include stillbirths, mummified foetus, early embryonic death and infertility 
(Dunne et al., 1965; Mengeling and Cutlip, 1976). There are no clinical signs 
associated with parvovirus. Therefore, animals should be screened regularly 
for this virus. ELISA-based diagnostic kits are available. 
6) Hepatitis E virus (HEV) is the sole member of the genus Hepevirus in the 
family Hepeviridae (ICTVdB, 2004). This RNA virus is the aetiological agent 
of enterically transmitted non-A, non-B, acute hepatitis (Balayan et al., 1983). 25 
 
HEV is involved in many hepatitis epidemics and outbreaks [reviewed in 
(Panda et al., 2007)]. The overall mortality in humans associated with HEV 
infection is 0.5-3%, but this can increase up to 15-20% in pregnant women 
(Mushahwar, 2008). The faecal-oral route (i.e. drinking contaminated water) 
is the main mode of transmission during an epidemic (Panda et al., 2007). 
Zoonotic transmission of HEV has been associated with pigs. Swine HEV 
was first described in 1997 (Meng et al., 1997) and it shared 97% homology 
with two strains of human HEV genotype 3 (Meng et al., 1998). HEV infection 
was associated with the ingestion of raw or under-cooked pig meat   
(Bouwknegt et al., 2007; Deest et al., 2007; Mizuo et al., 2005; Yazaki et al., 
2003), and with surgical training using pigs (Colson et al., 2007). In the 
context of xenotransplantation, the infection of laboratory monkeys, and 
detection of HEV in pigs bred in specific pathogen-free facilities, is a major 
concern (Yamamoto et al., 2008). 
Other exogenous porcine viruses whose presence has important economic 
consequences in swine farming, such as porcine reproductive and respiratory 
virus, classical swine fever virus, swine vesicular virus and foot-and-mouth 
viruses, present clear clinical features and cross-species infection in human 
have not be observed with the exception of one case of foot-and-mouth 
disease in 1966 (Armstrong et al., 1967). This episode highlighted how, 
although a human infection by these swine viruses is a rare event, it is still a 
risk that cannot be excluded. 
1.2.2 Porcine  Herpesviruses 
Herpesviruses are enveloped DNA viruses which can persist in the host in a 
latent phase without causing symptoms for long periods of time (ICTVdB, 
2006). Although herpesviruses usually have a narrow host range, cross-
species infection and adaptation to the new host have been described 
(Ehlers et al., 2008). Suid Herpesvirus type 1 (SuHV-1, Pseudorabies virus) 
is a member of subfamily α-herpesvirinae. Their natural host is swine, but 
cross-species infections have been described, causing severe neurological 
symptoms and death of the new host (Glass et al., 1994; Marcaccini et al., 
2008). However, infections of humans or primates have not been observed. 26 
 
Nevertheless, a potential zoonosis or recombination with human 
herpesviruses cannot be excluded.  
Porcine cytomegalovirus (PCMV) is a β-herpesvirus. In preclinical studies in 
pig-to-baboon transplantation, PMCV replication was enhanced due to 
immune suppressive protocols, and consumptive coagulopathy was 
observed in transplanted pig tissues in association with PMCV expression. 
However, no evidence of PCMV invasion and productive infection has been 
detected in NHP tissues (Gollackner et al., 2003; Mueller et al., 2004). PCMV 
can be eliminated by early weaning of the herds bred for xenotransplantation 
purpose (Mueller et al., 2004).  
Porcine lymphotropic herpes viruses (PLHV)-1,-2 and -3 belong to the 
subfamily γ-herpesvirinae and have high homology with human herpes virus 
8 (HHV-8, also known as Kaposi’s sarcoma virus) and Epstein-Barr virus 
(EBV). Despite PLHV not being activated in pig-to-baboon organ 
transplantation (Issa et al., 2008; Mueller et al., 2004), the transactivators of 
HHV-8 and EBV could activate PHLV (Santoni et al., 2006). Furthermore, the 
same strategy of early weaning proposed for PMCV proved to be ineffective 
for PHLV (Mueller et al., 2005). 27 
 
1.3 Retroviruses 
Retroviridae are a family of vertebrate viruses, divided into two subfamilies 
orthoretroviridae and spumaretrovirinae Only one genus has been described 
in the spumaretrovirinae subfamily, spumavirus, whereas six genera belong 
to the orthoretroviridae subfamily: α-retrovirus,  β-retrovirus,  γ-retrovirus,  δ-
retrovirus, ε-retrovirus and lentivirus (Linial et al 2005).  
1.3.1 Structure 
A retroviral particle’s diameter is in the range of 80-120nm, measured by thin-
section electron microscopy. The mature virions have a condensed protein 
core wrapped in a lipid envelope. The viral envelope is derived from the cell 
plasma membrane and is acquired during budding. The lipid composition of 
the envelope is rich in sphingomyelin and cholesterol, suggesting that the 
virus buds from cholesterol-rich rafts in the cell plasma membrane (Aloia et 
al., 1993; Briggs et al., 2003; Ono and Freed, 2005; Quigley et al., 1971). 
The envelope is scattered with glycoproteins, called Env. The Env protein is 
synthesised as a polyprotein precursor, and the leader signal in the N-
terminus directs the protein to the ER and then to the Golgi apparatus where 
the glycosylation process commences. In the Golgi apparatus, cellular 
proteases cleave Env into two subunits, surface (SU) and transmembrane 
(TM). During the transport to the cell surface, three SU and three TM 
oligomerise to form the spike, which will be present on the viral envelope 
(Eckert and Kim, 2001; Einfeld and Hunter, 1988; Kamps et al., 1991; Wyatt 
and Sodroski, 1998). The Env proteins interact with the cell surface proteins 
which mediate the fusion process and the subsequent entry of the virus in 
the cell. The determinant regions for the receptor usage are located in the N-
terminal region of SU in the variable region A and B (VRA and VRB) (Battini 
et al., 1992; Tailor and Kabat, 1997). In the N-terminus of the TM is located 
the fusion peptide, responsible for the fusion of the viral envelope with the 
cell membrane, which occurs following the interaction of SU with the receptor 
(Hunter, 1997). 28 
 
Matrix (MA) proteins are associated with the lipid envelope. In most 
retroviruses, MA proteins are myristylated at their N-terminus and this 
posttranscriptional modification appears to be essential for retroviral 
assembly (Bryant and Ratner, 1990; Gottlinger et al., 1989; Rein et al., 
1986). Furthermore, MA interacts with Env proteins during budding and it has 
been suggested for the lentivirus, human immunodeficiency virus (HIV)-1, 
that this interaction is required for the incorporation of the Env proteins in the 
virions (Freed and Martin, 1996; Yu et al., 1992).  
The condensed core in the retroviral particles is formed by the capsid 
proteins (CA) and is commonly referred to as the capsid. This structure 
contains the genomic viral material associated with the nucleocapsid proteins 
(NC). In all the orthoretroviruses, NC has one or two characteristic motifs 
(CX2CX4HX4C). Mutation of these domains results in the absence of the viral 
genome in the virions, suggesting a possible role for NC in the packaging of 
the genomic RNA into the nascent particles (Gorelick et al., 1988; Meric and 
Goff, 1989). Moreover, NC is important in the reverse transcription process 
(Meric and Goff., 1989) probably by promoting the annealing of the tRNA 
primers to the primer binding site, as well as facilitating the strand transfer 
(section 1.3.3). Indeed, NC has been shown to promote the annealing of 
complementary RNA sequences (Prats et al., 1988). 
MA, CA and NC are present in all the orthoretroviruses. They are encoded by 
the gag gene and synthesised as Gag polyprotein, then cleaved by the viral 
protease. Additionally, other Gag proteins may be produced, but they vary 
between retroviruses. For instance, murine leukaemia virus (MLV) gag 
encodes an additional protein p12 (figure 1.2), important for virus assembly 
and release as well as in the early stages of the infection (Yuan et al., 2002; 
Yuan et al., 1999). 29 
 
 
 
Figure 1.2 Genetic organisation and transcript processing of MLV.  
From the top, the genomic RNA has been represented with the following elements 
highlighted (from left to right): repeat region (R), unique region in 5’ end (U5), tRNA primer 
binding site (PBS), splicing donor site (SD), packaging signal (Ψ), four genes (gag, pro, pol, 
env), splicing acceptor site (SA), polypurine tract (PPT), unique region in 3’end (U3) and the 
polyadenylated tail (PA). Following reverse transcription, the viral DNA integrates as a 
provirus, characterised by the long terminal repeat (U5-R-U3). The full length viral transcript 
follows three possible routes: assembled in a new virion as genomic RNA (1), translated in 
the polyproteins Gag and Gag-Pro-Pol (2), spliced and translated in the envelope protein 
(Env) (3). Gag-Pro-Pol polyprotein is cleaved in the following components (from left to right): 
matrix (MA), p12, capsid (CA), nucleocapsid (NC), protease (Pro), reverse transcriptase (RT) 
with the ribonuclease H domain (RNase H), and integrase (IN). The Env is processed by 
removal of the leader signal (L) and cleavage between the two units: surface (SU), 
containing the variable region A (VRA) and B (VRB), and transmembrane (TM) containing 
the fusion peptide (FP) and the R peptide (RP). 
Genomic RNA 
Provirus 
Viral transcripts 
Viral proteins 30 
 
1.3.2 Genomic  RNA 
The genome of the retroviruses consists of two positive-sense, single-
stranded, RNA molecules. The size is between 7 to 12 kilobases. The 
genomic RNA is a dimer held together at the 5’ ends. The structure of each 
molecule resembles a cellular messenger RNA (mRNA). The 5’ end is 
capped and the 3’ end is polyadenylated. The genomic RNA inside the 
virions is the unspliced form of the viral transcripts. At both the extremities of 
the RNA molecules there are the repeat regions (R) followed by a unique 5’ 
sequence (U5) and a unique 3’sequence (U3). These regions form the long 
terminal repeats (LTRs) in the integrated provirus. Immediately after the U5, 
there is the primer binding site (PBS), the region for annealing to a specific 
cellular transfer RNA (tRNA) which will act as primer for the reverse 
transcription (section 1.3.3). Retroviruses use different tRNAs; tRNA
Lys (HIV-
1), tRNA
Pro (MLV and PERV subgroup C), tRNA
Gly (PERV subgroup A and 
B), are some examples. The genomic RNA is packaged into a retroviral 
particle by recognition of the packaging (or encapsidation) sequence, called 
Ψ, located near the 5’ end of the RNA molecules (figure 1.2). At the other 
end of the molecule there is a region important for reverse transcription, 
called the polypurine tract (PPT), immediately before the U3 (Vogt, 1997). 
The genome of all retroviruses encodes four main genes gag, pro, pol and 
env. In all of them, the Env protein is translated from a spliced mRNA which 
is formed by excision of the gag, pro and pol genes. The splice donor (SD) 
site is generally upstream of gag and the splice acceptor (SA) site 
immediately before env (Vogt, 1997). Structural proteins are synthesised 
from the gag gene. They are produced as a polyprotein successively cleaved 
by the viral protease, encoded by pro. The cleavage of the precursor Gag 
and Gag-Pol occurs during or after the assembly of the viral particle, leading 
to the maturation of an infectious virus. All the retroviruses possess two other 
enzymes encoded by the pol gene: reverse transcriptase (RT) and integrase 
(IN). RT is a RNA-dependent DNA polymerase. Using the viral genomic RNA 
as template, RT promotes the synthesis of a new single stranded DNA 
filament. RT possesses a second domain, a ribonuclease H (RNase H), 31 
 
which degrades the RNA filament during DNA synthesis (Telesnitsky and 
Goff, 1997). Once the viral DNA has been synthesised and translocated to 
the nucleus, IN promotes its integration into the cellular genome. The 
different steps in the integration process involve the following IN functions: 
nuclease (cleavage of the 3’ ends of the viral DNA), DNA binding and 
transesterification (3’-OH groups at the viral DNA ends are used to form 
phosphodiester bonds on the target cellular DNA leading to the joining of the 
two DNA filaments) (Brown, 1997).  
In addition to these four genes, some genera of retroviruses possess other 
accessory genes. For instance, γ-retroviruses are simple viruses and encode 
only the four genes described above, while lentiviruses are complex 
retroviruses and possess additional genes (e.g. HIV-1 encode six accessory 
genes: vif, vpr, tat, vpu, rev and nef) (Rabson and Graves, 1997; Swanstrom 
and Willis, 1997). 
1.3.3 Life  cycle 
Viruses need to infect a cell to reproduce (Figure 1.3). Retroviruses enter 
vertebrate cells by attachment to the cell surface, followed by interaction 
between the viral glycoprotein Env and specific host surface molecules 
(section 1.5). This binding causes conformational changes in the Env 
proteins, leading to the exposure of the fusion peptide at the N-terminus of 
TM, and its insertion into the cell plasma membrane. As a result, fusion 
between the viral envelope and the host cell membrane occurs, and the virus 
core is released into the cytosol [reviewed in (Colman and Lawrence, 2003; 
Eckert and Kim, 2001)]. The majority of the viral particles, however, enter the 
cell through endocytosis (Marechal et al., 1998). For lentiviruses such as 
HIV-1, this route leads to an abortive infection, with the virions being 
degraded by the proteasome (Fredericksen et al., 2002; Schwartz et al., 
1998). Other retroviruses, such as ecotropic and amphotropic MLV (Katen et 
al., 2001) and foamy virus (Picard-Maureau et al., 2003) can enter cells via 
the endocytic pathway, in a pH-dependent manner. The preferential route of 
entry for those retroviruses, which can use both, appears to be cell type 
specific (Kizhatil and Albritton, 1997). 32 
 
 
 
 
 
Figure 1.3 Retrovirus life cycle 
The retroviral life cycle, schematised here, is described in detail in section 1.3.3. 33 
 
Reverse transcription takes place in the cytoplasm of the cell and generates 
a linear, double-stranded DNA using the viral genomic RNA as template 
(Figure 1.4). The viral RT enzyme starts the synthesis of the minus-strand 
DNA filament using as primer the 3’ end of the tRNA which is annealed at the 
PBS in the genomic RNA (Figure 1.4 A). The minus strand DNA synthesis 
continues until RT reaches the 5’ end of the viral RNA (Figure 1.4 B). The 
RNase H domain of the RT digests the RNA filament in the newly 
synthesised hybrid RNA:DNA (Figure 1.4 C). The transfer of the minus-
strand DNA to the opposite end of the genomic RNA is guided by the 
repeated region, R (Figure 1.4 D). RT resumes the synthesis of the minus-
strand DNA. RNAse H digestion removes most of the RNA except the PPT, 
which is highly resistant to RNase H degradation (Figure 1.4 E). The 
undigested RNA sequence PPT serves as a primer for the synthesis of the 
plus-strand DNA (Figure 1.4 F). RT continues copying the minus-strand DNA 
into a portion of the tRNA used as initial primer, causing its removal (Figure 
1.4 G).The plus-strand DNA is transferred to anneal to the PBS site in the 
minus-strand DNA filament, and the synthesis of both strands completed 
(Figure 1.4 H and I). The final result is a blunt-ended, linear DNA duplex 
(Telesnitsky and Goff, 1997).  34 
 
 
Figure 1.4 Reverse transcritption 
The reverse transcription of the retroviral genomic RNA (white) starts with the synthesis of 
the minus-strand DNA (light grey) at the 3’ end of the primer tRNA, annealed at the primer 
binding site (PBS). The synthesis of the plus-strand DNA (dark grey) commences using the 
undigested polypurine tract (PPT) as primer. The final product is a linear, double-stranded 
DNA flanked by two identical long terminal repeats (LTR). 
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The viral DNA is associated with viral and cellular proteins, forming the 
preintegration complex (PIC), which is translocated to the nucleus. To gain 
access to the nucleus, most retroviruses depend on mitosis, where the 
nuclear membrane is disassembled. However, members of the genus 
lentivirus, such as HIV-1, can pass through an intact nuclear membrane. HIV-
1 PIC enters the nucleus via a nuclear localisation signal-mediated, active 
import through the nuclear pore (Bukrinsky et al., 1992; Gulizia et al., 1994; 
Heinzinger et al., 1994; von Schwedler et al., 1994). Once in the nucleus, the 
integrase-DNA complex binds to the DNA and the integrase catalyses the 
joining of the viral DNA with the host cell DNA. The cellular components of 
the DNA damage response system mediates the filling in of the nicks and 
gaps flanking the viral DNA [reviewed in (Smith and Daniel, 2006)]. The site 
of integration was initially thought to be random. However, a systematic large 
scale analysis of retroviral integration sites revealed virus-specific preferential 
integration sites [reviewed in: (Bushman et al., 2005)]. For instance, HIV-1 
and simian immunodeficiency virus (SIV) preferentially integrate in 
transcription units (Crise et al., 2005; Schroder et al., 2002), whereas MLV 
and porcine endogenous retrovirus (PERV) in the proximity of the 
transcriptional start sites and near CpG islands, regions abundant in CpG 
dinucleotide, which are undermethylated and associated with gene regulatory 
regions (Moalic et al., 2006; Wu et al., 2003).  
Transcription of the viral genes can occur efficiently after the integration of 
the viral DNA and it is mediated by the RNA polymerase II, the enzyme 
responsible for the synthesis of cellular mRNAs and some small nuclear 
RNAs. The transcription is promoted by the viral LTR. Direct repeat 
sequences in the U3 region of the LTR constitute an enhancer element 
(Laimins et al., 1984; Levinson et al., 1982) which contains a transcription 
factor-binding site (Speck and Baltimore, 1987). The promoter in the U3 
region contains the TATA element upstream of the transcription start site. 
PERV shares the same structural organisation of other γ-retroviruses, 
however, the direct repeats (i.e. enhancer) differ from other γ-retroviruses, 
and appear to bind a smaller number of transcription factors. Another region 
in the U3 region of the LTR upstream of the repeated elements have been 36 
 
predicted to contain transcription factor binding sites (Wilson et al., 2003). 
The cellular transcriptional machinery processes the viral transcripts as for 
any other cellular mRNAs, capping the 5’ end and adding a polyadenylated 
tail at the 3’ end. The full-length, unspliced transcript serves three possible 
roles: 1) viral genome, packaged into the nascent virions; 2) mRNA for Gag 
and Gag-Pol translation; 3) mRNA for Env translation, once spliced.  
The export to the cytoplasm of unspliced mRNAs requires the action of viral-
specific functions. HIV-1 produces an auxiliary protein, Rev (regulatory of 
virion), which acts as adaptor between the viral RNA and cellular export 
protein complex [reviewed in (Pollard and Malim, 1998)]. Other retroviruses, 
including human T- lymphotropic virus (HTLV), mouse mammary tumour 
virus (MMTV), equine infectious anaemia (EIAV), and feline 
immunodeficiency virus (FIV) encode Rev-like proteins (Magin et al., 1999; 
Mertz et al., 2005; Phillips et al., 1992; Rimsky et al., 1988). Simple 
retroviruses which do not encode accessory proteins rely upon the cis-acting 
element, for the export of the viral RNA. As examples, Mason-Pfizer monkey 
virus, simian retrovirus type D and Rous sarcoma virus possess a distinct 
RNA structure, called constitutive transport element (Bray et al., 1994; Ernst 
et al., 1997; Ogert et al., 1996; Zolotukhin et al., 1994). The Moloney MLV 
(MoMLV) packaging signal appears to be involved in the nuclear export of 
full-length RNA (Smagulova et al., 2005). 
Ribosomes bind to the viral RNA and start the translation with the start codon 
for Gag, skipping upstream start and stop codons, probably by internal 
ribosome entry site (IRES). Evidences for the presence of IRES in the RNA 
of MLV (Berlioz and Darlix, 1995; Deffaud and Darlix, 2000a), avian 
reticuloendotheliosis virus type A (Lopez-Lastra et al., 1997), Rous sarcoma 
virus (Deffaud and Darlix, 2000b) and HIV (Brasey et al., 2003; Buck et al., 
2001) have been described. Two polyproteins are synthesised, Gag and 
Gag-Pro-Pol from the same unspliced viral RNA. β-retroviruses, such as 
members of the avian sarcoma-leukosis virus group, differ from other 
retroviruses in that the Pro domain is contained in both precursors because 
Pro-coding sequence is placed in the gag reading frame (Bennett et al., 
1991; Schwartz et al., 1983). The regulation of the translation of the Gag-Pro-37 
 
Pol precursor allows the production of more Gag proteins than the enzymes 
encoded by pro and pol. Typically, 10 to 20 Gag molecules are made per 
molecule of Gag-Pro-Pol (Hatfield et al., 1992). Two mechanisms are 
exploited by retroviruses to generate the Gag-Pro-Pol precursor, both aimed 
to bypass the termination codon at the 3’ end of gag. Most retroviruses (α-, β-
retrovirus and lentivirus) use a ribosomal frameshift by ‘slipping’ backwards 
of one nucleotide (-1) and changing the open reading frame (ORF). In other 
retroviruses, such as the β-retrovirus mouse mammary tumour virus (MMTV) 
and δ-retrovirus human T-leukaemia virus (HTLV-1), pro lies in a different 
reading frame from gag and pol and therefore two (-1) frameshifts, one to 
create Gag-Pro and a second one for the Gag-Pro-Pol precursor, are 
required [(Hatfield et al., 1992) and reviewed in (Jacks, 1990)]. Contrastingly, 
γ-retroviruses read through the termination codon. For instance, in MLV the 
stop codon is occasionally misread as a glutamine (Yoshinaka et al., 1985). 
Electron microscopy has showed at least two pathways for retroviral 
assembly. For lentiviruses, α- and γ-retroviruses, the viral proteins are 
transported to the plasma membrane where the assembly takes place. 
Instead,  β- and δ–retroviral cores are assembled in the cytoplasm, and 
migrate to the plasma membrane where they bud from the cell. The cleavage 
of the polyprotein precursor by the viral protease occurs during and after the 
release of the virions (Swanstrom and Willis, 1997). The retrovirus budding 
has not been fully characterised yet. A region in the Gag precursor, late 
domain (L), has been described as critical for the release of the virions. The 
role of the L sequence appears to be the hijacking of the cellular machinery 
responsible for the budding of cargo-laden vesicles into the multivesicular 
bodies, such as the class E vesicular protein sorting machinery, which 
assembles into discrete complexes termed the endosomal sorting complex, 
required for transport (ESCRT)-I, -II, -III [reviewed in (Demirov and Freed, 
2004)].  
1.3.4 Retroviral  pathogenesis 
Retroviruses are associated with a wide variety of diseases including 
tumours, immunodeficiencies and neurological disorders. The first retrovirus 38 
 
was originally discovered in 1908 as transmissible oncogenic agents of 
erythro-myeloblastic leukaemia in chickens, later identified as the avian 
leukosis virus (ALV). Since then, many other tumourigenic retroviruses were 
described (Rosenberg and Jolicoeur, 1997). One possible mechanism of 
retrovirus-mediated oncogenesis is the expression of viral oncogenes. The 
first transforming gene identified was the src oncogene in Rous sarcoma 
virus, which highly resembles the cellular src gene in chicken DNA (Stehelin 
et al., 1976). Most of the viruses which carry oncogenes are replication-
defective because some, or all, of their genes were lost during the acquisition 
of the cellular oncogene. Other retroviruses induce tumours by provirus 
insertional mutagenesis. The viral integration site for these viruses has been 
mapped to the proximity of a cellular oncogene (called proto-oncogene). The 
promoter and enhancer elements in the proviral LTRs can increase the 
transcription of the proto-oncogene, leading to neoplasia (Hayward et al., 
1981; Neel et al., 1981). Some retroviruses cause tumorigenesis via an Env-
mediated mechanism, by interacting with cellular proteins and altering the 
transcriptional profile of the cells. A different mechanism to induce 
oncogenesis is represented by HTLV. HTLV-1 regulatory protein Tax, which 
potently increases transcription of viral gene from the LTR, also stimulates 
transcription of many cellular genes by binding cellular transcriptional factors, 
and may be involved in the leukaemogenesis [reviewed in (Maeda et al., 
2008)]. 
HIV-1 is the aetiological agent of the acquired immunodeficiency syndrome 
(AIDS). Other animal retroviruses which, as well as HIV, target immune 
system cells can induce immunodeficiencies (Aziz et al., 1989; Daniel et al., 
1985; Kanki et al., 1985; Letvin et al., 1985; Marx et al., 1984; Pedersen et 
al., 1987). 
Neurotropic retroviruses are associated with degeneration of neural function 
in the central nervous system (CNS). Retrovirus-induced spongiform 
encephalopathies, usually present without an inflammatory response, are 
characterised by neuronal loss and proliferation and hypertrophy of the glial 
cells (Andrews and Gardner, 1974; Swarz et al., 1981; Zachary et al., 1986). 39 
 
In humans, infection of CNS cells by HTLV-1 and HIV-1 causes neurological 
disease associated with an inflammatory response. Similar encephalopathies 
have been described in animals such as cats infected with a T-lymphotropic 
feline virus, later renamed feline immunodeficiency virus (FIV) (Pedersen et 
al., 1987). 
Retroviruses have been associated with other pathologies. As example, 
anaemia is induced in horses by the lentivirus EIAV [reviewed in (Montelaro 
et al., 1993)] and in cats by feline leukaemia virus C (Abkowitz, 1991). 
1.3.5 Endogenous  retroviruses 
Integration of a provirus in the genome of germ line cells may imply that the 
retrovirus can be transmitted vertically to the offspring according to 
Mendelian genetics, and become an endogenous retrovirus (Boeke and 
Stoye, 1997). It has been estimated that 8 to 10% of the human and mouse 
genome are constituted by retroviral sequences (Gifford and Tristem, 2003). 
Members of every genera of the family Retroviridae have been identified in 
vertebrates, with the exception of the deltaretrovirus genus (Gifford and 
Tristem, 2003; Gifford et al., 2008; Katzourakis et al., 2007). Most of the 
provirus sequences are transcriptionally silent or carry deletions or point 
mutations which render the retrovirus unable to replicate. However, some of 
the viral open reading frames are still active and full-length replication 
competent viruses have been observed in some species such as chicken, 
mouse and pigs [reviewed in (Best et al., 1997; Weiss, 2006)]. Several 
speculations arose regarding whether the expression of viral gene products 
might provide a selective advantage to the host. In support of this theory, 
there are some examples: 
1) protection from retroviral infection. Expression of Env proteins could 
prevent infection by retroviruses in the same interference group (retroviruses 
which uses the same receptor) by saturating, or down-regulating, the cellular 
receptors. For instance, murine locus Friend virus-4 (Fv-4) encodes an 
ecotropic MLV Env protein. Its expression conferred resistance in vitro and in 
vivo to ecotropic, but not amphotropic, MLV (Ikeda et al., 1985; Limjoco et al., 
1993). A different mechanism to prevent retrovirus infection has been 40 
 
described for the murine locus Fv-1 [section 1.6.1; (Yan et al., 2009)]. 
Sequence analysis of the Fv-1 locus showed that it derives from the CA 
protein of a murine endogenous retrovirus (Benit et al., 1997). In sheep, the 
defective CA protein of the endogenous Jaaksiekte sheep retrovirus 
(enJSRV) can block the exit of exogenous JSRV (Mura et al., 2004). 
2) placental function. Syncytiotrophoblast formation is one of the initial steps 
in the placenta development, and involves fusion of the cells of the 
trophoblast (the outer layer of the blastocyst). A possible involvement of 
endogenous Env in syncytiotrophoblast genesis has been suggested by the 
discovery of syncytin. This gene shows 100% amino acid identity with the 
Env protein of human endogenous retrovirus (HERV)-W, and is highly 
expressed in the placenta. Expression of syncytin in COS cells, and cells 
expressing the RD114 receptor (ASCT-2), resulted in the formation of large 
cell syncytia (Blond et al., 2000; Mi et al., 2000). Another fusogenic gene 
derived from an endogenous retrovirus (HERV-FRD) env gene has been 
identified and called syncytin-2 (Blaise et al., 2003). The cellular counterpart, 
the receptor major facilitator superfamily domain containing 2 (MFSD2), has 
a placental-specific expression and the proposed function is a carbohydrate 
transporter probably acting at the level of the syncytiotrophoblast (Esnault et 
al., 2008). Evidence to support the possible contribution of the endogenous 
retrovirus Env in the host physiology emerged from use of syncytin-A knock-
out mice. Syncytin-A and –B are two fully-coding mouse ERV env genes, 
which display fusogenic property when expressed in transfected cells and are 
highly expressed in the placenta (Dupressoir et al., 2005). Homozygous null 
embryos for syncytin-A gene died in utero due to defective development of 
the placenta, indicating a critical role for syncytin-A (Dupressoir et al., 2009). 
Similar, but less conclusive, results were obtained by in vivo knock-down of 
the Env of enJSRV (Dunlap et al., 2006). 
Contrastingly, endogenous retroviruses have been implicated in the 
development of diseases.  
1) cancer. An unambiguous causative association between ERVs and cancer 
has been proved only in mice. Mouse mammary tumour virus (MMTV) has 41 
 
been discovered in the milk of female mice as a filterable agent responsible 
for breast cancer (Boeke and Stoye, 1997). Recombination between infecting 
MLV and endogenous retroviruses leading to the generation of recombinant 
mink cell focus forming (MCF) viruses has been described as a hallmark in 
the development of leukaemia in AKR mice (Fan, 1997). Mobility and 
amplification of ERVs in murine tumour cells have been observed in murine 
neuroblastoma and melanoma (Pothlichet et al., 2006a; Pothlichet et al., 
2006b). In humans, the evidence for tumorigenesis induced by HERV is only 
circumstantial [reviewed in (Ruprecht et al., 2008)]. 
2) autoimmune disease. A role for ERV in autoimmune disease has been 
proposed on the basis of several pieces of evidence. Antibodies reactive 
against HERV proteins have been found in patients affected by systemic 
lupus erythematosis (Bengtsson et al., 1996; Li et al., 1996; Perl et al., 1995) 
and multiple sclerosis (Jolivet-Reynaud et al., 1999). Endogenous retroviral 
gene expression has been detected in several human autoimmune diseases 
(Conrad et al., 1997; Perron et al., 1997). However, there are no clear results 
which establish the causative role of ERV in inflammatory diseases [reviewed 
in (Voisset et al., 2008)]. 
Insight into the process of endogenisation has been offered by the discovery 
of the koala retrovirus (KoRV), detected in the wild and captive koalas as a 
full-length replication-competent provirus. Sequence analysis showed a 78% 
nucleotide similarity between the whole KoRV genome and the GALV’s, an 
exogenous gammaretrovirus associated with leukaemia and lymphoma in 
captive gibbon colonies (Hanger et al., 2000). A positive association was 
found between an increased level of KoRV RNA in the plasma of koalas and 
development of leukaemia or lymphoma (Tarlinton et al., 2005). As a 
endogenous virus, KoRV provirus sequences were detected in the germ line 
of the koalas analysed. However, the number and position of the provirus 
insertions vary between unrelated animals. Furthermore, while KoRV has 
been observed in all the koalas in North-East Australia, in the Southern 
mainland and islands there is a mixed prevalence of the virus with no animal 
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suggest that KoRV endogenisation is not fixed, and in the regions with a 
mixed prevalence it is likely that KoRV behave both as exogenous and 
endogenous virus (Tarlinton et al., 2006). To investigate the process of 
endogenisation, KoRV was compared with the closely related exogenous 
GALV. Critical motif differences between the 17 KoRV and 4 GALV 
sequences were identified which correlated with a reduced titre of the 
endogenous virus. These observations lead to the speculation that part of the 
process of retrovirus endogenisation involves the attenuation of the viral 
infectivity (Oliveira et al., 2007). 43 
 
1.4  Porcine endogenous retrovirus  
Four groups of β-retroviral and 10 groups of γ-retroviral sequences have 
been characterised by PCR using degenerated primers (Klymiuk et al., 2002; 
Patience et al., 2001). β-retroviral sequences were identified in the genomic 
DNA from animals of the Suidae and Tayassuidae families, indicating that 
some  β-retroviral sequences entered the porcine lineage before the 
separation between the Suidae and Tayassuidae families approximately 20 
million years ago (Ericsson et al., 2001; Patience et al., 2001). Instead, γ–
retroviral sequences were found only in the members of the Suidae family 
(Patience et al., 2001). In the pig genome the number of full length PERV 
copies is estimated to be between 50 and 200 (Akiyoshi et al., 1998; Le 
Tissier et al., 1997; Patience et al., 1997), but less than 10 are replication 
competent (Niebert et al., 2002). PERV sequences in different swine breeds 
revealed a heterogenous distribution among breeds and PERV copy number 
and chromosomal distribution also varied between individuals (Bosch et al., 
2000; Edamura et al., 2004; Herring et al., 2001; Lee et al., 2002; Li et al., 
2004; Rogel-Gaillard et al., 1999). This is of importance in 
xenotransplantation because it suggests that careful breeding could allow the 
elimination of replication-competent PERV and most problematic sequences, 
such as active PERV-C (section 1.4.2) from the animal donor. 
1.4.1 Replication-competent PERVs and host range 
Only the endogenous retroviruses representing the γ1 group (Patience et al., 
2001) have been observed spontaneously budding from porcine cells 
(Armstrong et al., 1971; Lieber et al., 1975; Todaro et al., 1974). Sequence 
analysis indicated closest homology with gibbon ape leukaemia virus 
(GALV), KoRV, MLV, FeLV and BaEV among retroviruses (Akiyoshi et al., 
1998; Czauderna et al., 2000; Hanger et al., 2000; Patience et al., 2001). In 
vitro analysis of the host range of PERV showed that these viral particles can 
infect human cells (Patience et al., 1997; Takeuchi et al., 1998). Infectious 
human tropic particles could be also produced from porcine primary 
peripheral blood mononuclear cells (PBMC), upon mitogenic stimulation in 
vitro (Wilson et al., 1998). Three groups of PERVs (A, B and C) have been 44 
 
described with high homology in the gag and pol genes. The major difference 
between PERV groups lies in the surface unit (SU) of Env, specifically in the 
regions VRA and VRB, which are responsible for receptor recognition 
(Akiyoshi et al., 1998; Le Tissier et al., 1997). All three PERV groups can 
infect porcine cells. PERV-A and PERV-B are human-tropic and their host 
range includes mink, cat and dog (PERV-A) and mink, mouse, rat and rabbit 
(PERV-B). PERV-C infection appears to be limited to pigs (Takeuchi et al., 
1998; Wilson et al., 2000). Initially, PERV infection of non-human primates 
cells was not detected (Martin et al., 1999; Takeuchi et al., 1998). However, 
MLV core particles pseudotyped with PERV-A Env were shown to infect 
baboon cells (Blusch et al., 2000a) and PERV transmission to baboon B-
lymphocytic cell lines was also detected, by PCR assay, after cocultivation 
with lethally irradiated PK15 cells (Templin et al., 2000). 
1.4.2 PERV  recombination 
Human-tropic PERVs isolated from NIH mini-pigs were shown to be 
recombinants between PERV-C and human-tropic PERV-A (Oldmixon et al., 
2002; Wilson et al., 2000). One of these recombinants, PERV-NIH, had a 
higher titre than PERV produced from PK15 cells (Wilson et al., 2000) 
Another isolate, PERV-A14/220, was shown to infect human cells with a 
significantly higher titre than other human-tropic PERV-A and PERV-B 
(Bartosch et al., 2004; Ericsson et al., 2003; Harrison et al., 2004). The main 
determinant for the increased titre has been mapped to the chimeric 
envelopes (Harrison et al., 2004). Both PERV-NIH and PERV-A14/220 Envs 
have the receptor binding domain (RBD) in the SU derived from PERV-A 
(hence, the human tropism) and the TM region from PERV-C (Wilson et al., 
2000; Bartosch et al., 2004; Harrison et al., 2004). In addition, PERV-
A14/220 has a higher reverse transcriptase activity than PERV-A, suggesting 
that also pol contributes to the higher titre of this isolate (Wood et al., 2009). 
The origin of these recombinations is not totally clear. PERV-A/C 
recombinant sequences were not found in the minipig genome, suggesting 
that the recombination was an event which occured de novo in each pig 
(Scobie et al., 2004; Wood et al., 2004). However, more recently, two 
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genome of four mini-pigs (Martin et al., 2006). It has been suggested that 
PERV-C sequences drive the recombination process (Wood et al., 2004). 
Therefore, the use of PERV-C-free pigs in xenotransplantation was 
advocated to reduce the risk of PERV infection [(Hector et al., 2007) and 
reviewed in (Denner, 2007)]. In the context of xenotransplantation, another 
risk associated with PERV recombination could be represented by the 
emergence of a novel retrovirus by recombination of PERV with HERVs. The 
likelihood of HERV sequence packaging in PERV particles has been studied 
and found to be very low, but it cannot be excluded (Suling et al., 2003). 
1.4.3  Diagnostic methods for PERV detection 
Before PERV was shown to be able to infect human cells (Patience et al., 
1997), porcine materials have been used to treat human diseases (Chari et 
al., 1994; Deacon et al., 1997; Fink et al., 2000; Groth et al., 1994; 
Reichenbacher, 1975). Retrospective studies have been conducted to 
assess a possible PERV infection (Clemenceau et al., 2001; Cunningham et 
al., 2001; Elliott et al., 2000; Heneine et al., 1998; Paradis et al., 1999; 
Patience et al., 1998). In the most extensive study (Paradis et al., 1999), 
PBMC and serum samples from 160 patients who underwent through 
different procedures (extracorporeal liver, splenic or kidney perfusion, 
pancreatic islet cells transplantation, skin xenograft ) were collected. The 
exposure time to the porcine materials varied between 15 minutes to 460 
days. Testing was carried out by real-time PCR on the DNA extracted from 
PBMCs using primers specific for PERV gag and pol sequences: 81% of the 
samples were PERV DNA-negative. The PERV DNA-positive samples were 
assessed by PCR for the presence of pig centromeric or mitochondrial DNA, 
and all were found positive, indicating microchimerism (i.e. presence of 
circulating porcine cells in the xenotransplant recipient, but not necessarily 
PERV infection of patient’s cells). No PERV RNA was found in the serum or 
saliva. Similar results using similar PCR-based methods were obtained in all 
the other studies, showing no evidence of PERV infection in patients 
exposed to the porcine materials (Clémenceau et al., 2001; Cunningham et 
al., 2001; Elliott et al., 2000; Heneine et al., 1998; Patience et al., 1998). Due 46 
 
to of the importance of follow up of the xenotransplantation patient, new 
improved PCR-based methods of detection have been developed to enhance 
the effectiveness and reliability of monitoring procedures (Blusch et al., 
2000b; Lovatt et al., 1999; Shah et al., 2003; Switzer et al., 1999). 
Immunological methods have also been developed and improved during 
recent years, mainly based on the detection of the virus in the cells or 
tissues, either by western blotting or immunostaining (Bartosch et al., 2002; 
Chiang et al., 2005; Fischer et al., 2003; Galbraith et al., 2000; Matthews et 
al., 1999; Tacke et al., 2001; Xu et al., 2003). Indirect diagnostic tools 
employed to detect viral infection have been the analysis of the presence of 
anti-PERV antibodies in the patients exposed to pig cells and tissues. No 
seroconversion was observed (Heneine et al., 1998; Patience et al., 1998; 
Paradis et al., 1999).  
1.4.4  Strategies to reduce the risk of PERV transmission 
The presence of αGal antigens on the surface of pig cells constitutes a major 
immunological obstacle in xenotransplantation (section 1.1.1). However, 
enveloped viruses produced from porcine cells are likely to acquire αGal 
antigens on their envelope and be readily neutralised by the human immune 
system (Rother et al., 1995; Takeuchi et al., 1997; Takeuchi et al., 1996). 
Indeed, it has been showed that natural xenoreactive antibodies can block 
PERV infection (McKane et al., 2004; McKane et al., 2003). The protection, 
offered by anti-αGal antibodies against PERV, would not be present when 
using transgenic pigs developed for xenotransplantation (section 1.1.1). 
PERV particles produced from transgenic porcine cells expressing 
complement regulatory proteins manifested a reduced susceptibility to 
neutralisation by the human immune system (Hazama et al., 2005; Magre et 
al., 2004; Okura et al., 2008; Takefman et al., 2002). PERV budding from 
αGal knock-out pig cells were found resistant to complement-mediated 
inactivation (Quinn et al., 2004). Novel strategies have to be developed to 
minimise the risk of PERV zoonosis in the context of xenotransplantation.  
1) A group of mini pigs have been shown not to produce human-tropic 
replication-competent (HTRC) PERV (Oldmixon et al., 2002; Wood et al., 47 
 
2004; Scobie et al., 2004). The non-transmitting phenotypes have been 
associated with the lack of critical PERV loci. Specifically, PERV-C locus is 
potentially associated with the ability to produce HTRC PERV-A/C or 
infectious PERV-C (Hector et al., 2007). Pigs lacking these specific loci could 
represent a safer source of xenografts (Garkavenko et al., 2008a; 
Garkavenko et al., 2008b). 
2) Small interfering RNAs (siRNAs) represent a highly conserved mechanism 
of posttranscriptional gene silencing based on sequence-specific degradation 
of a target mRNA [(Caplen et al., 2001; Fire et al., 1998; Hammond et al., 
2000; Zamore et al., 2000) and reviewed in (Matzke et al., 2001)]. 
Transfection of siRNA directed against PERV sequences (pol and gag 
genes) was able to suppress the viral expression in PERV-infected human 
cells (Karlas et al., 2004) and in porcine endothelial cells (Miyagawa et al., 
2005). From their initial work, Karlas and co-workers identified the most 
effective siRNAs sequence (pol2) able to achieve 90% PERV suppression 
when expressed under the control of the polymerase III H1-RNA gene 
promoter (Karlas et al., 2004). The long-term effectiveness of siRNA-Pol2 
was verified in the PERV-producing pig cell line PK15, as well as primary 
porcine cells by expressing the siRNA in a HIV-based lentiviral vector 
(Dieckhoff et al., 2007a). The final step was the production of transgenic pigs 
carrying the PERV-specific siRNA (Dieckhoff et al., 2008). Recently, another 
group have produced transgenic pigs that express siRNA against PERV gag 
and  pol sequences (Ramsoondar et al., 2009). Both studies produced a 
healthy transgenic litter (7 and 3 piglets, respectively) in which the presence 
of the siRNA was detected. In many porcine tissues the mRNA level of PERV 
genes was reduced. However, the suppression of PERV particle production 
could not be assessed. In fact, the amount of PERV proteins in the non-
transgenic pigs was not detectable and, therefore, it was impossible to 
compare PERV production between transgenic and non-transgenic animals 
(Dieckhoff et al., 2008; Ramsoondar et al., 2009).  
3) In addition to conventional antibodies, members of the Camelidae family 
(camels, llama and dromedaries) produce heavy-chain-only antibodies as 48 
 
natural, functional single chain antibodies (Hamers-Casterman et al., 1993). 
An antibody specific to p15 matrix protein was derived from a llama 
immunised with PERV-B Gag protein following screening of a single-chain 
antibody phagemid library. Intracellularly expressed antibody reduced the 
production of PERV-A and PERV-B Gag precursor more than 90% in 
selected single-clone PK15 cells (Dekker et al., 2003). In a similar way to the 
production of siRNA-transgenic pigs, xenotranplantation animal donors could 
be genetically modified to express this antibody to reduce PERV production.  
4) Engineering pigs to express human APOBEC3G could result in an animal 
donor less likely to transmit PERV. APOBEC proteins have been described 
as host restriction factors able to block viral infection (section 1.6.2). PERV 
transmission to human embryonic 293 cells was reduced from human 
APOBEC3G-transduced PK15 cells (Jonsson et al., 2007), and from HEK 
293 cells cotransfected with human or porcine APOBEC3 and PERV B 
genome (Dorrschuck et al., 2008). 
5) An alternative strategy for preventing PERV transmission involved 
remodelling of the pig cell surface glycoproteins by the transfer of N-glycan 
processing transferases into porcine cells. The expression of three enzymes 
(α-1,2 mannosidase Ib, α3-D-mannoside  β-1,2-N-acetylglucosaminyl 
transferase I, and α-mannosidase II) in pig endothelial cells was effective in 
reducing PERV infection of to human HEK 293 cells (Miyagawa et al., 2006). 
No reduction in PERV RNA level in the supernatant of porcine cells was 
detected. The high-mannose type N-linked sugars have been shown to be 
important for PERV infectivity, however their role is still unclear (Hazama et 
al., 2003; Miyagawa et al., 2006). 
6) Neutralising antibodies against PERV were produced by inoculation of the 
ectodomain of the transmembrane envelope protein p15E (amino acid 488-
597) into a goat (Fiebig et al., 2003). Antibodies present in the goat anti-
serum were able to neutralise PERV infection in vitro. These results showed 
that an anti-PERV vaccine could be a potentially successful strategy. 
However, effective vaccines against another γ-retrovirus, FeLV, have been 
produced (Hines et al., 1991; Poulet et al., 2003; Sparkes, 2003; Tartaglia et 49 
 
al., 1993; Tizard and Bass, 1991; Weijer et al., 1993; York and York, 1991), 
but none was able to provide a complete protection (Hofmann-Lehmann et 
al., 2007; Jarrett and Ganiere, 1996; Marciani et al., 1991). 
7) Antiviral chemotherapy is probably the most direct system to prevent 
PERV transmission. Reverse transcriptase and protease inhibitors developed 
for HIV-1 were tested to assess their efficacy against PERV. Only two 
nucleoside analog RT inhibitors zidovudine (AZT) and dideoxyinosine were 
found effective at concentrations achievable in vivo, (Powell et al., 2000; Qari 
et al., 2001; Stephan et al., 2001; Wilhelm et al., 2002). More recently, 
acyclic nucleoside phosphonates were indicated as promising compounds to 
reduce PERV replication (Shi et al., 2007). 50 
 
1.5   γ-RETROVIRUS RECEPTORS 
From a biochemical prospective, a receptor is an intrinsic membrane protein 
with both extracellular and intracellular domains. It possess a binding site on 
the extracellular domain which specifically recognises the signal molecule, 
the ligand. The interaction between ligand and receptor alters the tertiary or 
quaternary structure of the receptor, including the intracellular domain. These 
structural changes activate a downstream signalling pathway that can alter 
the biochemistry of the cell (Alberts et al., 2002). In contrast, a viral receptor, 
which is a molecule in the cell membrane, induces conformational changes in 
its ligand, the viral envelope glycoprotein.  
Viruses have exploited a wide variety of molecules to use as receptors, such 
as different families of proteins, carbohydrates and lipids [reviewed in 
(Haywood, 1994)]. The viral receptor mediates the binding of the virus to the 
cell surface and leads to its entry into the cell. In most cases, one molecule 
mediates both binding and fusion, such as for the γ-retroviruses. However, 
some other viruses, such as HIV-1, need a coreceptor (Choe et al., 1996). In 
addition, the initial step of viral infection consists of the adsorption of the virus 
to the cell surface, which can be receptor-independent, and mediated by 
many different cell surface molecules such as heparan sulphate 
proteoglycans, lectins (e.g. DC-SIGN and DC-SIGNR), integrins and 
glycolipids (Fortin et al., 1997; Jinno-Oue et al., 2001; Lee et al., 2001; 
Pohlmann et al., 2001; Saphire et al., 1999). Although other intracellular 
mechanisms may be present to restrict viral replication in a cell (section 1.6), 
the pattern of expression of the receptor on the surface of different cells 
defines the virus host range. For instance, murine leukaemia viruses (MLV) 
have been classified into four different host-range subgroups according to the 
distribution of their specific receptors among species. The receptor for 
ecotropic viruses is restricted to murine or rat cells, whereas the receptor for 
viruses with a xenotropic host range can be present on the cells of many 
different species but never on mice. Amphotropic and polytropic viruses use 
receptors found both on rodent and other species cells, but they do not 
interfere with one another, indicating that the receptors are distinct molecules 
(Rein, 1982; Rein and Schultz, 1984). 51 
 
For the γ-retroviruses, the process of fusion is not necessarily mediated 
directly by the cognate receptor. In some examples, the conformational 
changes in the Env glycoproteins that occur following the binding to the 
receptor enable the same, and other, Env molecules to trigger fusion 
(Anderson et al., 2000; Barnett and Cunningham, 2001; Barnett et al., 2001; 
Lavillette et al., 2001; Lavillette and Kabat, 2004; Lavillette et al., 2002b; 
Lavillette et al., 2000). 
Members of the genus γ-retrovirus use a small number of quite related 
receptors. This fact has been explained by different authors in opposite ways: 
a convergent [reviewed in (Overbaugh et al., 2001)] or divergent evolution 
[reviewed in (Tailor et al., 2003)]. In both these reviews, the authors use ad 
hoc examples to support their hypothesis. For instance, Overbaugh and 
coauthors emphasise that multiple γ-retroviruses use the phosphate transport 
proteins, Pit1 and Pit2, as receptor. Whereas, Tailor and coauthors use other 
examples to support their hypothesis, such as that the only avian retrovirus 
known to use a receptor with multiple transmembrane domains, avian 
reticuloendotheliosis viruses, is closely related to mammalian endogenous 
retrovirus (Barbacid et al., 1979). However, although Tailor and coauthors 
strongly support the divergent evolution, they admit a limited degree of 
convergent evolution in receptor choice.  
There are many similarities between γ-retrovirus receptors, and they will be 
discussed in the following sections.  
1.5.1 Receptor  cloning 
The first retroviral receptor that was molecularly cloned was the receptor for 
ecotropic MLV (E-MLV) (Battini et al., 1995; Battini et al., 1992), the cationic 
amino acid transporter-1 (CAT-1) (Albritton et al., 1989). The strategy used 
consisted of gene transfer of a cDNA library derived from the E-MLV 
permissive murine cell line NIH 3T3 into the resistant human cell line EJ, 
employing retroviral vectors which express a drug-resistant gene. EJ clones 
which have acquired susceptibility to E-MLV infection were selected by 
addition to the media of the drug. One year later, the receptor for gibbon ape 
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technique (O'Hara et al., 1990). This receptor was subsequently determined 
to also function as a receptor for wooly monkey virus, feline leukaemia virus 
B (FeLV-B) (Takeuchi et al., 1992), MLV10A1 (Miller and Miller, 1994; Wilson 
et al., 1995) and KoEV (Oliveira et al., 2006). Similarly, the receptor for 
amphotropic MLV (A-MLV), Ram-1 or Pit-2, was cloned through screening of 
a rat cDNA library introduced into a hamster cell line (Miller et al., 1994). The 
same protein, called GLVR-2 was cloned independently by another group 
using a different technique. Low-stringency hybridisation with a cDNA 
encoding GLVR-1 was used to isolate related phage clones from human HL-
60 and placental cDNA libraries (van Zeijl et al., 1994). 
Using the expression cloning technique other γ-retrovirus receptors have 
been cloned. The human ASCT-2 receptor or RDR, feline endogenous 
retrovirus RD114 and retrovirus D-type receptor, allows the infection of not 
only RD114 but also baboon endogenous retrovirus (BaEV) human 
endogenous retrovirus W (HERV-W), reticuloendotheliosis virus (REV) as 
well as β-retrovirus simian retrovirus type D (Rasko et al., 1999; Tailor et al., 
1999b). In the same year, the human receptor, XPR-1, that facilitates the 
entry for both xenotropic and polytropic MLV (X- and P-MLV-) has been 
cloned by three different groups independently (Battini et al., 1999; Tailor et 
al., 1999a; Yang et al., 1999). XPR-1 is also required for infection by 
xenotropic MLV-related virus (XMRV) (Dong et al., 2007). The receptor for 
feline leukaemia virus C (FeLV-C), FeLVCR-1, has been cloned from human 
and domestic cat cDNA libraries (Quigley et al., 2000; Tailor et al., 1999c). 
The existence of a homologue to FeLVCR-1, FeLVCR-2, was predicted by 
search of the NCBI database. FeLVCR-2 was then cloned and tested for 
supporting FeLV-C infection but was found to be non-functional (Brown et al., 
2006). Recently, a FeLV-A and FeLV-C hybrid Env, named FY981, was 
isolated from a primary FeLV isolate, and when pseudotyped can use 
FeLVCR-2 for infection (Shalev et al., 2009). Porcine endogenous retrovirus 
subgroup A (PERV-A) receptors (Ericsson et al., 2003) and the FeLV-A 
receptor, the feline orthologue of the human thiamine transport protein 1 
(THTR1), have been identified by using the same gene transfer approach 
(Mendoza et al., 2006). 53 
 
1.5.2 Receptor  topology 
All  γ-retrovirus receptors thus far discovered are multiple transmembrane 
(TM) proteins. The number of TM domains in these receptor is between 4, as 
predicted for the Mus caroli endogenous retrovirus (McERV) receptor and 14 
of CAT-1 (Table 1.1). The morphology has been initially predicted using 
bioinformatics tools such as hydro prediction software, and has been 
experimentally proven. Pit-2 was the first γ-retrovirus receptor whose 
topology was studied in detail (Salaun et al., 2001). A model of Pit-2 topology 
was obtained from different TM prediction programmes, such as 
PredictProtein (www.embl-heidelberg.de/predictrpotein/predict protein.htmL), 
DAS server (www.biomedi.su.se/-server/DAS) and TMHMM 
(www.cbs.dtu.dk/services/TMHMM). Extracellular N-glycosylation sites were 
assessed by creation of mutants and treatment of PNGase F, an enzyme 
which removes N-linked oligosaccharide chains. The orientation of the 
receptor extremities were studied by tagging either the C- or N-terminus.  
A similar study was conducted on Pit-1. Its topology was initially predicted by 
Kyte-Doolittle hydropathy plots to be 10 TM domains with both N-terminus 
and C-terminus being intracellular (Johann et al., 1992). Ten years later, 
Farrell and coworkers demonstrated, using HA-tagged Pit-1 in 
immunofluorescence, flow cytometry and glycosylation studies, that Pit-1 
topology was different with both N-terminus and C-terminus being 
extracellular (Farrell et al., 2002).  
Similar experiments have also been done to determine the topology of the 
FeLV-C receptor (Brown et al., 2006). N-glycosylation experiments (Marin et 
al 2003) have confirmed the ASCT2 topology previously predicted (Tailor et 
al., 1999b). So far there are no publications concerning the topology of PAR-
1 and PAR-2 [apart from a study described in this thesis, and also in 
(Mattiuzzo et al., 2007)], and THTR1, the receptors for PERV-A and FeLV-A, 
respectively.  
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1.5.3 Physiological  function 
All gammaretrovirus receptors, whose physiological function has been 
described, are transporters (Table 1.1). A few years after their cloning and 
sequencing, the physiological function has been hypothesised through the 
comparison with homologous proteins in simpler organisms and then 
experimentally proven. The E-MLV receptor, CAT-1 is a cationic amino acid 
transporter which shares homology with the Saccharomyces cerevisiae 
arginine and histidine permeases (Kim et al., 1991). GLVR-1 and GLVR-2 
share about 25% amino acid identity with a phosphate permease from 
Neurospora crassa and are sodium-dependent phosphate transporters in 
human cells (Kavanaugh et al., 1994; Olah et al., 1994). For other proteins 
the description of their cellular function preceded the characterisation of their 
role as viral receptors. Following the isolation of the cDNA for ASCT-2, which 
conferred RD114 susceptibility to otherwise non permissive murine cells, its 
amino acid sequence revealed 97% homology to a neutral amino acid 
transporter (hATB
0) (Kekuda et al., 1996). Indeed ASCT-2 was showed to 
function as a transporter of neutral amino acids (Rasko et al., 1999; Tailor et 
al., 1999b). When the feline receptor for FeLV-A was cloned, its sequence 
showed approximately 93% homology with the human high-affinity thiamine 
transporter-1 (huTHTR-1) (Mendoza et al., 2006). Similarly, the function of 
FeLVCR-1 was predicted to be a transporter by homology with members of 
the major facilitator superfamily of transporters (Quigley et al., 2000; Tailor et 
al 1999c). From the observation that cats infected with FeLV-C developed 
anaemia, the physiological function of FeLVCR-1 was hypothesised and then 
confirmed, as a heme exporter (Quigley et al., 2004). The function of other γ-
retrovirus receptors, such as XPR-1, is still unknown, or not confirmed, such 
as for PAR-1 and PAR-2 (section 3.1). 
For several receptors it has been showed that the transporter function is not 
necessary to support virus entry. This has been experimentally proven with 
mutated or truncated receptors: murine CAT-1 (Wang et al., 1994), human 
Pit-2 (Bottger and Pedersen, 2002; Salaun et al., 2004) and ASCT-2 (Tailor 
et al., 2001). Contrastingly, retroviral infection reduces the transport activity 55 
 
of the receptor (Olah et al., 1994; Wang et al., 1992; Wilson et al., 1995). The 
mechanisms proposed are Env protein-mediated confinement of the newly 
synthesised receptors to the cytosolic compartment (Heard and Danos, 1991; 
Jobbagy et al., 2000), or Env interaction with cellular proteins necessary for 
trafficking the receptor to the cell surface (Fujisawa and Masuda, 2007). The 
cell can compensate by upregulating transporters with the same solute 
specificity. Indeed, down-modulation of Pit-1 causes up-regulation of Pit-2 
and vice versa (Chien et al., 1997; Kavanaugh et al., 1994). However, for 
other receptors, the disruption of the transport function caused by retroviral 
infection has been implicated in the development of disease, such as the 
anaemia in cats infected with FeLV-A or FeLV-C (Qiugley et al., 2004; 
Mendoza et al., 2006). 
 
name retrovirus  function  topology  References 
CAT-1 
SLC7A1 
E-MLV  Cationic 
amino acids 
transporter 
 
(Albritton et al., 1989; 
Kim et al., 1991; 
Wang et., al 1992) 
Pit-1 
GLVR-1 
SLC20A1 
FeLV-B 
GALV 
Wooly 
monkey virus 
10A1MLV 
KoRV* 
Phosphate 
tranporter 
 
(O’Hara et al., 1990; 
Takeuchi et al., 
1992; Miller and 
Miller, 1994; Wilson 
et al., 1995; Olah et 
al., 1994; Farrell et 
al., 2002; Oliviera et 
al., 2006) 
Pit-2 
GLVR-2 
Ram-1 
SLC20A2 
A-MLV 
10A1MLV 
Phosphate 
tranporter 
 
(Miller and Miller, 
1994; Van Zeijl et al., 
1994) 
XPR-1  X-MLV 
P-MLV 
XMRV 
unknown 
 
(Battini et al., 1999; 
Tailor et al., 1999a; 
Yang et al., 1999; 
Dong et al., 2007) 
ASCT-1 
SLC1A4 
BaEV 
HERV-W 
Neutral 
amino acid 
transporter 
 
(Lavillette et al., 
2002a; Marin et al., 
2000) 
ASCT-2 
RDR 
SLC1A5 
RD114 
BaEV 
REV 
HERV-W 
Neutral 
amino acid 
transporter 
 
(Rasko et al, 1999; 
Tailor et al., 1999b; 
Blond et al., 2000; 
Marin et al., 2003)  
FeLVCR-1 FeLV-C 
FeLV FY981 
Heme 
exporter 
 
(Tailor et al 1999c; 
Quigley et al., 2000; 
Quigley et al., 2004; 
Shalev et al., 2009) 56 
 
FeLVCR-2 FeLV  FY981  Not 
confirmed 
 
(Brown et al., 2006; 
Shalev et al., 2009) 
PAR-1  PERV-A  unknown 
 
(Ericsson et al., 
2003; Mattiuzzo et 
al., 2007) 
PAR-2  PERV-A  unknown 
 
(Ericsson et al., 
2003; Mattiuzzo et 
al., 2007) 
THTR-1 FeLV-A 
FeLV FY981 
Thiamine 
transport 
 
(Mendoza et al., 
2006; Shalev et al., 
2009) 
MFSD2  HERV-FRD  Carbohydrate 
transport 
(predicted) 
 
(Esnault et al., 2008) 
PLLP 
(TM4SF11) 
McERV  Voltage-
dependent 
K
+channel 
(Miller et al., 2008) 
Table 1.1 Summary of the known γ-retrovirus receptors 
Highlighted in bold are endogenous viruses (second column). *KoRV has been described 
both as an endogenous and exogenous virus. 
 
1.5.4  Identification of sites critical for infection and binding 
Receptors are the main determinants for viral tropism. Polymorphic variation 
of the receptors confers resistance to retroviral infection between species or 
homologous proteins within the same species. The difference can be as little 
as a single amino acid. 
A few years after CAT-1 was cloned, a highly related (87%) gene was 
identified from a human T-cell line (Yoshimoto et al., 1991). Although the 
human homologue is very similar in sequence and in structure to murine 
CAT-1, it does not support E-MLV infection. To identify amino acid residues 
critical for E-MLV infection, human-mouse chimeric receptor molecules were 
created and tested for their ability to support infection and binding to Env 
gp70 (Albritton et al., 1993; Yoshimoto et al., 1993). The substitution of one 
amino acid residue, tyrosine at position 235 in the third extracellular domain 
in murine CAT-1 with the corresponding human amino acid proline, 
abrogated E-MLV infection. Conversely, the substitution of amino acids 242 57 
 
and 244 in the human receptor with the corresponding amino acids in the 
murine receptor enabled human CAT-1 not only to support infection but also 
to bind Env gp70.  
The identification of the binding site in Pit-1 and Pit-2 was more difficult until 
the correct topology was described (Farrell et al., 2002; Salaun et al., 2001). 
The first candidate proposed to be the binding site for both receptors was a 
nine amino acid sequence called region A at position 550-558 within Pit-1 
(Johann et al., 1992; Johann et al., 1993). Region A was predicted by Kyte-
Doolittle Hydropathy plots to be in an extracellular domain and mutation in 
this region abolished GALV and FeLV-B infection (Johann et al., 1992). 
Later, other regions of the human Pit-1 and Pit-2 have also been found to be 
important for infection (Chaudry and Eiden, 1997; Leverett et al., 1998; 
Lundorf et al., 1998; Tailor and Kabat, 1997), but only in 2002 was the role of 
region A clarified. Cells expressing a mutant Pit-1 protein in region A does 
not work as a receptor, but retains its ability to bind the virus. Region A 
influences infection by controlling the orientation of the Pit-1 molecule in the 
membrane and therefore the accessibility or steric hindrance of the viral 
binding site. Furthermore, through the construction of chimeric receptors 
between Pit-1 and Pit-2, a second region (region B) required for both viral 
entry and binding was identified (Farrell et al., 2002). The A-MLV binding site 
in Pit-2 has been identified in the first extracellular domain of the protein by 
studying chimeric Pit-1/Pit-2 receptors in a infection and binding assay 
(Feldman et al., 2004). 
The same approach has been conducted for ASCT-2 protein, in which a 
sequence of 21 amino acids in the second extracellular loop plays a critical 
role in determining receptor function for RD114, BaEV, HERV-W and SRV 
(Marin et al., 2003a).  
Attempts to identify the binding site in the FeLV-C receptor could not use 
chimeric human/mouse FLVCR-1 proteins because the murine homologue 
overexpressed in murine cell line works as a receptor, although the mouse 
cells are not permissive to FeLV-C infection (Tailor et al., 2000). The isolation 
of FLVCR-2, a closely related protein (52% amino acid identity) which did not 
support FeLV-C infection, enabled the generation of specific mutants to study 58 
 
the binding site (Brown et al., 2006). A single mutation (N463E) in the sixth 
extracellular domain in FLVCR-2 rendered this protein functional as FeLV-C 
receptor. The opposite mutation or the substitution of the whole ECL6 in 
FLVR-1 does not abrogate the infectivity. This allowed the identification of 
another region critical for FeLV-C infection, ECL1. However, neither ECL1 
nor ECL6 were recognised as a FeLV-C binding site; their role could be 
influencing membrane topology with a mechanism similar to Pit-1 region A 
(Brown et al., 2006). 
Critical determinants in XPR-1 for supporting X-MLV and P-MLV infection 
were discovered using chimeric constructs between human XPR-1 and the 
non-functional hamster homologue protein (Van Hoeven and Miller, 2005). 
Two entry determinants are present on XPR-1. One is located in the 
predicted ECL4 and can be used by both X-MLV and P-MLV. The second 
determinant is present in the ECL3 and can be only utilised by X-MLV. The 
identification of two different sites in the same receptor explained the 
phenomenon of non-reciprocal interference patterns where the infection by 
one virus (X-MLV) blocks infection by a second virus (P-MLV), but the 
infection of the second virus only slightly inhibits infection by the first virus 
(Chesebro and Wehrly, 1985; Miller and Wolgamot, 1997).  
1.5.5  Receptor-mediated barriers to infection 
Functional receptors do not always meditate a successful infection. Chinese 
hamster ovary (CHO) cells are resistant to infection by GALV and A-MLV 
(Miller and Miller, 1992, 1993). Overexpression of Pit-1 and Pit-2 cDNA 
isolated from CHO cells conferred susceptibility to GALV and A-MLV 
infection to CHO cells, indicating that these cells code for a functional 
receptor (Tailor et al., 2000). Similarly, delivery of FeLVCR-1 cloned from 
Mus dunni tail fibroblast (MDTF) cells renders these, otherwise resistant, 
cells susceptible to FeLV-C infection (Tailor et al., 2000). The hypothesis 
proposed was that functional receptors were expressed on the surface of 
these cells at a sub-threshold level and could be additionally inhibited by 
some masking factors (Tailor et al., 2000). One of these additional 
mechanisms to reduce, or prevent, retroviral infection is the secretion of 59 
 
inhibitors in the media (Miller and Miller, 1992, 1993). Secreted endogenous 
retrovirus ENV have been identified as such an inhibitor (Ikeda et al., 1985; 
Jung et al., 2002; McDougall et al., 1994; Wu et al., 2005). Another important 
masking factor has been associated to the N-glycosylation of the receptors. 
Cells resistant to retroviral infection became permissive following treatment 
with tunicamycin, a drug which prevent N-glycosylation of proteins (Lavillette 
et al., 2002a; Marin et al., 2000; Yan et al., 2008). A possible explanation 
was that the masking of the receptor, due to the endogenous retrovirus Env 
products described above, was prevented by misfolding of the viral 
glycoproteins in the presence of tunicamycin (Lavillette et al., 2002). In fact, 
processing and folding of Env glycoproteins requires N-linked glycosylation 
(Li et al., 1997; Polonoff et al., 1982). Although this is plausible, it does not 
completely explain the departure from resistance through abrogation of N-
glycosylation. In the absence of tunicamycin, mutation of the N-glycosylation 
site in the non-functional receptors hamster ASCT-1 and hamster, rat or Mus 
dunni CAT-1 enables these proteins to support RD114 interference group 
viruses and E-MLV infection, respectively (Eiden et al., 1994; Kubo et al., 
2004; Marin et al., 2003a; Yoshii et al., 2008). The proposed mechanism of 
restriction was that a heavy glycosylation of the receptors close to the binding 
site would prevent the interaction with the virus (Eiden et al., 1994; Kubo et 
al., 2004). Treatment of cells with liposomes composed of phosphatidyl 
serine, a phospholipid component of the cell membrane, mimicked the 
tunicamycin effect without removing N-linked glycosylic chains (Coil and 
Miller, 2005). RD114 and MoMLV infect murine NIH3T3 and hamster CHO 
cells upon treatment with phosphatidyl serine, indicating that fully 
glycosylated receptors can still support virus entry (Coil and Miller, 2005).  
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1.6  Host restriction factors 
In the continuous fight between the host and retrovirus, eukaryotic cells have 
evolved several proteins (called restriction factors) that interfere with the life 
cycle of retroviruses. Contrastingly, viruses evolved to evade these 
mechanisms, either by mutating the targets of the restriction, or developing 
countermeasures that antagonise the host cell factors.  
Mammalian host factors are the best described. They inhibit different steps in 
retroviral replication [reviewed in (Wolf and Goff, 2008), and summarised in 
figure 1.5]. These molecules could be employed to generate safer animal 
donors for xenotransplantation. Indeed, human and porcine APOBEC3 
(section 1.6.3) have been described to be active against PERV, and the 
creation of APOBEC3-expressing transgenic pigs has been proposed to 
reduce the risk of PERV transmission (Dorrschuck et al., 2008; Jonsson et 
al., 2007). 
 
Figure 1.5 Summary of restriction factors acting in different steps of the retroviral life 
cycle. 
Retroviral life cycle is depicted in this model. The restriction factors described in the text 
are highlighted in red. A, APOBEC, which is incorporated in the virions in the producing 
cells, but acts at the reverse transcription stage after infection of a new target cells. 61 
 
1.6.1  Early post entry restriction factors: Fv1 and TRIM protein family 
A genetic locus, Fv1  (Friend virus susceptibility gene 1), in mice was 
identified as responsible for resistance to infection by murine leukaemia virus 
(Odaka and Matsukura, 1969; Pincus et al., 1971) and the corresponding 
gene was cloned (Best et al., 1996). Fv1 interacts with the incoming virus 
core (Bassin et al., 1978) and prevents the nuclear translocation of the 
preintegration complex (Jolicoeur and Baltimore, 1976). This interaction, and 
the consequent restriction, can be abrogated by saturation of the Fv1 protein 
with replication defective viruses (Bassin et al., 1978). The viral determinant 
of the interaction with Fv1 lies at amino acid 110 of the CA protein (Kozak 
and Chakraborti, 1996).  
An Fv1-like restriction factor, able to block infection by some strains of MLV 
and called Ref1 (restriction factor 1), was described in other mammalian 
cells, including human (Towers et al., 2000). Although Ref1 blocks virus 
replication before reverse transcription, a step earlier than Fv1, the viral 
determinant for susceptibility to this restriction is the same as Fv1, amino 
acid 110 in the CA protein, and the restriction was saturable in a similar 
manner to Fv1 (Besnier et al., 2003; Towers et al., 2002). A Ref1-like 
restriction phenotype was also described that acted against lentivirus 
infection, and was called Lv1 (Besnier et al., 2002; Cowan et al., 2002; 
Hofmann et al., 1999; Munk et al., 2002).  
Rhesus macaque cells are permissive to infection by SIV but not HIV-1. The 
gene responsible for this tropism, Trim5α, was identified by a rhesus 
macaque cDNA library screen (Stremlau et al., 2004). Later, it was shown 
that the Ref1 and Lv1 restriction activity was encompassed by the product of 
the Trim5α gene (Hatziioannou et al., 2004; Keckesova et al., 2004; Perron 
et al., 2004; Yap et al., 2004).  
The tripartite motif (TRIM) protein family contains members characterised by 
three domains [(Reddy et al., 1992) and reviewed in (Nisole et al., 2005)]. At 
the N-terminus of almost all TRIM proteins is the RING (really interesting new 
gene) module, a cystein-rich zinc finger binding domain, involved in protein-
protein interactions (Borden, 1998). Many RING domains have intrinsic 62 
 
ubiquitin E3 ligase activity (Freemont, 2000). The second domain is B-box, 
zinc finger motif. Some TRIM proteins have two B-boxes, B1 and B2. Other 
than facilitating homo-interactions of the coiled-coil region (Cao et al., 1997), 
their function is still unknown. The third region is a coiled-coil domain, which 
mediates the homo- or hetero-oligomerisation of the TRIM proteins 
(Reymond et al., 2001).  
TRIM5α is the largest isoform of TRIM5 proteins, and contains at the C-
terminus a B30.2 or SPRY domain; this module interacts with retrovirus CA 
protein and determines the virus specificity of TRIM5α (Nakayama et al., 
2005; Perez-Caballero et al., 2005; Sebastian and Luban, 2005; Stremlau et 
al., 2005; Yap et al., 2005). In New World Owl monkey TRIM5, the B30.2 
domain has been replaced by cyclophilin A (CypA), creating the fusion 
protein TRIMCyp (Sayah et al., 2004). CypA is a peptidyl prolyl isomerase 
and interacts specifically with HIV-1 CA protein (Luban et al., 1993). Owl 
monkey TrimCyp emerged by the retrotransposition of the CypA cDNA 
between TRIM5 exon 7 and 8 (Sayah et al., 2004). Interestingly, a second 
and independent appearance of TrimCyp, was found in Old World monkeys 
(Liao et al., 2007; Newman et al., 2008; Wilson et al., 2008). However, in Old 
World monkey TRIMCyp, the transposition of CypA took place downstream 
of TRIM5 exon 8, and the restriction phenotype is different. In fact, it is able 
to block HIV-2 and feline immunodeficiency virus infection, but not HIV-1 
(Wilson et al., 2008). 
The mechanism of restriction mediated by Fv1 and TRIM5α is not completely 
understood. For TRIM5α there are several hypotheses. One possibility is that 
the interaction between the restriction factor and the virus CA protein 
promotes its rapid, premature disassembly (Stremlau et al., 2006). This is, 
however, more an observation of effect than an assessment of mechanism. 
Ubiquitine E3 ligase activity of the RING domain produces polyubiquitination 
of TRIM5α and rapid turnover via the proteasome (Diaz-Griffero et al., 2006). 
It can be speculated that together with the proteasomal degradation of 
TRIM5α, the TRIM5α-CA complex will also be subjected to the turnover, 
causing block to the infection. However, drug-induced inhibition of 
proteasome does not rescue the infectivity (Anderson et al., 2006; Wu et al., 63 
 
2006). A proteasomal-independent mechanism of CA degradation has been 
also proposed (Chatterji et al., 2006). 
Some other members of the TRIM family also display antiviral activity.  
TRIM28 (also known as Kap-1 or Tif1-β) has been identified as a factor 
required for the primer binding site-mediated restriction of MLV in embryonic 
carcinoma (EC) and embryonic stem (ES) cells (Wolf and Goff, 2007). Upon 
infection of EC and ES cells by MLV, the virus can integrate in the genome, 
but no viral mRNA can be detected (Barklis et al., 1986; Teich et al., 1977). 
Following differentiation, EC cells become susceptible to a new infection, but 
the integrated virus cannot be reactivated (Niwa et al., 1983). This 
mechanism of retrovirus silencing involved two different steps: an initially cell 
type-specific restriction (Akgun et al., 1991; Flanagan et al., 1989; Tsukiyama 
et al., 1989), and a subsequent proviral DNA methylation (Niwa et al., 1983). 
The target for the cell-specific transcriptional silencing is contained within the 
18 nucleotides encoding the primer binding site complementary to the proline 
tRNA, ((PBS)
Pro) in the MLV genome (Barklis et al., 1986; Feuer et al., 1989; 
Loh et al., 1988). A single G to A point mutation, known as a B2 mutation, in 
the PBS, or the substitution with a sequence complementary to a different 
cellular tRNA, could relieve the repression (Barklis et al., 1986; Grez et al., 
1990; Petersen et al., 1991). TRIM28 has been described as a transcriptional 
co-repressor, acting in association with the Krϋppel associated box (KRAB)-
containing zinc finger DNA-binding proteins (Friedman et al., 1996; Le 
Douarin et al., 1996; Schultz et al., 2002; Schultz et al., 2001). Through an 
electrophoresis mobility shift assay, TRIM28 was identified as a component 
of the PBS-mediated restriction complex in EC and ES cells (Wolf and Goff, 
2007). However, although TRIM28 is necessary for the restriction, it is not 
sufficient. The zinc finger protein ZFP809, a member of the KRAB-containing 
zinc finger protein family, has been showed to be the EC and ES cell-specific 
factor which acts as a bridge between proviral DNA and TRIM28 (Wolf and 
Goff, 2009). 
One of the best characterised, but poorly understood, TRIM proteins is 
TRIM19 or PML (promyelocytic leukemia protein). It has been associated 64 
 
with many cellular functions: cell proliferation (Wang et al., 1998), 
senescence (Pearson et al., 2000), transcriptional and translational 
regulation (Kentsis et al., 2001), apoptosis (Hofmann and Will, 2003) and 
signal transduction (Lin et al., 2004). PML has been implicated, but without 
conclusive results, in the resistance to infection by human herpes simplex 
virus (Maul et al., 1993), vesicular stomatitis virus, influenza A virus (Chelbi-
Alix et al., 1998), HIV-1 (Turelli et al., 2001), human foamy viruses (Regad et 
al., 2001) and Lassa virus and lymphocytic choriomeningitis virus (Asper et 
al., 2004).  
TRIM22, or Staf-50, is able to downregulate HIV-1 long terminal repeat-
directed transcription (Tissot and Mechti, 1995). TRIM45 has an indirect 
negative effect on viral replication because it inhibits the activities of 
transcription factors AP-1 and Elk-1 (Wang et al., 2004).  
1.6.2 APOBEC  proteins 
Apolipoprotein B mRNA-editing catalytic (APOBEC) proteins constitute a 
family of polynucleotide cytidine deaminases which catalyse the deamination 
of a cytosine (C) into a uracyl (U). APOBEC1 was the first member of this 
family to be described. It causes the production of a truncated APOB protein 
by deamination of C6666 and sequential introduction of a stop codon in the 
APOB mRNA (Teng et al., 1993). 
The role of APOBEC proteins in the restriction of retroviral infection was 
disclosed through the study of the HIV-1 accessory protein, virion infectivity 
factor (Vif). HIV-1 deficient in Vif cannot replicate in primary human T cells 
and macrophages, as well as a limited number of cell lines (Fisher et al., 
1987; Gabuzda et al., 1992; Sakai et al., 1993). Using a complementary 
cDNA subtraction screening for transcripts specifically expressed in non-
permissive cell, a 1.5 kilobases gene, CEM15, was isolated. Its expression in 
permissive cells recreates the non-permissive phenotype for Vif-deficient 
HIV-1 (Sheehy et al., 2002). CEM15 was later identified as a member of the 
APOBEC family, APOBEC3G (A3G) (Jarmuz et al., 2002). In the absence of 
Vif, A3G is incorporated into the HIV-1 particles and, during reverse 65 
 
transcription of viral RNA, deaminates C residues to U residues in the first 
strand DNA filament (Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 
2003). In the plus strand sequence these modification will produce a guanine 
to adenine (G-to-A) transition which cause inactivation of the provirus as a 
result of multiple mutation events, known as hypermutation (Yu et al., 2004b). 
Infectivity can be reduced also in absence of DNA editing (Newman et al., 
2005). The mechanism is not completely understood, but it is associated with 
a reduction in reverse transcription (Holmes et al., 2007; Iwatani et al., 2007; 
Mbisa et al., 2007).  
APOBEC-mediated restriction appears to be involved in the inactivation of 
endogenous retrovirus in murine and mouse genomes (Esnault et al., 2005; 
Lee et al., 2008). Porcine endogenous retroviruses and simian foamy virus 
may also be inhibited by human A3G (Delebecque et al., 2006; Dorrschuck et 
al., 2008; Jonsson et al., 2007). Other members of the APOBEC3 family act 
as restriction factors. In particular, APOBEC3B and 3C have a potent antiviral 
activity against simian immunodeficiency virus, but not HIV-1 (Yu et al., 
2004a). APOBEC-induced mutations are not peculiar to retroviruses. 
Hypermutated genome of hepatitis B virus (HBV) has been reported in vivo 
and in cell lines (Noguchi et al., 2005). In vitro experiments showed that not 
only A3G can generate this mutation but also A3C, A3B and A3F (Suspene 
et al., 2005). Moreover, murine APOBEC3 encodes for Recovery from Friend 
Virus gene 3 (Rfv3) (Santiago et al., 2008). Rfv3 was identified as a gene 
responsible for recovery from Friend virus (FV) viremia and for the generation 
of FV-specific neutralizing antibody (Chesebro and Wehrly, 1979; Doig and 
Chesebro, 1979). 
HIV-1 and SIV evolved a protein, Vif, to counteract the action of APOBECs. 
HIV-1 Vif counteracts the action of APOBECs by inducing polyubiquitination 
and proteasomal-mediated degradation (Conticello et al., 2003; Marin et al., 
2003b; Mehle et al., 2004; Sheehy et al., 2003; Yu et al., 2003). The 
interaction between Vif and A3G is species-specific (Bogerd et al., 2004; 
Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004). Foamy 
viruses also produce a protein, Bet, which antagonises A3G. However, Bet, 66 
 
instead of inducing degradation of A3G, prevents its packaging in the 
nascent viral particles (Russell et al., 2005). Other viruses have produced 
different mechanisms to counteract APOBEC-mediated restriction. Human T 
cell leukaemia virus inhibits the incorporation of A3G in the virions through a 
peptide motif in the C-terminus of the nucleocapsid domain which prevents 
the binding of A3G (Derse et al., 2007). Avoiding the packaging into the 
virions is a mechanism of evasion from APOBEC restriction used also by the 
β-retrovirus Mason-Pfizer monkey virus and murine leukaemia viruses 
(Doehle et al., 2006; Doehle et al., 2005). In addition, MLV escapes 
restriction by an alternative mechanism involving MLV protease (Abudu et al., 
2006). 
1.6.3  ZAP, a zinc finger antiviral protein 
The zinc finger antiviral protein (ZAP) was isolated by screening a rat cDNA 
library for new restriction factors able to block retrovirus infection (Gao et al., 
2002). The step of the viral life cycle targeted by ZAP was the production of 
new viral RNA (Gao et al., 2002). ZAP binds directly to both the viral RNA 
through four CCCH-type zinc finger motifs (Guo et al., 2004) and to 
components of the exosome (Guo et al., 2007). Following these 
observations, the restriction mechanism proposed is that ZAP mediates 
interaction between exosome and the newly transcribed viral RNA, resulting 
in the degradation of the latter (Guo et al., 2007). Zap-mediated restriction 
was also shown for alphavirus (Bick et al., 2003) and filovirus (Muller et al., 
2007). The viral determinants for the interaction with ZAP have been mapped 
for MLV (in the 3’LTR) and for the alphavirus Sindbis virus (Guo et al., 2004). 
Interestingly, the two regions have no significant homology (Guo et al., 2004). 
In humans, in addition to the homologue to rat ZAP, namely ZAP(S), a longer 
isoform, ZAP(L) have been described. It has been showed that ZAP(L) was 
more effective than ZAP(S) as an antiviral against MLV and alphaviruses 
such as semiliki forest virus (Kerns et al., 2008). 
1.6.4 Tetherin   
HIV-1 viral protein U (Vpu) (Cohen et al., 1988; Strebel et al., 1988) 
enhances the production of virions from cells (Klimkait et al., 1990). Vpu is 67 
 
necessary for the release of HIV-1 in certain cell types (Geraghty et al., 1994; 
Sakai et al., 1993), and in interferon-α-treated cells (Neil et al., 2007). 
Moreover, expression of Vpu in retroviral packaging cell lines could 
significantly enhance viral particle production (Kobinger et al., 1997). The 
presence of a dominant acting human cell restriction factor, counteracted by 
HIV-1 Vpu, was proposed following heterokaryon fusion experiments 
(Varthakavi et al., 2003). In the absence of Vpu, HIV-1 mature virions, 
produced in some human cell lines such as HeLa, accumulate on the cell 
surface and can be released by protease treatment (Neil et al., 2006). A 
specific restriction factor was identified by comparative microarray analysis of 
cells which did or did not need Vpu in order to successfully produce viral 
particles, together with their response to interferon α treatment (Neil et al., 
2008). Among less than ten candidates, CD317, also known as BST2 or 
HM1.24 antigen (Goto et al., 1994), was chosen for its localisation at the cell 
membrane and differential expression level in various cell lines. Expression 
of CD317, renamed tetherin by Neil et al., 2008, specifically inhibited the 
release of single cycle, VSV-G pseudotyped HIV-1 particles in the absence of 
HIV-1 Vpu by retaining them on the surface of the cell (Neil et al., 2008; Van 
Damme et al., 2008). Moreover, tetherin co-localised with HIV-1 Gag in the 
cell surface and in the intracellular compartments. However, when Vpu was 
co-transfected, this interaction was disrupted and tetherin co-localised with 
Vpu instead (Neil et al 2008; Van Damme et al 2008). Tetherin is involved in 
the growth and development of B cells (Ishikawa et al., 1995) and interacts 
indirectly with the actin cytoskeleton, playing a critical role in its organisation 
in polarised epithelial cells (Rollason et al., 2009). However, its biochemical 
function is undetermined. Tetherin topology is considered unusual: an amino-
terminal cytosolic tail, a single transmembrane domain, an extracellular 
coiled-coil region and a predicted carboxyl-terminal glycosyl 
phosphatidylinositol (GPI) anchor (Kupzig et al., 2003), and it is expressed as 
a homodimer (Ohtomo et al., 1999). The encounter between HIV-1 and 
tetherin could potentially take place in the lipid rafts in the cell membrane. In 
fact, tetherin is associated with the cholesterol rich rafts (Kupzing et al., 
2003), which have been implicated in the budding of HIV-1 (Aloia et al., 1988; 68 
 
Brugger et al., 2006; Nguyen and Hildreth, 2000; Ono and Freed, 2001). A 
model of the proposed tetherin-mediated restriction is depicted in Figure 1.6. 
Tetherin will be discussed in more details in section 5.1. 
 
Figure 1.6 Model for tetherin-mediated retrovirus retention.  
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1.7 Aims 
In this thesis the receptors for PERV subgroup A have been characterised. 
The aim was to identify important regions in the receptor responsible for the 
virus infection. This could help the development of strategies to prevent 
PERV transmission to human cells.  
In addition, the new knowledge acquired about the PERV-A receptor was 
employed to evaluate non-human primates as animal models for the study of 
the risk of PERV infection in the context of xenotransplantation.  
As a second aim, a newly described restriction factor, tetherin, was evaluated 
as a potential molecule for use in the development of transgenic pigs with a 
reduced risk of PERV transmission, and therefore representing a safer 
animal donor. 
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Chapter 2 
2  Materials and Methods 
 
2.1 Materials 
All buffers and solutions made in house are listed with their formulae in Table 
2.1 (section 2.4). 
 
2.2  Molecular biology methods 
Plasmid and primer sequences are listed and described in Table 2.2 and 
Table 2.3, respectively (section 2.4). 
2.2.1  Preparation and transformation of chemically competent 
bacterial cells 
10 µL of Escherichia Coli DH5α bacteria (Invitrogen) were grown in 5 mL of 
LB overnight in a shaking incubator at 37°C. The day after, the suspension 
was diluted 1:100 in LB containing 15mM MgCl2 and incubated at 37°C 
shaking for 2-3 hours until OD600 reached 0.4-0.6. The bacteria were spun 
down for 15 minutes at 3,500 g in a refrigerated centrifuge (CR4 22, Jouan). 
The pellet was resuspended in 125 mL of ice-cold solution A (Table 2.1). 
After centrifugation for 15 minutes at 3500 g at 4°C, the bacteria were 
resuspended in 12.5 mL of solution A, supplemented with 15% (v/v) glycerol. 
They were aliquoted and stored at -80°C.  
50 µL of competent bacteria were incubated with 100-300 ng of plasmid DNA 
or with the whole ligation reaction on ice for 30 minutes. After a heat shock of 
45 seconds at 42°C, 200-500 µL of LB were added. The bacteria were grown 
for 1 hour at 37°C, shaking, and spread in a LB agar plate supplemented with 
the appropriate antibiotic (Table 2.2.2, note). 
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2.2.2  Plasmid DNA mini preparations 
A single bacterial colony was inoculated into 5 mL of LB broth containing the 
appropriate antibiotic at the concentration indicated (Table 2.2.2, note). The 
culture was grown overnight in a shaking incubator (200-250 rpm). Bacteria 
were pelleted, and plasmids extracted using the Qiaprep Spin miniprep kit 
(Qiagen) or PureLink quick miniprep kit (Invitrogen). Bacterial pellets were 
resuspended in 250 µL of resuspension buffer and cells were then lysed by 
incubation for 5 minutes at room temperature with 250 µL of lysis buffer. The 
mixture was neutralised by addition of 350 µL of neutralisation buffer, and the 
resulting precipitate was pelletted by centrifugation. The supernatant 
containing plasmid DNA was applied to an anion-exchange resin column 
provided with the kit. Purified plasmid DNA was eluted in EB buffer and the 
concentration determined by spectophotometric analysis using a Nanodrop 
ND-100 (Nanodrop Technologies). Plasmid DNA preparations were 
considered of good quality when the absorbance ratio at wavelength 260nm/ 
280nm was between 1.8 and 2. 
2.2.3 Enzymatic  reactions 
Restriction enzymes used were obtained from Promega. Reactions were 
performed according to the manufacturer’s instructions in a final volume of 20 
µL for single, or 50 µL for a double, enzymatic digestion, in the appropriate 
buffer, at the temperature required by the enzyme for 1.5-2 hours. 
DNA ends were ligated in a 10-20 μl reaction containing 1xT4 buffer, 50 ng of 
the backbone construct, a ratio of at least 1:3 backbone:insert, DNA and 1μl 
of T4 DNA ligase [3U/μL] (Promega). Samples incubated either 1 hour at 
room temperature or 16-24 hours at 4
oC.  
2.2.4  Agarose gel electrophoresis 
DNA samples were separated by agarose gel electrophoresis made by 
dissolving 1-3 g of agarose (Sigma) in 100 mL of TAE. 0.5 μg/mL ethidium 
bromide (Sigma) was added to visualize DNA on a UV transilluminator. DNA 
samples were mixed with 6x loading buffer. 500 ng of 100bp or 1Kb 72 
 
GeneRuler DNA ladder (Fermentas) were included on each gel to allow size 
determination of DNA fragments. 
2.2.5  DNA purification from agarose gel 
DNA bands of the expected size were cut from the agarose gels and purified 
using Qiaquick Gel Extraction kit (Qiagen) according to the manufacturer’s 
instructions.  
2.2.6 Genomic  DNA  extraction 
Cells were harvested and washed twice in PBS. Genomic DNA was 
extracted using the DNeasy Blood and Tissue kit (Qiagen) following the 
manufacturer’s instructions. DNA was eluted in 100 µL of AE buffer and the 
concentration determined by spectophotometric analysis using a Nanodrop 
ND-100. 
2.2.7 RNA  extraction 
2-10x10
6 cells were harvested, washed twice in PBS, and resuspended in 
600 µL of a denaturing guanidine-thiocyanate-containing buffer (buffer RTL) 
supplemented with 1% (v/v) of β-mercaptoethanol. Cells were vortexed for at 
least one minute and frozen at -80ºC. The lysate was thawed and 70% (v/v) 
ethanol was added. Total RNA was extracted using an RNeasy mini kit 
(Qiagen) following the manufacturer’s instructions, and eluted in 50 µL of 
RNase-free water. RNA concentration was determined by spectophotometric 
analysis using a Nanodrop ND-100. 
2.2.8  Polymerase chain reaction (PCR) 
PCR were performed using KOD High Fidelity DNA polymerase (Novagen) or 
HotStartTaq DNA polymerase (Qiagen) in a Peltier thermal cycler (Dyad) 
equipped with a heated lid following the recipes, and the amplification 
parameters, reported below. PCR were conducted in a final volume of 50 µL. 
  73 
 
 
*dNTPs deoxynucleotide triphosphates 
Amplification Parameters: 
KOD HiFi DNA Polymerase 
 
HotStartTaq DNA Polymerase 
 
Component  KOD polymerase [2.5 U/µL]
(µL) 
HotStartTaq [5 U/ µL] 
(µL) 
10x PCR buffer  5  5 
dNTPs 2mM (Novagen)*  5   
dNTPs 10mM (Qiagen)*    1 
Forward primer 10 µM  2  2.5 
Reverse primer 10 µM  2  2.5 
MgCl2 25 mM  2  (in the PCR buffer at final 
concentration of 1.5 mM) 
DNA polymerase  1  0.5 
Distilled water     
Step  Time (seconds)  Temperature (ºC) 
Initial denaturation  120  98 
Three step cycling 
Denaturation 15  98 
Primer annealing  2  As reported in Table 2.3 
Extension 20  72 
Number of cycles: 25 
Final extension  420  72 
Step Time    Temperature  (ºC) 
Activation   15 minutes  94 
Three step cycling 
Denaturation 30  seconds  94 
Primer annealing  30 seconds  As reported in Table 2.3 
Extension 0.5-2  minutes  72 
Number of cycles: 35-40 
Final extension  7 minutes  72 74 
 
2.2.9  Reverse transcriptase (RT) reaction 
5 µg of total RNA were treated with 2 U of DNase I (New England Biolabs) in 
a final volume of 50 µL for 30 minutes at 37ºC. 5mM of EDTA was added to 
protect the RNA from being degraded during the 10 minutes of enzyme 
inactivation at 75ºC. 20 µL of the reaction were incubated with 1 µg of 
random primers (Promega) for 5 minutes at 70ºC, and then put on ice. A 
mixture containing 200 U of Moloney MLV reverse transcriptase (Promega), 
1x MoMLV reaction buffer, 25 U of recombinant RNasin ribonuclease 
inhibitor (Promega), 0.5 mM dNTPs (Qiagen) was added to the RNA-primer 
mix and incubated for 1 hour at 37ºC. Reverse transcriptase was inactivated 
by 10 minutes incubation at 65ºC. 
For quantitative RT-PCR, cDNA was generated from 1 µg of total RNA using 
the QuantiTect Reverse Transcription kit (Qiagen) in a final volume of 20 µL. 
A genomic ‘DNA wipe-out’ step is included in the kit, and a mixture of random 
primers and oligo d(T) were used to prime the RT reaction.  
2.2.10 Quantitative PCR 
Probe-based quantitative PCR was performed using the QuantiTect probe 
PCR kit (Qiagen) while SYBR Green-based quantitative PCR was conducted 
using the Quantitect SYBR Green PCR kit (Qiagen). One eighth of the RT 
reaction or 200 ng of genomic DNA were used per reaction. Each reaction 
was performed in a final volume of 25 µL in a 96-well plate using the ABI 
PRISM 7000 or Eppendorf RealPlex 4 real time thermal cycler. Quantitative 
PCR mix recipes and cycling conditions are reported below. Absolute 
quantification of gene copies were calculated using plasmids DNA standards 
as indicated in Table 2.2.1*. Plasmid used to generate standards for 18S 
rRNA (pCRBluntIITOPO-18S rRNA) was obtained by RT-PCR of RNA from 
293T cells using primers CF3;CR3 (Table 2.3.2). The PCR product was 
cloned into pCR BluntII-TOPO (invitrogen) following the manufacturer’s 
instructions. A 10-fold dilution series of plasmid DNA, range between 10
1 and 
10
5 copies, were used to generate the standard curves. For the 18S rRNA 
gene in the quantitative RT-PCR, the standard curve range was between 10
6 
and 10
10 copies. For SYBR Green-based quantitative PCR, a melting curve 75 
 
was run at the end of the reaction to confirm the absence of contamination, 
mispriming or primer-dimer artifacts. 
 
Probe-based quantitative PCR conditions 
SYBR Green quantitative conditions 
 
Component  Probe (µL)  SYBR Green (µL) 
2x PCR mastermix  12.5  12.5 
Forward primer 10 µM  1  0.75 
Reverse primer 10 µM  1  0.75 
Probe 5 µM  1   
Distilled water     
Step Time    Temperature  (ºC) 
Activation 10  minutes  95 
Two step cycling 
Denaturation 15  seconds  94 
Primer annealing, extension 
and fluorescence acquisition 
60 seconds  60 
Number of cycles: 40 
Step Time    Temperature  (ºC) 
Activation 10  minutes  95 
Three step cycling 
Denaturation 15  seconds  94 
Primer annealing  30 seconds  55 
Extension and 
fluorescence acquisition 
30 seconds  72 
Number of cycles: 40 
Melting curve 76 
 
2.2.11 PCR-based mutagenesis 
Plasmid mutagenesis was performed by designing two complementary 
primers containing the mutations of interest. PCR was performed using KOD 
HiFi DNA Polymerase (Novagen) on 100 ng of plasmid DNA. 
2.2.12  Construction of HA-tagged chimeric receptors  
HuPAR-2 was tagged at the N-terminus with an influenza virus HA-tag by 
PCR of the construct pcDNAhuPAR-2 (Ericsson et al., 2003) using KOD HiFi 
polymerase and the primers GF1 and GR1. GF1 primer introduced the Kozak 
sequence at the ATG of the receptor downstream of the EcoRI restriction site 
and the HA-tag in the N-terminus downstream of the ATG start codon. C-
terminal HA-tagged huPAR-2 was obtained by PCR using the primers GF2 
and GR2. Primer GR2 contained an HA-tag downstream of a HindIII 
restriction site. Using EcoRI and NotI restriction sites, the HA-tagged 
receptors were introduced again into pcDNA3. The C-terminal HA-tagged 
plasmid, pcDNA3/huPAR-2HA, contains two HindIII restriction sites, one in 
pcDNA3 and the other introduced, in frame, upstream of the HA-tag by the 
reverse primer. HA-tagged huPAR-1 and muPAR genes were obtained by 
PCR of constructs pcDNA3/huPAR-1 and pcDNA3/muPAR (Ericsson et al., 
2003) with the primer pairs GF2;GR3 (huPAR-1), and GF4;GR4 (muPAR). 
Using the HindIII restriction site present in the reverse primers, huPAR-1 and 
muPAR were cloned into pcDNA3/huPAR-2HA upstream of the HA-tag.  
An NheI restriction site was introduced into huPAR-2 at the site 
corresponding to that in muPAR [Genbank: AK008081, nucleotide 805] by 
PCR-based muatgenesis using primer pairs GF2;MR1 and MF1;GR5, then 
GF2;GR5, where primers MF1 and MR1 contain the nucleotide change. 
Primer GR5 includes a HindIII restriction site which allows the cloning of the 
mutant receptor into pcDNA3/huPAR-2HA. Chimeric receptors H2M a and f 
were obtained by mix-and-match cloning between huPAR-2 and muPAR 
using the restriction sites EcoRI and NheI. The other huPAR-2-derived 
chimeric receptors were produced in a similar way using mutagenesis 
primers MF2;MR2 (H2M e) and MF3;MR3 (H2M d) in association with the 
primers GF2;GR5. Similarly, muPAR-derived chimeric receptors were 77 
 
produced using primers MF4;MR4 (H2M b) and MF5;MR5 (H2M c) in 
combination with primers GF4;GR4. The mutant huPAR-1 carrying a proline 
or a serine at position 109 (H1M g or huPAR-1S109) was generated by PCR-
mutagenesis using the primers MF3;MR3 or MF9;MR9 in combination with 
the primers GF2;GR3.  
All the HA-tagged receptors were subcloned into the retroviral vector pCFCR 
(Table 2.2.2) using EcoRI and NotI restriction sites. 
The N178A mutation in huPAR-2 was introduced by PCR-mutagenesis using 
the primers MF6;MR6 in association with the primers GF2;GR5 and the 
mutant huPAR-2 was cloned into a partially digested pcDNA3/huPAR2HA 
using EcoRI and HindIII restriction sites. 
All the PCRs described above were performed using KOD HiFi polymerase in 
accordance with manufacturer’s instructions. Chimeric receptors were 
verified by sequencing based on a modification of the Sanger method and 
analysed using the CEQ 8000 DNA Sequencer (Beckman Coulter). 
2.2.13 Generation of soluble myc-tagged PERV-A14/220 SU Env 
The soluble surface unit of PERV-A 14/220 Envelope (PERV Env) was 
cloned into pCAGGS (Niwa et al., 1991) using the restriction sites BglII and 
NheI and a c-myc tag was introduced at the N-terminus of PERV Env using 
primers EF1 and ER1 (mycPERV Env). The sequence of human tissue 
plasminogen activator leader has been introduced in frame upstream to the 
c-myc tag by PCR of the construct PEE14 (Jeffs et al., 1996) using primers 
EF2 and ER2, bearing the enzymatic restriction sites KpnI and BglII, 
respectively. 
2.2.14 Receptors cloning 
Total RNA extracted from rat or NHP cells was reverse transcribed using 
Promega MoMLV RT (section 2.2.9). 5 µl of the reaction was used in an RT-
PCR using HotStartTaq polymerase and primers as indicated (Table 2.3.2). 
The PCR product was cloned into pcDNA3 using EcoRI and NotI restriction 
sites present in the forward and reverse primers, respectively. HA-tagged C-78 
 
terminal RatPAR was obtained by PCR using KOD HiFi polymerase and the 
primers CF1;CR2 which contain the HindIII restriction site, and introduced 
into partially digested pcDNA/HuPAR-2HA. This product was then subcloned 
into pCFCR. 
A ClaI restriction site was introduced into pcDNA3/huPAR-2HA upstream, in 
frame, with the HA-tag by PCR-mutagenesis using primers MF7;MR7 in 
association with primers GF2;MR8 (pcDNA3/huPAR-2ClaIHA). NHP PERV-A 
receptors were cloned by RT-PCR of total RNA extracted from NHP cells. 
PCR products were introduced into pcDNA3/huPAR-2ClaIHA using 
restriction sites EcoRI and ClaI present in the primer sequences. The mutant 
rhesus macaque PAR-1 containing a leucine at position 109 (rhPAR-1L109) 
was created by PCR-mutagenesis using the primers MF10;MR10 in 
combination with the primers CF5;CR5. 
All the HA-tagged receptors were also subcloned into the retroviral vector 
pCFCR using EcoRI and NotI restriction sites 
2.2.15 Cloning of porcine tetherin 
Total RNA was extracted from pig cells, and cDNA was produced using the 
QuantiTect Reverse transcription kit (section 2.2.9). 5 µL of the reaction were 
employed in a RT-PCR using HotStartTaq polymerase and primers 
CF7;CR7. The PCR product was cloned into a pGEM-Teasy vector in 
accordance with the manufacturer’s instruction. Porcine tetherin was 
subcloned into pcDNA3 by enzymatic restriction using EcoRI site. Lentiviral 
vectors carrying tetherin genes were produced by subcloning them from 
pCR-huTHN (Neil et al., 2008), pcDNA-PK15THN and pcDNA-IOWATHN 
into an HIV-based vector pSIN-Dual (Escors et al., 2008), downstream of the 
SFFV promoter via BamHI and NotI restriction sites. 79 
 
2.3  Cell culture methods 
Cell lines used and growth conditions are listed in Table 2.4 (section 2.4). 
2.3.1 Cell  transfection 
The day prior to transfection, cells were seeded in a 10 cm dish (d10) or a 6-
well plate (p6). The number of cells plated varied for each cell line to achieve 
a density of 80-90% of confluence. 18 µL (d10) or 6 µL (p6) of Fugene-6 
transfection reagent (Roche) was diluted in 200 µL (d10) or 100 µL (p6) of 
Optimem serum-free medium (Gibco). 3 µg (d10) or 1 µg (p6) of plasmid was 
added to the Fugene-Optimem mixture, incubated at room temperature for 15 
minutes and then added to the cells.  
2.3.2  Pseudotyped virus production 
Pseudotyped viruses were produced by transient three-plasmid transfection 
(Besnier et al., 2002; Soneoka et al., 1995). A mix containing the following 
quantities of plasmids was prepared in a total volume of 15 µL of TE buffer: 
1.5 µg of retroviral vector, 1 µg of packaging vector plasmid and 1 µg of 
envelope expression plasmid (Table 2.2.2). 18 µL of Fugene-6 was diluted in 
200 µL of Optimem and the plasmid mix added. After an incubation of 15 
minutes at room temperature, the mixture was added to 80% confluent 293T 
cells, seeded in a 10 cm dish the day before. The following day the medium 
of transfected cells was replaced with 8 mL of fresh DMEM supplemented 
with 10% (v/v) FBS. Virus-containing supernatant were harvested at 48 and 
72 hours post-transfection, filtered through 0.45 µm filters and either used to 
infect target cells or stored at -80
oC. 
Pseudotyped viruses described in chapter five were produced from 1x10
6 
293T cells seeded in a 6-well plate, using 6 µL of Fugene-6 diluted in 100 µL 
of Optimem. Plasmid mix was composed of 600 ng of retroviral vector, 400 
ng of packaging vector plasmid, 400 ng of envelope-expressing plasmid and 
200 ng of plasmid encoding the tetherin gene, with or without HIV-1 vpu 
gene. 
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2.3.3 EGFP(PERV)  production 
293T cells were seeded in a 10cm dish and, the day after, transfected with 3 
µg of pCRPERV-A14/220 encoding full length replication-competent PERV-
A14/220. 48 hours later, 1x10
5 cells were seeded in a 6-well plate and, the 
day after infected with a VSV-G-pseudotyped MLV vector carrying the EGFP 
gene, prepared as described (section 2.3.2). Cells were kept in culture. In the 
supernatant, a mixed population of viruses was expected: PERV-A14/220 
wild type and PERV-A14/220 particles carrying the MLV-based retroviral 
vector encoding the EGFP gene, EGFP(PERV). After two months in culture, 
titre of EGFP(PERV) (section 2.3.4) was stabilised at 2±0.8x10
5 EGFP 
transducing units per mL, titered on 293T cells. The PERV-A14/220 [wild 
type and EGFP(PERV)] titre detected using an anti-PERV CA antibody and 
colony counting (section 2.3.5) was 3±0.1x10
6 293T cells infectious unit per 
mL. The multiplicity of infection (MOI) was calculated as: 
 
2.3.4  EGFP-pseudotyped virus titration 
5x10
4 cells were plated in a 12-well plate one day prior to transduction. Serial 
dilutions of virus-containing supernatant were prepared in DMEM 
supplemented with 8 µg/mL polybrene (hexadimethrine bromide, Sigma). 500 
µL of each dilution was added to the target cells. After 48 hours, cells were 
trypsinised, fixed in 500 µL of 1% (w/v) paraformaldheyde in PBS and 
assessed for EGFP expression by flow cytometry. The titre in EGFP 
transducing unit per mL (Etu/mL) was calculated as average of the data 
points where less than 30% of the cells were EGFP positive, according to the 
following formula:  
 
  
    Titre  x  Volume  of  infection  (ml) 
   M O I =  
     N u m b e r   o f   c e l l s  
      EGFP-positive cells x number of seeded cells x dilution factor 
         Titre (Etu/mL)= 
      V o l u m e   o f   i n f e c t i o n  
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2.3.5 PERV  titration 
Titration of PERV infectious particles in the supernatant of producing cells 
was performed using a colony formation assay (Bartosch et al., 2002). 3x10
4 
293T cells were seeded in a 48-well plate the day prior to infection. Serial 
dilutions of the virus-containing supernatant were prepared in DMEM 
supplemented with 4 µg/mL polybrene. 200 µL of each dilution was added to 
the cells. After 72 hours, cells were fixed with an ice-cold 1:1 mixture of 
methanol and acetone. Cells were washed twice in PBS and blocked for 10 
minutes at room temperature with 10% (v/v) FBS in PBS, followed by a hour 
incubation with anti-PERV capsid antibody (Table 2.5) diluted in washing 
buffer (2% (v/v) FBS in PBS). Following two washes, a hour incubation with 
secondary goat anti-rabbit IgG conjugated to alkaline phosphatase (AP) 
(Jackson Immunoresearch) diluted 1:250 in washing buffer was performed. 
After two washes in washing buffer, and two more in PBS, AP was detected 
using NBT/BCIP (Nitro blue tetrazolium chloride/ toluidine salt of 5-Bromo-4-
chloro-3-indolyl phosphate) ready-to-use tablets (Roche) according to the 
manufacturer’s instructions. AP-positive colonies were counted using the 
visible light microscope, and the titre determined as infectious units per mL 
(i.u./mL): 
 
 
2.3.6 Cell  transduction 
Retroviral and lentiviral vectors, prepared as described in section 2.3.2, were 
used to deliver PERV-A receptors and tetherin genes. Target cells were 
seeded the day prior to transduction in a 12-well plate (p12) or a 6-well plate 
(p6) at the density of 5x10
4 (p12) or 1x10
5 (p6) cells per well. 0.5 mL (p12) or 
1 mL (p6) of the 0.45 µm-filtered pseudotyped virus containing supernatant 
was added to the cells in the presence of 8 µg/mL polybrene. After 48 to 72 
hours, cells were employed in the different assays. 
 
   Number  of  AP-positive  colonies  x  dilution  factor 
Titre (i.u./mL) =  
     Volume  of  infection 82 
 
2.3.7  Flow cytometry staining 
Cells were harvested using 5mM EDTA in PBS, and washed twice in PBS. 
5x10
5 cells per stain were blocked for a hour on ice with 10% (v/v) FBS in 
PBS. Cells were incubated with primary antibody diluted in washing buffer 
(2% (v/v) FBS in PBS) for an hour on ice. After two washes, cells were 
incubated with 1:100 dilution of phycoerythrin (PE)-conjugated secondary 
anti-mouse IgG antibody (Jackson Immunoresearch) in washing buffer for 45 
minutes on ice. The samples were washed twice in washing buffer, 
resuspended in 500 µL of 1% (w/v) paraformaldehyde in PBS and analysed 
by flow cytometry using the Becton Dickinson FACSCalibur and Cell Quest 
software. 
When staining both intracellular and extracellular proteins, cells were fixed 
prior to the immunostaining with 4% (w/v) paraformaldehyde in PBS for 20 
minutes at room temperature, and permeabilised with 0.2% (w/v) saponin 
(Fluka) in PBS for 10 minutes at room temperature. Saponin, at the 
concentration of 0.2% (w/v), was added to all the buffers during the 
immunostaining. 
2.3.8  PERV envelope binding assay 
Cells were detached using 5mM EDTA in PBS, washed twice, and 5x10
5 
cells for each sample were resuspended in 0.5 mL of soluble PERV Env-
containing supernatant. Two different soluble PERV Env proteins were used.  
In chapter three, c-myc tagged PERV-A14/220 SU Env was produced by 
transfection of 293T cells with mycPERV Env plasmid (2.2.13) as described 
(2.3.1). Cells were incubated with soluble mycPERV Env for an hour at 37
oC, 
and washed twice in washing buffer (2% (v/v) FBS in PBS). Samples were 
incubated with anti-human myc antibody diluted in washing buffer for an hour 
on ice. Following two washes, cells were resuspended in washing buffer 
containing 1:200 dilution of PE-conjugated secondary anti-mouse IgG 
antibody. After 45 minutes incubation on ice, cells were washed, fixed in 1% 
(w/v) paraformaldehyde in PBS, and analysed by flow cytometry. 
In chapter four, soluble PERV-A360 and PERV-C360 Env were used. The 
first N-terminal 360 amino acids of PERV-A NIH and PERV-C were 83 
 
introduced, in frame, upstream of amino acids 96-323 of the rabbit 
immunoglobulin  γ-heavy chain gene (rIgG) in the plasmid pSK100 
(Gemeniano et al., 2006). Soluble proteins were produced by transfection of 
293T cells. One day post-transfection the medium was replaced with 8 mL of 
DMEM supplemented with 10% (v/v) FBS and 1x proteinase inhibitor 
cocktail, Complete mini (Roche). The concentration of PERV Env-rIgG fusion 
proteins was determined by an enzyme-linked immunosorbent assay (ELISA) 
(section 2.3.9). 5x10
5 cells were incubated for a hour on ice with 0.5 mL of 
transfected 293T cell supernatant containing 200 ng/mL of PERV-A360 or 
PERV-C360 Env proteins. Cells were washed twice and incubated for 45 
minutes on ice in washing buffer containing a 1:50 dilution of fluorescein 
isothiocyanate (FITC)-conjugated anti-rabbit IgG (Jackson Immunoresearch). 
Following two washes, cells were fixed in 1% (w/v) paraformaldehyde in PBS 
and analysed by flow cytometry. 
2.3.9 Enzyme-linked  immunosorbent assay (ELISA) 
Maxisorp 96-well plate (Nunclon) was coated overnight at 4
oC with 500 ng of 
monoclonal anti-rabbit IgG (γ-chain specific) clone RG-96 (Sigma) per well 
diluted in 100 µL of coating buffer (pH 9.6). One day later, wells were washed 
three times with PBS and blocked with 4% (w/v) bovine serum albumin (BSA) 
in PBS for 30 minutes at room temperature. Two-fold serial dilutions of the 
PERV Env containing supernatant were added to each well and incubated for 
an hour at room temperature. Wells were washed three times with 0.1% (v/v) 
Tween-20 in PBS before adding horseradish peroxidase (HRP)-conjugated 
polyclonal anti-rabbit IgG (Dako) diluted 1:1000 in 2% (w/v) BSA in PBS. 
After a hour incubation at room temperature wells were washed 3 times with 
0.1% (v/v) Tween-20 in PBS and once in PBS before adding 100 µL of 
SureBlue TMB (tetramethylbenzidine) substrate (Kirkegaard & Perry 
Laboratories) per well. The reaction was allowed to proceed for 15 minutes 
and then stopped with 100 µL of 1M HCl. The optical density of each well 
was read at wavelength 450nm. The amount of IgG was calculated from a 
standard curve obtained by two fold serial dilution of rabbit IgG (Dako), range 
250-7.8 ng/mL. Samples were run in duplicate. 84 
 
 
2.3.10  Immunofluorescence microscopy 
The day post transfection (section 2.3.1), 293T cells expressing HA-tagged 
huPAR-2 were split in three and plated on cover slides and incubated for 
further a 48 hours. Cells were fixed by incubation with 4% (w/v) 
paraformaldehyde in PBS for 20 minutes at room temperature. The 
permeabilised samples were obtained by incubation with 0.1% (w/v) saponin 
in PBS for 10 minutes at room temperature. For the permeabilized samples, 
0.1% (w/v) saponin was added to all the buffers. Slides were washed in PBS 
and placed on a 30 µL drop of washing buffer (2% (w/v) BSA in PBS) 
containing a dilution of the primary antibody (Table 2.5) and incubated for a 
hour at 37
oC in a humidified chamber. Cells were then washed three times 
and placed on a 30 µL drop of washing buffer containing the secondary 
antibody FITC-conjugated anti-mouse IgG (diluted 1:100) for 45 minutes at 
37
oC in a humidified chamber. After three washes, the cover slides were 
mounted in Vecta Shield mounting medium containing propidium iodide 
(Vector Laboratories). Images were acquired using DM IRE2 confocal 
microscope (Leica).  
Immunostaining of PERV particles attached on the cell surface (section 
4.2.9) was performed as described above. However, permeabilisation was 
conducted by incubating the cells with 0.2% (v/v) Triton X-100 (Sigma) in 
PBS for 10 minutes at room temperature. The secondary antibody used was 
FITC-conjugated anti-rabbit IgG, diluted 1:100 in washing buffer. 
2.3.11  Western blotting 
Cells from a confluent well of a 6-well plate were lysed in 100 µL of radio 
immunoprecipitation assay (RIPA) buffer supplemented with 1x proteinase 
inhibitor cocktail, Complete mini, for 30 minutes on ice. Cell debris were 
removed by centrifugation at 12000g at 4ºC for 8 minutes. 1 mL of the viral 
particles, containing supernatant of virus-producing cells seeded in the 6-well 
plate was pelleted by centrifugation for 4 hours at 16000g at 4ºC, and 
resuspended in 50 µL of 2x Laemmli buffer. After the addition of Laemmli 85 
 
buffer to 24 µL of the cell lysate, these samples and 24 µL of the 
concentrated viral particles were boiled for 5 minutes and separated by 10% 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Table 2.1). For the glycosylation study (section 3.2.3), 24 µL of cell lysate 
was incubated with 3 µL of G7 buffer and 3 µL of PNGase F [500U/µL] (New 
England Biolabs) for 2 hours at 37
oC. 10 µL of 4x Laemmli buffer was added 
and the samples boiled for 5 minutes. 
Proteins were transferred onto a methanol-activated polyvinylidene fluoride 
(PVDF) membrane (Amersham Biosciences) using a semidry blotting system 
(Amersham Biosciences). The membrane was blocked in 5% (w/v) non-fat 
dried milk (Oxoid) in PBS and then probed for an hour at room temperature 
with a primary antibody diluted in 2% (w/v) milk in PBS (Table 2.5), followed 
by three washes with 0.1% (v/v) Tween-20 in PBS. The membrane was then 
incubated with an HRP-conjugated secondary antibody diluted in 2% (w/v) 
milk/PBS (1:3000 for anti-rabbit IgG or 1:10000 for anti-mouse IgG) for 1hr at 
room temperature. Following three washes with 0.1% (v/v) Tween-20 in PBS, 
and one in PBS alone, signals were detected by incubation with ECL 
chemiluminescence reagent (Amersham Biosciences) and exposure to X-ray 
film (Hyperfilm, Amersham Biosciences). 
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2.4 Appendix 
 
Table 2.1 Buffers and solutions 
 
1X PBS (phosphate-buffered saline)  1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 
154 mM NaCl, pH 7.4 
1x TAE (tris-acetate-EDTA)  40 mM Tris (pH 7.8), 20 mM sodium 
acetate, 1 mM EDTA 
TE (tris-EDTA)  10 mM Tris-Cl, 1mM EDTA, pH 8.0 
EB (Qiagen)  10 mM Tris-Cl, pH 8.5 
AE (Qiagen)  10 mM Tris-Cl, 0.5mM EDTA, pH 9.0 
6x loading buffer  30% (v/v) glycerol, 0.25%;(w/v) 
bromophenol blue, 0.25% (w/v) 
xylene cyanol FF 
Solution A   10 mM MnCl2, 50 mM CaCl2, 10 mM 
2-(N-morpholino)ethanesulfonic acid 
(MES) pH6.3 
ELISA coating buffer  0.16% (w/v) Na2CO3, 0.29% (w/v) 
NaHCO3, 0.02% (w/v) NaN3, pH 9.6 
Luria-Bertani (LB) broth  1% (w/v) bacto-tryptone (BD), 0.5% 
Bacto yeast extract (BD), 1% NaCl 
(Sigma), pH 7.0 
LB agar  1% (w/v) bacto-tryptone, 0.5% Bacto 
yeast extract, 1% NaCl, 1.5% (w/v) 
bacto-agar (BD), pH 7.0 
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Western blotting solutions 
RIPA buffer  50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1% (v/v) Igepal ca-630, 0.5% 
(w/v) sodium deoxycholic acid, 10% 
(w/v) SDS, 1% (v/v) Triton X-100 
4x Laemmli buffer  200 mM Tris-HCl (pH 6.8), 40% (v/v) 
glycerol, 8% (w/v) SDS, 0.2% (w/v) 
bromophenol blue, 10% (v/v) β-
mercaptoethanol 
1x running buffer  0.3% (w/v) Trizma (Sigma), 1.9% 
(w/v) glycine (Sigma), 0.1% (w/v) 
SDS 
1x semi-dry transfer buffer  0.3% (w/v) Trizma, 1.4% (w/v) 
glycine, 0.1% (w/v) SDS, 20% (v/v) 
methanol 
 
10% SDS-polyacrylamide gel recipe 
components  Resolving (mL)  Stacking (mL) 
40% acrylamide mix (Bio-Rad)  12.5  1.25 
1.5 M Tris (pH 8.8)  12.5   
1 M Tris (pH 6.8)    1.25 
10% SDS  0.5  0.1 
10% ammonium persulfate  0.5  0.1 
TEMED (tetramethylethylenediamine)  0.02  0.01 
Distilled water  24  7.25 
Final volume  50  10 
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Table 2.2 List of the plasmids 
Table 2.2.1 Transfection plasmids 
Name Gene  Reference 
*pcDNAhuPAR-1  huPAR-1  Ericsson et al., 2003 
*pcDNAhuPAR-2  huPAR-2  Ericsson et al., 2003 
pcDNAmuPAR  muPAR  Ericsson et al., 2003 
N-HA pcDNAhuPAR-2   N-terminal HA tagged 
huPAR-2 
Mattiuzzo et al., 2007; 
section 2.2.12 
C-HA pcDNAhuPAR-2  C-terminal HA tagged 
huPAR-2 
Mattiuzzo et al., 2007; 
section 2.2.12 
pcDNAhuPAR2N178A  C-terminal HA tagged 
huPAR-2 carrying mutation 
N178A 
Mattiuzzo et al., 2007; 
section 2.2.12 
*pcDNAratPAR  ratPAR  Mattiuzzo et al., 2007 
*pCRIIBlunt18S rRNA  nt 101-1932 human rRNA 
NCBI acc no. M10098.1 
Mattiuzzo et al., 2007; 
section 2.2.10 
pCAGGSmycPERV 
Env 
N-terminal myc-tagged 
PERV-A14/220 SU Env 
Mattiuzzo et al., 2007; 
section 2.2.13 
pSKPERV-A360Env   a.a. 1-360 PERV-A NIH Env  Gemeniano et al., 
2006 
pSKPERV-C360 Env  a.a. 1-360 PERV-C Env  Gemeniano et al., 
2006 
pCR-huTHN Human  tetherin  Neil et al., 2008 
pcDNAPK15THN  Pig tetherin from PK15 cells  Section 2.2.15 
*pcDNAIOWATHN  Pig tetherin from ST-IOWA 
cells 
Section 2.2.15 
pcDNAVpu  HIV-1 NL4.3 Vpu  Neil et al., 2006 
All plasmids carried an ampicillin-resistance gene with the exception of 
pCRIIBlunt18S rRNA, which encodes kanamycin resistance gene (Table 2.2.2) 
*These plasmids were used as quantitative PCR standards 89 
 
Table 2.2.2 Pseudotyped virus production 
Name drug 
resistance 
Gene Reference 
pCNCG Ampicillin  Neo
R ;EGFP  (Soneoka et al., 1995) 
pCNCR Ampicillin  Neo
R;RFP  A kind gift from Prof. 
Greg Towers 
pCFCR∆EcoRI  Ampicillin  Fv1;RFP  (Ylinen et al., 2005) 
pSIN-DUAL Ampicillin  Hygro
R;  (Escors et al., 2008) 
pHRSIN-CSGW Ampicillin EGFP  (Demaison et al., 2002) 
pCMV intron  Ampicillin  MoMLV GagPol  (Collins et al., 1995) 
phCMV-PERV-
A14/220  
Ampicillin PERV-A14/220 
GagPol 
(Wood et al., 2009) 
pCMV8.91 Ampicillin  HIV-1  GagPol  (Zufferey et al., 1997) 
pMDG  Ampicillin  VSV-G  (Naldini et al., 1996) 
FBPERV14/220 
SALF 
Ampicillin PERV-A14/220 
Env 
A kind gift from Dr. 
Birke Bartosch 
phCMV-MLVA  Ampicillin  MLV-A Env  (Sandrin et al., 2002) 
pCRPERV14/220   Kanamicin PERV-A14/220 
genome 
(Bartosch et al., 2004) 
Neo
R geneticin ( G-418 sulphate) resistance; Hygro
R Hygromycin B 
resistance 
Antibiotic concentration in LB broth and agar plate was ampicillin 100 µg/mL; 
kanamycin 50 µg/mL. 
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Table 2.2.3 pCFCR∆EcoRI-derived constructs 
Name Gene 
pCFCR-huPAR2 C-terminal  HA-tagged  huPAR-2 
pCFCR-huPAR1 C-terminal  HA-tagged  huPAR-2 
pCFCR-muPAR C-terminal  HA-tagged  muPAR 
pCFCR-ratPAR C-terminal  HA-tagged  ratPAR 
pCFCR-rhPAR-1 C-terminal  HA-tagged  rhPAR-1 
pCFCR-rhPAR-2 C-terminal  HA-tagged  rhPAR-2 
pCFCR-AGMPAR-1 C-terminal HA-tagged AGMPAR-1 
pCFCR-AGMPAR-2 C-terminal HA-tagged AGMPAR-2 
pCFCR-cynPAR-1 C-terminal  HA-tagged  cynPAR-1 
pCFCR-cynPAR-2 C-terminal  HA-tagged  cynPAR-2 
pCFCR-baPAR-1 C-terminal  HA-tagged  baPAR-1 
pCFCR-baPAR-2 C-terminal  HA-tagged  baPAR-2 
H2M a  huPAR-2 with a.a. 1-161 from muPAR 
H2M b  huPAR-2 with a.a.108-110 from muPAR 
H2Mc   huPAR-2 with a.a 109 from muPAR 
H2M d  muPAR with a.a. 109 from huPAR-2 
H2M e  muPAR with a.a. 108-110 from huPAR-2 
H2M f  muPAR with a.a. 1-161 from huPAR-2 
H1M g  huPAR-1 with a.a. 109 from muPAR 
huPAR-1S109 huPAR-1  with  a.a.109 from rhPAR-1 
rhPAR-1L109  rhPAR-1 with a.a.109 from huPAR-1 
Genes are cloned between EcoRI and NotI restriction sites 
  91 
 
Table 2.2.4 pSIN-DUAL-derived constructs 
Name gene 
pDUAL-huTHN Human  tetherin 
pDUAL-PK15THN PK15  cells-derived tetherin 
pDUAL-IOWATHN  ST-IOWA cell-derived tetherin 
Genes are cloned between BamHI and NotI restriction sites 92 
 
Table 2.3 List of the primers 
 
 
 Table 2.3.1 Construction of HA-tagged chimeric receptors 
name  Sequence (5’         3’)  T (
oC) 
annealing 
Comment 
GF1  TTA CAA GAA TTC
d GCC ACC ATG 
G
iTT TAC CCA TAC GAT GTT CCA GAT 
TAC GCT
h GCA GCA CCC ACG CTG 
GGC CGT CTG GTG CTG A 
60 N-HA  huPAR-2 
EcoRI and Kozak 
sequence 
GR1  GAT CCT AAG CGG CCG C
eTC AGG 
GGC CAC AGG GGT CTA 
60 huPAR-2  NotI 
GF2  GAT TGA TGA ATT C
dAC CAC CAT 
GG
iC AGC ACC CAC G 
60 huPAR-2  EcoRI 
and Kozak 
sequence 
GR2  GAT CTT GCG GCC GC
eT CAA GCG 
TAT TCT GGA ACA TCG TAT GGG 
TA
hA AGC TT
cG GGG CCA CAG GGG 
TCT ACA CAG TCC TTT CTG CTT TG 
60 C-HA  huPAR-2 
GR3  GAA GGT AAG CTT
c GAG GCC ACA 
CTG GTC 
60 huPAR-1  HindIII 
GF4  GAT TGA TGA ATT C
dAC CAC CAT 
GG
iC AGC ACC TCC G 
56 muPAR  EcoRI 
and Kozak 
sequence 
GR4  GAA GGT AGG CTT
c GAG GCC ACA 
CTG GTC 
56 muPAR  HindIII 
GR5  CGT GGC ATC TAG ATT AAG CTT
c 
GGG GCC ACA GGG GTC 
60 huPAR-2  HindIII 
MF1  CCT GTG TGC TAG CCC TAG TGC AA  48  huPAR-2 NheI 
MR1  TTG CAC TAG GGC TAG CAC ACA GG  48  huPAR-2 NheI 
MF2  GCC CCA GTG GCA GGG AAG CCG 
TAC TCT GTG GCC TTC CTA 
52 H2Me 93 
 
 
 
cHindIII, 
dEcoRI, 
eNotI, 
hinfluenza virus HA tag, 
iKozak sequence. 
MR2  TAG GAA GGC CAC AGA GTA CGG 
CTT CCC TGC CAC TGG GGC 
52 H2Me 
MF3  GCC CCA GTG GCA GGG CAG CCC 
CAC TCT GTG GCC TTC CTA 
52 H2Md;  H1Mg 
MR3  TAG GAA GGC CAC AGA GTG GGG 
CTG CCC TGC CAC TGG GGC 
52 H2Md;  H1Mg 
MF4  GCC CCA GTG GCA GGA CAG CTC 
CAC TCA GTG GCC TTC CTA 
52 H2Mb 
MR4  TAG GAA GGC CAC TGA GTG GAG 
CTG TCC TGC CAC TGG GGC 
52 H2Mb 
MF5  GCC CCA GTG GCA GGA AAG CTC 
TAC TCG GTG GCC TTC CTA 
52 H2Mc 
MR5  TAG GAA GGC CAC CGA GTC GAG 
CTT TCC TGC CAC TGG GGC 
52 H2Mc 
MF6  AGA GGT GCC AGC GGT GGG CGC T  52  huPAR-2 N178A 
MR6  AGC GCC CAC CGC TGG CAC CTC T  52  huPAR-2 N178A 
MF7  GAC CCC TGT GGC CCC ATC GAT 
TAC CCA TAC GAT GTT 
56 huPAR-2ClaIHA 
MR7  AAC ATC GTA TGG GTA ATC GAT 
GGG GCC ACA GGG GTC 
60 huPAR-2ClaIHA 
MR8  GTT CTT TCC GCC TCA GAA GC  56  pcDNA3 
MF9  GCA GGA CAG TCG CAT TCT GTG G  60  huPAR-1S109 
MR9  CCA CAG AAT GCG ACT GTC CTG C  60  huPAR-1S109 
MF10  GCA GGA CAG TTG CAT TCC GTG  58  rhPAR-1S109 
MR10  CAC GGA ATG CAA CTG TCC TGC  58  rhPAR-1S109 94 
 
Table 2.3.2 cloning primers 
name  Sequence (5’       3’)  T (
oC) 
annealing 
Comment 
EF1  AGC TGG AGA TCT
a GAG CAG AAA 
CTC ATC TCT GAA GAG GAT CTG
g 
CTT GTG ACC AGT CCG AAC TCC CAT 
AAA CCC TTA TCT CTC ACC 
58 PERV  Env 
ER1  ATG TTC TTA GCT AGC
b CTA TTC ATC 
AAG GAT TGC TTT TTC CGG 
58 PERV  Env 
EF2  GCC AGA GGA GGT ACC
f GCC ACC 
ATG GAT GCA ATG AAG AGA G 
62 mycPERV  Env 
ER2  GGG TAA GAT CT
aG GCT CCT CTT 
CTG AAT CGG GCA TGG ATT TCC 
TGG CTG GGC 
62 mycPERV  Env 
CF1  GAT TGA TGA ATT C
dAC CAC CAT 
GG
iC AGC ACC 
56 ratPAR 
CR1  TGA CTG AGC GGC CGC
e TCA AGG 
GCC ACA CTG ATC CAC 
56 ratPAR 
CR2  GCA GGT AAG CTT
c AGG GCC ACA 
CTG ATC 
56 ratPAR 
CF3  TAC CTG GTT GAT CCT GCC AGT A  60  18S rRNA 
CR3  TTA CGA CTT TTA CTT CCT CTA GAT 
AG 
60 18S  rRNA 
CF4  GTC CAG AAT TC
dA CCA CCA TGG
i 
CAG CAC CCA TG 
60 rhPAR-2 
CR4  CAA GGA TCG AT
lG GGG CCA CAG G  60  rhPAR-2 
CF5  GTT CCA GAA TTC
d ACC ACC ATG 
G
iCA GCA CCC ACA CCC AGC 
60 rhPAR-1 
CR5  CAA GGA TCG AT
lG GAG TCA CAG 
GGG TCT GC 
60 rhPAR-1 
CF6  GTT CCA GAA TTC
d ACC ACC ATG  60 AGMPAR-1 95 
 
 
aBglII, 
bNheI, 
cHindIII, 
dEcoRI, 
eNotI, 
fKpnI, 
ghuman c-myc tag, 
hinfluenza 
virus HA tag, 
iKozak sequence, 
lClaI. 
 
Table 2.3.3 Sequencing primes 
Name   Sequence (5’      3’)  T (
oC) 
annealing 
Comment 
T7promoter CGA  CTC ACT ATA GGG AGA 
CCC 
52 pcDNA3 
BGH polyA  TTA GGA AAG GAC AGT GGG 
AGT 
52 pcDNA3 
Chicken 
promoter-F 
TTC TCC ATC TCC AGC CTC 
GGG 
48 pCAGGS 
RabbitpolyA-R  CCC ATA TGT CCT TCC GAG 
TGA 
48 pCAGGS 
M13-F  GTT TTC CCA GTC ACG AC  56  pGEM 
M13-R  GGA AAC AGC TAT GAC CAT G  58  pGEM 
 
G
iCA GCA CC ACA CCC GGC 
CF7  ACA CCT CAG GTC AGC AG  50  poTHN 
CR7  ATG TCA CCT AGT TTG TAT TCC  50  poTHN 96 
 
Table 2.3.4 Quantitative PCR primers 
 
name  Sequence (5’         3’)  Comment 
QF1  CTG CCT TCC AGG GTC TTC TG  huPAR-1 
QR1  TGA GGA CTC TTC CAC CTC TTC CT  huPAR-1 
QF2  TCA GGG CCT GAA CTT CAA CTG  huPAR-2 
QR2  GCA ATG GCA AAG CCT CTT CT  huPAR-2 
QF3  TCA AGG TGT CTC CCA TCA ATT TC  ratPAR 
QR3  CGT CAA CAC CCA AAA GAA TGT G  ratPAR 
QF4  TCG AGG CCC TGT AAT TGG AA  18S rRNA 
QR4  CTT GCC CTC CAA TGG ATC CT  18S rRNA 
QF5  AGC CTA CTT GGG ATG ATT GTC AA  PERV gag 
QR5  GGC CCC AGG AAC ATT TTT TC  PERV gag 
QF6  GTA CCC ACA GGG GGC TTA GGA TC  NHP PAR-1 
QR6  CTT GGT GGC TCT TGC AAT GGT G  NHP PAR-1 
QF7  GCA GGG CCT GAA CTT CCA TTG  NHP PAR-2 
QR8  AAG GCA CCCA TGG GCT GAG AAC  NHP PAR-2 
QF9  GTG AGC TGC TTG AGG GAA TC  poTHN 
QR9  TTG ACA TTC CTG CTG TGC TC  poTHN 
QF10  ACC TGC AAC CAC ACT GTG ATG  huTHN 
QR10  CAA GCT CCT CCA CTT TCT TTT GTC  huTHN 97 
 
Table 2.3.5 Quantitative PCR probes 
Name   Sequence (5’      3’)  Comment 
P1  CCA CCA TCT GTA CCC ACA  huPAR-1 
P2 CAG  GAG  CAG  AGG AGG  huPAR-2 
P3  CTG AGC GTT TCT CTG  ratPAR 
P4  AGT CCA CTT TAA ATC CTT  18S rRNA 
All probes are dual-labelled 5’-FAM/3’-TAMRA. 98 
 
Table 2.4 List of the cell lines 
 
Name ATTC  no.  Description 
293T
1 (DuBridge  et  al., 
1987) 
Human embryonic kidney. Epithelial. 
Express SV40 large T antigen  
COS-7  CRL-1651 African green monkey kidney. 
Fibroblast. Express SV40 large T 
antigen 
FRhK-4  CRL-1688 Rhesus macaque kidney. Epithelial 
HeLa   CCL-2  Human cervical carcinoma. Epithelial 
HSN  (Currie and Gage, 
1973) 
Rat fibrosarcoma. Fibroblast 
HT1080 CCL-121  Human  fibrosarcoma.Epithelial 
MDTF (Lander  and 
Chattopadhyay, 
1984) 
Mus dunni tail fibroblast 
MPK
2  CCL-166 Mini pig kidney. Fibroblast 
NIH3T3 CRL-1658  Mouse  NIH/Swiss embryonic fibroblast 
NRK CRL-6509  Rattus norvegicus Kidney. Epithelial 
PK15
2  CCL-33 Sus scrofa kidney. Epithelial 
QT6  CRL-1708 Quail fibrosarcoma. Epithelial 
RAT2  CRL-1764 Rattus norvegicus fibroblast 
ST-IOWA
2  (Quinn et al., 2004)  Sus scrofa testis. Fibroblast 
VERO  CCL-81  African green monkey kidney. 
Epithelial 
XC CCL-165  Rattus norvergicus epithelial 
ATCC American Type Culture Collection 
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
supplemented with foetal bovine serum (FBS) 10% (v/v) (Biosera) at 37ºC 
with 5% CO2. 99 
 
1 293T cells were grown in DMEM supplemented with Glutamax (Gibco) and 
15% (v/v) FBS at 37ºC with 10% CO2 
2 Pig cell lines were grown in DMEM supplemented with 10% (v/v) FBS and 
0.1 mM non-essential amino acids (Gibco). 
 
Table 2.5 Primary antibodies 
 
Name animal  source  Dilution  Reference 
PERV capsid  Rabbit, anti-serum 1:250  (IM) 
1:100 (IF) 
1:1000(WB) 
Bartosch et al 
2004 
HA.11 Mouse,  monoclonal 1:100  (IF,  FC) 
1:1000 (WB) 
Covance 
 MMS-101R 
human c-myc 
(9E10) 
Mouse, monoclonal  1:100 (FC)  Santa Cruz 
biotechnologies 
sc-40 
human actin 
AC-40 
Mouse, monoclonal  1:1000 (WB)  Sigma, A 4700 
Human CD71 
3H3077 
Mouse, monoclonal  1:100 (IF,FC)  Santa Cruz 
biotechnologies, 
sc-70772 
IM in situ immunostaining; IF immunofluorescence; FC flow cytometry; WB 
western blotting 
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Chapter 3 
3   Host range determinants of PERV-A receptors 
 
3.1 Introduction 
A better understanding of PERV biology is required to predict the possible 
risk associated with infection in xenotransplantation recipients and to develop 
therapeutics to prepare for such an eventuality. Three subgroups of 
replication-competent PERV have been described that differ in their envelope 
sequence, and therefore host range (section 1.4.1). The studies on PERV 
entry have followed two lines of investigation: viral envelope and cellular 
receptor. 
By comparison with the sequence of MLV Env, functional regions of PERV 
Env have been predicted (Le Tissier et al., 1997). These regions are the 
variable region A (VRA) and B (VRB), which in MLV are responsible for the 
receptor usage (Battini et al., 1995; Battini et al., 1992), and the proline rich 
region (PRR) considered important for the correct display of Env proteins on 
the viral surface and during the fusion process (Lavillette et al., 1998; Weimin 
Wu et al., 1998). For PERV Env, the characterisation of the determinants for 
viral infectivity was initially done through the comparison of the high-titre 
human recombinant PERV-A14/220 isolate with a prototype cell line-derived 
PERV-A. The PRR in the C-terminal of the SU derived from PERV-C 
envelope was shown to increase the titre of the recombinant PERV-A/C 
envelope up to 500 fold if in association with an amino acid mutation (V140I) 
between the VRA and VRB (Harrison et al., 2004). PRR was shown to be 
necessary for PERV-A, but not PERV-B, binding to the target cells 
(Gemeniano et al., 2006; Watanabe et al., 2005). Changing 4 amino acids in 
the C-terminal region of pig-tropic PERV-C SU with the correspondents in the 
human tropic PERV-A SU enabled PERV-C Env binding and entry into 
human cells (Argaw et al., 2008). Furthermore, PERV can infect cells lacking 
its receptor. PERV-A can infect non permissive rat and mouse cells in 
presence of soluble GALV receptor binding domain (RBD) (Lavillette and 101 
 
Kabat, 2004). The proposed mechanism was the activation in trans of 
conformational changes in the receptor which lead to the fusion between the 
viral and cellular membrane. This alternative pathway for infection was 
described for MLV (Barnett and Cunningham, 2001; Lavillette et al., 2001) 
and suggested for FeLV-T, which can infect cells only in presence of FeLV-B 
SU or a soluble factor called Felix, a RBD domain of an endogenous 
retrovirus (Anderson et al., 2000; Barnett et al., 2003). 
Only the receptor for PERV subgroup A has been identified. PERV-A 
receptor (PAR) was cloned using a similar approach described previously for 
other gammaretrovirus receptors (section 1.5.1). A human cDNA library 
derived from PERV-A permissive cells was delivered via retroviral 
transduction into resistant rabbit SIRC cells. The retroviral vector contained a 
drug resistance gene which allowed the selection of the transduced cells (i.e. 
those which bear a cDNA encoding for a protein able to support PERV-A 
entry). The cDNA clone selected, named huPAR-1, corresponded to the 
human sequence FLJ11856, coding for a protein characterised by a domain 
of unknown function DUF1011. In the GenBank database a second human 
gene homologous to huPAR-1 (huPAR-2, accession number FLJ10060) and 
a murine homologue (muPAR, accession number AK008081) were identified. 
Rabbit SIRC cells, expressing either huPAR-1 or huPAR-2, were sensitive to 
PERV-A and PERV-A14/220 but not PERV-B or –C. Expression of muPAR 
did not mediate PERV-A infection. The hydrophobicity profiles of huPAR-1 
predicted multiple transmembrane domains (10 or 11) similar to other 
gammaretrovirus receptors (section 1.5.2). The mRNA for huPARs was 
found in a wide variety of human tissues by Northern blot analysis (Ericsson 
et al., 2003). From the NCBI EST profile, huPAR-1 appears to be 
ubiquitously expressed while huPAR-2 ESTs were detected mainly in the 
placenta and few other body sites (Figure 3.1).  
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3.1 EST profile for huPAR-1 and huPAR-2 
Approximate gene expression patterns as inferred from EST counts reported in Unigene 
database (www.ncbi.nlm.niih.gov/unigene) for huPAR-1 (grey, Hs.6459) and huPAR-2 
(black, Hs.632247) on 15
th December 2009. 
As a result of its predicted structure, huPAR-1 was identified as a G protein-
coupled receptor (GPR172A or GPCR41). However, all the γ–retrovirus 
receptors identified at present function as transporters (section 1.5.4). 
Characterisation of huPAR physiological function has been controversial. In a 
study aimed at identifying the human homologue of rat γ-hydroxybutyrate 
(GHB) receptor, two cDNA clones from a human frontal cortex cDNA library 
were selected. One of these shared the same amino acid sequence of 
huPAR-1 and the second one was a variant with a frame shift which caused 
an addition of 42 residues in the C-terminus (Andriamampandry et al., 2007). 
This paper presents several problems. Negative controls were not always 
included, the physiological uptake of GHB in different tissues does not 
correspond to the EST profile and mRNA distribution of huPAR-1, and there 
is no data showing the expression in vivo of the alternative huPAR-1 form 
with the longer C-tail.  103 
 
HuPAR-2 has been described as a riboflavin (vitamin B2) transporter (RFT1) 
(Yonezawa et al., 2008). A rat kidney cDNA library was used to select the 
cDNA of a multitransmembrane protein of uncharacterised function. The 
sequence corresponded to the rat protein similar to GPR172B (huPAR-2) 
(GenBank accession number XM_001075182). Riboflavin was identified as 
substrate of rat RFT (rRFT) from the screening against 25 compounds. The 
human homologue (huPAR-2) named hRFT was also shown to be able to 
increase uptake of radiolabelled riboflavin when expressed in HEK-293 and 
Caco-2 cells. A major problem in this paper was the lack of mention of 
huPAR-1, which is as closely related to rRFT as huPAR-2 (section 3.2.5) and 
ubiquitously expressed (Figure 3.1). By knocking down hRFT in HEK-293 
cells, a significant reduction in the riboflavin uptake was observed. However, 
huPAR-2 expression is low in these cells in comparison with huPAR-1 
(section 4.2.4). It would be important to test whether huPAR-1 has the same 
function as huPAR-2 and measure its expression in huPAR-2 knocked down 
cells to better interprete the data. Overall, further investigation is needed to 
assess the physiological function of PARs. 
In this chapter, PERV-A entry in human and rodent cells has been 
investigated. The aim was to identify determinants in PERV-A receptor 
critical for its interaction with the virus. This could provide information for the 
development of strategies to characterise and eventually prevent PERV-A 
infection. 
A major part of this chapter has been published (Mattiuzzo et al., 2007). 
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3.2 Results 
3.2.1  PERV-A resistant murine cells express a non-functional receptor 
Two human PERV-A receptors (huPAR-1 and huPAR-2) and their murine 
homologue (muPAR) have been identified (Ericsson et al., 2003). Alignment 
of the amino acid sequences revealed that huPAR-1 shares 86.1% and 
81.1% identity with huPAR-2 and muPAR, respectively. HuPAR-2 and 
muPAR have 79.6% identical amino acids (Figure 3.2). However, while 
huPAR-1 and huPAR-2 expression on PERV-A resistant rabbit SIRC cells 
successfully mediated virus entry, muPAR did not (Ericsson et al., 2003). 
Furthermore, PERV host range studies showed that murine cells are 
resistant to PERV-A infection (Takeuchi et al., 1998; Wilson et al., 2000). The 
role of muPAR in PERV-A resistance in murine cells has been investigated. 
Human 293T cells, mus dunni MDTF and quail QT6 cells were transduced 
with a MLV-based retroviral vector carrying huPAR-1, huPAR-2 or muPAR 
genes. 5x10
4 transduced cells were infected with EGFP pseudotype rescued 
by PERV-A14/220 [EGFP(PERV), section 2.3.3]. After 48 hours, cells were 
analysed by flow cytometry and the efficiency of infection determined by the 
percentage of EGFP positive cells. PERV-A14/220 pseudotyped virus did not 
infect murine MDTF or quail QT6 cells. Murine cells bearing a functional 
receptor (huPAR-1 or huPAR-2) were susceptible to EGFP(PERV) infection, 
suggesting that PERV-A block in these cells occurred at entry level (Figure 
3.3). MuPAR was unable to mediate EGFP(PERV) infection in resistant 
MDTF and QT6 cells. This result was in agreement with a previous report 
showing that muPAR does not function as a PERV-A receptor (Ericsson et 
al., 2003). 
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Figure 3.2 PAR amino acid sequences alignment 
Amino acid sequences retrieved from Entrez protein database (www.ncbi.nlm.nih.gov/entrez) 
of huPAR-1 (NP_078807.1), huPAR-2 (NP_060456.3), muPAR (NP_083919) and ratPAR 
(NP_001103140) were aligned using ClustalW software (Larkin et al., 2007). 
  
 
muPAR           MAAPPLGRLVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEGWSLPSYLSVLVALGNL 60 
ratPAR          MAAPPLGRLVLTHLLVALFGMGSWIAVNGIWVELPVVVKELPEGWSLPSYLSVLVALGNL 60 
huPAR-2         MAAPTLGRLVLTHLLVALFGMGSWAAVNGIWVELPVVVKDLPEGWSLPSYLSVVVALGNL 60 
huPAR-1         MAAPTPARPVLTHLLVALFGMGSWAAVNGIWVELPVVVKELPEGWSLPSYVSVLVALGNL 60 
                ****. .* *************** **************:**********:**:****** 
 
muPAR           GLLLVTLWRRLARGKGEQVPIRVVQGLGIVGTGLLASLWNHVAPVAGKPYSVAFLTLAFV 120 
ratPAR          GLLLVTLWRRLAPGKSERIPIQVVQGLSIVGTGLLAPLWSNMALVAGQLHSVAFLTLAFV 120 
huPAR-2         GLLVVTLWRQLAPGKGEQVPIQVVQVLSVVGTALLAPLWHHVAPVAGQLHSVAFLTLALV 120 
huPAR-1         GLLVVTLWRRLAPGKDEQVPIRVVQVLGMVGTALLASLWHHVAPVAGQLHSVAFLALAFV 120 
                ***:*****:** **.*::**:*** *.:***.***.** ::* ***: :*****:**:* 
 
muPAR           LALACCASNVTFLPFLSHLPPPFLRSFFLGQGLSALLPCVLALGQGVGRLECLHVPANRT 180 
ratPAR          LALSCCASNVTFLPFLSHLPPPFLRSFFLGQGLSALLPCVLALAQGVGRLECLHVPANGT 180 
huPAR-2         LAMACCTSNVTFLPFLSHLPPPFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPTNGT 180 
huPAR-1         LALACCASNVTFLPFLSHLPPRFLRSFFLGQGLSALLPCVLALVQGVGRLECPPAPINGT 180 
                **::**:************** ********************* ********  .* * * 
 
muPAR           TGPPIEVSPINFPERFSATTFFWVLTALLGTSAAAFQGLLLLLPSPTSEPT--TGTGLRV 238 
ratPAR          TGPPIKVSPINFPERFSAGTFFWVLTALLGTSAAAFQGLLLLLPSPPPEAT--MGTGLRV 238 
huPAR-2         SGP-----PLDFPERFPASTFFWALTALLVTSAAAFRGLLLLLPSLPSVTTGGSGPELQL 235 
huPAR-1         PGP-----PLDFLERFPASTFFWALTALLVASAAAFQGLLLLLPPPPSVPTGELGSGLQV 235 
                .**     *::* ***.* ****.***** :*****:*******. .. .*   *. *:: 
 
muPAR           ETPGTEEEEEEEE-ASPLQEPPGQVAGIVSSPDPKAHQLFSSRSACLLGLLAITNALTNG 297 
ratPAR          ETPGTEEEEEEEE-ASPLQEPPGQVASIVSSPDPKAHRLFSSRSACLLGLLAITNALTNG 297 
huPAR-2         GSPGAEEEEKEEEEALPLQEPPSQAAGTIPGPDPEAHQLFSAHGAFLLGLMAFTSAVTNG 295 
huPAR-1         GAPGAEEEVEESS---PLQEPPSQAAGTTPGPDPKAYQLLSARSACLLGLLAATNALTNG 292 
                 :**:*** :*..   ******.*.*.  ..***:*::*:*::.* ****:* *.*:*** 
 
muPAR           VLPAVQSFSCLPYGRLAYHLAVVLGSCANPLACFLAMAVLCRSLAGLCGLSLLGMLLGSY 357 
ratPAR          VLPAVQSFSCLPYGRLAYHLAVVLGSSANPLACFLAMAVLCRSLAGLYGLCLLGMFFGTY 357 
huPAR-2         VLPSVQSFSCLPYGRLAYHLAVVLGSAANPLACFLAMGVLCRSLAGLVGLSLLGMLFGAY 355 
huPAR-1         VLPAVQSFSCLPYGRLAYHLAVVLGSAANPLACFLAMGVLCRSLAGLGSLSLLGVFCGGY 352 
                ***:**********************.**********.********* .*.***:: * * 
 
muPAR           LMTLAALSPCPPLVGTSAGVVLVVLSWVLCAGTFSYIKVAISSMLHSGGRPALLAAGVAI 417 
ratPAR          LMTLAVLSPCPPLVGTSAGVVLVVLSWVLCAGVFSYIKVATSSMLHSGGRPALLAAGVAI 417 
huPAR-2         LMALAILSPCPPLVGTTAGVVLVVLSWVLCLCVFSYVKVAASSLLHGGGRPALLAAGVAI 415 
huPAR-1         LMALAVLSPCPPLVGTSAGVVLVVLSWVLCLGVFSYVKVAASSLLHGGGRPALLAAGVAI 412 
                **:** **********:*************  .***:*** **:**.************* 
 
muPAR           QVGSLLGAVAMFPPTSIYRVFRSGKDCVDQCGL 450 
ratPAR          QVGSLLGAIAMFPPTSVYPVFRSGEDCVDQCGP 450 
huPAR-2         QVGSLLGAGAMFPPTSIYHVFQSRKDCVDPCGP 448 
huPAR-1         QVGSLLGAVAMFPPTSIYHVFHSRKDCADPCDS 445 
                ******** *******:* **:* :**.* *.  
 106 
 
 
 
 
Figure 3.3 HuPAR and muPAR-mediated PERV-A infection  
PERV-A permissive human 293T cells and resistant murine MDTF and quail QT6 cells were 
transduced with a VSV-G pseudotyped MLV-based retroviral vector carrying huPAR-1 
(grey), huPAR-2 (white) or muPAR (striped) genes. 5x10
4 PAR-transduced or parental 
(black) cells were infected with 500 µL of 293T supernatant containing EGFP(PERV) 
particles. Infection efficiency was measured as percentage of EGFP positive cells assessed 
by flow cytometry analysis. Histograms represent the average of two independent 
experiments (± standard error of the mean). Arrows indicate that the infection was under the 
detection limit of 0.1%. 
  107 
 
3.2.2  Identification of critical amino acids in muPAR for its receptor 
function 
Critical sites in the γ-retrovirus receptor for infection have usually been 
identified by comparing a functional and a non-functional receptor (section 
1.5.2). Following the same approach, human-mouse chimeric receptors were 
generated and expressed in PERV-A resistant QT6 cells. HuPAR-2 was 
chosen over huPAR-1 because it could mediate a higher infection efficiency 
either in QT6 cells (Figure 3.3) or in rabbit SIRC (Ericsson et al., 2003). The 
NheI restriction site was introduced into huPAR-2 at the same position as in 
muPAR and used to create chimera H2M a and f in which the first 483 
nucleotides were exchanged between the two receptors. C-terminal HA-
tagged chimeric constructs were expressed in QT6 cells by transduction with 
a MLV-based retroviral vector. Receptor expression was assessed by cell 
surface immunostaining using an anti-HA antibody. Ability to mediate PERV-
A entry was tested by infection with EGFP(PERV). H2M f was unable to 
support PERV-A infection in QT6 cells while the converse muPAR mutant 
did, indicating that critical sites were included within the first 483 nucleotides 
(Figure 3.4). Using the alignment of the amino acid sequences, 3 residues 
shared between huPAR-1 and -2 (QLH) but different in muPAR (KPY) were 
identified in the N-terminal 161 amino acids. Mutant huPAR-2 containing 
murine KPY residues (H2M b) were compared against muPAR carrying 
human QLH amino acids (H2M e) for the ability to support PERV-A infection. 
Only the chimeric receptor bearing human QLH residues could confer to QT6 
cells susceptibility to EGFP(PERV) infection (Figure 3.4). The analysis was 
narrowed down to identify one single amino acid which if expressed in 
huPAR-2 (P at position 109, H2M d) could reduce PERV-A infection in 
H2Md-transduced QT6 cells under the detectable limit. Conversely, when 
mutant muPAR carrying the substitution P109L (H2M c) was expressed in 
QT6 cells EGFP(PERV) infection was detected (Figure 3.4). Furthermore to 
test the importance of the amino acid 109, a chimeric huPAR-1 with mutation 
L109P was generated (H1M g). QT6 cells expressing H1M g were not 
susceptible to EGFP(PERV) infection (Figure 3.4). These results suggested 
that proline 109 in muPAR is responsible for PERV-A resistance in mouse 108 
 
cells. These observations were confirmed by a recently published report 
(Marcucci et al., 2009). 
 
 
Figure 3.4 Identification of critical residues in PAR for PERV-A infection 
Quail QT6 cells were transduced with MLV-based retroviral vector carrying HA-tagged 
huPAR-2 (white), muPAR (black), huPAR-1 (grey) or chimeric receptor genes. Receptor 
expression was assessed by immunostaining using an anti-HA antibody and flow cytometry 
analysis. Representative histograms of HA-staining of PAR-expressing QT6 cells are 
showed in Figure 3. 6. Percentage of HA positive cells for each receptor is reported (black 
diamond). 5x10
4 cells were infected with EGFP(PERV) at MOI on 293T cells of 2. Efficiency 
of EGFP transduction is expressed as percentage of EGFP positive cells. Histograms 
represent the average of three independent experiments (± standard error of the mean). 
Arrows indicate that the infection was under the detectable limit of 0.1%. 
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3.2.3  Investigation of huPAR-2 topology 
To understand the mechanism by which one single amino acid substitution 
could dramatically change the function of PAR, the localisation of this residue 
in the receptor structure was investigated. Firstly, the topology of huPAR was 
predicted. Previous hydrophobicity profile analysis predicted 10 or 11 
transmembrane domains (Ericsson et al., 2003). I submitted huPAR-2 amino 
acid sequence to TMHMM server v2.0 (www.cbs.dtu.dk/services/TMHMM) 
(Krogh et al., 2001) and the update model showed 11 transmembrane 
domains, 5 extracellular loops (ECL), an intracellular N-terminus and 
extracellular C-terminus. To gather evidence supporting this prediction, the 
orientation of the extremities was assessed.  
Two constructs were generated: huPAR-2 HA-tagged either at the N-terminal 
or at the C-terminal end. The receptors were transfected into 293T cells and 
their expression analysed at the immunofluorescence microscope or by flow 
cytometry analysis. Only the C-terminus HA-tagged huPAR-2 was visualised 
by cell surface staining using an anti-HA antibody. A similar staining was 
obtained using an anti-human transferrin receptor antibody (anti-CD71), a 
protein expressed on the cell surface of active proliferating cells. N-terminal 
tagged huPAR-2 was observed only after saponin treatment, which 
permeabilises cells allowing the antibodies to stain intracellular target (Figure 
3.5 A and B). These results are in agreement with the updated topology 
prediction of 11 transmembrane domains. 
Further evidences supporting the predicted topology were obtained through a 
glycosylation study. HuPAR-2 has been predicted to contain one N-
glycosylation site at amino acid 178 using NetNGlyc 1.0 software 
(www.cbs.dtu.dk/services/NetNGlyc) (Blom et al., 2004). N-glycosylation 
sites are usually located in extracellular regions of membrane proteins and 
asparagine 178 in huPAR-2 is indeed located in the predicted third ECL. 
Therefore, proving that asparagine 178 is an N-glycosylation site would add 
strength to the topology proposed. A mutant HA-tagged huPAR-2 bearing the 
amino acid substitution asparagine 178 to alanine (N178A) was generated 
and upon transfection of QT6 could support EGFP(PERV) infection with a 110 
 
similar efficiency than the wild type (Figure 3.6 A). 293T cells were 
transfected with HA-tagged huPAR-2 wild type or the mutant N178A and cell 
lysates were processed with PNGase F, an enzyme which removes N-linked 
oligosaccharide chains. Proteins were separated by SDS-PAGE and 
immunoblotted using an anti-HA antibody. The western blot analysis showed 
a shift of the signal in the wild type huPAR-2 treated with PNGase F from 55 
KDa to 48 KDa (Figure 3.6 B), indicating that huPAR-2 carries N-linked 
oligosaccharide chains. Furthermore, the mutant N178A produced a 48 KDa 
band with or without PNGase F treatment (Figure 3.6 B), confirming that 
N178 is indeed an N-glycosylation site.  
The results obtained in this section, by the analysis of huPAR-2 topology, 
supported the proposed model described above (Figure 3.6 C). Similar 
models were obtained by submitting huPAR-1 and muPAR amino sequence 
to TMHMM server v2.0 and NetNGlyc 1.0 software. 
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Figure 3.5 Cellular localisation of huPAR-2 C- and N-terminal ends 
1x10
6 293T cells were seeded and the day after transfected with C- or N-terminal HA-tagged 
huPAR-2 constructs. 72 hours later, cells were fixed and permeabilised (right column) or not 
(left column) with saponin. Cells were immunostained with a mouse anti-HA (C-HA huPAR-2 
and N-HA huPAR-2) or anti-transferrin receptor (anti-CD71) antibody. A) Cells were 
incubated with an FITC-conjugate anti-mouse IgG antibody (green) and nuclei 
counterstained with propidium iodide (red), contained in the mounting solution. Images show 
representative fields acquired using DM IRE2 confocal microscope (oil immersion objective 
63X). B) Cells were incubated with a PE-conjugated anti-mouse antibody and processed by 
flow cytometry. Percentage of HA- and CD71-positive cells (bold line) was calculated by 
comparison to cells treated only with the secondary antibody (grey filled). Histograms 
showed one representative of two independent experiments. 
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Figure 3.6 N-linked glycosylation of huPAR-2 
A) QT6 cells were transfected with pcDNA3 (EP), C-terminal HA tagged huPAR-2 wild type 
(huPAR-2) or the mutant with asparagines 178 substituted with an alanine (huPAR-2N178A). 
After 48 hours, 5x10
4 transfected cells were seeded and the day after infected with 
EGFP(PERV) at MOI on 293T cells of 2. Three days later cells were examined by flow 
cytometry. Dot plots showed a representative experiment. B) 1x10
6 293T cells were seeded 
and the day after transfected with pcDNA3 (-), untagged huPAR-2 (wild type), C-terminal 
HA-tagged huPAR-2 (C-HA wild type) or HA-tagged huPAR-2 mutant with the asparagine 
178 substituted with an alanine (C-HA N178A). After 48 hours, cells were lysed in RIPA 
buffer and treated (+) or not (-) with PNGase F. Proteins were separated in a 10% SDS-
PAGE and immunoblotted using an anti-HA antibody or an anti-actin antibody as input 
control.  C) HuPAR-2 topology model derived by hydrophobicity algorithms (Krogh et al., 
2001) and the experiment results (Figure 3.5 and 3.6B). 
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3.2.4  Proline 109 abrogates PERV-A Env binding to PAR 
Amino acid 109 was located in the second ECL according to huPAR-2 
topology. To investigate the mechanism responsible for the abrogation of 
PERV-A infection by proline 109 in muPAR, receptor binding to PERV-A Env 
was analysed.  
Quail QT6 cells were transduced with a MLV-based vector carrying HA-
tagged huPAR-1, huPAR-2, muPAR, huPAR-2P109 and muPARL109 genes. 
Receptor expression was assessed by immunostaining using an anti-HA 
antibody and flow cytometry analysis. Transduced cells expressed similar 
levels of receptors as showed by HA staining (Figure 3.7 A). Parental and 
receptor-transduced cells were incubated with soluble, c-myc tagged PERV-
A14/220 (mycPERV) Env protein and immunostained using an anti-myc 
antibody. No difference was observed between parental QT6 cells incubated 
in the presence or absence of mycPERV Env (Figure 3.7 B wt). Expression 
of huPAR-1 and -2, but not muPAR, produced a shift towards higher 
fluorescence intensity in presence of mycPERV Env, indicating that human 
receptors can mediate the binding to viral Env. QT6 cells expressing huPAR-
2 bearing a proline at amino acid 109 were unable to bind soluble mycPERV 
Env in this assay. These results suggested that proline 109 in muPAR could 
be responsible for the lack of infection in mouse cells by altering PERV Env 
binding to the receptor. However, muPAR with the amino acid substitution 
P109L did not rescue the binding to mycPERV Env (Figure 3.7 B), even if it 
supported PERV-A infection (Figure 3.4). This discrepancy between the 
binding and infection results could be due to a better binding of the trimeric 
Env present on viral particles than the soluble monomeric form used in this 
assay. Moreover, other regions in the muPAR molecule could be important 
for the binding. For example, through the comparison of huPAR-1 and 
huPAR-2, the region comprised between amino acids 152-285 (from the third 
ECL till the seventh transmembrane region) was identified as responsible for 
ten-fold functional superiority of huPAR-2 over huPAR-1 (Marcucci et al., 
2009).  
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Figure 3.7 Soluble PERV-A binding to PARs 
QT6 cells were transduced to express HA-tagged huPAR-1, huPAR-2, muPAR or the 
chimeric receptors, huPAR-2 with the leucine at amino acid position 109 substituted with a 
proline (huPAR-2/P109) or muPAR with the converse mutation (muPAR/L109). A) Receptor 
expression was assessed by immunostaining using an anti-HA antibody. Percentage of HA-
positive cells (bold line) was calculated by comparison with wild type cells (grey filled). B) 
5x10
5 cells were incubated with 1 mL of 293T cells supernatant either untransfected (grey 
filled) or transfected with N-terminal c-myc tagged soluble PERV-A14/220 SU Env (bold 
line). Cells were immunostained using an anti-human c-myc antibody and a PE-conjugated 
anti-mouse IgG secondary antibody. Histograms show a representative result of three 
independent experiments. 117 
 
3.2.5  Cloning and characterisation of rat PERV-A receptor 
Rat cells are resistant to PERV-A infection (Takeuchi et al., 1998). To 
investigate whether a non-functional receptor could be responsible for PERV-
A resistance, similar to mouse cells, rat PERV-A receptor (ratPAR) was 
cloned. In the NCBI database a homologue to huPAR was identified 
(accession number XM_343272). RatPAR has amino acid identities of 90.4% 
with muPAR, and 79.3% and 79.0% with huPAR-1 and huPAR-2, 
respectively (alignment shown in Figure 3.2). Specific primers were designed 
based on the sequence XM_343272 and employed in a PCR using cDNA 
from PERV-A resistant rat NRK cells as a template. The ratPAR sequence 
cloned had 2 amino acids different from the sequence deposited in GenBank. 
Amino acid sequence alignment showed that ratPAR shared the same ECL2 
sequence with huPAR-1 and huPAR-2 (Figure 3.8 A). HA-tagged receptors 
were delivered by transduction with a retroviral vector into human 293T, rat 
NRK and quail QT6 cells. The receptors function, to support PERV-A entry, 
was tested by infection with pseudotyped EGFP(PERV) and monitoring 
EGFP expression by flow cytometry. PERV-A resistant cells became 
susceptible upon expression of huPAR-1, huPAR-2 and ratPAR but not 
muPAR (Figure 3.8 B). RatPAR could also mediate PERV-A infection in QT6 
cells as efficiently as huPAR-1 (Figure 3.8 B). Furthermore, QT6 cells 
expressing similar levels of huPAR-1 and ratPAR receptors (Figure 3.8 C, HA 
staining), bound with the same efficiency to soluble PERV Env (Figure 3.8 C, 
mycPERV Env binding). These results showed that ratPAR acted as a 
functional receptor for PERV-A infection and suggested that a different 
mechanism was responsible for PERV-A resistance in rats. 
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Figure 3.8 Characterisation of rat PERV-A receptor 
A) Amino acid sequences of huPAR-2, huPAR-1, muPAR and ratPAR were aligned using 
ClustalW programme. Partial sequences, containing second extracellular loop (ECL2, 
underlined) are shown. B) Human 293T and PERV-A resistant rat NRK and quail QT6 cells 
were transduced with an MLV-based retroviral vector carrying huPAR-1 (grey), huPAR-2 
(white), muPAR (diagonally striped) or ratPAR (horizontally striped) genes. 5x10
4 PAR-
transduced or parental (black) cells were infected with 500 µL of 293T supernatant 
containing EGFP(PERV) particles. Infection efficiency was measured as percentage of 
EGFP positive cells assessed by flow cytometry analysis. Histograms represent the average 
of two independent experiments (± standard error of the mean). Arrows indicate the infection 
was under the detection limit of 0.1% C) QT6 cells were transduced to express huPAR-1 or 
ratPAR. Receptor expression was assessed by immunostaining using an anti-HA antibody 
(top panels). Percentage of HA-positive cells (bold line) was calculated by comparison with 
wild type cells (grey filled). 5x10
5 cells were incubated with one mL of 293T cells supernatant 
either untransfected (grey filled) or transfected with N-terminal c-myc tagged soluble PERV-
A14/220 SU Env (bold line) (bottom panels). Cells were immunostained using an anti-human 
c-myc antibody and a PE-conjugated anti-mouse IgG secondary antibody. Histograms show 
a representative result of three independent experiments.  
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3.2.6  Endogenous expression of ratPAR in rat cells  
Because rat cells encode a functional receptor, a possible explanation for 
their resistance to PERV-A infection could be a low level of ratPAR 
expression. An anti-PAR antibody is not available; therefore the mRNA level 
of ratPAR was measured and compared to huPAR-1 mRNA from highly 
susceptible human 293T and HeLa cells. 
Total mRNA was extracted from human and rat cells and the copy numbers 
for huPAR-1 and ratPAR were estimated. On average rat cells expressed a 4 
times lower level of ratPAR than huPAR-1 in human cells, with the exception 
of HSN cells where the difference was up to 25-fold (Figure 3.9). However, to 
determine whether the difference in the receptor mRNA levels between rat 
and human cells could be responsible for the lack of PERV-A infection in rat 
cells, further experiments were required.  
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Figure 3.9 Endogenous expression of PERV-A receptors 
Total RNA was extracted from human 293T, HeLa and HT1080 cells (white) and rat NRK, 
HSN, XC and Rat2 cells (grey). 1 µg was reverse described and one eighth was used in a 
probe-based quatitative RT-PCR using primers QF1, QR1 and probe P1 (for huPAR-1) and 
QF3,QR3 and probe P3 (for ratPAR) (Table 2.3.4). PAR copy numbers were determined by 
comparison with a standard curve and normalised to one copy of 18S rRNA. Samples were 
run in duplicate. Histograms represent the average of three independent experiments (± 
standard error of the mean). Efficiency of infection was determined by infection of 5x10
4 cells 
with EGFP(PERV) at MOI on 293T of 2 and expressed as percentage of EGFP-positive 
cells. PERV-A infection on HT1080 was not performed. However, HT1080 cells were 
reported to be permissive to LacZ(PERV-A) transduction (Takeuchi et al., 1998).  
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3.2.7  Analysis of post-entry restriction factor in rat cells 
Before analysing whether rat resistance to PERV-A infection was due to a 
low expression of ratPAR, other possible mechanisms of retroviral block were 
investigated. The most well described restriction factors acting against 
retroviruses post-entry but prior to provirus integration are Fv1 and TRIM5α 
(section 1.6.1). Their expression in otherwise permissive cells caused a 
reduction in sensitive virus titre of more than 10-fold (Hartley et al., 1970; 
Stremlau et al., 2004; Towers et al., 2000). The viral determinant for 
restriction was mapped in both cases to the CA protein (Besnier et al., 2003; 
Kozak and Chakraborti, 1996; Perron et al., 2004; Towers et al., 2002). 
To analyse whether a similar mechanism occurred with PERV-A in rat cells, 
VSV-G pseudotyped viruses carrying an MLV-based retroviral vector 
expressing EGFP were produced by transfection of 293T cells together with 
packaging plasmid expressing PERV-A14/220 or Moloney MLV (MoMLV) 
GagPol. MoMLV GagPol was used as control because it has been shown to 
be resistant to post-entry restriction (Keckesova et al., 2004; Kozak, 1985; 
Perron et al., 2004). After 48 hours, the pseudotyped viruses were titrated on 
human 293T and rat NRK cells. On 293T cells no difference was observed in 
the infection efficiency between pseudotyped viruses bearing PERV-A14/220 
GagPol or MoMLV GagPol (Figure 3.10, 293T). In rat NRK cells, PERV-
A14/220 GagPol caused a 4-fold reduction in the pseudotyped viruses 
compared to MoMLV GagPol (Figure 3.10, NRK). Although these results may 
suggest the possibility of a weak restriction factor present in rat cells, such a 
small degree of reduction cannot explain the lack of PERV-A infection 
observed (Figure 3.8 B). Moreover, in rat HSN cells the efficiency of 
transduction obtained with VSV-G pseudotyped PERV-A14/220 or 
amphotropic MLV4070 in which env gene was substituted with egfp gene 
was similar (Harrison et al., 2004). Taken together these observations 
suggested that post-entry restriction is not responsible for PERV-A resistance 
in rat cells. 
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Figure 3.10 Analysis of post-entry block to PERV-A infection in rat cells 
VSV-G pseudotyped particles containing MLV-based retroviral vector expressing EGFP, and 
Moloney MLV (white) or PERV-A14/220 (grey) GagPol were produced by transfection of 
293T cells. Viral titres were determined by infection of 293T or NRK cells and monitoring of 
EGFP expression by flow cytometry. Histograms represent the average of two independent 
experiments (± standard error of the mean). 
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3.2.8  Evaluation of N-liked glycosylation in rat cells on PERV-A 
infection 
Removal of N-linked glycosylation by tunicamycin treatment of resistant cells 
was shown to rescue retroviral infectivity (section 1.5.5). In this section a 
possible role for N-linked glycosylation in PERV-A resistance in rat cells 
would be investigated. 
Rat NRK, HSN, XC, Rat2 cells were treated overnight with tunicamycin. 
Human 293T and murine MDTF cells were used as (positive and negative, 
respectively) controls for PERV-A infection. For each cell line tunicamycin 
dose was chosen according to the toxicity observed (Figure 3.11). Cells were 
infected with EGFP(PERV) and 72 hours later analysed using flow cytometry. 
EGFP transduction of untreated rat cells was under the detection limit. 
However, upon tunicamycin treatment, a low PERV-A infection could be 
observed in NRK and Rat2 cells (Figure 3.11). Removal of N-linked 
glycosylation slightly enhanced PERV-A infectivity in some, but not all, rat 
cells, suggesting that receptor masking by N-glycosylation could not be the 
cause of PERV-A resistance in rats. 
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Figure 3.11 Tunicamycin treatment of rat cells 
5x10
4 rat NRK, HSN, XC, Rat2, human 293T and murine MDTF cells were treated (grey) or 
not (white) with tunicamycin at the concentration stated. The day after, cells were infected 
with 500 µL of 293T supernantant containing EGFP(PERV). PERV-A transduction efficiency 
was assessed by flow cytometry analysis and expressed as percentage of EGFP cells. 
Histograms represent the average of two independent experiments (± standard error of the 
mean). Arrows indicate that the infection was under that the detection limit of 0.1%. 
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3.2.9  Analysis of inhibitors secreted from rat cells 
Another receptor-mediated block to retroviral infection described in literature 
was the secretion of inhibitors from resistant cells (Miller and Miller, 1992, 
1993). To investigate whether a similar mechanism was acting to prevent 
PERV-A infection in rat cells, huPAR-2 and ratPAR-transduced QT6 cells 
were grown overnight and then infected with VSV-G pseudotyped MLV 
carrying EGFP gene or EGFP(PERV) in the presence of conditioned media 
from rat NRK cells. No clear difference was observed in the EGFP 
transduction efficiency, indicating that no inhibitors to PERV-A infection were 
secreted from rat cells (Figure 3.12). 
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Figure 3.12 PERV-A infection in conditioned media of rat cells 
5x10
4 huPAR-2 (A) and ratPAR (B)-transduced QT6 cells were incubated overnight with 
media alone (grey) or conditioned media from confluent rat NRK cells (diluted 1:1) (white). 
The day after cells were infected with VSV-G pseudotyped MLV particles carrying a retroviral 
vector encoding EGFP at MOI on 293T cells of 0.2 or EGFP(PERV) at MOI on 293T cells of 
2. Titres were determined by EGFP monitoring by flow cytometry. Histograms represent the 
average of two independent experiments (± standard error of the mean). 
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3.2.10 PERV-A infection dependence on ratPAR expression  
To understand whether endogenous ratPAR expression in rat cells was too 
low to support PERV-A infection, a correlation between the amount of 
exogenous ratPAR and pseudotyped EGFP(PERV) infection was 
investigated. Rat NRK, HSN and XC cells were transduced with a retroviral 
vector carrying the ratPAR gene and infected with EGFP(PERV). RatPAR 
mRNA copy number in RatPAR-transduced cells was measured by probe-
based quantitative RT-PCR and plotted against PERV infection efficiency, 
expressed as EGFP positive cells. All three rat cell lines became susceptible 
to PERV-A infection when the level of ratPAR mRNA was increased 40 to 
500-fold by the exogenously expressing ratPAR (Figure 3.13 A). 
To provide evidence for the dependence of PERV-A infection on ratPAR 
expression level, QT6 cells were transduced with a retroviral vector carrying 
HA-tagged ratPAR gene. Clonal populations were isolated and the level of 
ratPAR expression on the cell surface of these cells determined as mean 
fluorescence intensity of HA staining. RatPAR-transduced QT6 cells 
expressing different amounts of receptors were infected with EGFP(PERV). 
Pseudotyped PERV-A infection efficiency was dependent on the ratPAR 
expression level (Figure 3.13 B).  
These results showed that upon overexpression of ratPAR, rat cells become 
sensitive to PERV-A infection and the efficiency of PERV-A entry correlates 
with the amount of receptor expressed. This suggested that in rat cells 
ratPAR is expressed at a subthreshold level and cannot mediate PERV-A 
infection. 
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Figure 3.13 PERV-A infection dependence on ratPAR expression 
A) Rat NRK (circle) HSN (square) and XC (triangle) cells were transduced with a MLV-based 
retroviral vector carrying ratPAR gene. Two independent transductions were performed for 
NRK and HSN cells. Total RNA from ratPAR-transduced (black) or parental (white) cells was 
extracted and 1 µg were reverse transcribed. One eighth of the final volume was employed 
in a probe-based quantitative RT-PCR, using primers QF3 and QR3 and probe P3 (table 
2.3.4). The amount of ratPAR mRNA was inferred by comparison with standard curve and 
normalised to 10
10 copies of 18S rRNA. Samples were run in duplicate. Dots represent the 
average of two independent experiments. 5x10
4 ratPAR-transduced and parental cells were 
seeded and the day after infected with EGFP(PERV) at MOI on 293T cell of 2. After 72 130 
 
hours, PERV-A infection efficiency was determined by flow cytometry as percentage of 
EGFP positive cells and plotted against the amount of ratPAR mRNA. Dots represent the 
average of three independent experiments. B) Quail QT6 cells were transduced with a 
retroviral vector carrying HA-tagged ratPAR gene and single clone populations were 
isolated. For each individual QT6 clones, the amount of ratPAR on cell surface was 
determined by immunostaining using anti-HA antibody. The clones were divided according to 
mean fluorescence intensity (MFI), i.e. ratPAR expression: low (MFI:10-60), medium (60-
200) and high (>200). Dots represent the average of the MFI from two independent 
experiments. Each clone was plotted according to PERV-A infection efficiency, determined 
by infection of 5x10
4 cells with EGFP(PERV) at MOI on 293T cells of 2 and expressed as 
percentage of EGFP positive cells. Data represent the average of two independent 
infections.  
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3.3 Discussion 
PERV-A can enter human cells through two paralogous proteins, huPAR-1 
and huPAR-2 (Ericsson et al., 2003). Rodent cells are resistant to PERV-A 
infection (Takeuchi et al., 1998). In this chapter, the mechanism of non-
permissivity to PERV-A infection in murine and rat cells has been 
investigated to better understand the molecular mechanism of PERV-A entry. 
The murine homologue to huPAR, muPAR, has been identified (Ericsson et 
al., 2003). Murine MDTF and quail QT6 cells are resistant to PERV-A entry. 
Upon expression of huPAR-1 and huPAR-2, but not muPAR, these cells 
become susceptible to virus infection (Figure 3.3), suggesting that PERV-A 
block occurs at entry level and that muPAR is not a functional receptor for 
PERV-A.  
In other γ-retrovirus receptors, it has been shown that few amino acid 
changes between homologous receptors in different species determine the 
ability to mediate virus entry (Albritton et al., 1993; Eiden et al., 1996; Johann 
et al., 1992; Lundorf et al., 1998; Marin et al., 2003a; Tailor et al., 1993; 
Yoshimoto et al., 1993). Chimeric receptor of huPAR-2 and muPAR have 
been generated and tested for their receptor function (Figure 3.4). One single 
amino acid substitution in huPAR-2 from leucine at position 109 to the murine 
corresponding proline was able to abrogate PERV-A infection. Conversely, 
muPAR bearing leucine109 instead of a proline, could mediate PERV-A entry 
in resistant quail QT6 cells. No other part of the receptor had the same 
dramatic effect on the function. These data were confirmed by a recently 
published report (Marcucci et al., 2009). 
Because proline 109 in muPAR could abrogate PERV-A infection, its 
localisation in the structure of the receptor was investigated. HuPAR-1, 
huPAR-2 and muPAR have the same topology model according to a 
transmembrane protein prediction software (TMHMM) characterised by 11 
transmembrane domains, 5 ECLs, an intracellular N-terminus and 
extracellular C-terminus (figure 3.6 C). The analysis of the orientation of the 
extremities (Figure 3.5) and the unique N-glycosylation site (Figure 3.6 B) 132 
 
provided evidences in support of the predicted topology. From this model 
amino acid 109 is localised in the ECL2. I hypothesised that this region could 
be PERV-A binding site and that the change in the structure of the loop due 
to the pro-to-leu substitution in muPAR could prevent virus binding and 
hence infection. Supporting data for this hypothesis was obtained by soluble 
PERV-A SU binding to QT6 cells that were expressing different PAR. 
Successful binding was observed for functional receptor huPAR-1 and 
huPAR-2 but not for muPAR. However, in QT6 cells expressing the mutant 
huPAR-2 with the substitution leu-to-pro at amino acid 109, the binding was 
abrogated (Figure 3.7 B). However, the exchange of proline 109 with a 
leucine in muPAR did not rescue the binding to soluble PERV-A SU, even if it 
did support infection (Figure 3.7 B). A possible explanation is that the trimeric 
form of Env present on the viral particle surface binds better than the 
monomeric soluble form used in the assay. Furthermore, other regions in the 
muPAR could be involved to achieve a binding efficiency which equals to 
huPAR.  
Rat cells as well as mouse cells are resistant to PERV-A infection (Figure 
3.3, Figure 3.8 B). However the mechanism appeared different. Firstly, the 
amino acid sequence of the ECL2 in ratPAR is identical to that of huPAR-1 
and huPAR-2, and does not share the proline 109 (Figure 3.8 A). 
Furthermore, upon overexpression of their own ratPAR, rat cells become 
susceptible to PERV-A infection, indicating that ratPAR is able to mediate 
PERV-A entry (Figure 3.8 B). In addition, when QT6 cells express similar 
amount of huPAR-1 and ratPAR, the efficiency in soluble PERV-A SU Env 
binding is similar (Figure 3.8 C). As these results indicated that rat cells 
encode a functional PERV-A receptor, other mechanisms of resistance were 
investigated. 
For other γ-retroviruses it has been shown that overexpression of the 
receptor rescued viral infection in the resistant cell lines of their origin (Tailor 
et al., 2000). The mechanism for this resistance was explained as masking, 
interference or a subthreshold level of expression of the receptor (Eiden et 
al., 1994; Lavillette et al., 2002a; Marin et al., 2000; Miller and Miller, 1992, 133 
 
1993; Tailor et al., 2000). These mechanisms were evaluated for PERV-A 
infection in rat cells. Firstly, the presence of a post-entry restriction factor 
acting on PERV-A GagPol was examined. In fact, although data presented in 
this chapter indicated that rat cells are insensitive to PERV-A infection by a 
receptor-mediated block, overexpression of a functional receptor in rat cells 
could also cause the entry of a greater amount of virus and saturate a 
restriction factor acting post-entry. As the best described restriction factor 
blocking retroviral infection prior integration are Fv1 and TRIM5α and they 
both target the viral capsid (section 1.6.1), VSV-G pseudotyped retroviral 
particles containing PERV-A14/220 GagPol were compared in their efficiency 
of EGFP transduction in rat cells with similar pseudotyped virus bearing the 
non restricted MoMLV GagPol. The titre obtained with PERV-A 14/220 
GagPol was 4 times lower than that obtained with MoMLV GagPol (Figure 
3.10). This reduction is lower than that obtained for sensitive N-tropic MLV 
and HIV-1 with Fv1 and TRIM5α (Stremlau et al., 2004; Towers et al., 2000) 
and it is not enough to fully block PERV-A infection in rat cells. Therefore, 
although the presence of a weak restriction factor in rat cells, acting on 
PERV-A14/220 GagPol, cannot be excluded, it did not explain the 
mechanism of resistance to PERV-A infection in rat cells. 
Likewise, removal of N-linked polysaccharide chains by tunicamycin 
treatment could partially rescue PERV-A infection in some rat cell lines. 
However, because the effect was not observed in all the rat cell lines tested 
and the degree of infection was more than 10-fold lower than in 293T cells 
(Figure 3.11), the receptor masking by N-linked glycosylation could not be 
considered the main mechanism of resistance to PERV-A infection. Presence 
of inhibitory factors in the media of cells was not detected by EGFP(PERV) 
infection of different cell lines in the presence of conditioned media from rat 
NRK cell (Figure 3.12).  
Endogenous ratPAR mRNA expression in rat cells was measured by 
quantitative RT-PCR and compared to the level of huPAR-1 mRNA in PERV-
A susceptible human cells. On average rat cells express 4 times less 
receptor than human cells (Figure 3.9). To test whether this difference could 134 
 
be responsible for the resistance of rat cells to PERV-A infection, the amount 
of exogenously expressed ratPAR mRNA was correlated to the efficiency of 
EGFP transduction of the pseudotyped PERV-A14/220. Rat cells became 
PERV-A sensitive when the amount of ratPAR mRNA was increased of 40 to 
500-fold (Figure 3.13 A). Moreover, it was possible to correlate a higher 
efficiency of PERV-A infection with a higher level of ratPAR expression in 
QT6 cell clones expressing different amount of HA-tagged receptor (Figure 
3.13 B). These results suggested that ratPAR expression in rat cells is under 
the threshold level which allowed PERV-A infection. However, it is not clear 
whether this subthreshold level is due to a low transcription (i.e. mRNA 
expression) or other mechanisms which prevent the display of ratPAR on the 
cell surface. 
In conclusion, two closely related species, rat and mice, have different 
mechanisms to escape PERV-A infection. Murine cells encode a homologue 
of huPAR which is defective in PERV-A receptor function. Since one single 
amino acid exchange in muPAR can rescue PERV-A infection, this indicates 
a critical region in the receptor, likely involved in the virus binding. In contrast, 
rat cells express a functional receptor. My results suggest that the level of 
ratPAR expression is below a threshold level required to support PERV-A 
entry, but the mechanism for this is not clear. These results could help 
identifying possible targets for the development of therapeutics that block 
PERV-A infection, such as neutralising antibodies and peptides mimicking 
the receptor. 
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Chapter 4 
4   Evaluation of PERV-A receptors in non-human 
primates 
 
4.1 Introduction 
Although PERV infection has not been detected in retrospective analysis of 
patients treated with porcine cells and tissues (Clemenceau et al., 2001; 
Cunningham et al., 2001; Elliott et al., 2000; Heneine et al., 1998; Paradis et 
al., 1999; Patience et al., 1998), this risk in xenotransplantation in future 
cannot be excluded. Retroviruses are responsible for several human and 
animal pathologies (section 1.3.4) and therefore the possible consequences 
following PERV infection must be investigated. Small animals as well as non-
human-primates (NHP) have been employed as models. 
The most common small animal model chosen has been either severe 
combined immunodeficiency (SCID) or nude mice. In SCID mice, due to a 
mutation in a DNA-dependent protein kinase, T and B cells are unable to 
differentiate and therefore both humoral and cellular immune response are 
not functional. Nude mice have no T cell response. Immunocompromised 
mice were considered a good model because they mimic the 
immunosuppression in xenotransplantation patients. Infection by PERV of 
mouse tissues has been quite controversial. Initial reports showed that PERV 
produced from pig pancreatic cells transplanted in SCID mice could infect 
mouse tissues but the virus appeared not to be transcriptionally active in 
murine cells, suggesting a non-productive infection (Deng et al., 2000; van 
der Laan et al., 2000). Although microchimaerism was observed, the ratio 
between PERV-specific sequences and porcine cell sequences in mouse 
tissues was higher than in pig cells, inferring amplification of PERV genomes 
by PERV infection of mouse cells. Similar results were obtained in nude mice 
(Clemenceau et al., 2002; Zhang et al., 2005). However, when 
microchimaerism was avoided by injection of cell-free viruses, PERV 
infection of murine cells was not detected in vitro or in SCID mice (Irgang et 136 
 
al., 2005). Following the cloning of human PERV-A receptors, the 
homologuous muPAR was found not functional in supporting PERV-A 
infection (Ericsson et al., 2003). The murine model was therefore considered 
not permissive to PERV-A infection, which is more problematic than PERV-B 
because PERV-A is present in the pig genome at higher level than PERV-B 
(Le Tissier et al., 1997) and can recombine with PERV-C to produce high-
titre human tropic recombinant PERV (Bartosch et al., 2004; Harrison et al., 
2004; Oldmixon et al., 2002; Wilson et al., 2000). However, 
immunodeficiency mice were still used to test PERV infection of human cells 
in vivo. SCID mice were injected with human peripheral blood leukocytes and 
porcine cells were transplanted. Human cells were infected by PERV in vivo 
(Kuddus et al., 2004; McKane et al., 2003). The interpretation of these results 
was complicated by the discovery that PERV particles could be pseudotyped 
in vivo with endogenous xenotropic MLV which can mediate infection 
(Martina et al., 2005; Yang et al., 2004). A different model which allowed 
investigation of PERV infection in a fully competent animal was represented 
by transgenic mice expressing huPAR-2. In this system not only could PERV 
infection be observed in mouse cells but the immune response could be also 
evaluated. After infection with cell-free virus (to avoid microchimaerism) 
PERV DNA, RNA and proteins were detected in several murine tissues and 
some mice developed anti-PERV antibodies (Martina et al., 2006). 
NHP represent an ideal animal model to evaluate the immunological 
response to pig xenografts because similar to humans, NHPs possess 
circulating anti-αGal antibody (section 1.1.1). In several studies conducted 
using transgenic pigs, the animal of choice was mainly baboon (Papio 
hamadras) or cynomolgus monkey (Macaca fascicularis) [reviewed in:(Ekser 
et al., 2009)]. Surveillance for PERV infection of these animals could assess 
the risk of PERV transmission to xenotransplant recipients. Pig-to-NHP 
transplantation could offer the opportunity to study long term exposure to the 
xenograft and to analyse more tissues, two advantages in comparison to the 
retrospective studies in humans exposed to porcine materials. Studies 
conducted on NHP injected with cell-free high titre viruses, cells or solid 
organ transplantation in immunosuppressed animals showed no evidence of 137 
 
PERV infection [(Elliott et al., 2005; Isaac et al., 2005; Moscoso et al., 2005; 
Nishitai et al., 2005; Specke et al., 2009) and reviewed in (Denner, 2003)]. 
The use of NHP to assess the risk of PERV transmission has been debated. 
Initial studies showed that NHP cell lines were non-permissive for PERV 
infection (Martin et al., 1999; Patience et al., 1997; Takeuchi et al., 1998; 
Wilson et al., 2000). Other reports, which used PCR or RT-PCR to detected 
PERV sequences, suggested that NHP cells are susceptible (Blusch et al., 
2000a; Specke et al., 2001; Templin et al., 2000). Using a high titre PERV 
derived from NIH minipigs and adapted in vitro through three passages in 
human cells it was possible to show that PERV carrying a reporter gene (β-
galactosidase) could infect rhesus macaque and African green monkey 
(AGM) cell lines. In the infected NHP cells, PERV provirus and transcripts 
were detected but no reverse transcriptase activity was found in the 
supernatant of these cells, suggesting that PERV infection of NHP cells was 
not productive (Ritzhaupt et al., 2002). However the mechanism responsible 
for the poor infectivity and the lack of PERV replication in NHP cells was not 
explained. 
The cloning of PERV-A receptors (Ericsson et al., 2003) and the isolation of 
the high-titre recombinant PERV-A14/220 (Oldmixon et al., 2002) allowed the 
re-evaluation of PERV infection in NHP cells. In this chapter, the aim was to 
clarify the reasons for the low susceptibility of NHP cells to PERV infection 
and provide information which can be used in the choice of the NHP species 
to use as animal model to study PERV transmission. 
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4.2   Results 
 
4.2.1   The low PERV permissivity is mainly caused by reduced entry in 
NHP cells. 
Infection and replication of PERV-A were monitored in different NHP cell 
lines as shown in figure 4.1. 
PERV entry was analysed by infection of 5x10
4 AGM COS7 and VERO cells 
and rhesus macaque FRhK4 cells with serial dilution of the EGFP(PERV) 
supernatant (section 2.3.3). PERV-A titre on COS7 and FRhK4 cells was 
more than two orders of magnitude lower than that on human 293T cells 
(2x10
5 Etu/mL). The level of infection of AGM VERO cells was under the 
detection limit (10 Etu/mL) (Figure 4.2 A). To test whether weak PERV-A 
receptor activity could be responsible for the low infectivity, COS-7, VERO 
and FRhK4 cells were transduced with a retroviral vector carrying huPAR-2 
gene. EGFP(PERV) titre on huPAR-transduced NHP cells increased at least 
37 times in comparison with the parental cells (Figure 4.2 A). Although the 
level of huPAR-2 expression in NHP cells was not assessed, expression of a 
functional receptor increased the permissivity of NHP cells to PERV infection, 
suggesting a possible role for NHP PAR in the low level of infectivity.  
After EGFP(PERV) infection, wild type and huPAR-transduced cells were 
kept in culture for the following experiments. 
A week post-infection, the level of PERV gag gene in the NHP cell genome 
was investigated. 200 ng of genomic DNA was processed in a SYBR Green-
based quantitative PCR reaction using PERV gag specific primers (table 
2.3.4). PERV Gag copy number in the different NHP cells correlated with the 
titre determined by EGFP expression. Notably, PERV gag was detected in 
wild type VERO cells, although EGFP expression was under the sensitivity 
limit of the infection assay (Figure 4.2 B).  
1 µg of total RNA, extracted from wild type and huPAR-transduced cells two 
weeks post-infection, was reverse transcribed and one eighth was processed 
in SYBR Green-based quantitative RT-PCR. Similar to the results obtained 139 
 
from the genomic DNA analysis, the level of transcription of PERV Gag 
correlated with the EGFP(PERV) titre (Figure 4.2 C). 
To determine whether PERV can productively infect NHP cells, the presence 
of infectious viral particles in the supernatant of infected cells was 
investigated. 1x10
6 HuPAR-transduced and parental cells were seeded and 
the day after their supernatant was collected and serial dilutions were used to 
infect 293T cells. PERV titre was determined 3 days later by colony counting 
of the infected cells, immunostained with an anti-PERV CA antibody.  
No infectious viruses were present in the supernatant of wild-type FRhK4 and 
VERO cells for up to three weeks post infection. For VERO cells, 5 i.u./mL 
detected at weeks 2 and 3 were at the borderline of this assay sensitivity, 
hence not a clear indication of a productive infection. Instead, viral titre in the 
supernatant of wild type COS7 and huPAR-transduced cells grew in the first 
two weeks and stabilised at week three (Figure 4.2 D). Interestingly, the 
difference in the titre produced from COS7 wild-type versus huPAR-
transduced cells was similar to the difference in the (EGFP)PERV infection of 
this cell line. Taken together, these results suggested that once PERV 
successfully entered the NHP cells, provirus could integrate in the host 
genome, viral genes be transcribed and infectious particles produced. 
Therefore, an inefficient cell entry was likely to be responsible for the low 
susceptibility of NHP cells to PERV-A. 
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Figure 4.1 Diagram of the analysis of PERV infection in NHP cell 
Four critical steps (A-D, results shown in corresponding panels in Figure 4.2) in the 
virus life cycle (left column) were analysed using the methods described in the 
middle column performed at specific post-infection time points (right column). 
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Figure 4.2 Monitoring of PERV infection in NHP cells 
Rhesus macaque FRhK4 cells and AGM COS7 and VERO cells were transduced with a 
VSV-G pseudotyped MLV-based vector carrying human PAR-2 gene (huPAR-2). 5x10
4 
huPAR-2 transduced (grey bars) or wild type (white bars) cells were infected with serial 
dilution of PERV(EGFP) with the highest MOI (on 293T cells) being 2. A) 72 hours post 
infection, efficiency of EGFP delivery was determined by flow cytometry. Titres were 
calculated as previously described (section 2.3.4). and expressed as EGFP transducing 
units (Etu)/mL. EGFP(PERV) infection on VERO cells was under the detection limit 
(<10Etu/mL, arrow). Histograms represent the average of three independent experiments (± 
standard error of the mean). B) One week post-infection, genomic DNA was extracted and 
200 ng was employed per reaction in a SYBR Green-based quantitative PCR using PERV 
gag specific primers QF5,QR5 (Table 2.3.4). C) Two weeks post-infection, total RNA was 
extracted and 1 µg was reverse transcribed. One eighth was employed in a SYBR Green-
based quantitative RT-PCR using PERV gag specific primers. The amount of gag copies 
was inferred by a standard curve and normalised per 18S rRNA copy. Each sample was run 
in duplicate. Histograms represent the average of two independent experiments (± standard 
error of the mean). D) At the different time points indicated, 1x10
6 huPAR2-transduced (grey 
square) or wild type (white circles) FRhK4, COS7 and VERO cells were seeded. The day 
after, supernatant was collected and 5 fold dilutions used to infect 293T cells. 72 hours later, 
cells were immunostained with an anti-PERV CA antibody. Alkaline phosphatase positive 
colonies were counted at the visible light microscope and titres determined as infectious unit 
per mL (i.u./mL). Data represent the average of two independent experiments (± standard 
error of the mean). 
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4.2.2   Functional analysis of the NHP PERV-A receptors 
The NCBI database was searched for homologous sequences to huPAR-1 
and huPAR-2 in NHP. Chimpanzee and rhesus macaque PAR-1 and PAR-2 
were identified. Baboon PAR-2 (baPAR-2) has been cloned previously 
(Ericsson et al., 2003). NHP PARs have been cloned by RT-PCR of the RNA 
extracted from primary cells or cell lines as summarised in table 4.1. Both 
baPAR-2 and rhesus macaque PAR-1 (rhPAR-1) sequences, cloned from 
primary baboon PBMC and FRhK4 cells respectively, had one amino acid 
different (L19F or C309Y) from the sequences deposited in GenBank. 
However, rhPAR-2 cloned from FRhK4 cells had the same amino acid 
sequence as XP_001099620.1. 
Amino acid sequences were aligned using ClustalW programme. 
Extracellular domain 2 (ECL2) was located according to the huPAR-2 
topology (section 3.2.3). The sequence of ECL2 was well conserved among 
different species with the exception of a serine instead of a leucine at amino 
acid 109 in rhPAR-1, cynomologus monkey PAR-1 (cynPAR-1) and baboon 
PAR-1 (baPAR-1) (Figure 4.3 A). This mutation was of particular interest 
because it was located at a.a. 109, which has been previously described as 
critical for PERV-A infection and binding (section 3.2.2 and 3.2.4). 
To test the ability of the NHP receptors to support PERV-A entry, NHP PARs 
were HA-tagged at the C-terminus and subcloned into a MLV-based retroviral 
vector. PERV-A resistant QT6 cells were transduced using VSV-G 
pseudotyped MLV particles carrying PAR genes. More than 50% of the cells 
expressed the receptors as assessed by flow cytometry analysis after 
immunostaining with an anti-HA antibody (Figure 4.3 B diamond). PAR-
expressing cells were infected with EGFP(PERV) and the titre determined by 
monitoring EGFP signal. The titres have been represented as percentage of 
the titre obtained on huPAR-1-QT6 cells (Figure 4.3 B bars). All the PARs 
tested conferred permissivity to PERV-A entry in QT6 cells, with the 
exceptions of cynPAR-1, baPAR-1, rhPAR-1. These receptors share the 
serine at a.a. 109, which is different from the other receptors (Figure 4.3 A). 
To test whether the L109S change was responsible for the inability to support 144 
 
PERV-A entry, a huPAR mutant carrying a serine instead of leucine in ECL2 
(huPAR-1S109) and a rhPAR-1 with the opposite mutation (rhPAR-1L109) 
were generated. Once expressed in QT6 cells rhPAR-1L109 could efficiently 
mediated PERV-A entry. Instead, the ability of huPAR-1S109 to function as 
receptor was reduced up to 85% (Figure 4.3 B). The amino acid substitution 
in position 109 appeared to have a negative effect on the receptor function. 
 
 
Receptor  species  NCBI acc no.  cell origin  primers 
huPAR‐1  Homo sapiens  NP_078807.1  Ericsson et al 2003 
chimPAR‐1  Pan troglodytes  XP_0010990939.1 not cloned 
AGMPAR‐1  Cercopithecus aethiops  n/a  COS7;VERO  CF6;CR5 
baPAR‐1  Papio anubis  n/a  PMBC  CF6;CR5 
rhPAR‐1  Macaca mulatta  XP_001090939.1  FRhK4  CF5;CR5 
cynPAR‐1  Macaca fascicularis  n/a  primary splenocytes  CF6;CR5 
huPAR‐2  Homo sapiens  NP_060456.3  Ericsson et al 2003 
chimPAR‐2  Pan troglodytes  XP_523560.1  not cloned 
AGMPAR‐2  Cercopithecus aethiops  n/a  COS7;VERO  GF2;GR5
baPAR‐2  Papio hamadras  Q863Y8.1  Ericsson et al 2003    
   Papio anubis     PBMC  CF4;CR4 
rhPAR‐2  Macaca mulatta  XP_001099620.1  FRhK4  CF4;CR4 
cynPAR‐2  Macaca fascicularis  n/a  primary splenocytes  CF4;CR4 
 
Table 4.1 List of NHP PERV-A receptors 
PERV-A receptors used in this chapter are listed. NCBI accession number is reported for the 
deposited protein sequences. For the receptors cloned in this thesis, the cell lines or primary 
cells from which total RNA have been extracted and the primers used for PAR amplification 
are indicated. 
 
   145 
 
 
 
 
Figure 4.3 Functional analysis of NHP PARs 
A) Human (huPAR-1 and huPAR-2), mouse (muPAR), rat (ratPAR), chimpanzee (chimPAR-
1 and chimPAR-2), rhesus macaque (rhPAR-1 and rhPAR-2) PAR and baboon PAR-2 
(baPAR-2) sequences were present in the NCBI database (Table 4.1). African green monkey 
(AGMPAR-1 and AGMPAR-2), cynomolgus macaque (cynPAR-1 and cynPAR-2) PAR and 
baboon PAR-1 (baPAR-1) sequences were obtained by RT-PCR of RNA extracted from 
NHP cell lines and primary cells using specific primers (Table 4.1). Amino acid sequences 
were aligned using ClustalW software. Extracellular loop 2 (ECL2) in huPAR-2 as defined in 
section 3.2.3 is indicated (red line) and the three amino acids different between muPAR and 146 
 
huPARs are highlighted (red). All the primates and rat PAR sequence share the same three 
amino acids as huPARs (bold). RhPAR-1, cynPAR-1 and baPAR-1 had one amino acid 
different (red). B) C-terminal HA-tagged PAR sequences were cloned into a MLV-based 
vector and introduced into quail QT6 cells by transduction of VSV-G pseudotype retroviral 
particles. Percentage of HA-positive cells was calculated by cell surface staining of the 
transduced cells (black diamond). 5x10
4 PAR expressing QT6 cells were seeded and the 
day after infected with serial dilution of (EGFP)PERV-containing supernatant. The highest 
MOI as determined on 293T cells was equal to 2. After 72 hours, EGFP expression was 
monitored and titres inferred. EGFP(PERV) titre on huPAR-1 expressing QT6 cells was 
1.7±0.5x10
4 Etu/mL and arbitrarily chosen as 100% infection. Histograms represent the 
average of three independent experiments (± standard error of the mean). 
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4.2.3  Serine 109 abrogates PERV-A binding 
The mutation of amino acid 109 from leucine to proline in muPAR (section 
3.2.2) or serine in rhPAR-1, cynPAR-1 and baPAR-1 reduced the ability of 
PERV-A to use these proteins as receptors. MuPAR and huPAR-1P109 
binding to soluble PERV-A Env was undetectable. The effect of the serine in 
ECL2 on the binding was investigated. QT6 cells expressing huPAR-1 or 
huPAR-1S109 were incubated with soluble PERV-A360 Env (section 2.3.8). 
The cells were stained using a FITC-conjugated anti-rabbit IgG antibody and 
processed in flow cytometry (Figure 4.4 A). Incubation with PERV-A360 
produced a shift toward higher fluorescence intensity only in cells expressing 
huPAR-1 but not for those carrying huPAR-1S109. Conversely, rhPAR-1 was 
unable to bind soluble PERV-A360 but a positive signal was detected for 
rhPAR-1L109 (Figure 4.4 B). These results suggested that S109 in rhPAR-1 
not only negatively affects the receptor function but also the binding to 
PERV-A Env.  
 
 
Figure 4.4 PERV-A Env binding of rhPAR-1 
5x10
5 QT6 cells, stably expressing HA-tagged PARs, were incubated with 100 ng of PERV-
A360 Env protein and a secondary FITC-conjugated anti-rabbit IgG antibody. Cells were 
analysed by flow cytometry. Cells carried the following receptors huPAR-1 (A, black filled). 
huPAR-1S109 (A, grey line), rhPAR-1 (B, black filled) and rhPAR-1L109 (B, grey line). 
Graphs show a representative result of two independent experiments. 148 
 
4.2.4  Expression of endogenous PERV-A receptors 
AGM cells encode two functional receptors while rhesus macaque cells carry 
only one, rhPAR-2. To understand the poor permissivity of NHP cells to 
PERV-A, the expression of PARs in NHP cells were investigated. Although 
the amount of the receptors displayed on the cell surface would be more 
informative, due to the lack of an anti-PAR antibody, the mRNA level was 
measured by quantitative RT-PCR. PERV-A susceptible human cell lines 
293T, HT1080, HeLa and primary PBMC were used as a comparison.  
PAR-1 mRNA level was found similar in NHP and human cells. Primary cells 
express about five times less PAR-1 mRNA than the cell lines (Figure 4.5). 
The amount of PAR-2 mRNA was more variable. All human cells and AGM 
VERO had a low level of PAR-2, at least 2.5 order of magnitude inferior of 
PAR-1. Instead, FRhK4 cells, primary baboon PBMC and cynomolgus 
splenocytes expressed ten times more PAR-2 mRNA than human cells and 
VERO, with the difference between PAR-1 and PAR-2 mRNA reduced to 
about 5 fold in primary cells (Figure 4.5). 
Rhesus macaque, cynomolgus monkey and baboon express the mRNA for a 
not functional receptor (PAR-1) at a similar level to human cells. PERV-A 
infection in these NHP is probably mediated by PAR-2, whose mRNA is 
expressed at a lower level than PAR-1, hence the poor permissivity to PERV-
A. These data showed also that AGM VERO and COS7 cells had two 
functional receptors and their mRNA was expressed at a similar level to 
highly permissive human cell lines. Therefore, other causes will be evaluated 
to understand PERV-A infection in NHP cells. 
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Figure 4.5 Expression of mRNA for endogenous PAR 
Total RNA was extracted from NHP and human cell lines and primary cells and 1 µg was 
reverse transcribed. One eighth of the final volume of the reaction was employed in a SYBR 
Green-based quantitative RT-PCR. Primers used were QF6,QR6 for NHP PAR-1 (white 
bars, left) QF1, QR1 for huPAR-1 (white bars, right) QF7,QR7 for NHP PAR-2 (grey bars, 
left) and QF2,QR2 for human PAR-2 (grey bars, right) (Table 2.3.4). PAR copy number was 
inferred from standard curves and normalised per 18S rRNA copy. Histograms represent 
average of at least two independent experiments (± standard error of the mean). 
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4.2.5   Lack of a post-entry restriction acting on PERV Gag-Pol 
Restriction factors acting in a way similar to Fv1 and TRIM5α are the best 
characterised (section 1.6.1). Their expression in, otherwise permissive, cells 
have been showed to reduce retroviral titre more than 10-fold (Stremlau et 
al., 2004; Towers et al., 2000). The viral determinant for restriction was 
mapped in both cases on the CA protein (Besnier et al., 2003; Kozak and 
Chakraborti, 1996; Perron et al., 2004; Towers et al., 2002). Their block can 
be abrogated by virus input saturation (i.e. using a high multiplicity of 
infection) (Towers et al., 2002). 
VSV-G pseudotyped viruses with a MLV-based retroviral vector expressing 
EGFP were generated by transfection of 293T cells together with packaging 
plasmid expressing GagPol of either PERV-A14/220 or unrestricted MoMLV 
(Keckesova et al., 2004; Kozak, 1985; Perron et al., 2004). 48 hours post 
transfection, the pseudotyped viruses were titrated on human 293T, AGM 
COS7 and VERO cells. Titre of the MoMLV/VSV-G virus was similar between 
human and AGM cells. PERV-A14/220 GagPol titre was reduced only 5-fold 
in AGM cells in comparison to 293T cells (Figure 4.6 A), suggesting that 
there is no strong restriction factor acting on PERV GagPol.  
To further demonstrate that the major determinant of low PERV permissivity 
in AGM cells is at receptor level and not at a post-entry step, psudotyped 
viruses with different Env proteins were generated. 293T cells were co-
transfected with an MLV-based retroviral vector carrying EGFP gene, a 
plasmid encoding PERV-A14/220 GagPol and either PERV-A14/220 or MLV-
A Env expressing plasmid. Viruses were titrated on 293T, COS7 and VERO 
cells by monitoring EGFP expression. MLV-A Env was able to rescue the titre 
of the pseudotyped viruses in AGM cells to a similar level than that seen in 
human cells, suggesting that the inhibition of PERV infection in AGM cells 
occurs at cell entry level (Figure 4.6 B). 
The presence of a saturable post-entry restriction factor was further 
investigated. Two different viruses were produced by three plasmid 
transfection of 293T cells, both have PERV-A14/220 Gag-Pol and PERV-151 
 
A14/220 Env. MLV-based retroviral vector encoding EGFP (PERV/EGFP) or 
pcDNA (PERV) were cotransfected. Human 293T, murine NIH3T3 and AGM 
COS7 and VERO cells were incubated with different amount of PERV. After 
6 hours, cells were infected with a fixed volume of PERV/EGFP supernatant. 
No difference was registered in the PERV/EGFP titre using different ratio 
(v/v) of the two viruses (Figure 4.6 C). These data suggested that no 
restriction factors acting in a Fv1 or Trim5 similar way can be held 
responsible for the poor susceptibility of NHP cells to PERV-A. 
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Figure 4.6 Analysis of post-entry block of PERV-A in AGM cells 
A) VSV-G pseudotyped viruses carrying MLV-based retroviral vector encoding the EGFP 
gene were produced by co-transfection of 293T cells with packaging plasmids for PERV-
A14/220 GagPol (grey) or MoMLV GagPol (white). Titres on human 293T, AGM COS7 and 
VERO cells were determined by flow cytometry analysis of EGFP expression. Histograms 
represent the average of two independent experiments (± standard error of the mean). B) 
Pseudotyped viruses were generated by co-transfection of 293T with MLV-based retroviral 
vector carrying EGFP gene, PERV-A14/220 GagPol and PERV-A14/220 Env (grey) or MLV-
A Env (white). 293T, COS7 and VERO cells were infected with serial dilution of the virus-
containing supernatant and titres determined by monitoring EGFP expression. Histograms 
represent the average of two independent experiments (± standard error of the mean). 
Arrows indicated a titre under the detectable limit (10 Etu/mL) C) Two pseudotyped viruses 
were produced by three plasmid transfection of 293T cells, both having PERV-A14/220 
GagPol and Env. MLV-based vector carrying EGFP gene for the reporter virus 
(PERV/EGFP) or pcDNA3 for the saturation virus (PERV) were co-transfected. 5x10
4 293T 
(grey), COS7 (white), VERO (black) or NIH3T3 (striped) cells were seeded. Prior to infection, 
cells were incubated with different amount of saturation virus, with a range between 0 and 
500 µL for COS7, VERO and NIH3T3 cells and between 0 and 100 µL for 293T cells. After 6 
hours cells were infected with 250 µL (COS7, VERO and NIH3T3) or 50 µL (293T) of the 
PERV/EGFP-containing supernatant. The fixed amount of reporter virus was chosen to 
achieve a percentage of infection of about 1% in 293T and COS7 cells. Histograms 
represent the average of two independent experiments (± standard error of the mean). 
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4.2.6  Absence of inhibitor secreted from NHP cells 
Secretion of inhibitor molecules in the medium has been described as 
mechanism for MLV-A and GALV inhibition in hamster cells (Miller and Miller, 
1992, 1993).  
Human 293T cells were incubated overnight with dilutions of the conditioned 
medium from COS7, VERO or 293T cells and infected with serial dilution of 
PERV(EGFP) in presence of conditioned medium. After 72 hours, EGFP was 
monitored by flow cytometry and the titre calculated. No significant effect was 
observed (Figure 4.7). No factors able to reduce the infection of PERV-A 
were detected in the supernatant of NHP cells. 
 
 
 
 
 
Figure 4.7 PERV-A infection in conditioned media from NHP cells. 
5x10
4 293T cells were seeded and incubated overnight with 0.45µm filtered conditioned 
media (or dilutions as indicated) harvested from confluent 293T (white), COS7 (grey) or 
VERO (black) cells. The day after, cells were infected with serial dilution of EGFP(PERV) in 
conditioned media. Titres were determined by flow cytometry analysis. Histograms represent 
the average of two independent experiments (± standard error of the mean). 155 
 
4.2.7  Tunicamycin treatment of NHP cells partially rescued PERV-A 
infection but not binding 
Removal of N-linked glycosylation by tunicamycin treatment of the target 
cells has been showed rescuing retroviral infectivity in certain cell lines 
(section 1.5.5). 
To test whether N-linked glycosylation could play a role in AGM cells low 
susceptibility to PERV-A infection, 293T, COS7 and VERO cells were 
infected with serial dilution of EGFP(PERV) after overnight treatment with 
tunicamycin. Drug concentration was chosen for each cell line according to 
its toxicity (Figure 4.8 legend). Titres were inferred from EGFP expression. 
Tunicamycin had no effect on PERV infection of 293T cells. Instead, the viral 
titre on tunicamycin-treated AGM cells was more than 10 fold higher than 
untreated cells (Figure 4.8 A). These data suggested that removal of N-linked 
glycosylation in AGM cells could relieve a possible block to PERV-A infection 
or compensate an independent inhibition mechanism. To better understand 
the role of tunicamycin in the improvement of the susceptibility to PERV-A, I 
analysed the effect this drug had on PERV-A binding on AGM cells. 
COS7, VERO and 293T cells were grown overnight in presence of 
tunicamycin. The day after, 5x10
5 treated and untreated cells were incubated 
with soluble PERV-A360 Env or PERV-C360 Env, as negative control. 
Binding to the cells was detected by staining with a FITC-conjugated anti-
rabbit IgG antibody and analysed by flow cytometry (Figure 4.8 B). PERV-
A360 Env, but not PERV-C360, successfully bound to 293T cells. As for 
infectivity, no difference was notable after tunicamycin treatment. No binding 
was detected to AGM cells either tunicamycin-treated or untreated. These 
results could suggest that tunicamycin treatment can partially rescue PERV-
A infectivity in AGM cells but not the binding. However, the lack of binding 
when infection was measured could be due to a low sensitivity of this assay.  
  156 
 
 
 
Figure 4.8 Tunicamycin treatment of NHP cells 
A) 5x10
4 cells were treated for 16 hours with tunicamycin at the final concentration of 100 
ng/mL (293T cells) or 200 ng/mL (COS7 and VERO cells). Tunicamycin-treated (grey) or 
untreated (white) cells were infected with serial dilution of EGFP(PERV). After 72 hours, 
titres were inferred by EGFP expression monitored by flow cytometry. Histograms represent 
the average of four independent experiments (± standard error of the mean). B) 5x10
5 
tunicamycin-treated (+T) and untreated 293T, COS7 and VERO cells were incubated with 
100 ng in 0.5 mL of soluble PERV-A360 Env (A) or the same amount of PERV-C360 Env 
(C), as negative control. PERV Env binding was detected using a FITC-conjugated anti-
rabbit IgG antibody and flow cytometry analysis. Graphs show a representative result of 
three independent experiments.  
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4.2.8   Analysis of tunicamycin effect on PAR-overexpressing cells 
To improve the study of the tunicamycin effect on different PARs and cells, 
huPAR-1 and AGMPAR-1 were stably overexpressed on COS7 and VERO 
cells as well as on quail QT6 cells. Receptors were delivered using an MLV-
based retroviral vector and cells were transduced between 2 and 3 times until 
more than 98% of the cells expressed the HA-tagged PARs. 
The level of the HA-tagged receptor on the cell surface was determined by 
staining of the cells with an anti-HA antibody and flow cytometry analysis. 
The mean fluorescence intensity (MFI) for each cell population was 
normalised to the MFI of the wild type cells (Figure 4.9 A and B). 5x10
4 cells 
were seeded and incubated overnight in presence of tunicamycin. The day 
after, cells were either infected with EGFP(PERV) or processed for the 
binding to PERV-A360 Env. Whilst PERV infection of 293T and quail QT6 
cells was not affected by tunicamycin treatment, the susceptibility of AGM 
cells to PERV-A infection was increased regardless the receptor (huPAR-1 or 
AGMPAR-1) expressed (Figure 4.9 A). This result indicated that tunicamycin 
partial rescue of permissivity to PERV-A in AGM cells was cell-specific and 
did not depend on the receptor expressed. 
The binding of PERV-A360 Env was quantified by flow cytometry analysis. 
The MFI obtained by incubating cells with soluble PERV-A360 Env was 
normalised to the MFI produced using PERV-C360 Env. Binding to AGM 
cells was measurable only when PARs were overexpressed. Tunicamycin 
treatment reduced the amount of Env bound to the cells. From analysis using 
a visible light microscope of the tunicamycin-treated cells and from the 
morphological gate of the cells during flow cytometry analysis, the reduction 
in the binding did not appear to be due to toxicity of the tunicamycin 
treatment.  
To further confirm tunicamycin effect on PERV-A infection and binding, single 
clone populations, expressing different amounts of huPAR-1 or AGMPAR-1, 
were generated. Quail QT6 and AGM COS7 cells were transduced with a 
retroviral vector carrying C-terminal tagged huPAR-1 or AGMPAR-1. Single 158 
 
clones were picked and receptor level on cell surface was measured by 
staining with an anti-HA antibody and flow cytometry analysis. MFI for each 
clone was normalised to the MFI of the wild type cells. Cell clones were 
treated overnight with tunicamycin and processed for PERV-A infection and 
PERV-A360 Env binding as described above for the PAR-transduced bulk 
population. Tunicamycin treatment increased susceptibility to PERV-A 
infection only for COS7 cell clones while QT6 cell clones were unaffected 
(Figure 4.10 A and B). No difference in the binding to PERV-A360 Env was 
observed between tunicamycin-treated and untreated cell clones (Figure 4.10 
C and D). 
Taken together these results showed that PERV-A infection in AGM cells, but 
not human or quail cells, was increased by tunicamycin treatment, although 
the mechanism is unclear. Results on soluble PERV-A Env binding to AGM 
cells suggested that tunicamycin treatment do not enhance virus binding to 
the receptor. 
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Figure 4.9 Tunicamycin treatment of exogenous PAR-expressing cells 
Quail QT6, AGM COS7 and VERO cells were stably transduced with VSV-G pseudotyped 
MLV-vector carrying HA-tagged huPAR-1 or AGMPAR-1. More than 98% of the cells were 
positive for anti-HA antibody staining (graphs in Figure 4.12). MFI for each population has 
been normalised to (i.e. divided by) the MFI of the wild type (HA staining-negative) cells 
(black diamond). Cells were treated for 16 hours with tunicamycin at the final concentration 
of 100 ng/mL (293T cells), 200 ng/mL (COS7 and VERO cells) or 25 ng/mL (QT6 cells). A) 
Tunicamycin-treated (grey) or untreated (white) cells were infected with serial dilution of 
EGFP(PERV). After 72 hours, titres were inferred by EGFP expression monitored by flow 
cytometry analysis. Histograms represent the average of two independent experiments (± 
standard error of the mean). B) 5x10
5 tunicamycin-treated (grey) and untreated (white) cells 
were incubated with 100 ng in 0.5 mL of soluble PERV-A360 Env or PERV-C360 Env. PERV 
Env binding was detected using a FITC-conjugated anti-rabbit IgG antibody and flow 
cytometry analysis. Histograms represent the binding measured as MFI obtained with PERV-
A360 Env normalised to MFI recorded with PERV-C360 Env. 
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Figure 4.10  Dependence of  PERV-A infection and Env binding on PAR expression 
level 
Quail QT6 (black) and AGM COS7 (white) cells were stably transduced with VSV-G 
pseudotyped MLV-vector carrying HA-tagged huPAR-1 (diamond) or AGMPAR-1 (circle). 
Single cell clones were grown and the level of the receptor tested by staining with an anti-HA 
antibody. Clones with different MFI (normalised on the MFI of wild type cells) were selected. 
5x10
4 tunicamycin treated (B) or untreated (A) cells were seeded and, the day after, infected 
with serial dilutions of EGFP(PERV). Titres were inferred from EGFP expression and 
showed in correlation with the HA surface staining. Each dot represents the average of two 
independent experiments. 5x10
5 tunicamycin-treated (D) or untreated (C) cells were 
incubated with 100 ng in 0.5 mL of PERV-A360 Env or PERV-C360 Env. PERV Env binding 
was detected by immunostaining with a FITC-conjugated anti-rabbit IgG antibody and 
showed as MFI Env-A360 normalised on the MFI Env-C360. Dots in the graph represent the 
average of two independent experiments. 162 
 
4.2.9  Tunicamycin does not affect PERV-A attachment to the cell 
surface 
Different cell surface molecules other than the receptor could mediated 
PERV-A adsorption to the cells and facilitate the interaction with the cognate 
receptor and indirectly influence the infectivity. Tunicamycin treatment 
prevents N-linked glycosylation of all the cellular proteins. Therefore, I 
investigated whether tunicamycin-mediated enhancement of PERV-A 
infection in NHP cells could be due to an increased attachment to 
deglycosylated proteins other than the receptor.  
2x10
5 293T, QT6, COS7 and VERO cells were seeded on a cover slip and 
treated overnight with tunicamycin. The day after, cells were incubated with 
4.5x10
6 i.u/mL of PERV-A and stained with an anti-PERV CA antibody and 
visualised by confocal microscopy. Although a quantitative analysis has not 
been conducted, the representative fields showed that no clear difference in 
the amount of viruses attached on the cell surface after tunicamycin 
treatment was observed for AGM cells (Figure 4.11). 
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Figure 4.11 PERV-A attachment to the cell surface 
2X10
5 cells were seeded on a cover glass and treated or not with different concentration of 
tunicamycin: 100 ng/mL (293T cells), 200 ng/mL (COS7 and VERO cells) or 25 ng/mL (QT6 
cells). The day after, cells were incubated with 1.5 mL of EGFP(PERV), fixed, permeabilised 
and immunostained with an anti-PERV CA antibody followed by the FITC-conjugated 
secondary antibody. Cover glasses were mounted on a slide with mounting solution 
containing propidium iodide to counterstain the nuclei (red). Images show representative 
fields acquired using DM IRE2 confocal microscope (oil immersion objective 63X). Viral 
particles appeared as green dot associated to the cells. Cells incubated with media alone, 
without virus, have been used as negative control. 
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4.2.10 No evidence of PAR intracellular entrapment in NHP cells 
One of the mechanisms proposed for tunicamycin-mediated rescue of 
retroviral infection was that the lack of N-linked glycosylation could cause 
misfolding of inhibitory molecule such as an ERV Env (Lavillette et al., 2000). 
Results presented above suggested that NHP low permissivity to PERV-A 
infection could not be due to a cellular molecule secreted in the supernatant 
(section 4.2.6). However, AGM cells could produce a molecule which 
interacts with the newly synthesised PARs preventing their display on the cell 
surface. To test this hypothesis, the cell surface level of PAR was compared 
to their intracellular amount. 
QT6, COS7 and VERO cells expressing HA-tagged huPAR-1 or AGMPAR-1 
(section 4.2.8) were fixed and immunostained using an anti-HA antibody in 
presence (intracellular) or absence (extracellular) of saponin, a chemical 
which permeabilised the cell plasma membrane. Although, a higher level of 
intracellular receptor was expected, the MFI of saponin-treated cells was 
lower in all the cells in comparison with those surface-stained (Figure 4.12). 
This could be due to technical problems. The ratio between HA stainings with 
or without saponin was calculated after normalisation against MFI of wild type 
cells (table 4.2). No significant AGM cell-specific difference was observed. 
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Figure 4.12 Expression of exogenous PAR in the stably transduced cells 
Quail QT6, AGM COS7 and VERO cells were stably transduced with VSV-G pseudotyped 
MLV-vector carrying HA-tagged huPAR-1 (A) or AGMPAR-1 (B). Cells were fixed and 
permeabilised (+) or not (-) with saponin 0.2% (w/v) in PBS. Receptor level was inferred by 
immunostaining using an anti-HA antibody and a PE-conjugated anti-mouse IgG antibody. 
Cells were analysed by flow cytometry. 167 
 
 
 
Table 4.2 Ratio of HA staining of saponin-treated or untreated cells 
Mean fluorescence intensity (MFI) values were calculated using CellQuest software and 
normalised on MFI values of the wild type cells. For each sample MFI ratio represented the 
MFI obtained with a cell surface staining (i.e. no saponin) divided by MFI of saponin-treated 
cells. 
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4.3   Discussion 
NHP are considered an ideal animal model to evaluate the risk of PERV 
transmission in the context of xenotransplantation [reviewed in (Denner, 
2003)]. Pig-to-NHP transplantation is currently used to test the immunological 
response to xenograft [reviewed in (Ekser et al., 2009)]. Furthermore, in 
comparison to retrospective studies on patients treated with porcine materials 
PERV transmission in NHP could be investigated in a variety of tissues not 
limited, as in human recipients, to PBMC and serum. NHP could also be 
treated with drugs to simulate the immunosuppression required in 
xenotransplantation. However, PERV infection in NHP cells in vitro does not 
occur with the same ease than in certain human cells (Blusch et al., 2000a; 
Martin et al., 1999; Specke et al., 2001; Takeuchi et al., 1998; Templin et al., 
2000; Wilson et al., 2000). Therefore, inferring information applicable to 
human xenotransplantation from the pig-to-NHP transplantation model could 
be misleading. Understanding the reason for the poor susceptibility of NHP 
cells to PERV infection could clarify the suitability and the limitations, and 
help in the choice, of an ideal animal model. 
A previous study of PERV transmission in NHP cells concluded that PERV 
infection in NHP cells was not productive (Ritzhaupt et al., 2002). In this 
chapter, I evaluated PERV infection in NHP cells and give indications of 
possible reasons behind the poor susceptibility of NHP cells to PERV-A. 
Using a pseudotyped PERV-A14/220 virus carrying an EGFP reporter gene, 
different steps in the virus life cycle were evaluated. Upon transduction of 
NHP cells, EGFP expression was confirmed in AGM COS7 and rhesus 
macaque FRhK4 cells (Figure 4.2 A). Furthermore PERV gag gene was 
detected in both cellular genomic DNA and RNA (Figure 4.2 B and C). These 
data agreed with previous studies in which following PERV infection, viral 
sequences were detected by PCR in the genomic DNA and RNA of infected 
NHP cells (Blusch et al., 2000a; Ritzhaupt et al., 2002). To understand 
whether PERV can productively infect NHP cells, the presence of infectious 
particles in the supernatant of PERV-infected NHP cells was investigated. 
AGM COS7 cells produced virions able to infect 293T cells up to three weeks 169 
 
post PERV infection, albeit at low titres (Figure 4.2 D). To further confirm the 
ability of PERV infected NHP cells to produce infectious viral particles and to 
understand which step in the virus life cycle was responsible for the low 
permissivity to PERV, NHP cells were transduceded with the human PERV-A 
receptor-2 (Ericsson et al., 2003). Indeed, pseudotyped EGFP(PERV) titre on 
huPAR-2 expressing NHP cells was at least 37 times higher. PERV infection 
on AGM VERO cells, which was undetectable in the wild type cell, was at 
similar levels to huPAR2-transduced COS7 and FRhK4 cells (Figure 4.2 A). 
Infectious virions were produced in all NHP cells, as determined by the 
infection assay on 293T cells (Figure 4.2 D). These results suggested that 
low efficiency in PERV entry is the major cause for the low permissivity of 
NHP cells.  
To better evaluate PERV entry in these cells, NHP PARs were analysed. 
Two PARs in human cells were identified (Ericsson et al., 2003) but only one 
in mice, rats and pigs. From sequences present in the NCBI database, it was 
likely that primates have two PARs as humans. While chimpanzee and 
rhesus macaque homologues to huPAR-1 and huPAR-2 sequences were 
already deposited in GenBank, PAR sequences for AGM, baboon and 
cynomolgus monkey was cloned by RT-PCR of RNA extracted from NHP 
cells. BaPAR-2 has been previously cloned (Ericsson et al., 2003). Protein 
sequence alignment revealed that rhPAR-1, cynPAR-1 and baPAR-1 have 
one amino acid difference from huPARs in the second extracellular loop at 
position 109, where muPAR possesses the critical proline responsible for the 
PERV-A resistance (section 3.2.2). The ability of the different NHP PARs to 
support PERV-A entry was tested. PERV-resistant quail QT6 cells were 
transduced to stably express NHP PARs. The receptors were HA-tagged at 
the C-terminal to verify their display on the cell surface. PERV-A titre on 
PAR-expressing QT6 cells was measured and revealed that all NHP PAR 
receptors were functional except for those containing serine at a.a. 109 
(Figure 4.3 B). To confirm the role of this serine in the rhPAR-1 function as 
receptor, two chimeric receptors were generated: huPAR-1 in which leucine 
109 was changed into a serine (huPAR-1S109) and rhPAR-1 with a leucine 
in position 109 instead of the serine. Infection assay on QT6 cells expressing 170 
 
these chimeric receptors revealed that rhPAR-1L109 was able to mediate 
PERV-A entry in QT6 cells (Figure 4.3 B) and binding to a soluble PERV-A 
Env (Figure 4.4 B). Conversely, PERV-A titre on QT6 cells expressing 
huPAR-1S109 was strongly reduced (Figure 4.3 B) and the receptor was 
unable to mediate the binding to PERV-A Env (Figure 4.4 A). These data 
suggested that a single amino acid substitution in PAR-1 of rhesus macaque, 
cynomolgus monkey and baboon cells disrupted their function as receptor, 
leaving these NHP with only one functional receptor (PAR-2). Instead, AGM 
cells encode two functional receptors, as in human cells.  
Low sensitivity to PERV-A infection in AGM cells mirrored the resistance in 
rat cells. In both cases, cells encode functional receptors. In rat cells a 
subthreshold level of ratPAR expression was associated to PERV-A 
resistance, AGM PARs expression in AGM cells was investigated. The lack 
of an anti-PAR antibody prevented the analysis of the receptor displayed on 
the cell surface. Therefore PAR mRNA was analysed by quantitative RT-
PCR (Figure 4.5). The two functional receptors in AGM COS7 and VERO 
cells were expressed at a similar level to PARs in human cells. However, the 
mRNA level of expression could not correlate with the amount of protein 
expressed on the cell surface. Furthermore, other mechanisms could be 
preventing PERV-A infection in AGM cells. The reason for the low 
permissivity of AGM cells to PERV-A were investigated further. 
Post-entry restriction factors acting in a Fv-1 or TRIM5α similar way were 
evaluated by comparison of the infection efficiency on 293T and AGM COS7 
and VERO cells of pseudotyped retroviral particles carrying either PERV-
A14/220 or MoMLV GagPol. The titre obtained with PERV-A14/220 GagPol 
in AGM cells was 5 fold lower than that on 293T cells (Figure 4.6 A), while 
the difference of PERV-A infection between 293T cells and AGM cells is 
more than 200 times (Figure 4.8 A, untreated). Therefore, although a weak 
post-entry restriction factor could contribute to the low permissivity of PERV-
A in AGM cells, this could not be considered the main mechanism of 
inhibition. Furthermore, infection with a pseudotyped PERV-A14/220 bearing 171 
 
MLV-A Env could rescue the titre on AGM cells (Figure 4.6 B), suggesting 
that the major block to PERV-A infection in AGM cells occurs at entry level.  
Infection of 293T cells in conditioned media from AGM cells did not alter 
PERV-A titre, suggesting that no inhibitor is secreted from these cells (Figure 
4.7). Receptor entrapment in cytosolic compartment was also analysed. QT6, 
COS7 and VERO cells were stably transduced to express huPAR-1 or 
AGMPAR-1. Cell surface display of the receptor was measured by HA-
staining. After permeabilisation, the total amount of HA-tagged receptor in the 
cells was evaluated. If a mechanism was present in AGM cells which prevent 
the trafficking to the cell surface, I would expect that the ratio between the 
cell surface-displayed and total amount of PAR in NHP would be 
considerably lower than in QT6 cells. My data did not show evidence for 
reduced surface display of exogenously expressed PAR in NHP cells (Figure 
4.12 and Table 4.2) However, it cannot be excluded that endogenously 
expressed AGM PAR already saturates possible inhibitors of PAR trafficking. 
Tunicamycin-treatment of AGM cells prior to PERV infection could enhance 
the virus permissivity in these cells (Figure 4.8 A) but did not affect binding 
(Figure 4.9). These results have been confirmed also for PAR-
overexpressing AGM cells, but not for quail QT6 cells (Figure 4.9). 
Tunicamycin-mediated enhacement of PERV infection was similar in AGM 
cells expressing huPAR-1 and AGMPAR-1, suggesting that the effect is cell-
specific (Figure 4.9 and 4.10). In particular, when the same level of PAR-1 
(i.e. same MFI) was expressed on the cell surface of QT6 and COS7 cells, 
titres obtained on QT6 cells were more than 10-fold higher than those on 
COS7 cells. Tunicamycin treatment drastically reduced this difference (Figure 
4.10). 
Immunofluorescence analysis of PERV attachment on the cell surface of 
AGM cells did not show any difference after tunicamycin-treatment (Figure 
4.11). This suggested that tunicamycin-mediated enhancement of PERV 
infection does not involve a change in the N-linked glycosylation of other cell 
surface molecules, implicated in virus adsorption. Therefore, it is possible 
that tunicamycin enhances PERV-A infection through removal of N-linked 172 
 
polysaccharide chains from PAR in AGM cells. This possibility could be 
tested by the comparison of AGMPAR and an N-glycosylation deficient 
mutant, lacking the asparagine at position 178 (section 3.2.3) in their ability to 
mediate PERV-A entry in AGM cells.  
In summary, the results from this chapter suggested that poor susceptibility 
of rhesus macaque, cynomolgus and baboon cells to PERV-A infection is 
due to a serine in the critical ECL2 of PAR-1 which not only prevent PERV-A 
entry but also binding. Infection observed in these monkey cells may be 
mediated by a functional PAR-2. However, the level of expression of its 
mRNA is lower than PAR-1 in human cells, hence the poor permissivity of 
these cells to PERV-A. Therefore, rhesus macaque and cynomolgus 
monkey, which have been the prevalent choice as animal models in pig-to-
NHP transplantation [reviewed in (Ekser et al., 2008)], are probably not the 
most suitable model to predict the risk of PERV transmission in pig-to-human 
transplantation. Because AGM cells express two functional receptors at 
similar level than human cells, they could represent a better animal model to 
evaluate PERV infection. However, no clear explanation was obtained for the 
poor susceptibility of AGM cells to PERV-A. From the results presented in 
this chapter, tunicamycin-treatment could increase PERV-A infection in AGM 
cells, but through an unknown mechanism.  
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Chapter 5 
5  . Inhibition of PERV release from pig cells by 
tetherin 
 
5.1 Introduction 
Genetically modified pigs have been developed to overcome the 
immunological barrier in xenotransplantation (section 1.1.1). The same 
strategy has been also employed to reduce the risk of PERV associated 
zoonosis. Multi-transgenic animals are seen as an optimised source of 
xenografts, characterised by low probability of PERV infection, absence of 
hyperacute immune reaction and reduced cellular rejection (Sykes, 2008). 
Currently, only two groups have adopted this strategy and produced 
transgenic pigs expressing small interfering RNAs for the inhibition of PERV 
expression (Dieckhoff et al., 2009; Dieckhoff et al., 2008; Ramsoondar et al., 
2009). Both groups found a reduction in PERV gene transcription. However, 
PERV proteins were not detectable in either non-transgenic controls or in the 
transgenic animals, which renders the interpretation of their results difficult 
(Dieckhoff et al., 2008; Ramsoondar et al., 2009). Other molecules have 
been investigated and could potentially be employed in the development of 
safer transgenic pigs for use as animal donors in human transplantation: 
intracellularly expressed antibodies directed against PERV Gag (Dekker et 
al., 2003), sugar modifying enzymes to remodel PERV envelope glycoprotein 
(Miyagawa et al., 2006) and the restriction factor human APOBEC3G 
(Dorrschuck et al., 2008; Jonsson et al., 2007).  
In this chapter, another possible candidate molecule whose expression in 
transgenic animals could reduce the risk posed by PERV has been 
evaluated. Tetherin (BST-2, CD317, HM1.24) has recently been described as 
a restriction factor in human cells able to block the release of some groups of 
enveloped viruses (section 1.6.4). Tetherin (THN) expression varies in 
different cell types and can be induced by type I interferon (IFN) (Blasius et 
al., 2006; Neil et al., 2008). Its mechanism of action involves the tethering of 174 
 
nascent viral particles to the cell membrane of the virus-producing cells (Neil 
et al., 2008). THN-mediated block to virus production appears to be able to 
inhibit the production of a broad range of enveloped viruses. In fact, 
members of other retroviral families, including alpharetrovirus, betaretrovirus, 
deltaretrovirus, gammaretrovirus, lentivirus and spumavirus (Jouvenet et al., 
2009; Neil et al., 2008), filoviruses such as Marburg virus and Ebola virus 
(Jouvenet et al., 2009; Sakuma et al., 2009), and the arenavirus Lassa virus 
(Sakuma et al., 2009) are all sensitive to inhibition by human THN. In 
addition, a proteomic study revealed that CD317 protein levels decreased in 
the presence of human herpesvirus 8 K5 protein (Bartee et al., 2006), 
suggesting a possible antagonising role similar to that of HIV-1 Vpu. While 
THN-mediated block of virus release seems to be part of the innate type I 
IFN-dependent generally immunity to enveloped viruses, the viral 
countermeasures to this restriction are species-specific. Among primate 
lentiviruses only few encode a Vpu protein (Bailes et al., 2003; Bibollet-
Ruche et al., 2004; Courgnaud et al., 2003; Courgnaud et al., 2002; Gao et 
al., 1999). HIV-1 Vpu can antagonise human THN but is ineffective against 
other primate THNs (Gupta et al., 2009a; Jia et al., 2009; McNatt et al., 2009) 
or non primate THNs (Goffinet et al., 2009; Gupta et al., 2009a; McNatt et al., 
2009). The determinants of susceptibility to HIV-1 Vpu have been mapped to 
the transmembrane region of THN (Gupta et al., 2009a; Jia et al., 2009; 
McNatt et al., 2009; Rong et al., 2009). Vpu antagonised THN by removing 
the restriction factor from the cell membrane via a β–TrCP/E3 ubiquitin ligase 
complex (Douglas et al., 2009; Mitchell et al., 2009) similar to the mechanism 
described for the surface down-modulation of CD4 by HIV-1 Vpu (Margottin 
et al., 1998). Viruses lacking Vpu protein have developed other counteracting 
systems. In rhesus macaque simian immunodeficiency virus (SIVmac), the 
accessory protein Nef has assumed the function of overcoming THN-
mediated restriction (Jia et al., 2009; Zhang et al., 2009). For other viruses, 
the anti-THN role is played by the envelope glycoprotein, possibly with a 
different mechanism from Vpu. Specifically, Ebola glycoprotein antagonised 
THN-mediated restriction (Kaletsky et al., 2009), and tantalus monkey SIV 
Env was able to counteract tantalus monkey, rhesus macaque, sooty 175 
 
mangabees monkey and human THNs (Gupta et al., 2009b). Furthermore, 
HIV-2 envelope enhances the production of HIV-1 particles in a Vpu-like 
pattern (Abada et al., 2005; Bour et al., 1996; Bour and Strebel, 1996; Ritter 
et al., 1996), suggesting its possible role as a countermeasure for THN block. 
To understand whether THN can be used to generate transgenic pigs with 
reduced PERV production, a porcine homologue to human THN has been 
cloned and characterised. The ability of human and porcine THN to inhibit the 
release of PERV from virus-producing cells has been investigated. In fact, 
contrary to previous studies where infection by an exogenous virus in THN-
expressing cells was examined, the situation is reverse in pig cells. PERV is 
already integrated and continuously produced, while THN would been 
exogenously delivered. 
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5.2 Results 
5.2.1  PERV-producing porcine cells express a homologue of human 
tetherin 
Human THN (huTHN) mRNA sequence (Genbank accession number: 
NM_004335.2) was submitted as template in the pig EST database using the 
basic local alignment search tool software [BLAST, (Altschul et al., 1997)]. 
The first 18 hits share the same sequence (data not shown). Among these, 
sequence EW580921.2 was arbitrarily chosen to design primers that anneal 
to the hypothetical transcriptional start and end of the porcine tetherin 
candidate. As huTHN gene has been reported to be IFN-inducible and silent 
in certain cell lines (Neil et al., 2008), we used three pig cell lines as a 
potential cDNA source for pig homologue to huTHN. Total RNA from PK15, 
MPK and ST-IOWA cells, was extracted and reverse transcribed as 
previously described (section 2.2.9). The cDNA was employed as template in 
a PCR using the porcine THN primers CF7 and CR7 (Table 2.3.2). The 
expected 533bp band was visualised in an agarose gel (Figure 5.1 A) and 
the PCR products cloned into pGEM T-easy vector. The analysis of the 
sequences obtained from MPK and ST-IOWA PCR products revealed a 
perfect match with the EST EW580921.2. However, the PK15 product 
sequence presented two mismatches at nucleotides 351 and 427, which are 
non-synonymous substitutions (Figure 5.1 B). Direct sequencing of the PK15 
THN cDNA showed that PK15 cells express two types of cDNA: one the 
same as EW580921.2 and the other with changes at positions 351 and 427 
(Figure 5.1, chromatograms). 
 
Human cell lines, 293T and HeLa, express significantly different level of 
huTHN. As a consequence, while retroviral particles successfully bud from 
293T cells, they are withheld on the cell surface of HeLa cells by a THN-
mediated mechanism (Neil et al., 2008). To determine the level of porcine 
THN expressed in pig cells, cDNA from PK15, MPK and ST-IOWA was 
processed by quantitative RT-PCR and compared to the huTHN mRNA level 
in 293T and HeLa cells (Figure 5.2). THN mRNA expression in pig cells is 177 
 
estimated to be 35 times higher than human 293T cells but 5 times lower 
than HeLa cells. The implication for virus production will be analysed in the 
following sections. 
 
 
 
Figure 5.1 Cloning of a porcine homologue of human tetherin 
A)1µg of total RNA from pig PK15, MPK and ST-IOWA cell lines was reverse transcribed 
using QuantiTect Reverse Transcription kit and one quarter of the volume of the resulting 
cDNA used as template in a RT-PCR using primers CF7 and CR7 (Table 2.3.2). The 
products were run in a 1.5% agarose gel and visualised by High Performance ultraviolet 178 
 
transilluminator (UVP). The band sizes were approximately determined by comparison with 
GeneRuler 100bp DNA ladder (M). B) PCR products were gel extracted, cloned into pGEM 
T-easy vector, and sequenced using primers M13F and M13R (Table 2.3.3). The porcine 
sequences were aligned against huTHN sequence using ClustalW programme. The two 
different amino acids between PK15 and MPK/IOWA THN sequences were indicated (•). The 
nucleotide polymorphisms in PK15THN were visualised in chromatograms obtained by direct 
sequencing of the PCR product using primers CF7 and CR7. 
 
 
 
 
Figure 5.2 Endogenous expression of porcine tetherin in pig cells 
1 µg of total RNA from pig PK15, MPK and ST-IOWA, and human 293T and HeLa cell lines 
was reverse transcribed in a final volume of 20 µl. For each reaction, 2.5 µl of cDNA were 
added to the QuantiTect SYBR Green PCR mix together with the specific primers: QF9 and 
QR9 for pig THN, QF10 and QR10 for huTHN, and QF4 and QR4 for 18S rRNA gene. 
Samples were run in triplicate. The amount of copies for each gene was extrapolated from 
analysis of the standard curves. Histograms represent porcine and human THN number of 
copies normalised to one 18S rRNA copy. 
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5.2.2  Porcine tetherin blocks release of retroviral particles 
MPK and PK15 cells produce infectious PERV particles although porcine 
tetherin is well expressed in these cells. The ability of porcine THN to inhibit 
viral release similarly to huTHN has been investigated. Due to the two amino 
acids difference in their sequences, both PK15 tetherin (PK15THN) and 
MPK/ST-IOWA tetherin (IOWATHN) were analysed. 
EGFP-expressing viruses were prepared by transfection of 293T cells with 
MLV-based retroviral vector CNCG, carrying the reporter EGFP gene, and 
packaging plasmids encoding PERV-A14/220 GagPol and PERV-A14/220 
Env (PERV2a/PERV2a), or Moloney MLV GagPol and amphotropic MLV Env 
(MoMLV/MLV-A). Viral titres were determined by infection of 293T cells with 
serial dilutions of the supernatant from the producing cells, followed by 
monitoring EGFP expression.  
Co-transfection of human or porcine THN reduced PERV-A and MLV titres 
30 to 80-fold in comparison to those with an empty plasmid (pcDNA3) (Figure 
5.3 A). Cell lysate of PERV2a/PERV2a-producing cells and the 
corresponding supernatant were immunoblotted using a polyclonal rabbit 
anti-PERV CA antibody. Expression of human and porcine THN did not affect 
the amount of cell-associated Gag (Figure 5.3 B, cell lysate), but reduced the 
presence of mature virions (processed capsid protein p30) in the supernatant 
(Figure 5.3 B, SN). Furthermore, no significant difference in the reduction of 
released titre could be observed between huTHN, PK15THN and IOWATHN. 
These data agreed with an observation by Gupta and colleagues in our 
collaboration showing that huTHN and IOWATHN equally inhibit HIV-based 
lentiviral vector pseudotyped with VSV-G (Gupta et al., 2009b). 
These results confirmed that both porcine THNs we cloned were able to 
block the release of retroviral particles. The two amino acid mutations in the 
PK15THN sequence did not affect its restriction function. 
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Figure 5.3 Porcine tetherin blocking of PERV and MLV release 
A) EGFP expressing viruses, PERV2a/PERV2a and MoMLV/MLV-A, were produced by 
three plasmid transfection of 1x10
6 293T cells together with 200 ng of huTHN plasmid (grey), 
PK15THN (black), IOWATHN (striped) or an equal amount of empty plasmid (white). Viral 
titres were determined by infection of 293T cells with serial dilutions of the supernatant and 
monitoring EGFP expression by flow cytometry. Histograms represented the average of two 
independent experiments (± standard error of the mean). B) Two days post-transfection, 
virus-producing cells were harvested and lysed in RIPA buffer. Supernatant from these cells 
was concentrated by centrifugation and resuspended in Laemmli buffer. A quarter of the total 
cell lysate and the supernatant were separated in a 10% SDS-PAGE. Proteins were 
immunoblotted using rabbit polyclonal anti-PERV capsid antibody. In the cell lysates (upper 
panel) capsid precursor (p60), the intermediate forms and the processed capsid (p30) were 
visible. In the supernatant (SN, bottom panel) p30 was the main form represented. 181 
 
5.2.3  Porcine tetherin is insensitive to HIV-Vpu 
As eukaryotic cells evolve many factors to block viral infection (section 1. 6), 
viruses develop countermeasures to overcome them. Due to selective 
pressure, restriction factors and antagonistic viral proteins are often species-
specific, although sometimes some cross-species effect can be observed. 
HIV-1 Vpu is able to inhibit the restriction posed by THN in human cells (Neil 
et al., 2008), and its effect on porcine THN has been investigated.  
PERV2a/PERV2a, carrying the reporter gene EGFP, has been produced by 
three plasmid transfection of 293T cells in the presence of either human or 
porcine THN, or an empty vector, as negative control. By co-transfection of 
an expression plasmid encoding HIV-1 vpu gene, PERV2a/PERV2a titre in 
the presence of human THN was rescued to the control level (empty plasmid, 
EP). However, HIV-1 Vpu expression did not rescue the reduction of viral titre 
caused by porcine THNs, PK15THN and IOWATHN (Figure 5.4 A). Western 
blot analysis of the producing-cell lysates confirmed that similar amount of 
Gag was produced in the cells (Figure 5.4 B, cell lysates), but it was 
differentially released in the supernatant (Figure 5.4 B, SN), consistent with 
the infection assay (Figure 5.4 A). 
These results showed that the block to PERV budding by porcine THN 
cannot be overcome by HIV-1 Vpu. The same insensitivity of porcine THN to 
HIV-1 Vpu has also been shown using VSV-G pseudotyped HIV particles as 
assay virus (Gupta et al., 2009b). 
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Figure 5.4 Porcine tetherin block is not antagonised by HIV-1 Vpu 
A) PERV 2a/PERV2a carrying the reporter gene EGFP was produced by transfection of 
293T cells together with 200 ng of huTHN, PK15THN, IOWATHN or equal amount of empty 
plasmid (EP). 200 ng of an expression plasmid encoding HIV-1 Vpu (white) or the backbone 
alone (pcDNA3, grey) was also co-transfected. Released virus was titred on 293T cells and 
monitored by flow cytometry. Histograms represented the average of two experiments and 
the error bars the standard error of the mean. B) PERV2a/PERV2a was produced in the 
presence of human (huTHN) or porcine (PK15THN and IOWATHN) tetherin and with (+) or 
without (-) HIV-1 Vpu protein. Producing cells and supernatants (SN) were processed by 
SDS-PAGE and immunoblotted using an anti-PERV CA antibody. Precursor and 
intermediate forms of PERV capsid were visualised in the cell lysate (upper panel), while 
fully processed p30 was the main form present in the supernatant (SN, bottom panel). 183 
 
5.2.4  No evidence for tetherin countermeasure expressed by PERV-
A14/220 
Few lentiviruses encode a Vpu-like protein (Bibollet-Ruche et al., 2004). In 
other primate lentiviruses, such as rhesus macaque SIV, anti-tetherin 
function has been assumed by Nef protein (Jia et al., 2009; Zhang et al., 
2009). Furthermore, it has recently been shown that envelope glycoprotein of 
tantalus monkey SIV, can antagonise tantalus, rhesus, sooty mangabees 
monkey tetherins as well as human tetherin (Gupta et al., 2009b). Similarly, a 
filovirus, Ebola virus, overcomes human tetherin-mediated restriction with its 
own envelope glycoprotein (Kaletsky et al., 2009). However, there are no 
reports on how simple retroviruses such as MLV or PERV can avoid tetherin-
mediated restriction. 
293T cells were transfected with a retroviral vector expressing the reporter 
gene EGFP, PERV2a GagPol and VSV-G expressing plasmids, and porcine 
THN-encoding plasmids. To investigate the ability of PERV-A14/220 
(PERV2a) envelope to antagonise THN block, increasing amounts of 
PERV2a Env plasmid were added to the plasmid mix. After 48 hours, the 
virus released in the supernatant was titrated on murine, PERV-A-resistant, 
NIH3T3 cells. These cells were chosen to monitor VSV-G-mediated EGFP 
transduction specifically, and avoid a contribution in the titre from PERV2a-
pseudotyped viral particles. In the absence of PERV2a Env, PK15THN and 
IOWATHN reduced the viral titre about 10-fold compared to an empty 
plasmid (EP). The addition of PERV2a Env had no effect on PERV2a/VSV-G 
titre (Fig 5.5 A, pcDNA3), and did not rescue its reduction caused by porcine 
THN (Fig 5.5 A). These data suggested that PERV-A Env cannot counteract 
THN-mediated restriction.  
As PERV2a Env alone could not inhibit the restriction posed by THN, I tested 
whether any other part of the PERV2a genome could. EGFP(MLV) viruses 
bearing MLV-A Env were produced by transfection of 293T cells together 
with 200 ng of IOWATHN plasmid. Serial dilutions of the full length PERV2a 
genome were co-transfected. The viral titre was determined by infection of 
murine NIH3T3 cells. The PERV2a genome was unable to rescue the 10-fold 184 
 
reduction of the viral titre caused by IOWATHN (Figure 5.5 B). To 
corroborate this result, the effect of PERV expression on HIV-1 inhibition by 
THN was also examined. An HIV-based vector expressing EGFP (pHRSIN-
CSGW) was transfected into 293T cells together with packaging plasmids 
p8.91, encoding HIV-1 GagPol and pMDG, carrying the VSV-G gene. Human 
or porcine THN was co-transfected in the presence of 200 ng of PERV2a 
genomic plasmid or an irrelevant construct as negative control (pCNCR). The 
amount of virus released in the supernatant was titrated on 293T cells. The 
PERV2a genome was unable to overcome the 20- to 85-fold reduction in 
EGFP(HIV) titre (Figure 5.5 C). 
Taken together these results showed no evidence of an antagonistic effect of 
PERV2a genome against either human or porcine THN.  185 
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Figure 5.5 PERV-A14/220 Env or genome does not counteract tetherin 
A) EGFP encoding MoMLV/MLVA viruses were produced by co-transfection of 293T cells 
with 200 ng of porcine THN, PK15THN (white circles), IOWATHN (black squares) or an 
empty plasmid (grey triangles). In addition, a mixture of PERV-A14/220 Env plasmid 
(PERV2a Env) and empty plasmid pcDNA3, with the total amount of plasmids being 400 ng, 
was cotransfected. The quantity of PERV2a Env plasmid is indicated in the graph. Viral 
particles released in the supernatant were titred by EGFP-transduction of NIH3T3 cells and 
the mean of the titre indicated with the standard error of the mean. B) Retroviral particles 
carrying the EGFP gene with MoMLV core and amphotropic MLV Env were produced in 
293T cells in the presence of 200 ng of IOWATHN plasmid (black squares) or empty plasmid 
(grey triangles). Increasing amounts of full length PERV2a genome was co-transfected 
together with the empty vector pcDNA3 to equalise the total quantity of plasmids to 400 ng. 
Titre was determined by transduction of NIH3T3 cells and monitoring for EGFP expression 
by flow cytometry. C) VSV-G pseudotyped HIV particles expressing EGFP were produced by 
transfection of 293T together with of 200 ng of huTHN, PK15THN, IOWATHN or empty 
plasmid (EP). 200 ng of PERV2a genome (white) or MLV-based vector carrying RFP gene 
(CNCR, grey), used as an irrelevant control, were added to the transfection mix. Serial 
dilutions of the supernatant were employed to transduce 293T cells. Titres were inferred by 
EGFP expression measured by flow cytometry and the average represented as histograms 
(± standard error of the mean). 
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5.2.5  Porcine tetherin is able to reduce the release of PERV particles 
from pig cells 
HuTHN is type I IFN-inducible. Upon treatment of 293T cells with INF-α, the 
huTHN mRNA amount increases more than 20-fold (Neil et al., 2008). The 
same dose of INF-α in 293T cells reduces the yield of Vpu-deleted HIV-1 
particles released in the supernatant about 10-fold (Neil et al., 2007). To 
understand whether THN can reduce the amount of PERV particles budding 
from pig cells, the endogenous THN response to type I IFN was assessed, 
and the effect of IFN treatment on PERV production in PK15 cells examined. 
Pig PK15 cells were treated for 24 hours in the presence of 2000U/mL of 
type I INF-β. Cells were lysed and the mRNA extracted. The amount of 
porcine THN was quantified by SYBR Green-based quantitative RT-PCR. 
IFN-β induced an increase in porcine THN mRNA level 15 times that of 
untreated cells (Figure 5.6 A). 
Serial dilutions of the supernatant from untreated and IFNβ–treated PK15 
cells were employed to infect 293T cells. After 72 hours, PERV titre was 
determined by in situ immunostaining of the infected cells using an anti-
PERV CA antibody. The PERV titre from IFN-β-treated cells was reduced to 
26% that obtained from untreated cells (Figure 5.6 B). The immunoblot of cell 
lysates and supernatant from untreated and IFN-β-treated PK15 cells 
showed a similar amount of cell associated PERV Gag (Figure 5.6 C, cell 
lysates) but a reduction of processed Gag in the supernatant (Figure 5.6 C, 
SN). 
These results showed that similar to huTHN, its porcine homologue is indeed 
type I IFN-inducible. INF-β treatment of PK15 cells reduced PERV release, 
possibly via pig THN induction. These data support the hypothesis that 
overexpressing THN in porcine PERV-producing cells could in fact reduce 
the release of infectious virus. 
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Figure 5.6 Porcine tetherin can reduce PERV particle release from pig cells 
1x10
6 PK15 cells were seeded in a 6-well plate and 2 hours later 2000U/mL of IFN-β was 
added to the media. A) The day after, cell were lysed and total RNA extracted. 1 µg was 
reverse transcribed and one eighth was employed as template in a SYBR Green-based 
quantitative RT-PCR, using primers QF9 and QR9 for porcine THN and QF4 and QR4 for 
18S rRNA gene (table 2.3.4). Samples were run in triplicate and the number of porcine THN 
copies were normalised per copy of 18S rRNA. Histograms represent the average of two 
independent experiments (± standard error of the mean). B) 24 hours after the addition of 
IFN-β, the supernatant from PK15 cells was used to infect 293T cells and two days later, 
PERV titre was determined by in situ immunostaining of infected 293T cells using rabbit anti-
PERV CA antibody. Histograms represent the average of two independent experiments (± 
standard error of the mean). The reduction in PERV titre in IFNβ-treated cells was found to 
be significant by t-test (p=0.002) C) PK15 cells treated for 24 hours with IFNβ and untreated 
cells were harvested and lysed in RIPA buffer. Their supernatant was spun down and 
resuspended in Laemmli buffer. One fourth of the cell lysate and the supernatant was 
processed by 10% SDS-PAGE and PERV proteins detected using anti-PERV CA antibody. 
In the cell lysates (upper panel) capsid precursor (p60), the intermediate forms and the 
processed capsid (p30) were visible. In the supernatant (SN, bottom panel) p30 was the 
main form represented. 
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5.2.6  Exogenous expression of tetherin in PK15 cells decreases PERV 
release 
A critical step in the evaluation of THN as a novel strategy to improve the 
biosafety of porcine donors in xenotransplantation is the ability of 
exogenously expressed human or porcine THN to inhibit the release of 
continuously produced PERV particles from pig cells and this needs to be 
analysed. 
Human or pig THN gene was introduced into porcine PK15 cells by HIV-
based retroviral particles, carrying also the hygromycin B resistance gene. 
After 24 hours, hygromycin B was added to the media and the cells were 
cultivated for the following two weeks to obtain a cell population which was 
hygromycin B resistant and expressed THN. 
Firstly, the expression of the THN in PK15 cells was assessed. Total RNA 
from transduced and selected cells was processed in a SYBR Green-based 
quantitative RT-PCR, and the amount of THN mRNA was quantified. Bulk 
population of PK15THN and IOWATHN-transduced cells expressed, on 
average, 10-fold more pig THN mRNA than parental cells (Figure 5.7 A). In 
huTHN-transduced cells, the amount of huTHN was at a similar level to that 
in HeLa cells (Figure 5.2).  
Once the overexpression of THN was assessed, PERV particle release in the 
supernatant was analysed. The day before infection, THN-expressing PK15 
and parental cells were seeded in equal number. Serial dilutions of their 
supernatant were employed to infect 293T cells, and titre was determined by 
in situ immunostaining of infected cells using an anti-PERV CA antibody. 
PERV titre from PK15THN and IOWATHN stably expressing cells showed a 
reduction of 60% in comparison to that from parental cells. Expression of 
huTHN reduced PERV titre to 23% that of untransduced cells (Figure 5.7 B). 
These data was supported by western blot analysis of the cell lysates and 
supernatants from THN-transduced PK15 cells. Whilst the amount of Gag in 
the cell lysate appeared to be the same between all the samples (Figure 5.7 
C, cell lysate), the presence of mature particles in the supernatant of PK15 191 
 
overexpressing THN was reduced up to 16% that of the parental cells (Figure 
5.7 C, SN and band intensity). 
These results suggested that overexpression of THN can be employed to 
reduce the level of viral particles budding from porcine PERV-producing cells.  192 
 
 
Figure 5.7 Exogenous expression of tetherin in PK15 cells decreases PERV release 
PK15 cells were stably transduced by VSV-G pseudotyped HIV-based vector encoding both 
human or porcine THN and hygromycin B resistance genes. The day following transduction, 193 
 
Hygromycin B at the concentration of 200 µg/mL was added to the media and the cells 
cultivated for two weeks. A) 1µg of RNA extracted from THN-transduced PK15 or parental 
cells was reverse transcribed in a reaction volume of 20 µL. SYBR Green-based quantitative 
RT-PCR was conducted on 2.5 µL of cDNA using primers QF9 and QR9 for porcine THN, 
QF10 and QR10 for huTHN, and QF4 and QR4 for the 18S rRNA gene. Samples were run in 
triplicate. The amount of copies for each gene was inferred by standard curves. Histograms 
represent porcine (poTHN, grey) and human (huTHN, white) THN copies normalised to one 
18S rRNA copy. B) 1x10
6 THN-transduced PK15 or parental cells were seeded and the day 
after, serial dilutions of their supernatant was used to infect 293T cells. Titres were 
determined by in situ immunostaining using an anti-PERV CA antibody. Titres of THN-
transduced PK15 were calculated as percentage of the titre from parental cells. Histograms 
represent the average of two independent experiments (± standard error of the mean). The 
statistical validity of PERV titre reduction in transduced-PK15 was assessed with t-test. P 
values were 0.001 for huTHN, 0.028 for PK15THN and 0.013 for IOWATHN. C) Supernatant 
from 1x10
6 THN-transduced PK15 or parental cells was spun down and resuspended in 
2xLaemmli buffer. Cells were lysed in RIPA buffer. One fourth of the cell lysate and the 
supernatant was separated by SDS-PAGE and immunoblotted using an anti-PERV CA 
antibody. The chemiluminescence signal was detected by incubation with ECL western 
blotting reagent and exposed to a X-ray film. The 3 differently processed capsid forms were 
detected in the cell lysate (upper panel) while in the supernatant (SN) p30 was the most 
present (bottom panel). Band intensities were determined by analysis of the film with the 
Kodak 1D programme.  
  194 
 
5.3 Discussion 
Genetically modified pigs have been generated to overcome the 
immunological barrier in pig-to-human transplantation (section 1.1.1). The 
same approach has been employed to reduce the risk of PERV transmission 
by generating transgenic pigs expressing shRNAs against PERV transcripts 
(Dieckhoff et al., 2009; Dieckhoff et al., 2008; Ramsoondar et al., 2009). In 
this chapter a newly described restriction factor, THN, has been investigated 
as a possible candidate to use in the development of genetically modified pig 
donors which will enhance biosafety in xenotransplantation.  
PERV particles have been observed budding from porcine cell lines and 
primary cells (section 1.4.1). Initially, I evaluated whether porcine cells 
encode a homologue to THN and its expression level. By BLAST analysis, a 
possible candidate was found in the porcine EST database. As THN is 
differentially expressed in human cell lines (Neil et al., 2008), three pig cell 
lines were used as source of cDNA to clone porcine THN. The sequences 
obtained matched with the EST sequence deposited in the NCBI database, 
with the exception of two non-synonymous nucleotide changes in the PK15 
THN (Figure 5.1 B). PK15 cells appeared to possess two heterologous THN 
alleles. Indeed, by direct sequencing of the cDNA from PK15 cells, the 
chromatograms showed a polymorphism for both changes (Figure 5.1 B). 
Since the physiological function of THN remains unclear, speculation on the 
significance of these polymorphisms is difficult. However, the impact of these 
two amino acid changes on THN-mediated restriction has been analysed in 
this chapter (PK15THN).  
Both porcine THNs have similar ability to huTHN for reducing PERV and 
MLV production when co-transfected with the virus-encoding plasmids in 
293T cells (Figure 5.3 A). As showed by western blot analysis, THN 
expression had no impact on viral protein synthesis, but did on the release of 
the viral particles in the supernatant (Figure 5.3 B). The expression of porcine 
THN in different cell lines was evaluated by quantitative PCR and compared 
to that in the human cell lines 293T, which is highly permissive to virus 
production, and HeLa cells, from which retroviral particles could be efficiently 195 
 
released only in the presence of factors antagonising huTHN, such as HIV-1 
Vpu (Figure 5.2). Porcine THN mRNA was expressed at similar level among 
pig cells. In comparison to human cells, the three porcine cell lines appeared 
to have 35 times more mRNA for THN than 293T cells but 5 times less than 
HeLa cells. 
As PERV-producing cells express a discrete level of a porcine THN, it is 
possible that PERV possesses some countermeasure which acts against this 
endogenous level of THN and allows PERV production. Therefore, PERV 
countermeasures for THN were investigated. At least three different viruses, 
tantalus monkey SIV, HIV-2 and Ebola virus, use their envelope to counteract 
THN-mediated restriction (Abada et al., 2005; Bour et al., 1996; Bour and 
Strebel, 1996; Gupta et al., 2009b; Kaletsky et al., 2009; Ritter et al., 1996). 
The ability to antagonise THN restriction has been evaluated for PERV-
A14/220 Env protein. The addition of increasing amount of a plasmid 
encoding PERV-A14/220 Env did not alter the titre of PERV virus produced 
from 293T cells in the presence of human or porcine THNs (Figure 5.5 A). 
The same results were obtained by introducing increasing amount of a 
plasmid encoding the whole genome of PERV-A14/220 (Figure 5.5 B and C). 
These data suggested that PERV-A14/220 does not possess an anti-THN 
function. 
Inhibition of PERV particle release by endogenous porcine THN from pig 
cells was tested. Human THN is type I IFN-inducible (Blasius et al., 2006; 
Neil et al., 2008). Treatment of PERV-producing PK15 cells with IFN-β 
caused an upregulation of porcine THN mRNA (Figure 5.6 A) and a reduction 
of PERV titre (Figure 5.6 B). The decrease of PERV production was 
associated with a diminished amount of PERV Gag in the supernatant 
(Figure 5.6 C). These results suggest that IFN-β-induced overexpression of 
porcine THN can inhibit the release of PERV particles in porcine cells. 
Whether or not endogenous THN is acting in pig cells to control PERV 
production under normal physiological condition is unclear.  
The final goal was to assess whether exogenously expressed THN could 
block PERV release from porcine cells. PERV-producing PK15 cells were 196 
 
stably transduced with a lentiviral vector carrying the human or porcine THN 
gene and a hygromycin B resistance gene, for selection of transduced cells. 
The mRNA level of THN was similar to that of huTHN in HeLa cells (Figure 
5.7 A and 5.2). PERV titre from THN-overexpressing cells was 23% that 
obtained from wild type cells (Figure 5.7 B) and this correlated with a 
reduction of PERV Gag in the supernatant (Figure 5.7 C).  
These results showed that by overexpressing THN it was possible to reduce 
virus release from continuously producing cells. Although these data are 
encouraging, a complete block of PERV production was not achieved. To 
improve the system, clones, producing higher amount of THN could be 
examined. Previous works using shRNAs have showed a similar degree of 
reduction in PERV production. Reverse transcriptase activity in the 
supernatant of primary porcine cells was reduced to 25% when shRNA 
against PERV Pol was expressed (Dieckhoff et al., 2007a) and titre of 
infectious particles generated from porcine endothelial cell expressing 
shRNA against PERV proteins was 85% lower than parental cells (Miyagawa 
et al., 2006). Genetically modified pigs could be generated expressing THN 
together with other anti-PERV strategies (e.g. shRNAs), which target a 
different step of the retroviral life cycle and therefore are unlikely to interfere 
with each other, to decrease the risk of PERV transmission. 
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Chapter 6 
6 Discussion 
Porcine cells and tissues have been used to treat human diseases (Chari et 
al., 1994; Deacon et al., 1997; Fink et al., 2000; Groth et al., 1994; 
Reichenbacher, 1975) and, at present, two clinical trials are taking place in 
Russia and New Zealand to treat type I diabetes by injection of porcine, 
insulin-producing cells (DIABECELL
(R)) (http://www.lctglobal.com/lct-
diabecell-diabetes-treatment.php). Initial studies of pig-to-human 
transplantation in the 1990s have been interrupted following the discovery 
that porcine endogenous retroviruses produced from pig cells can infect 
human cells in vitro (Patience et al., 1997). Yet, retrospective studies on 
patients exposed to porcine materials failed to detect any evidence of PERV 
transmission. Moreover, no disease has been associated with PERV in pigs, 
although higher PERV expression was found in melanomas of Munich 
miniature swine Troll, when compared with normal tissue (Dieckhoff et al., 
2007b). The risks of a cross-species infection are unpredictable, as human 
history exemplified (Kramer et al., 2007; de Wit and Fouchier, 2008; 
Alexander and Brown, 2000; Gao et al., 1999; Keele et al., 2006; Paton et al., 
1999; Chua et al., 1999; Chua, 1999; Smith et al., 2009; Garten et al., 2009; 
Drosten et al., 2003). Potential pathologies associated with PERV infection 
could be deduced by similarity with diseases described for other member of 
the  γ-retrovirus genus, which PERV belongs to: development of tumours, 
leukaemia and neurodegeneration (section 1.3.4). Therefore, during the past 
12 years, many studies have been conducted on four main aspects of PERV: 
1) Virus biology: replication-competent PERV subgroups and their tropism 
(Akiyoshi et al., 1998; Le Tissier et al., 1997; Patience et al., 2001; Takeuchi 
et al., 1998; Wilson et al., 2000), viral determinant for infectivity (Argaw et al., 
2008; Gemeniano et al., 2006; Marcucci et al., 2008; Watanabe et al., 2005), 
recombination (Bartosch et al., 2004; Harrison et al., 2004; Oldmixon et al., 
2002; Wilson et al., 2000) and critical PERV loci in the pig genome (Herring 
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2) Diagnostic tools to monitor PERV expression in both porcine donor and 
human recipient (Bartosch et al., 2002; Blush et al., 2000; Chiang et al., 2005 
Fisher et al., 2003; Galbraith et al., 2000; Lovatt et al., 1999; Matthews et al., 
1999; Shah et al., 2003; Switzer et al., 1999; Tacke et al., 2001; Xu et al., 
2003). 
3) Virus-host interaction. This aspect has been particularly difficult to study 
due to the lack of evidence of PERV infection in humans and the 
unavailability of a suitable animal model. The receptors used by PERV 
subgroup A to infect human cells have been identified (Ericsson et al., 2003) 
and many animal models evaluated (Clemenceau et al., 2002; Deng et al., 
2000; Elliott et al., 2005; Isaac et al., 2005; Moscoso et al., 2005; Nishitai et 
al., 2005; Ritzhaupt et al., 2002; Specke et al., 2009; Specke et al., 2001; 
Templin et al., 2000; van der Laan et al., 2000; Zhang et al., 2005). 
4) Strategies to prevent PERV infection. Most of these are focussed on the 
improvement of the safety of the animal donor, like selection of low risk 
PERV transmission animals (Garkavenko et al., 2008a; Garkavenko et al., 
2008b; Hector et al., 2007) or discovery of inhibitory molecules which can be 
employed for the generation of transgenic pigs (Dekker et al., 2003; 
Dieckhoff et al., 2009; Dieckhoff et al., 2008; Dorrschuck et al., 2008; 
Jonsson et al., 2007; Miyagawa et al., 2006; Ramsoondar et al., 2009). 
Vaccine and anti-viral drugs have also been considered (Fiebig et al., 2003; 
Powell et al., 2000; Qari et al., 2001; Shi et al., 2007; Stephan et al., 2001; 
Wilhem et al., 2002). 
In this thesis two of these aspects have been explored: virus-host interaction, 
specifically the study of the cellular receptor used by PERV-A to infect cells, 
and the evaluation of a new strategy to reduce the risk of PERV 
transmission. 
In chapter three, PERV-A receptor was characterised in order to gain a better 
understanding of the mechanism of virus entry in human cells. Two functional 
PERV-A receptors (huPAR-1 and huPAR-2) have been identified in human 
cells (Ericsson et al., 2003). Critical regions for PERV-A infection in the 199 
 
receptor have been characterised using chimeric receptors between huPAR-
2 and the murine homologue, muPAR, which does not support PERV-A 
infection (Ericsson et al., 2003 and Figure 3.3). A single amino acid (a.a. 109) 
was shown to be important not only for PERV-A infection but also for the 
virus binding (Figures 3.4 and 3.7). These results, together with experimental 
evidence of the receptor topology (Figures 3.5 and 3.6), suggested that the 
second extracellular loop, where a.a. 109 is located, is the virus binding site, 
or at least a part of it. These data may help develop reagents that block 
PERV entry, such as neutralising antibodies and peptides mimicking the 
receptor. Furthermore, the characterisation of an important structural domain 
in the PERV-A receptors, obtained in chapter three, allowed the investigation 
of the mechanism behind the poor susceptibility to PERV-A of non-human 
primate (NHP) cells, conducted in chapter four. 
As mentioned above, a major problem in the prediction of the consequences 
of PERV infection is the lack of a suitable animal model. Because NHP are 
currently employed in xenotransplantation to evaluate the immunological 
response to porcine xenografts, it would be ideal to monitor PERV 
transmission at the same time. However, to extrapolate information that may 
be applied to pig-to-human transplantation, NHP cells should be as 
permissive to PERV-A as are human cells. Instead, data presented in the 
literature suggest this not to be the case (Blusch et al., 2000a; Martin et al., 
1999; Specke et al., 2001; Takeuchi et al., 1998; Templin et al., 2000; Wilson 
et al., 2000). It was initially reported that although PERV can infect NHP 
cells, it cannot replicate in them, because of an unknown mechanism 
(Ritzhaupt et al., 2002). However, my results suggest that once PERV 
successfully enters NHP cells, infectious particles could be produced (Figure 
4.2). These results were obtained by endowing NHP cells with huPAR-2, 
suggesting that virus entry is a critical step in the low permissivity of NHP 
cells. Indeed, rhesus macaque, cynomolgus monkey and baboon PAR-1 
receptors were unable to support PERV-A infection (Figure 4.3). By 
comparison with the data obtained from the analysis of muPAR (Figure 3.4), 
it was possible to determine that a.a. 109 was the main determinant for the 
inability of rhPAR-1, cynPAR-1 and baPAR-1 to mediate virus infection. The 200 
 
low permissivity to PERV-A of cells from these NHP species is probably due 
to a PAR-2-mediated entry. However, the level of expression of PAR-2 is 
lower than huPAR-1 in human cells (Figure 4.5). These results suggest that 
rhesus macaque, baboon and cynomolgus monkey represent a less than 
ideal model to evaluate the risk of PERV transmission in humans. Yet, they 
are the most used NHP species in pig-to-NHP transplantation [reviewed in 
Eckser et al., 2009)] and most PERV transmission studies on NHP animals in 
vivo were conducted on baboons and rhesus monkeys (Moscoso et al., 2005; 
Nishitai et al., 2005; Simon et al., 2003; Specke et al., 2009; Switzer et al., 
2001).  
More promising could be the use of African green monkey as a model. Both 
AGMPAR-1 and AGMPAR-2 are able to support PERV-A infection (Figure 
4.3), and they are expressed in at least two AGM cell lines, COS7 and 
VERO, at a similar level to human cell lines (Figure 4.5). However, AGM cells 
are poorly infected by PERV-A. It is interesting to note that the resistance to 
PERV-A by rodents and NHPs is similar. In both cases, some genera in the 
same order (mus or macaca and papio) have a mutation in the receptor (at 
the same amino acid) which disrupts its ability to support PERV-A entry, 
while others (rattus or chlorocebus) encode functional receptors but are still 
refractory to PERV-A infection. In chapter four and three, I tried to unveil the 
mechanism behind the poor (or lack of) susceptibility to PERV-A in AGM and 
rat cells. In both cases, I couldn’t obtain a clear answer. RatPAR expression 
is lower in rat cells than huPAR-1 in human cells (Figure 3.9), and PERV-A 
infection depends on PAR expression levels (Figure 3.13), suggesting that 
ratPAR is expressed at a subthreshold level. However, an explanation for the 
low expression of ratPAR could not be found. In AGM cells, the expression 
level of PARs is similar to those in human cells (Figure 4.5). In addition, once 
the same amount of huPAR-1 and AGMPAR-1 was expressed on the cell 
surface of PERV-A resistant QT6 cells, the efficiency of EGFP transduction 
was similar (Figure 4.9 A), suggesting a comparable affinity of the receptors 
for the virus. Some of the receptor-mediated block mechanisms described for 
γ–retroviruses have been investigated and none of them could clearly be 
held responsible for the low permissivity of NHP cells to PERV-A (Figure 4.3-201 
 
5-6-7-8). Since tunicamycin treatment could rescue infectivity (Figure 4.8-9-
10), its possible mechanism was investigated. My first hypothesis was that a 
heavy N-glycosylation of the receptor could prevent PERV binding, and that 
tunicamycin treatment could relieve this block. However, tunicamycin 
treatment did not increase receptor binding (Figure 4.8-9-10), suggesting that 
receptor masking by a heavy glycosylation was not the cause of the poor 
PERV-A susceptibility. Secondly, I looked at PERV attachment to the cell 
surface of tunicamycin-treated and untreated cells. No difference was 
observed (Figure 4.11). Therefore, I excluded that tunicamycin treatment was 
affecting a different molecule, other than the receptor, involved in the 
adsorption of the virus on the cell surface. Finally, I looked at the ratio 
between the amount of receptor expressed on the cell surface versus the 
total amount in the cell, to investigate a possible mechanism of entrapment of 
the receptor in the cytosol which could be relieved by tunicamycin treatment. 
There was no evidence of a difference between AGM cells and QT6 cells 
(Figure 4.12). To conclude, AGM with a functional PAR could potentially be a 
suitable animal model to evaluate the risk associated with PERV 
transmission to humans in xenotransplantation. However, further 
investigations should be conducted to clarify the mechanism behind the poor 
permissivity of AGM cells to PERV-A and to examine PERV-A infection in 
primary cell culture. 
In chapter five, I evaluated a newly described restriction factor as a possible 
strategy to prevent PERV transmission. Tetherin (also known as BST2, 
CD317, HM1.24) has been shown to retain enveloped viruses from different 
families on the surface of the producing cells, inhibiting virus release (Neil et 
al., 2008, Jouvenet et al., 2009; Sakuma et al., 2009). This anti-viral 
mechanism appears to be part of the innate immune system response 
(Blasius et al. 2006; Neil et al., 2008). To examine whether a similar 
mechanism was present in pigs, the porcine homologue to huTHN was been 
cloned (Figure 5.1) and its activity against PERV and another retrovirus 
(MLV-A) confirmed (Figure 5.3). The efficiency of pig THN in inhibiting viral 
particles release in the supernatant of the producing cells was similar to that 
of huTHN (Figure 5.3). A stable expression of either human or porcine THN 202 
 
in pig PK15 cells could significantly reduce the virus production (Figure 5.7). 
From these results two main points of discussion emerged.  
Firstly, by overexpression of THN in porcine cells, PERV production could 
only be reduced but not completely blocked. This system could be improved 
by selection of a clonal population with higher expression of THN and 
minimal production of PERV. Indeed, similar strategies, already employed to 
reduce PERV transmission, never achieved a total lack of virus production 
from porcine cell lines or primary cells. Expression of shRNA directed against 
PERV Pol led to a 25% reduction in reverse transcriptase activity in the 
supernatant of shRNA-transduced pig PBMC (Dieckhoff et al., 2007a). 
Similar results were obtained when antibodies against PERV p15 Matrix were 
expressed in PK15 cells where, in a clonal population, RT activity was 
reduced to 7% that from parental cells (Dekker et al., 2003). Suggested 
improvement to the system by these articles was the expression of multiple 
shRNAs or antibodies, respectively. However, by combining different 
strategies which act in different steps of the viral life cycle a better protection 
could be achieved. In this case, THN could represent an ideal candidate to 
be employed together with shRNAs, which target viral transcripts before 
translation. In addition, THN has an advantage over other systems through 
its ability to target a broad range of enveloped viruses (multiple genera of 
retroviruses, filoviruses and potentially herpesviruses). Therefore, 
overexpression of THN in the cells of a pig donor could represent a safer 
strategy also against unknown enveloped viruses. However, a long term 
observation of the cells overexpressing THN should be conducted to exclude 
pathological effects. 
Secondly, porcine THN is expressed in the PERV-producing cell lines PK15 
and MPK (Figure 5.2). Upregulation of THN mRNA by less than 20-fold by 
INF-β-treatment induced a reduction of viral particles released in the 
supernatant (Figure 5.6). Furthermore, from the results presented in Figures 
5.4 and 5.5, no countermeasures against THN have been found in the PERV 
genome. It is puzzling to understand what is happening in pigs in vivo. To 
assess whether THN is somehow controlling PERV release, THN-knock 203 
 
down pig cells could be examined. If PERV titre increases upon THN-knock 
down, it would suggest that endogenous porcine THN is acting against PERV 
in vivo. Furthermore, since different human cells express unequal amount of 
THN (Neil et al., 2008), various porcine primary cells and tissues should be 
tested for tetherin production. In the scenario that THN was expressed at a 
low level, speculation could be made that PERV has not developed an anti-
THN countermeasure because there was not enough selective pressure. 
   204 
 
References 
Abada, P., Noble, B., and Cannon, P.M. (2005). Functional domains within 
the human immunodeficiency virus type 2 envelope protein required to 
enhance virus production. J Virol 79, 3627-3638. 
Abkowitz, J.L. (1991). Retrovirus-induced feline pure red blood cell aplasia: 
pathogenesis and response to suramin. Blood 77, 1442-1451. 
Abudu, A., Takaori-Kondo, A., Izumi, T., Shirakawa, K., Kobayashi, M., 
Sasada, A., Fukunaga, K., and Uchiyama, T. (2006). Murine retrovirus 
escapes from murine APOBEC3 via two distinct novel mechanisms. Curr Biol 
16, 1565-1570. 
Adams, D.H., Kadner, A., Chen, R.H., and Farivar, R.S. (2001). Human 
membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from 
hyperacute rejection in primates. Xenotransplantation 8, 36-40. 
Akgun, E., Ziegler, M., and Grez, M. (1991). Determinants of retrovirus gene 
expression in embryonal carcinoma cells. J Virol 65, 382-388. 
Akiyoshi, D.E., Denaro, M., Zhu, H., Greenstein, J.L., Banerjee, P., and 
Fishman, J.A. (1998). Identification of a full-length cDNA for an endogenous 
retrovirus of miniature swine. J Virol 72, 4503-4507. 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. 
(2002). Cell communication. In Molecular Biology of the Cell (New York, 
USA, Garland Science), p. 833. 
Albritton, L.M., Kim, J.W., Tseng, L., and Cunningham, J.M. (1993). 
Envelope-binding domain in the cationic amino acid transporter determines 
the host range of ecotropic murine retroviruses. J Virol 67, 2091-2096. 
Albritton, L.M., Tseng, L., Scadden, D., and Cunningham, J.M. (1989). A 
putative murine ecotropic retrovirus receptor gene encodes a multiple 
membrane-spanning protein and confers susceptibility to virus infection. Cell 
57, 659-666. 205 
 
Alexander, D.J., and Brown, I.H. (2000). Recent zoonoses caused by 
influenza A viruses. Rev Sci Tech 19, 197-225. 
Aloia, R.C., Jensen, F.C., Curtain, C.C., Mobley, P.W., and Gordon, L.M. 
(1988). Lipid composition and fluidity of the human immunodeficiency virus. 
Proc Natl Acad Sci U S A 85, 900-904. 
Aloia, R.C., Tian, H., and Jensen, F.C. (1993). Lipid composition and fluidity 
of the human immunodeficiency virus envelope and host cell plasma 
membranes. Proc Natl Acad Sci U S A 90, 5181-5185. 
Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., 
and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation 
of protein database search programs. Nucleic Acids Res 25, 3389-3402. 
Anderson, J.L., Campbell, E.M., Wu, X., Vandegraaff, N., Engelman, A., and 
Hope, T.J. (2006). Proteasome inhibition reveals that a functional 
preintegration complex intermediate can be generated during restriction by 
diverse TRIM5 proteins. J Virol 80, 9754-9760. 
Anderson, M.M., Lauring, A.S., Burns, C.C., and Overbaugh, J. (2000). 
Identification of a cellular cofactor required for infection by feline leukemia 
virus. Science 287, 1828-1830. 
Andersson, J.O., and Andersson, S.G. (2000). A century of typhus, lice and 
Rickettsia. Res Microbiol 151, 143-150. 
Andrews, J.M., and Gardner, M.B. (1974). Lower motor neuron degeneration 
associated with type C RNA virus infection in mice: neuropathological 
features. J Neuropathol Exp Neurol 33, 285-307. 
Andriamampandry, C., Taleb, O., Kemmel, V., Humbert, J.P., Aunis, D., and 
Maitre, M. (2007). Cloning and functional characterization of a gamma-
hydroxybutyrate receptor identified in the human brain. FASEB J 21, 885-
895. 206 
 
Argaw, T., Figueroa, M., Salomon, D.R., and Wilson, C.A. (2008). 
Identification of residues outside of the receptor binding domain that 
influence the infectivity and tropism of porcine endogenous retrovirus. J Virol 
82, 7483-7491. 
Armstrong, J.A., Porterfield, J.S., and De Madrid, A.T. (1971). C-type virus 
particles in pig kidney cell lines. J Gen Virol 10, 195-198. 
Armstrong, R., Davie, J., and Hedger, R.S. (1967). Foot-and-mouth disease 
in man. Br Med J 4, 529-530. 
Asper, M., Sternsdorf, T., Hass, M., Drosten, C., Rhode, A., Schmitz, H., and 
Gunther, S. (2004). Inhibition of different Lassa virus strains by alpha and 
gamma interferons and comparison with a less pathogenic arenavirus. J Virol 
78, 3162-3169. 
Aziz, D.C., Hanna, Z., and Jolicoeur, P. (1989). Severe immunodeficiency 
disease induced by a defective murine leukaemia virus. Nature 338, 505-508. 
Bailes, E., Gao, F., Bibollet-Ruche, F., Courgnaud, V., Peeters, M., Marx, 
P.A., Hahn, B.H., and Sharp, P.M. (2003). Hybrid origin of SIV in 
chimpanzees. Science 300, 1713. 
Balayan, M.S., Andjaparidze, A.G., Savinskaya, S.S., Ketiladze, E.S., 
Braginsky, D.M., Savinov, A.P., and Poleschuk, V.F. (1983). Evidence for a 
virus in non-A, non-B hepatitis transmitted via the fecal-oral route. 
Intervirology 20, 23-31. 
Barbacid, M., Hunter, E., and Aaronson, S.A. (1979). Avian 
reticuloendotheliosis viruses: evolutionary linkage with mammalian type C 
retroviruses. J Virol 30, 508-514. 
Barklis, E., Mulligan, R.C., and Jaenisch, R. (1986). Chromosomal position or 
virus mutation permits retrovirus expression in embryonal carcinoma cells. 
Cell 47, 391-399. 207 
 
Barnett, A.L., and Cunningham, J.M. (2001). Receptor binding transforms the 
surface subunit of the mammalian C-type retrovirus envelope protein from an 
inhibitor to an activator of fusion. J Virol 75, 9096-9105. 
Barnett, A.L., Davey, R.A., and Cunningham, J.M. (2001). Modular 
organization of the Friend murine leukemia virus envelope protein underlies 
the mechanism of infection. Proc Natl Acad Sci U S A 98, 4113-4118. 
Barnett, A.L., Wensel, D.L., Li, W., Fass, D., and Cunningham, J.M. (2003). 
Structure and mechanism of a coreceptor for infection by a pathogenic feline 
retrovirus. J Virol 77, 2717-2729. 
Barrette, R.W., Metwally, S.A., Rowland, J.M., Xu, L., Zaki, S.R., Nichol, S.T., 
Rollin, P.E., Towner, J.S., Shieh, W.J., Batten, B., et al. (2009). Discovery of 
swine as a host for the Reston ebolavirus. Science 325, 204-206. 
Bartee, E., McCormack, A., and Fruh, K. (2006). Quantitative membrane 
proteomics reveals new cellular targets of viral immune modulators. PLoS 
Pathog 2, e107. 
Bartosch, B., Stefanidis, D., Myers, R., Weiss, R., Patience, C., and 
Takeuchi, Y. (2004). Evidence and consequence of porcine endogenous 
retrovirus recombination. J Virol 78, 13880-13890. 
Bartosch, B., Weiss, R.A., and Takeuchi, Y. (2002). PCR-based cloning and 
immunocytological titration of infectious porcine endogenous retrovirus 
subgroup A and B. J Gen Virol 83, 2231-2240. 
Bassin, R.H., Duran-Troise, G., Gerwin, B.I., and Rein, A. (1978). Abrogation 
of Fv-1b restriction with murine leukemia viruses inactivated by heat or by 
gamma irradiation. J Virol 26, 306-315. 
Battini, J.L., Danos, O., and Heard, J.M. (1995). Receptor-binding domain of 
murine leukemia virus envelope glycoproteins. J Virol 69, 713-719. 208 
 
Battini, J.L., Heard, J.M., and Danos, O. (1992). Receptor choice 
determinants in the envelope glycoproteins of amphotropic, xenotropic, and 
polytropic murine leukemia viruses. J Virol 66, 1468-1475. 
Battini, J.L., Rasko, J.E., and Miller, A.D. (1999). A human cell-surface 
receptor for xenotropic and polytropic murine leukemia viruses: possible role 
in G protein-coupled signal transduction. Proc Natl Acad Sci U S A 96, 1385-
1390. 
Bengtsson, A., Blomberg, J., Nived, O., Pipkorn, R., Toth, L., and Sturfelt, G. 
(1996). Selective antibody reactivity with peptides from human endogenous 
retroviruses and nonviral poly(amino acids) in patients with systemic lupus 
erythematosus. Arthritis Rheum 39, 1654-1663. 
Benit, L., De Parseval, N., Casella, J.F., Callebaut, I., Cordonnier, A., and 
Heidmann, T. (1997). Cloning of a new murine endogenous retrovirus, 
MuERV-L, with strong similarity to the human HERV-L element and with a 
gag coding sequence closely related to the Fv1 restriction gene. J Virol 71, 
5652-5657. 
Bennett, R.P., Rhee, S., Craven, R.C., Hunter, E., and Wills, J.W. (1991). 
Amino acids encoded downstream of gag are not required by Rous sarcoma 
virus protease during gag-mediated assembly. J Virol 65, 272-280. 
Berlioz, C., and Darlix, J.L. (1995). An internal ribosomal entry mechanism 
promotes translation of murine leukemia virus gag polyprotein precursors. J 
Virol 69, 2214-2222. 
Berns, K.I., Bergoin, M., Bloom, M., Lederman, M., Muzyczka, N., Siegl, G., 
Tal, J., and Tattersall, P. (2004). 00.050. Parvoviridae. In ICTVdB - The 
Universal Virus Database, version 3, C. Büchen-Osmond, ed. (New York, 
USA, ICTVdB Management, Columbia University). 
Besnier, C., Takeuchi, Y., and Towers, G. (2002). Restriction of lentivirus in 
monkeys. Proc Natl Acad Sci U S A 99, 11920-11925. 209 
 
Besnier, C., Ylinen, L., Strange, B., Lister, A., Takeuchi, Y., Goff, S.P., and 
Towers, G.J. (2003). Characterization of murine leukemia virus restriction in 
mammals. J Virol 77, 13403-13406. 
Best, S., Le Tissier, P., Towers, G., and Stoye, J.P. (1996). Positional cloning 
of the mouse retrovirus restriction gene Fv1. Nature 382, 826-829. 
Best, S., Le Tissier, P.R., and Stoye, J.P. (1997). Endogenous retroviruses 
and the evolution of resistance to retroviral infection. Trends Microbiol 5, 313-
318. 
Bhatti, F.N., Schmoeckel, M., Zaidi, A., Cozzi, E., Chavez, G., Goddard, M., 
Dunning, J.J., Wallwork, J., and White, D.J. (1999). Three-month survival of 
HDAFF transgenic pig hearts transplanted into primates. Transplant Proc 31, 
958. 
Bibollet-Ruche, F., Bailes, E., Gao, F., Pourrut, X., Barlow, K.L., Clewley, 
J.P., Mwenda, J.M., Langat, D.K., Chege, G.K., McClure, H.M., et al. (2004). 
New simian immunodeficiency virus infecting De Brazza's monkeys 
(Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. 
J Virol 78, 7748-7762. 
Bick, M.J., Carroll, J.W., Gao, G., Goff, S.P., Rice, C.M., and MacDonald, 
M.R. (2003). Expression of the zinc-finger antiviral protein inhibits alphavirus 
replication. J Virol 77, 11555-11562. 
Blaise, S., de Parseval, N., Benit, L., and Heidmann, T. (2003). Genomewide 
screening for fusogenic human endogenous retrovirus envelopes identifies 
syncytin 2, a gene conserved on primate evolution. Proc Natl Acad Sci U S A 
100, 13013-13018. 
Blasius, A.L., Giurisato, E., Cella, M., Schreiber, R.D., Shaw, A.S., and 
Colonna, M. (2006). Bone marrow stromal cell antigen 2 is a specific marker 
of type I IFN-producing cells in the naive mouse, but a promiscuous cell 
surface antigen following IFN stimulation. J Immunol 177, 3260-3265. 210 
 
Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S. 
(2004). Prediction of post-translational glycosylation and phosphorylation of 
proteins from the amino acid sequence. Proteomics 4, 1633-1649. 
Blond, J.L., Lavillette, D., Cheynet, V., Bouton, O., Oriol, G., Chapel-
Fernandes, S., Mandrand, B., Mallet, F., and Cosset, F.L. (2000). An 
envelope glycoprotein of the human endogenous retrovirus HERV-W is 
expressed in the human placenta and fuses cells expressing the type D 
mammalian retrovirus receptor. J Virol 74, 3321-3329. 
Blusch, J.H., Patience, C., Takeuchi, Y., Templin, C., Roos, C., Von Der 
Helm, K., Steinhoff, G., and Martin, U. (2000a). Infection of nonhuman 
primate cells by pig endogenous retrovirus. J Virol 74, 7687-7690. 
Blusch, J.H., Roos, C., and Nitschko, H. (2000b). A polymerase chain 
reaction-based protocol for the detection of transmission of pig endogenous 
retroviruses in pig to human xenotransplantation. Transplantation 69, 2167-
2172. 
Boeke, J., and Stoye, J.P. (1997). Retrotransposons, Endogenous 
Retroviruses, and the Evolution of Retroelement. In Retroviruses, J.M. Coffin, 
S.H. Hughes, and H.E. Varmus, eds. (Cold Spring Harbor Laboratory Press), 
pp. 345-362. 
Bogerd, H.P., Doehle, B.P., Wiegand, H.L., and Cullen, B.R. (2004). A single 
amino acid difference in the host APOBEC3G protein controls the primate 
species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U 
S A 101, 3770-3774. 
Borden, K.L. (1998). RING fingers and B-boxes: zinc-binding protein-protein 
interaction domains. Biochem Cell Biol 76, 351-358. 
Bosch, S., Arnauld, C., and Jestin, A. (2000). Study of full-length porcine 
endogenous retrovirus genomes with envelope gene polymorphism in a 
specific-pathogen-free Large White swine herd. J Virol 74, 8575-8581. 211 
 
Bottger, P., and Pedersen, L. (2002). Two highly conserved glutamate 
residues critical for type III sodium-dependent phosphate transport revealed 
by uncoupling transport function from retroviral receptor function. J Biol 
Chem 277, 42741-42747. 
Bour, S., Schubert, U., Peden, K., and Strebel, K. (1996). The envelope 
glycoprotein of human immunodeficiency virus type 2 enhances viral particle 
release: a Vpu-like factor? J Virol 70, 820-829. 
Bour, S., and Strebel, K. (1996). The human immunodeficiency virus (HIV) 
type 2 envelope protein is a functional complement to HIV type 1 Vpu that 
enhances particle release of heterologous retroviruses. J Virol 70, 8285-
8300. 
Bouwknegt, M., Lodder-Verschoor, F., van der Poel, W.H., Rutjes, S.A., and 
de Roda Husman, A.M. (2007). Hepatitis E virus RNA in commercial porcine 
livers in The Netherlands. J Food Prot 70, 2889-2895. 
Brasey, A., Lopez-Lastra, M., Ohlmann, T., Beerens, N., Berkhout, B., Darlix, 
J.L., and Sonenberg, N. (2003). The leader of human immunodeficiency virus 
type 1 genomic RNA harbors an internal ribosome entry segment that is 
active during the G2/M phase of the cell cycle. J Virol 77, 3939-3949. 
Bray, M., Prasad, S., Dubay, J.W., Hunter, E., Jeang, K.T., Rekosh, D., and 
Hammarskjold, M.L. (1994). A small element from the Mason-Pfizer monkey 
virus genome makes human immunodeficiency virus type 1 expression and 
replication Rev-independent. Proc Natl Acad Sci U S A 91, 1256-1260. 
Briggs, J.A., Wilk, T., and Fuller, S.D. (2003). Do lipid rafts mediate virus 
assembly and pseudotyping? J Gen Virol 84, 757-768. 
Brown, I.H., Harris, P.A., McCauley, J.W., and Alexander, D.J. (1998). 
Multiple genetic reassortment of avian and human influenza A viruses in 
European pigs, resulting in the emergence of an H1N2 virus of novel 
genotype. J Gen Virol 79 ( Pt 12), 2947-2955. 212 
 
Brown, J.K., Fung, C., and Tailor, C.S. (2006). Comprehensive mapping of 
receptor-functioning domains in feline leukemia virus subgroup C receptor 
FLVCR1. J Virol 80, 1742-1751. 
Brown, P.O. (1997). Integration. In Retroviruses, J.M. Coffin, S.H. Hughes, 
and V. H.E., eds. (Cold Spring Harbor Laboratory Press), pp. 165-167. 
Brugger, B., Glass, B., Haberkant, P., Leibrecht, I., Wieland, F.T., and 
Krausslich, H.G. (2006). The HIV lipidome: a raft with an unusual 
composition. Proc Natl Acad Sci U S A 103, 2641-2646. 
Brunetti, D., Perota, A., Lagutina, I., Colleoni, S., Duchi, R., Calabrese, F., 
Seveso, M., Cozzi, E., Lazzari, G., Lucchini, F., et al. (2008). Transgene 
Expression of Green Fluorescent Protein and Germ Line Transmission in 
Cloned Pigs Derived from In Vitro Transfected Adult Fibroblasts. Cloning 
Stem Cells. 
Bryant, M., and Ratner, L. (1990). Myristoylation-dependent replication and 
assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 87, 
523-527. 
Buck, C.B., Shen, X., Egan, M.A., Pierson, T.C., Walker, C.M., and Siliciano, 
R.F. (2001). The human immunodeficiency virus type 1 gag gene encodes an 
internal ribosome entry site. J Virol 75, 181-191. 
Bukrinsky, M.I., Sharova, N., Dempsey, M.P., Stanwick, T.L., Bukrinskaya, 
A.G., Haggerty, S., and Stevenson, M. (1992). Active nuclear import of 
human immunodeficiency virus type 1 preintegration complexes. Proc Natl 
Acad Sci U S A 89, 6580-6584. 
Bushman, F., Lewinski, M., Ciuffi, A., Barr, S., Leipzig, J., Hannenhalli, S., 
and Hoffmann, C. (2005). Genome-wide analysis of retroviral DNA 
integration. Nat Rev Microbiol 3, 848-858. 
Cao, T., Borden, K.L., Freemont, P.S., and Etkin, L.D. (1997). Involvement of 
the rfp tripartite motif in protein-protein interactions and subcellular 
distribution. J Cell Sci 110 ( Pt 14), 1563-1571. 213 
 
Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. (2001). 
Specific inhibition of gene expression by small double-stranded RNAs in 
invertebrate and vertebrate systems. Proc Natl Acad Sci U S A 98, 9742-
9747. 
Castrucci, M.R., Campitelli, L., Ruggieri, A., Barigazzi, G., Sidoli, L., Daniels, 
R., Oxford, J.S., and Donatelli, I. (1994). Antigenic and sequence analysis of 
H3 influenza virus haemagglutinins from pigs in Italy. J Gen Virol 75 ( Pt 2), 
371-379. 
Chari, R.S., Collins, B.H., Magee, J.C., DiMaio, J.M., Kirk, A.D., Harland, 
R.C., McCann, R.L., Platt, J.L., and Meyers, W.C. (1994). Brief report: 
treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver 
transplantation. N Engl J Med 331, 234-237. 
Chatterji, U., Bobardt, M.D., Gaskill, P., Sheeter, D., Fox, H., and Gallay, P.A. 
(2006). Trim5alpha accelerates degradation of cytosolic capsid associated 
with productive HIV-1 entry. J Biol Chem 281, 37025-37033. 
Chaudry, G.J., and Eiden, M.V. (1997). Mutational analysis of the proposed 
gibbon ape leukemia virus binding site in Pit1 suggests that other regions are 
important for infection. J Virol 71, 8078-8081. 
Chelbi-Alix, M.K., Quignon, F., Pelicano, L., Koken, M.H., and de The, H. 
(1998). Resistance to virus infection conferred by the interferon-induced 
promyelocytic leukemia protein. J Virol 72, 1043-1051. 
Chesebro, B., and Wehrly, K. (1979). Identification of a non-H-2 gene (Rfv-3) 
influencing recovery from viremia and leukemia induced by Friend virus 
complex. Proc Natl Acad Sci U S A 76, 425-429. 
Chesebro, B., and Wehrly, K. (1985). Different murine cell lines manifest 
unique patterns of interference to superinfection by murine leukemia viruses. 
Virology 141, 119-129. 
Chiang, C.Y., Chang, J.T., Lin, M.S., Wang, S.R., and Chang, H.Y. (2005). 
Characterization of a monoclonal antibody specific to the Gag protein of 214 
 
porcine endogenous retrovirus and its application in detecting the virus 
infection. Virus Res 108, 139-148. 
Chien, M.L., Foster, J.L., Douglas, J.L., and Garcia, J.V. (1997). The 
amphotropic murine leukemia virus receptor gene encodes a 71-kilodalton 
protein that is induced by phosphate depletion. J Virol 71, 4564-4570. 
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., 
Mackay, C.R., LaRosa, G., Newman, W., et al. (1996). The beta-chemokine 
receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 
85, 1135-1148. 
Chua, K.B. (2003). Nipah virus outbreak in Malaysia. J Clin Virol 26, 265-275. 
Chua, K.B., Bellini, W.J., Rota, P.A., Harcourt, B.H., Tamin, A., Lam, S.K., 
Ksiazek, T.G., Rollin, P.E., Zaki, S.R., Shieh, W., et al. (2000). Nipah virus: a 
recently emergent deadly paramyxovirus. Science 288, 1432-1435. 
Chua, K.B., Goh, K.J., Wong, K.T., Kamarulzaman, A., Tan, P.S., Ksiazek, 
T.G., Zaki, S.R., Paul, G., Lam, S.K., and Tan, C.T. (1999). Fatal encephalitis 
due to Nipah virus among pig-farmers in Malaysia. Lancet 354, 1257-1259. 
Chua, K.B., Koh, C.L., Hooi, P.S., Wee, K.F., Khong, J.H., Chua, B.H., Chan, 
Y.P., Lim, M.E., and Lam, S.K. (2002). Isolation of Nipah virus from 
Malaysian Island flying-foxes. Microbes Infect 4, 145-151. 
Clemenceau, B., Jegou, D., Martignat, L., and Sai, P. (2001). Long-term 
follow-up failed to detect in vitro transmission of full-length porcine 
endogenous retroviruses from specific pathogen-free pig islets to human 
cells. Diabetologia 44, 2044-2055. 
Clemenceau, B., Jegou, D., Martignat, L., and Sai, P. (2002). Microchimerism 
and transmission of porcine endogenous retrovirus from a pig cell line or 
specific pathogen-free pig islets to mouse tissues and human cells during 
xenografts in nude mice. Diabetologia 45, 914-923. 215 
 
Cohen, E.A., Terwilliger, E.F., Sodroski, J.G., and Haseltine, W.A. (1988). 
Identification of a protein encoded by the vpu gene of HIV-1. Nature 334, 
532-534. 
Coil, D.A., and Miller, A.D. (2005). Phosphatidylserine treatment relieves the 
block to retrovirus infection of cells expressing glycosylated virus receptors. 
Retrovirology 2, 49. 
Collins, M.K.L., Weiss, R.A., Takeuchi, Y., and Cosset, F.L. (1995). patent 
GB9517263.1. 
Colman, P.M., and Lawrence, M.C. (2003). The structural biology of type I 
viral membrane fusion. Nat Rev Mol Cell Biol 4, 309-319. 
Colson, P., Kaba, M., Bernit, E., Motte, A., and Tamalet, C. (2007). Hepatitis 
E associated with surgical training on pigs. Lancet 370, 935. 
Conrad, B., Weissmahr, R.N., Boni, J., Arcari, R., Schupbach, J., and Mach, 
B. (1997). A human endogenous retroviral superantigen as candidate 
autoimmune gene in type I diabetes. Cell 90, 303-313. 
Conticello, S.G., Harris, R.S., and Neuberger, M.S. (2003). The Vif protein of 
HIV triggers degradation of the human antiretroviral DNA deaminase 
APOBEC3G. Curr Biol 13, 2009-2013. 
Courgnaud, V., Abela, B., Pourrut, X., Mpoudi-Ngole, E., Loul, S., Delaporte, 
E., and Peeters, M. (2003). Identification of a new simian immunodeficiency 
virus lineage with a vpu gene present among different cercopithecus 
monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J Virol 77, 
12523-12534. 
Courgnaud, V., Salemi, M., Pourrut, X., Mpoudi-Ngole, E., Abela, B., Auzel, 
P., Bibollet-Ruche, F., Hahn, B., Vandamme, A.M., Delaporte, E., et al. 
(2002). Characterization of a novel simian immunodeficiency virus with a vpu 
gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides 
new insights into simian/human immunodeficiency virus phylogeny. J Virol 
76, 8298-8309. 216 
 
Cowan, S., Hatziioannou, T., Cunningham, T., Muesing, M.A., Gottlinger, 
H.G., and Bieniasz, P.D. (2002). Cellular inhibitors with Fv1-like activity 
restrict human and simian immunodeficiency virus tropism. Proc Natl Acad 
Sci U S A 99, 11914-11919. 
Cozzi, E., Bhatti, F., Schmoeckel, M., Chavez, G., Smith, K.G., Zaidi, A., 
Bradley, J.R., Thiru, S., Goddard, M., Vial, C., et al. (2000). Long-term 
survival of nonhuman primates receiving life-supporting transgenic porcine 
kidney xenografts. Transplantation 70, 15-21. 
Crise, B., Li, Y., Yuan, C., Morcock, D.R., Whitby, D., Munroe, D.J., Arthur, 
L.O., and Wu, X. (2005). Simian immunodeficiency virus integration 
preference is similar to that of human immunodeficiency virus type 1. J Virol 
79, 12199-12204. 
Cunningham, D.A., Herring, C., Fernandez-Suarez, X.M., Whittam, A.J., 
Paradis, K., and Langford, G.A. (2001). Analysis of patients treated with living 
pig tissue for evidence of infection by porcine endogenous retroviruses. 
Trends Cardiovasc Med 11, 190-196. 
Currie, G.A., and Gage, J.O. (1973). Influence of tumour growth on the 
evolution of cytotoxic lymphoid cells in rats bearing a spontaneously 
metastasizing syngeneic fibrosarcoma. Br J Cancer 28, 136-146. 
Czauderna, F., Fischer, N., Boller, K., Kurth, R., and Tonjes, R.R. (2000). 
Establishment and characterization of molecular clones of porcine 
endogenous retroviruses replicating on human cells. J Virol 74, 4028-4038. 
Dai, Y., Vaught, T.D., Boone, J., Chen, S.H., Phelps, C.J., Ball, S., Monahan, 
J.A., Jobst, P.M., McCreath, K.J., Lamborn, A.E., et al. (2002). Targeted 
disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. Nat 
Biotechnol 20, 251-255. 
Daniel, M.D., Letvin, N.L., King, N.W., Kannagi, M., Sehgal, P.K., Hunt, R.D., 
Kanki, P.J., Essex, M., and Desrosiers, R.C. (1985). Isolation of T-cell tropic 
HTLV-III-like retrovirus from macaques. Science 228, 1201-1204. 217 
 
de Wit, E., and Fouchier, R.A. (2008). Emerging influenza. J Clin Virol 41, 1-
6. 
Deacon, T., Schumacher, J., Dinsmore, J., Thomas, C., Palmer, P., Kott, S., 
Edge, A., Penney, D., Kassissieh, S., Dempsey, P., et al. (1997). Histological 
evidence of fetal pig neural cell survival after transplantation into a patient 
with Parkinson's disease. Nat Med 3, 350-353. 
Deest, G., Zehner, L., Nicand, E., Gaudy-Graffin, C., Goudeau, A., and Bacq, 
Y. (2007). [Autochthonous hepatitis E in France and consumption of raw pig 
meat]. Gastroenterol Clin Biol 31, 1095-1097. 
Deffaud, C., and Darlix, J.L. (2000a). Characterization of an internal 
ribosomal entry segment in the 5' leader of murine leukemia virus env RNA. J 
Virol 74, 846-850. 
Deffaud, C., and Darlix, J.L. (2000b). Rous sarcoma virus translation 
revisited: characterization of an internal ribosome entry segment in the 5' 
leader of the genomic RNA. J Virol 74, 11581-11588. 
Dekker, S., Toussaint, W., Panayotou, G., de Wit, T., Visser, P., Grosveld, F., 
and Drabek, D. (2003). Intracellularly expressed single-domain antibody 
against p15 matrix protein prevents the production of porcine retroviruses. J 
Virol 77, 12132-12139. 
Delebecque, F., Suspene, R., Calattini, S., Casartelli, N., Saib, A., Froment, 
A., Wain-Hobson, S., Gessain, A., Vartanian, J.P., and Schwartz, O. (2006). 
Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol 80, 
605-614. 
Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., 
Grez, M., and Thrasher, A.J. (2002). High-level transduction and gene 
expression in hematopoietic repopulating cells using a human 
immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral 
vector containing an internal spleen focus forming virus promoter. Hum Gene 
Ther 13, 803-813. 218 
 
Demirov, D.G., and Freed, E.O. (2004). Retrovirus budding. Virus Res 106, 
87-102. 
Deng, Y.M., Tuch, B.E., and Rawlinson, W.D. (2000). Transmission of 
porcine endogenous retroviruses in severe combined immunodeficient mice 
xenotransplanted with fetal porcine pancreatic cells. Transplantation 70, 
1010-1016. 
Denner, J. (2003). Porcine endogenous retroviruses (PERVs) and 
xenotransplantation: screening for transmission in several clinical trials and in 
experimental models using non-human primates. Ann Transplant 8, 39-48. 
Denner, J. (2007). Transspecies transmissions of retroviruses: new cases. 
Virology 369, 229-233. 
Derse, D., Hill, S.A., Princler, G., Lloyd, P., and Heidecker, G. (2007). 
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is 
mediated by elements in nucleocapsid. Proc Natl Acad Sci U S A 104, 2915-
2920. 
Deschamps, J.Y., Roux, F.A., Sai, P., and Gouin, E. (2005). History of 
xenotransplantation. Xenotransplantation 12, 91-109. 
Diaz-Griffero, F., Li, X., Javanbakht, H., Song, B., Welikala, S., Stremlau, M., 
and Sodroski, J. (2006). Rapid turnover and polyubiquitylation of the 
retroviral restriction factor TRIM5. Virology 349, 300-315. 
Dieckhoff, B., Karlas, A., Hofmann, A., Kues, W.A., Petersen, B., Pfeifer, A., 
Niemann, H., Kurth, R., and Denner, J. (2007a). Inhibition of porcine 
endogenous retroviruses (PERVs) in primary porcine cells by RNA 
interference using lentiviral vectors. Arch Virol 152, 629-634. 
Dieckhoff, B., Kessler, B., Jobst, D., Kues, W., Petersen, B., Pfeifer, A., 
Kurth, R., Niemann, H., Wolf, E., and Denner, J. (2009). Distribution and 
expression of porcine endogenous retroviruses in multi-transgenic pigs 
generated for xenotransplantation. Xenotransplantation 16, 64-73. 219 
 
Dieckhoff, B., Petersen, B., Kues, W.A., Kurth, R., Niemann, H., and Denner, 
J. (2008). Knockdown of porcine endogenous retrovirus (PERV) expression 
by PERV-specific shRNA in transgenic pigs. Xenotransplantation 15, 36-45. 
Dieckhoff, B., Puhlmann, J., Buscher, K., Hafner-Marx, A., Herbach, N., 
Bannert, N., Buttner, M., Wanke, R., Kurth, R., and Denner, J. (2007b). 
Expression of porcine endogenous retroviruses (PERVs) in melanomas of 
Munich miniature swine (MMS) Troll. Vet Microbiol 123, 53-68. 
Doehle, B.P., Bogerd, H.P., Wiegand, H.L., Jouvenet, N., Bieniasz, P.D., 
Hunter, E., and Cullen, B.R. (2006). The betaretrovirus Mason-Pfizer monkey 
virus selectively excludes simian APOBEC3G from virion particles. J Virol 80, 
12102-12108. 
Doehle, B.P., Schafer, A., Wiegand, H.L., Bogerd, H.P., and Cullen, B.R. 
(2005). Differential sensitivity of murine leukemia virus to APOBEC3-
mediated inhibition is governed by virion exclusion. J Virol 79, 8201-8207. 
Doig, D., and Chesebro, B. (1979). Anti-Friend virus antibody is associated 
with recovery from viremia and loss of viral leukemia cell-surface antigens in 
leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody 
production. J Exp Med 150, 10-19. 
Dong, B., Kim, S., Hong, S., Das Gupta, J., Malathi, K., Klein, E.A., Ganem, 
D., Derisi, J.L., Chow, S.A., and Silverman, R.H. (2007). An infectious 
retrovirus susceptible to an IFN antiviral pathway from human prostate 
tumors. Proc Natl Acad Sci U S A 104, 1655-1660. 
Dorrschuck, E., Munk, C., and Tonjes, R.R. (2008). APOBEC3 proteins and 
porcine endogenous retroviruses. Transplant Proc 40, 959-961. 
Douglas, J.L., Viswanathan, K., McCarroll, M.N., Gustin, J.K., Fruh, K., and 
Moses, A.V. (2009). Vpu Directs the Degradation of the HIV Restriction 
Factor BST-2/tetherin via a {beta}TrCP-dependent Mechanism. J Virol. 
Drake, J.W., and Holland, J.J. (1999). Mutation rates among RNA viruses. 
Proc Natl Acad Sci U S A 96, 13910-13913. 220 
 
Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, 
S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A., et al. (2003). 
Identification of a novel coronavirus in patients with severe acute respiratory 
syndrome. N Engl J Med 348, 1967-1976. 
DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., and Calos, 
M.P. (1987). Analysis of mutation in human cells by using an Epstein-Barr 
virus shuttle system. Mol Cell Biol 7, 379-387. 
Dunlap, K.A., Palmarini, M., Varela, M., Burghardt, R.C., Hayashi, K., 
Farmer, J.L., and Spencer, T.E. (2006). Endogenous retroviruses regulate 
periimplantation placental growth and differentiation. Proc Natl Acad Sci U S 
A 103, 14390-14395. 
Dunne, H.W., Gobble, J.L., Hokanson, J.F., Kradel, D.C., and Bubash, G.R. 
(1965). Porcine reproductive failure associated with a newly identified 
"SMEDI" group of picorna viruses. Am J Vet Res 26, 1284-1297. 
Dupressoir, A., Marceau, G., Vernochet, C., Benit, L., Kanellopoulos, C., 
Sapin, V., and Heidmann, T. (2005). Syncytin-A and syncytin-B, two 
fusogenic placenta-specific murine envelope genes of retroviral origin 
conserved in Muridae. Proc Natl Acad Sci U S A 102, 725-730. 
Dupressoir, A., Vernochet, C., Bawa, O., Harper, F., Pierron, G., Opolon, P., 
and Heidmann, T. (2009). Syncytin-A knockout mice demonstrate the critical 
role in placentation of a fusogenic, endogenous retrovirus-derived, envelope 
gene. Proc Natl Acad Sci U S A 106, 12127-12132. 
Eckert, D.M., and Kim, P.S. (2001). Mechanisms of viral membrane fusion 
and its inhibition. Annu Rev Biochem 70, 777-810. 
Edamura, K., Nasu, K., Iwami, Y., Nishimura, R., Ogawa, H., Sasaki, N., and 
Ohgawara, H. (2004). Prevalence of porcine endogenous retrovirus in 
domestic pigs in Japan and its potential infection in dogs xenotransplanted 
with porcine pancreatic islet cells. J Vet Med Sci 66, 129-135. 221 
 
Ehlers, B., Dural, G., Yasmum, N., Lembo, T., de Thoisy, B., Ryser-
Degiorgis, M.P., Ulrich, R.G., and McGeoch, D.J. (2008). Novel mammalian 
herpesviruses and lineages within the Gammaherpesvirinae: cospeciation 
and interspecies transfer. J Virol 82, 3509-3516. 
Eiden, M.V., Farrell, K., and Wilson, C.A. (1994). Glycosylation-dependent 
inactivation of the ecotropic murine leukemia virus receptor. J Virol 68, 626-
631. 
Eiden, M.V., Farrell, K.B., and Wilson, C.A. (1996). Substitution of a single 
amino acid residue is sufficient to allow the human amphotropic murine 
leukemia virus receptor to also function as a gibbon ape leukemia virus 
receptor. J Virol 70, 1080-1085. 
Einfeld, D., and Hunter, E. (1988). Oligomeric structure of a prototype 
retrovirus glycoprotein. Proc Natl Acad Sci U S A 85, 8688-8692. 
Ekser, B., Rigotti, P., Gridelli, B., and Cooper, D.K. (2009). 
Xenotransplantation of solid organs in the pig-to-primate model. Transpl 
Immunol 21, 87-92. 
Elliott, R.B., Escobar, L., Calafiore, R., Basta, G., Garkavenko, O., 
Vasconcellos, A., and Bambra, C. (2005). Transplantation of micro- and 
macroencapsulated piglet islets into mice and monkeys. Transplant Proc 37, 
466-469. 
Elliott, R.B., Escobar, L., Garkavenko, O., Croxson, M.C., Schroeder, B.A., 
McGregor, M., Ferguson, G., Beckman, N., and Ferguson, S. (2000). No 
evidence of infection with porcine endogenous retrovirus in recipients of 
encapsulated porcine islet xenografts. Cell Transplant 9, 895-901. 
Ericsson, T., Oldmixon, B., Blomberg, J., Rosa, M., Patience, C., and 
Andersson, G. (2001). Identification of novel porcine endogenous 
betaretrovirus sequences in miniature swine. J Virol 75, 2765-2770. 
Ericsson, T.A., Takeuchi, Y., Templin, C., Quinn, G., Farhadian, S.F., Wood, 
J.C., Oldmixon, B.A., Suling, K.M., Ishii, J.K., Kitagawa, Y., et al. (2003). 222 
 
Identification of receptors for pig endogenous retrovirus. Proc Natl Acad Sci 
U S A 100, 6759-6764. 
Ernst, R.K., Bray, M., Rekosh, D., and Hammarskjold, M.L. (1997). A 
structured retroviral RNA element that mediates nucleocytoplasmic export of 
intron-containing RNA. Mol Cell Biol 17, 135-144. 
Escors, D., Lopes, L., Lin, R., Hiscott, J., Akira, S., Davis, R.J., and Collins, 
M.K. (2008). Targeting dendritic cell signaling to regulate the response to 
immunization. Blood 111, 3050-3061. 
Esnault, C., Heidmann, O., Delebecque, F., Dewannieux, M., Ribet, D., 
Hance, A.J., Heidmann, T., and Schwartz, O. (2005). APOBEC3G cytidine 
deaminase inhibits retrotransposition of endogenous retroviruses. Nature 
433, 430-433. 
Esnault, C., Priet, S., Ribet, D., Vernochet, C., Bruls, T., Lavialle, C., 
Weissenbach, J., and Heidmann, T. (2008). A placenta-specific receptor for 
the fusogenic, endogenous retrovirus-derived, human syncytin-2. Proc Natl 
Acad Sci U S A 105, 17532-17537. 
Fan, H. (1997). Leukemogenesis by Moloney murine leukemia virus: a 
multistep process. Trends Microbiol 5, 74-82. 
Farrell, K.B., Russ, J.L., Murthy, R.K., and Eiden, M.V. (2002). Reassessing 
the role of region A in Pit1-mediated viral entry. J Virol 76, 7683-7693. 
Feldman, S.A., Farrell, K.B., Murthy, R.K., Russ, J.L., and Eiden, M.V. 
(2004). Identification of an extracellular domain within the human PiT2 
receptor that is required for amphotropic murine leukemia virus binding. J 
Virol 78, 595-602. 
Feuer, G., Taketo, M., Hanecak, R.C., and Fan, H. (1989). Two blocks in 
Moloney murine leukemia virus expression in undifferentiated F9 embryonal 
carcinoma cells as determined by transient expression assays. J Virol 63, 
2317-2324. 223 
 
Fiebig, U., Stephan, O., Kurth, R., and Denner, J. (2003). Neutralizing 
antibodies against conserved domains of p15E of porcine endogenous 
retroviruses: basis for a vaccine for xenotransplantation? Virology 307, 406-
413. 
Fink, J.S., Schumacher, J.M., Ellias, S.L., Palmer, E.P., Saint-Hilaire, M., 
Shannon, K., Penn, R., Starr, P., VanHorne, C., Kott, H.S., et al. (2000). 
Porcine xenografts in Parkinson's disease and Huntington's disease patients: 
preliminary results. Cell Transplant 9, 273-278. 
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, 
C.C. (1998). Potent and specific genetic interference by double-stranded 
RNA in Caenorhabditis elegans. Nature 391, 806-811. 
Fischer, N., Krach, U., Niebert, M., and Tonjes, R.R. (2003). Detection of 
porcine endogenous retrovirus (PERV) using highly specific antisera against 
Gag and Env. Virology 311, 222-228. 
Fisher, A.G., Ensoli, B., Ivanoff, L., Chamberlain, M., Petteway, S., Ratner, 
L., Gallo, R.C., and Wong-Staal, F. (1987). The sor gene of HIV-1 is required 
for efficient virus transmission in vitro. Science 237, 888-893. 
Flanagan, J.R., Krieg, A.M., Max, E.E., and Khan, A.S. (1989). Negative 
control region at the 5' end of murine leukemia virus long terminal repeats. 
Mol Cell Biol 9, 739-746. 
Fortin, J.F., Cantin, R., Lamontagne, G., and Tremblay, M. (1997). Host-
derived ICAM-1 glycoproteins incorporated on human immunodeficiency 
virus type 1 are biologically active and enhance viral infectivity. J Virol 71, 
3588-3596. 
Fredericksen, B.L., Wei, B.L., Yao, J., Luo, T., and Garcia, J.V. (2002). 
Inhibition of endosomal/lysosomal degradation increases the infectivity of 
human immunodeficiency virus. J Virol 76, 11440-11446. 224 
 
Freed, E.O., and Martin, M.A. (1996). Domains of the human 
immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for 
envelope incorporation into virions. J Virol 70, 341-351. 
Freemont, P.S. (2000). RING for destruction? Curr Biol 10, R84-87. 
Friedman, J.R., Fredericks, W.J., Jensen, D.E., Speicher, D.W., Huang, X.P., 
Neilson, E.G., and Rauscher, F.J., 3rd (1996). KAP-1, a novel corepressor 
for the highly conserved KRAB repression domain. Genes Dev 10, 2067-
2078. 
Fujisawa, R., and Masuda, M. (2007). Ecotropic murine leukemia virus 
envelope protein affects interaction of cationic amino acid transporter 1 with 
clathrin adaptor protein complexes, leading to receptor downregulation. 
Virology 368, 342-350. 
Gabbay, Y.B., Borges, A.A., Oliveira, D.S., Linhares, A.C., Mascarenhas, 
J.D., Barardi, C.R., Simoes, C.M., Wang, Y., Glass, R.I., and Jiang, B. 
(2008). Evidence for zoonotic transmission of group C rotaviruses among 
children in Belem, Brazil. J Med Virol 80, 1666-1674. 
Gabuzda, D.H., Lawrence, K., Langhoff, E., Terwilliger, E., Dorfman, T., 
Haseltine, W.A., and Sodroski, J. (1992). Role of vif in replication of human 
immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 66, 6489-
6495. 
Galbraith, D.N., Kelly, H.T., Dyke, A., Reid, G., Haworth, C., Beekman, J., 
Shepherd, A., and Smith, K.T. (2000). Design and validation of 
immunological tests for the detection of Porcine endogenous retrovirus in 
biological materials. J Virol Methods 90, 115-124. 
Galili, U. (2001). The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) 
in xenotransplantation. Biochimie 83, 557-563. 
Galili, U., Mandrell, R.E., Hamadeh, R.M., Shohet, S.B., and Griffiss, J.M. 
(1988). Interaction between human natural anti-alpha-galactosyl 225 
 
immunoglobulin G and bacteria of the human flora. Infect Immun 56, 1730-
1737. 
Gao, F., Bailes, E., Robertson, D.L., Chen, Y., Rodenburg, C.M., Michael, 
S.F., Cummins, L.B., Arthur, L.O., Peeters, M., Shaw, G.M., et al. (1999). 
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 
436-441. 
Gao, G., Guo, X., and Goff, S.P. (2002). Inhibition of retroviral RNA 
production by ZAP, a CCCH-type zinc finger protein. Science 297, 1703-
1706. 
Garkavenko, O., Wynyard, S., Nathu, D., Muzina, M., Muzina, Z., Scobie, L., 
Hector, R.D., Croxson, M.C., Tan, P., and Elliott, B.R. (2008a). Porcine 
endogenous retrovirus transmission characteristics from a designated 
pathogen-free herd. Transplant Proc 40, 590-593. 
Garkavenko, O., Wynyard, S., Nathu, D., Simond, D., Muzina, M., Muzina, Z., 
Scobie, L., Hector, R.D., Croxson, M.C., Tan, P., et al. (2008b). Porcine 
endogenous retrovirus (PERV) and its transmission characteristics: a study 
of the New Zealand designated pathogen-free herd. Cell Transplant 17, 
1381-1388. 
Garten, R.J., Davis, C.T., Russell, C.A., Shu, B., Lindstrom, S., Balish, A., 
Sessions, W.M., Xu, X., Skepner, E., Deyde, V., et al. (2009). Antigenic and 
genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses 
circulating in humans. Science 325, 197-201. 
Gemeniano, M., Mpanju, O., Salomon, D.R., Eiden, M.V., and Wilson, C.A. 
(2006). The infectivity and host range of the ecotropic porcine endogenous 
retrovirus, PERV-C, is modulated by residues in the C-terminal region of its 
surface envelope protein. Virology 346, 108-117. 
Geraghty, R.J., Talbot, K.J., Callahan, M., Harper, W., and Panganiban, A.T. 
(1994). Cell type-dependence for Vpu function. J Med Primatol 23, 146-150. 226 
 
Gifford, R., and Tristem, M. (2003). The evolution, distribution and diversity of 
endogenous retroviruses. Virus Genes 26, 291-315. 
Gifford, R.J., Katzourakis, A., Tristem, M., Pybus, O.G., Winters, M., and 
Shafer, R.W. (2008). A transitional endogenous lentivirus from the genome of 
a basal primate and implications for lentivirus evolution. Proc Natl Acad Sci U 
S A 105, 20362-20367. 
Glass, C.M., McLean, R.G., Katz, J.B., Maehr, D.S., Cropp, C.B., Kirk, L.J., 
McKeirnan, A.J., and Evermann, J.F. (1994). Isolation of pseudorabies 
(Aujeszky's disease) virus from a Florida panther. J Wildl Dis 30, 180-184. 
Goffinet, C., Allespach, I., Homann, S., Tervo, H.M., Habermann, A., Rupp, 
D., Oberbremer, L., Kern, C., Tibroni, N., Welsch, S., et al. (2009). HIV-1 
antagonism of CD317 is species specific and involves Vpu-mediated 
proteasomal degradation of the restriction factor. Cell Host Microbe 5, 285-
297. 
Gollackner, B., Mueller, N.J., Houser, S., Qawi, I., Soizic, D., Knosalla, C., 
Buhler, L., Dor, F.J., Awwad, M., Sachs, D.H., et al. (2003). Porcine 
cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation. 
Transplantation 75, 1841-1847. 
Gorelick, R.J., Henderson, L.E., Hanser, J.P., and Rein, A. (1988). Point 
mutants of Moloney murine leukemia virus that fail to package viral RNA: 
evidence for specific RNA recognition by a "zinc finger-like" protein 
sequence. Proc Natl Acad Sci U S A 85, 8420-8424. 
Goto, T., Kennel, S.J., Abe, M., Takishita, M., Kosaka, M., Solomon, A., and 
Saito, S. (1994). A novel membrane antigen selectively expressed on 
terminally differentiated human B cells. Blood 84, 1922-1930. 
Gottlinger, H.G., Sodroski, J.G., and Haseltine, W.A. (1989). Role of capsid 
precursor processing and myristoylation in morphogenesis and infectivity of 
human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86, 5781-
5785. 227 
 
Grez, M., Akgun, E., Hilberg, F., and Ostertag, W. (1990). Embryonic stem 
cell virus, a recombinant murine retrovirus with expression in embryonic stem 
cells. Proc Natl Acad Sci U S A 87, 9202-9206. 
Groth, C.G., Korsgren, O., Tibell, A., Tollemar, J., Moller, E., Bolinder, J., 
Ostman, J., Reinholt, F.P., Hellerstrom, C., and Andersson, A. (1994). 
Transplantation of porcine fetal pancreas to diabetic patients. Lancet 344, 
1402-1404. 
Gubler, D.J. (1988). Dengue. In Epidemiology of arthropod-borne viral 
diseases, T.P. Monath, ed. (Boca Raton, Fla, CRC Press, Inc), pp. 223-260. 
Gulizia, J., Dempsey, M.P., Sharova, N., Bukrinsky, M.I., Spitz, L., Goldfarb, 
D., and Stevenson, M. (1994). Reduced nuclear import of human 
immunodeficiency virus type 1 preintegration complexes in the presence of a 
prototypic nuclear targeting signal. J Virol 68, 2021-2025. 
Guo, X., Carroll, J.W., Macdonald, M.R., Goff, S.P., and Gao, G. (2004). The 
zinc finger antiviral protein directly binds to specific viral mRNAs through the 
CCCH zinc finger motifs. J Virol 78, 12781-12787. 
Guo, X., Ma, J., Sun, J., and Gao, G. (2007). The zinc-finger antiviral protein 
recruits the RNA processing exosome to degrade the target mRNA. Proc Natl 
Acad Sci U S A 104, 151-156. 
Gupta, R.K., Hue, S., Schaller, T., Verschoor, E., Pillay, D., and Towers, G.J. 
(2009a). Mutation of a single residue renders human tetherin resistant to 
HIV-1 Vpu-mediated depletion. PLoS Pathog 5, e1000443. 
Gupta, R.K., Mlcochova, P., Pelchen-Matthews, A., Petit, S.J., Mattiuzzo, G., 
Pillay, D., Takeuchi, Y., Marsh, M., and Towers, G.J. (2009b). Simian 
Immunodeficiency Virus envelope glycoprotein counteracts tetherin/BST-
2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A. 
Gurley, E.S., Montgomery, J.M., Hossain, M.J., Bell, M., Azad, A.K., Islam, 
M.R., Molla, M.A., Carroll, D.S., Ksiazek, T.G., Rota, P.A., et al. (2007). 228 
 
Person-to-person transmission of Nipah virus in a Bangladeshi community. 
Emerg Infect Dis 13, 1031-1037. 
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., 
Hamers, C., Songa, E.B., Bendahman, N., and Hamers, R. (1993). Naturally 
occurring antibodies devoid of light chains. Nature 363, 446-448. 
Hammer, C. (2002). Xenotransplantation for liver therapy or: Can porcine 
hepatocytes generate physiological functions sufficient for a human patient in 
ALF? Int J Artif Organs 25, 1019-1028. 
Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J. (2000). An 
RNA-directed nuclease mediates post-transcriptional gene silencing in 
Drosophila cells. Nature 404, 293-296. 
Hanger, J.J., Bromham, L.D., McKee, J.J., O'Brien, T.M., and Robinson, 
W.F. (2000). The nucleotide sequence of koala (Phascolarctos cinereus) 
retrovirus: a novel type C endogenous virus related to Gibbon ape leukemia 
virus. J Virol 74, 4264-4272. 
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., 
Watt, I.N., Neuberger, M.S., and Malim, M.H. (2003). DNA deamination 
mediates innate immunity to retroviral infection. Cell 113, 803-809. 
Harrison, I., Takeuchi, Y., Bartosch, B., and Stoye, J.P. (2004). Determinants 
of high titer in recombinant porcine endogenous retroviruses. J Virol 78, 
13871-13879. 
Hartley, J.W., Rowe, W.P., and Huebner, R.J. (1970). Host-range restrictions 
of murine leukemia viruses in mouse embryo cell cultures. J Virol 5, 221-225. 
Hatfield, D.L., Levin, J.G., Rein, A., and Oroszlan, S. (1992). Translational 
suppression in retroviral gene expression. Adv Virus Res 41, 193-239. 
Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., and Bieniasz, 
P.D. (2004). Retrovirus resistance factors Ref1 and Lv1 are species-specific 
variants of TRIM5alpha. Proc Natl Acad Sci U S A 101, 10774-10779. 229 
 
Hayward, W.S., Neel, B.G., and Astrin, S.M. (1981). Activation of a cellular 
onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 
290, 475-480. 
Haywood, A.M. (1994). Virus receptors: binding, adhesion strengthening, and 
changes in viral structure. J Virol 68, 1-5. 
Hazama, K., Miyagawa, S., Miyazawa, T., Yamada, J., Tomonaga, K., Ota, 
M., Matsuda, H., and Shirakura, R. (2003). The significance of N-linked 
glycosylation in pig endogenous retrovirus infectivity. Biochem Biophys Res 
Commun 310, 327-333. 
Hazama, K., Miyagawa, S., Yamamoto, A., Kubo, T., Miyazawa, T., 
Tomonaga, K., Watanabe, R., Okumura, M., Matsuda, H., and Shirakura, R. 
(2005). The effect of complement regulatory protein expression on pig 
endothelial cells to porcine endogenous retrovirus lyses by human sera. 
Transplant Proc 37, 503-505. 
Heard, J.M., and Danos, O. (1991). An amino-terminal fragment of the Friend 
murine leukemia virus envelope glycoprotein binds the ecotropic receptor. J 
Virol 65, 4026-4032. 
Hector, R.D., Meikle, S., Grant, L., Wilkinson, R.A., Fishman, J.A., and 
Scobie, L. (2007). Pre-screening of miniature swine may reduce the risk of 
transmitting human tropic recombinant porcine endogenous retroviruses. 
Xenotransplantation 14, 222-226. 
Heinzinger, N.K., Bukinsky, M.I., Haggerty, S.A., Ragland, A.M., 
Kewalramani, V., Lee, M.A., Gendelman, H.E., Ratner, L., Stevenson, M., 
and Emerman, M. (1994). The Vpr protein of human immunodeficiency virus 
type 1 influences nuclear localization of viral nucleic acids in nondividing host 
cells. Proc Natl Acad Sci U S A 91, 7311-7315. 
Heneine, W., Tibell, A., Switzer, W.M., Sandstrom, P., Rosales, G.V., 
Mathews, A., Korsgren, O., Chapman, L.E., Folks, T.M., and Groth, C.G. 230 
 
(1998). No evidence of infection with porcine endogenous retrovirus in 
recipients of porcine islet-cell xenografts. Lancet 352, 695-699. 
Herring, C., Quinn, G., Bower, R., Parsons, N., Logan, N.A., Brawley, A., 
Elsome, K., Whittam, A., Fernandez-Suarez, X.M., Cunningham, D., et al. 
(2001). Mapping full-length porcine endogenous retroviruses in a large white 
pig. J Virol 75, 12252-12265. 
Hines, D.L., Cutting, J.A., Dietrich, D.L., and Walsh, J.A. (1991). Evaluation 
of efficacy and safety of an inactivated virus vaccine against feline leukemia 
virus infection. J Am Vet Med Assoc 199, 1428-1430. 
Hofmann-Lehmann, R., Cattori, V., Tandon, R., Boretti, F.S., Meli, M.L., 
Riond, B., Pepin, A.C., Willi, B., Ossent, P., and Lutz, H. (2007). Vaccination 
against the feline leukaemia virus: outcome and response categories and 
long-term follow-up. Vaccine 25, 5531-5539. 
Hofmann, T.G., and Will, H. (2003). Body language: the function of PML 
nuclear bodies in apoptosis regulation. Cell Death Differ 10, 1290-1299. 
Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., Scammell, 
J., Ferrigno, P., and Sodroski, J. (1999). Species-specific, postentry barriers 
to primate immunodeficiency virus infection. J Virol 73, 10020-10028. 
Holmes, I.H., Boccardo, G., Estes, M.K., Furuichi, M.K., Hoshino, Y., Joklik, 
W.K., McCrae, M., Mertens, P.P.C., Milne, R.G., Samal, K.S.K., et al. (2006). 
00.060.0.03. Rotavirus. In ICTVdB - The Universal Virus Database, version 
4, C. Büchen-Osmond, ed. (New York, USA, Columbia University). 
Holmes, R.K., Koning, F.A., Bishop, K.N., and Malim, M.H. (2007). 
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription 
products in the absence of hypermutation. Comparisons with APOBEC3G. J 
Biol Chem 282, 2587-2595. 
Hsu, V.P., Hossain, M.J., Parashar, U.D., Ali, M.M., Ksiazek, T.G., Kuzmin, 
I., Niezgoda, M., Rupprecht, C., Bresee, J., and Breiman, R.F. (2004). Nipah 231 
 
virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 10, 2082-
2087. 
Hunter, E. (1997). Viral Entry and Receptors. In Retroviruses, J.M. Coffin, 
S.H. Hughes, and H.E. Varmus, eds. (Cold Spring Harbor Laboratory Press), 
pp. 100-104. 
ICTVdB (2004). 00.084. Hepeviridae. In ICTVdB - The Universal Virus 
Database, C. Büchen-Osmond, ed. (New York, USA, Columbia University). 
ICTVdB (2006). 00.031. Herpesviridae. In ICTVdB - The Universal Virus 
Database, version 3, C. Büchen-Osmond, ed. (New York, Columbia 
University). 
Ikeda, H., Laigret, F., Martin, M.A., and Repaske, R. (1985). Characterization 
of a molecularly cloned retroviral sequence associated with Fv-4 resistance. 
J Virol 55, 768-777. 
Irgang, M., Karlas, A., Laue, C., Specke, V., Tacke, S.J., Kurth, R., 
Schrezenmeir, J., and Denner, J. (2005). Porcine endogenous retroviruses 
PERV-A and PERV-B infect neither mouse cells in vitro nor SCID mice in 
vivo. Intervirology 48, 167-173. 
Isaac, J.R., Skinner, S., Elliot, R., Salto-Tellez, M., Garkavenko, O., Khoo, A., 
Lee, K.O., Calne, R., and Wang, D.Z. (2005). Transplantation of neonatal 
porcine islets and sertoli cells into nonimmunosuppressed nonhuman 
primates. Transplant Proc 37, 487-488. 
Ishikawa, J., Kaisho, T., Tomizawa, H., Lee, B.O., Kobune, Y., Inazawa, J., 
Oritani, K., Itoh, M., Ochi, T., Ishihara, K., et al. (1995). Molecular cloning and 
chromosomal mapping of a bone marrow stromal cell surface gene, BST2, 
that may be involved in pre-B-cell growth. Genomics 26, 527-534. 
Issa, N.C., Wilkinson, R.A., Griesemer, A., Cooper, D.K., Yamada, K., Sachs, 
D.H., and Fishman, J.A. (2008). Absence of replication of porcine 
endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with 232 
 
prolonged pig cell microchimerism after pig-to-baboon xenotransplantation. J 
Virol 82, 12441-12448. 
Iwatani, Y., Chan, D.S., Wang, F., Maynard, K.S., Sugiura, W., Gronenborn, 
A.M., Rouzina, I., Williams, M.C., Musier-Forsyth, K., and Levin, J.G. (2007). 
Deaminase-independent inhibition of HIV-1 reverse transcription by 
APOBEC3G. Nucleic Acids Res 35, 7096-7108. 
Jacks, T. (1990). Translational suppression in gene expression in 
retroviruses and retrotransposons. Curr Top Microbiol Immunol 157, 93-124. 
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and 
Navaratnam, N. (2002). An anthropoid-specific locus of orphan C to U RNA-
editing enzymes on chromosome 22. Genomics 79, 285-296. 
Jarrett, O., and Ganiere, J.P. (1996). Comparative studies of the efficacy of a 
recombinant feline leukaemia virus vaccine. Vet Rec 138, 7-11. 
Jeffs, S.A., McKeating, J., Lewis, S., Craft, H., Biram, D., Stephens, P.E., and 
Brady, R.L. (1996). Antigenicity of truncated forms of the human 
immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol 77 ( Pt 7), 
1403-1410. 
Jia, B., Serra-Moreno, R., Neidermyer, W., Rahmberg, A., Mackey, J., 
Fofana, I.B., Johnson, W.E., Westmoreland, S., and Evans, D.T. (2009). 
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction 
by tetherin/BST2. PLoS Pathog 5, e1000429. 
Jinno-Oue, A., Oue, M., and Ruscetti, S.K. (2001). A unique heparin-binding 
domain in the envelope protein of the neuropathogenic PVC-211 murine 
leukemia virus may contribute to its brain capillary endothelial cell tropism. J 
Virol 75, 12439-12445. 
Jobbagy, Z., Garfield, S., Baptiste, L., Eiden, M.V., and Anderson, W.B. 
(2000). Subcellular redistribution of Pit-2 P(i) transporter/amphotropic 
leukemia virus (A-MuLV) receptor in A-MuLV-infected NIH 3T3 fibroblasts: 
involvement in superinfection interference. J Virol 74, 2847-2854. 233 
 
Johann, S.V., Gibbons, J.J., and O'Hara, B. (1992). GLVR1, a receptor for 
gibbon ape leukemia virus, is homologous to a phosphate permease of 
Neurospora crassa and is expressed at high levels in the brain and thymus. J 
Virol 66, 1635-1640. 
Johann, S.V., van Zeijl, M., Cekleniak, J., and O'Hara, B. (1993). Definition of 
a domain of GLVR1 which is necessary for infection by gibbon ape leukemia 
virus and which is highly polymorphic between species. J Virol 67, 6733-
6736. 
Jolicoeur, P., and Baltimore, D. (1976). Effect of Fv-1 gene product on 
proviral DNA formation and integration in cells infected with murine leukemia 
viruses. Proc Natl Acad Sci U S A 73, 2236-2240. 
Jolivet-Reynaud, C., Perron, H., Ferrante, P., Becquart, L., Dalbon, P., and 
Mandrand, B. (1999). Specificities of multiple sclerosis cerebrospinal fluid 
and serum antibodies against mimotopes. Clin Immunol 93, 283-293. 
Jonsson, S.R., LaRue, R.S., Stenglein, M.D., Fahrenkrug, S.C., Andresdottir, 
V., and Harris, R.S. (2007). The restriction of zoonotic PERV transmission by 
human APOBEC3G. PLoS One 2, e893. 
Jouvenet, N., Neil, S.J., Zhadina, M., Zang, T., Kratovac, Z., Lee, Y., McNatt, 
M., Hatziioannou, T., and Bieniasz, P.D. (2009). Broad-spectrum inhibition of 
retroviral and filoviral particle release by tetherin. J Virol 83, 1837-1844. 
Jung, Y.T., Lyu, M.S., Buckler-White, A., and Kozak, C.A. (2002). 
Characterization of a polytropic murine leukemia virus proviral sequence 
associated with the virus resistance gene Rmcf of DBA/2 mice. J Virol 76, 
8218-8224. 
Kaletsky, R.L., Francica, J.R., Agrawal-Gamse, C., and Bates, P. (2009). 
Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola 
glycoprotein. Proc Natl Acad Sci U S A 106, 2886-2891. 
Kamps, C.A., Lin, Y.C., and Wong, P.K. (1991). Oligomerization and 
transport of the envelope protein of Moloney murine leukemia virus-TB and of 234 
 
ts1, a neurovirulent temperature-sensitive mutant of MoMuLV-TB. Virology 
184, 687-694. 
Kanki, P.J., McLane, M.F., King, N.W., Jr., Letvin, N.L., Hunt, R.D., Sehgal, 
P., Daniel, M.D., Desrosiers, R.C., and Essex, M. (1985). Serologic 
identification and characterization of a macaque T-lymphotropic retrovirus 
closely related to HTLV-III. Science 228, 1199-1201. 
Karlas, A., Kurth, R., and Denner, J. (2004). Inhibition of porcine endogenous 
retroviruses by RNA interference: increasing the safety of 
xenotransplantation. Virology 325, 18-23. 
Katen, L.J., Januszeski, M.M., Anderson, W.F., Hasenkrug, K.J., and Evans, 
L.H. (2001). Infectious entry by amphotropic as well as ecotropic murine 
leukemia viruses occurs through an endocytic pathway. J Virol 75, 5018-
5026. 
Katzourakis, A., Tristem, M., Pybus, O.G., and Gifford, R.J. (2007). Discovery 
and analysis of the first endogenous lentivirus. Proc Natl Acad Sci U S A 104, 
6261-6265. 
Kavanaugh, M.P., Miller, D.G., Zhang, W., Law, W., Kozak, S.L., Kabat, D., 
and Miller, A.D. (1994). Cell-surface receptors for gibbon ape leukemia virus 
and amphotropic murine retrovirus are inducible sodium-dependent 
phosphate symporters. Proc Natl Acad Sci U S A 91, 7071-7075. 
Keckesova, Z., Ylinen, L.M., and Towers, G.J. (2004). The human and 
African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral 
restriction factor activities. Proc Natl Acad Sci U S A 101, 10780-10785. 
Keele, B.F., Van Heuverswyn, F., Li, Y., Bailes, E., Takehisa, J., Santiago, 
M.L., Bibollet-Ruche, F., Chen, Y., Wain, L.V., Liegeois, F., et al. (2006). 
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313, 
523-526. 
Kekuda, R., Prasad, P.D., Fei, Y.J., Torres-Zamorano, V., Sinha, S., Yang-
Feng, T.L., Leibach, F.H., and Ganapathy, V. (1996). Cloning of the sodium-235 
 
dependent, broad-scope, neutral amino acid transporter Bo from a human 
placental choriocarcinoma cell line. J Biol Chem 271, 18657-18661. 
Kentsis, A., Dwyer, E.C., Perez, J.M., Sharma, M., Chen, A., Pan, Z.Q., and 
Borden, K.L. (2001). The RING domains of the promyelocytic leukemia 
protein PML and the arenaviral protein Z repress translation by directly 
inhibiting translation initiation factor eIF4E. J Mol Biol 312, 609-623. 
Kerns, J.A., Emerman, M., and Malik, H.S. (2008). Positive selection and 
increased antiviral activity associated with the PARP-containing isoform of 
human zinc-finger antiviral protein. PLoS Genet 4, e21. 
Kim, J.W., Closs, E.I., Albritton, L.M., and Cunningham, J.M. (1991). 
Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. 
Nature 352, 725-728. 
Kim, N.Y., Jung, W.W., Oh, Y.K., Chun, T., Park, H.Y., Lee, H.T., Han, I.K., 
Yang, J.M., and Kim, Y.B. (2007). Natural protection from zoonosis by alpha-
gal epitopes on virus particles in xenotransmission. Xenotransplantation 14, 
104-111. 
Kizhatil, K., and Albritton, L.M. (1997). Requirements for different 
components of the host cell cytoskeleton distinguish ecotropic murine 
leukemia virus entry via endocytosis from entry via surface fusion. J Virol 71, 
7145-7156. 
Klenk, H.-D., Cox, N.J., Lamb, R.A., Mahy, B.W.J., Nakamura, K., P.A., N., 
Palese, P., and Rott, R.A. (2004). 00.046. Orthomyxoviridae. In ICTVdB - 
The Universal Virus Database, version 3, C. Büchen-Osmond, ed. (New 
York, USA, ICTVdB Management, Columbia University). 
Klimkait, T., Strebel, K., Hoggan, M.D., Martin, M.A., and Orenstein, J.M. 
(1990). The human immunodeficiency virus type 1-specific protein vpu is 
required for efficient virus maturation and release. J Virol 64, 621-629. 236 
 
Klymiuk, N., Muller, M., Brem, G., and Aigner, B. (2002). Characterization of 
porcine endogenous retrovirus gamma pro-pol nucleotide sequences. J Virol 
76, 11738-11743. 
Kobinger, G.P., Mouland, A.J., Lalonde, J.P., Forget, J., and Cohen, E.A. 
(1997). Enhancement of retroviral production from packaging cell lines 
expressing the human immunodeficiency type 1 VPU gene. Gene Ther 4, 
868-874. 
Kolber-Simonds, D., Lai, L., Watt, S.R., Denaro, M., Arn, S., Augenstein, 
M.L., Betthauser, J., Carter, D.B., Greenstein, J.L., Hao, Y., et al. (2004). 
Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear 
transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl 
Acad Sci U S A 101, 7335-7340. 
Kozak, C.A. (1985). Susceptibility of wild mouse cells to exogenous infection 
with xenotropic leukemia viruses: control by a single dominant locus on 
chromosome 1. J Virol 55, 690-695. 
Kozak, C.A., and Chakraborti, A. (1996). Single amino acid changes in the 
murine leukemia virus capsid protein gene define the target of Fv1 
resistance. Virology 225, 300-305. 
Kramer, L.D., Li, J., and Shi, P.Y. (2007). West Nile virus. Lancet Neurol 6, 
171-181. 
Krogh, A., Larsson, B., von Heijne, G., and Sonnhammer, E.L. (2001). 
Predicting transmembrane protein topology with a hidden Markov model: 
application to complete genomes. J Mol Biol 305, 567-580. 
Kubo, Y., Ishimoto, A., Ono, T., Yoshii, H., Tominaga, C., Mitani, C., 
Amanuma, H., and Yamamoto, N. (2004). Determinant for the inhibition of 
ecotropic murine leukemia virus infection by N-linked glycosylation of the rat 
receptor. Virology 330, 82-91. 
Kuddus, R.H., Metes, D.M., Nalesnik, M.A., Logar, A.J., Rao, A.S., and Fung, 
J.J. (2004). Porcine cell microchimerism but lack of productive porcine 237 
 
endogenous retrovirus (PERV) infection in naive and humanized SCID-beige 
mice treated with porcine peripheral blood mononuclear cells. Transpl 
Immunol 13, 15-24. 
Kupzig, S., Korolchuk, V., Rollason, R., Sugden, A., Wilde, A., and Banting, 
G. (2003). Bst-2/HM1.24 is a raft-associated apical membrane protein with 
an unusual topology. Traffic 4, 694-709. 
Kuwaki, K., Tseng, Y.L., Dor, F.J., Shimizu, A., Houser, S.L., Sanderson, 
T.M., Lancos, C.J., Prabharasuth, D.D., Cheng, J., Moran, K., et al. (2005). 
Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-
knockout pigs as donors: initial experience. Nat Med 11, 29-31. 
Lai, L., Kolber-Simonds, D., Park, K.W., Cheong, H.T., Greenstein, J.L., Im, 
G.S., Samuel, M., Bonk, A., Rieke, A., Day, B.N., et al. (2002). Production of 
alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. 
Science 295, 1089-1092. 
Laimins, L.A., Gruss, P., Pozzatti, R., and Khoury, G. (1984). 
Characterization of enhancer elements in the long terminal repeat of Moloney 
murine sarcoma virus. J Virol 49, 183-189. 
Lander, M.R., and Chattopadhyay, S.K. (1984). A Mus dunni cell line that 
lacks sequences closely related to endogenous murine leukemia viruses and 
can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-
forming viruses. J Virol 52, 695-698. 
Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., 
McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., et al. (2007). 
Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-2948. 
Lavillette, D., Boson, B., Russell, S.J., and Cosset, F.L. (2001). Activation of 
membrane fusion by murine leukemia viruses is controlled in cis or in trans 
by interactions between the receptor-binding domain and a conserved 
disulfide loop of the carboxy terminus of the surface glycoprotein. J Virol 75, 
3685-3695. 238 
 
Lavillette, D., and Kabat, D. (2004). Porcine endogenous retroviruses infect 
cells lacking cognate receptors by an alternative pathway: implications for 
retrovirus evolution and xenotransplantation. J Virol 78, 8868-8877. 
Lavillette, D., Marin, M., Ruggieri, A., Mallet, F., Cosset, F.L., and Kabat, D. 
(2002a). The envelope glycoprotein of human endogenous retrovirus type W 
uses a divergent family of amino acid transporters/cell surface receptors. J 
Virol 76, 6442-6452. 
Lavillette, D., Maurice, M., Roche, C., Russell, S.J., Sitbon, M., and Cosset, 
F.L. (1998). A proline-rich motif downstream of the receptor binding domain 
modulates conformation and fusogenicity of murine retroviral envelopes. J 
Virol 72, 9955-9965. 
Lavillette, D., Ruggieri, A., Boson, B., Maurice, M., and Cosset, F.L. (2002b). 
Relationship between SU subdomains that regulate the receptor-mediated 
transition from the native (fusion-inhibited) to the fusion-active conformation 
of the murine leukemia virus glycoprotein. J Virol 76, 9673-9685. 
Lavillette, D., Ruggieri, A., Russell, S.J., and Cosset, F.L. (2000). Activation 
of a cell entry pathway common to type C mammalian retroviruses by soluble 
envelope fragments. J Virol 74, 295-304. 
Le Douarin, B., Nielsen, A.L., Garnier, J.M., Ichinose, H., Jeanmougin, F., 
Losson, R., and Chambon, P. (1996). A possible involvement of TIF1 alpha 
and TIF1 beta in the epigenetic control of transcription by nuclear receptors. 
EMBO J 15, 6701-6715. 
Le Tissier, P., Stoye, J.P., Takeuchi, Y., Patience, C., and Weiss, R.A. 
(1997). Two sets of human-tropic pig retrovirus. Nature 389, 681-682. 
Lee, B., Leslie, G., Soilleux, E., O'Doherty, U., Baik, S., Levroney, E., 
Flummerfelt, K., Swiggard, W., Coleman, N., Malim, M., et al. (2001). cis 
Expression of DC-SIGN allows for more efficient entry of human and simian 
immunodeficiency viruses via CD4 and a coreceptor. J Virol 75, 12028-
12038. 239 
 
Lee, J.H., Webb, G.C., Allen, R.D., and Moran, C. (2002). Characterizing and 
mapping porcine endogenous retroviruses in Westran pigs. J Virol 76, 5548-
5556. 
Lee, Y.N., Malim, M.H., and Bieniasz, P.D. (2008). Hypermutation of an 
ancient human retrovirus by APOBEC3G. J Virol 82, 8762-8770. 
Letvin, N.L., Daniel, M.D., Sehgal, P.K., Desrosiers, R.C., Hunt, R.D., 
Waldron, L.M., MacKey, J.J., Schmidt, D.K., Chalifoux, L.V., and King, N.W. 
(1985). Induction of AIDS-like disease in macaque monkeys with T-cell tropic 
retrovirus STLV-III. Science 230, 71-73. 
Leverett, B.D., Farrell, K.B., Eiden, M.V., and Wilson, C.A. (1998). Entry of 
amphotropic murine leukemia virus is influenced by residues in the putative 
second extracellular domain of its receptor, Pit2. J Virol 72, 4956-4961. 
Levinson, B., Khoury, G., Woude, G.V., and Gruss, P. (1982). Activation of 
SV40 genome by 72-base pair tandem repeats of Moloney sarcoma virus. 
Nature 295, 568-572. 
Li, D.D., Duan, Z.J., Zhang, Q., Liu, N., Xie, Z.P., Jiang, B., Steele, D., Jiang, 
X., Wang, Z.S., and Fang, Z.Y. (2008). Molecular characterization of unusual 
human G5P[6] rotaviruses identified in China. J Clin Virol 42, 141-148. 
Li, J.M., Fan, W.S., Horsfall, A.C., Anderson, A.C., Rigby, S., Larsson, E., 
and Venables, P.J. (1996). The expression of human endogenous retrovirus-
3 in fetal cardiac tissue and antibodies in congenital heart block. Clin Exp 
Immunol 104, 388-393. 
Li, Z., Ping, Y., Shengfu, L., Hong, B., Youping, L., Yangzhi, Z., and Jingqiu, 
C. (2004). Phylogenetic relationship of porcine endogenous retrovirus 
(PERV) in Chinese pigs with some type C retroviruses. Virus Res 105, 167-
173. 
Li, Z., Pinter, A., and Kayman, S.C. (1997). The critical N-linked glycan of 
murine leukemia virus envelope protein promotes both folding of the C-240 
 
terminal domains of the precursor polyprotein and stability of the 
postcleavage envelope complex. J Virol 71, 7012-7019. 
Liao, C.H., Kuang, Y.Q., Liu, H.L., Zheng, Y.T., and Su, B. (2007). A novel 
fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its 
susceptibility to HIV-1 infection. AIDS 21 Suppl 8, S19-26. 
Lieber, M.M., Sherr, C.J., Benveniste, R.E., and Todaro, G.J. (1975). Biologic 
and immunologic properties of porcine type C viruses. Virology 66, 616-619. 
Limjoco, T.I., Dickie, P., Ikeda, H., and Silver, J. (1993). Transgenic Fv-4 
mice resistant to Friend virus. J Virol 67, 4163-4168. 
Lin, H.K., Bergmann, S., and Pandolfi, P.P. (2004). Cytoplasmic PML 
function in TGF-beta signalling. Nature 431, 205-211. 
Loh, T.P., Sievert, L.L., and Scott, R.W. (1988). Negative regulation of 
retrovirus expression in embryonal carcinoma cells mediated by an intragenic 
domain. J Virol 62, 4086-4095. 
Lopez-Lastra, M., Gabus, C., and Darlix, J.L. (1997). Characterization of an 
internal ribosomal entry segment within the 5' leader of avian 
reticuloendotheliosis virus type A RNA and development of novel MLV-REV-
based retroviral vectors. Hum Gene Ther 8, 1855-1865. 
Lovatt, A., Black, J., Galbraith, D., Doherty, I., Moran, M.W., Shepherd, A.J., 
Griffen, A., Bailey, A., Wilson, N., and Smith, K.T. (1999). High throughput 
detection of retrovirus-associated reverse transcriptase using an improved 
fluorescent product enhanced reverse transcriptase assay and its 
comparison to conventional detection methods. J Virol Methods 82, 185-200. 
Luban, J., Bossolt, K.L., Franke, E.K., Kalpana, G.V., and Goff, S.P. (1993). 
Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A 
and B. Cell 73, 1067-1078. 241 
 
Luby, S.P., Rahman, M., Hossain, M.J., Blum, L.S., Husain, M.M., Gurley, E., 
Khan, R., Ahmed, B.N., Rahman, S., Nahar, N., et al. (2006). Foodborne 
transmission of Nipah virus, Bangladesh. Emerg Infect Dis 12, 1888-1894. 
Ludwig, S., Stitz, L., Planz, O., Van, H., Fitch, W.M., and Scholtissek, C. 
(1995). European swine virus as a possible source for the next influenza 
pandemic? Virology 212, 555-561. 
Lundorf, M.D., Pedersen, F.S., O'Hara, B., and Pedersen, L. (1998). Single 
amino acid insertion in loop 4 confers amphotropic murine leukemia virus 
receptor function upon murine Pit1. J Virol 72, 4524-4527. 
Maeda, N., Fan, H., and Yoshikai, Y. (2008). Oncogenesis by retroviruses: 
old and new paradigms. Rev Med Virol 18, 387-405. 
Magin, C., Lower, R., and Lower, J. (1999). cORF and RcRE, the Rev/Rex 
and RRE/RxRE homologues of the human endogenous retrovirus family 
HTDV/HERV-K. J Virol 73, 9496-9507. 
Magre, S., Takeuchi, Y., Langford, G., Richards, A., Patience, C., and Weiss, 
R. (2004). Reduced sensitivity to human serum inactivation of enveloped 
viruses produced by pig cells transgenic for human CD55 or deficient for the 
galactosyl-alpha(1-3) galactosyl epitope. J Virol 78, 5812-5819. 
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. 
(2003). Broad antiretroviral defence by human APOBEC3G through lethal 
editing of nascent reverse transcripts. Nature 424, 99-103. 
Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004). A single amino acid 
determinant governs the species-specific sensitivity of APOBEC3G to Vif 
action. J Biol Chem 279, 14481-14483. 
Marcaccini, A., Lopez Pena, M., Quiroga, M.I., Bermudez, R., Nieto, J.M., 
and Aleman, N. (2008). Pseudorabies virus infection in mink: a host-specific 
pathogenesis. Vet Immunol Immunopathol 124, 264-273. 242 
 
Marciani, D.J., Kensil, C.R., Beltz, G.A., Hung, C.H., Cronier, J., and Aubert, 
A. (1991). Genetically-engineered subunit vaccine against feline leukaemia 
virus: protective immune response in cats. Vaccine 9, 89-96. 
Marcucci, K.T., Argaw, T., Wilson, C.A., and Salomon, D.R. (2009). 
Identification of two distinct structural regions in a human porcine 
endogenous retrovirus receptor, HuPAR2, contributing to function for viral 
entry. Retrovirology 6, 3. 
Marcucci, K.T., Martina, Y., Harrison, F., Wilson, C.A., and Salomon, D.R. 
(2008). Functional hierarchy of two L domains in porcine endogenous 
retrovirus (PERV) that influence release and infectivity. Virology 375, 637-
645. 
Marechal, V., Clavel, F., Heard, J.M., and Schwartz, O. (1998). Cytosolic 
Gag p24 as an index of productive entry of human immunodeficiency virus 
type 1. J Virol 72, 2208-2212. 
Margottin, F., Bour, S.P., Durand, H., Selig, L., Benichou, S., Richard, V., 
Thomas, D., Strebel, K., and Benarous, R. (1998). A novel human WD 
protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER 
degradation pathway through an F-box motif. Mol Cell 1, 565-574. 
Marin, M., Lavillette, D., Kelly, S.M., and Kabat, D. (2003a). N-linked 
glycosylation and sequence changes in a critical negative control region of 
the ASCT1 and ASCT2 neutral amino acid transporters determine their 
retroviral receptor functions. J Virol 77, 2936-2945. 
Marin, M., Rose, K.M., Kozak, S.L., and Kabat, D. (2003b). HIV-1 Vif protein 
binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 
9, 1398-1403. 
Marin, M., Tailor, C.S., Nouri, A., and Kabat, D. (2000). Sodium-dependent 
neutral amino acid transporter type 1 is an auxiliary receptor for baboon 
endogenous retrovirus. J Virol 74, 8085-8093. 243 
 
Martella, V., Colombrita, D., Lorusso, E., Draghin, E., Fiorentini, S., De 
Grazia, S., Banyai, K., Ciarlet, M., Caruso, A., and Buonavoglia, C. (2008). 
Detection of a porcine-like rotavirus in a child with enteritis in Italy. J Clin 
Microbiol 46, 3501-3507. 
Martin, S.I., Wilkinson, R., and Fishman, J.A. (2006). Genomic presence of 
recombinant porcine endogenous retrovirus in transmitting miniature swine. 
Virol J 3, 91. 
Martin, U., Steinhoff, G., Kiessig, V., Chikobava, M., Anssar, M., 
Morschheuser, T., Lapin, B., and Haverich, A. (1999). Porcine endogenous 
retrovirus is transmitted neither in vivo nor in vitro from porcine endothelial 
cells to baboons. Transplant Proc 31, 913-914. 
Martina, Y., Kurian, S., Cherqui, S., Evanoff, G., Wilson, C., and Salomon, 
D.R. (2005). Pseudotyping of porcine endogenous retrovirus by xenotropic 
murine leukemia virus in a pig islet xenotransplantation model. Am J 
Transplant 5, 1837-1847. 
Martina, Y., Marcucci, K.T., Cherqui, S., Szabo, A., Drysdale, T., Srinivisan, 
U., Wilson, C.A., Patience, C., and Salomon, D.R. (2006). Mice transgenic for 
a human porcine endogenous retrovirus receptor are susceptible to 
productive viral infection. J Virol 80, 3135-3146. 
Marx, P.A., Maul, D.H., Osborn, K.G., Lerche, N.W., Moody, P., Lowenstine, 
L.J., Henrickson, R.V., Arthur, L.O., Gilden, R.V., Gravell, M., et al. (1984). 
Simian AIDS: isolation of a type D retrovirus and transmission of the disease. 
Science 223, 1083-1086. 
Mascarenhas, J.D., Leite, J.P., Lima, J.C., Heinemann, M.B., Oliveira, D.S., 
Araujo, I.T., Soares, L.S., Gusmao, R.H., Gabbay, Y.B., and Linhares, A.C. 
(2007). Detection of a neonatal human rotavirus strain with VP4 and NSP4 
genes of porcine origin. J Med Microbiol 56, 524-532. 
Matthews, A.L., Brown, J., Switzer, W., Folks, T.M., Heneine, W., and 
Sandstrom, P.A. (1999). Development and validation of a Western 244 
 
immunoblot assay for detection of antibodies to porcine endogenous 
retrovirus. Transplantation 67, 939-943. 
Matthijnssens, J., Ciarlet, M., Heiman, E., Arijs, I., Delbeke, T., McDonald, 
S.M., Palombo, E.A., Iturriza-Gomara, M., Maes, P., Patton, J.T., et al. 
(2008). Full genome-based classification of rotaviruses reveals a common 
origin between human Wa-Like and porcine rotavirus strains and human DS-
1-like and bovine rotavirus strains. J Virol 82, 3204-3219. 
Mattiuzzo, G., Matouskova, M., and Takeuchi, Y. (2007). Differential 
resistance to cell entry by porcine endogenous retrovirus subgroup A in 
rodent species. Retrovirology 4, 93. 
Matzke, M., Matzke, A.J., and Kooter, J.M. (2001). RNA: guiding gene 
silencing. Science 293, 1080-1083. 
Maul, G.G., Guldner, H.H., and Spivack, J.G. (1993). Modification of discrete 
nuclear domains induced by herpes simplex virus type 1 immediate early 
gene 1 product (ICP0). J Gen Virol 74 ( Pt 12), 2679-2690. 
Mbisa, J.L., Barr, R., Thomas, J.A., Vandegraaff, N., Dorweiler, I.J., 
Svarovskaia, E.S., Brown, W.L., Mansky, L.M., Gorelick, R.J., Harris, R.S., et 
al. (2007). Human immunodeficiency virus type 1 cDNAs produced in the 
presence of APOBEC3G exhibit defects in plus-strand DNA transfer and 
integration. J Virol 81, 7099-7110. 
McCurry, K.R., Kooyman, D.L., Alvarado, C.G., Cotterell, A.H., Martin, M.J., 
Logan, J.S., and Platt, J.L. (1995). Human complement regulatory proteins 
protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1, 
423-427. 
McDougall, A.S., Terry, A., Tzavaras, T., Cheney, C., Rojko, J., and Neil, J.C. 
(1994). Defective endogenous proviruses are expressed in feline lymphoid 
cells: evidence for a role in natural resistance to subgroup B feline leukemia 
viruses. J Virol 68, 2151-2160. 245 
 
McKane, B.W., Ramachandran, S., Xu, X.C., Olack, B.J., Chapman, W.C., 
and Mohanakumar, T. (2004). Natural antibodies prevent in vivo transmission 
of porcine islet-derived endogenous retrovirus to human cells. Cell 
Transplant 13, 137-143. 
McKane, B.W., Ramachandran, S., Yang, J., Xu, X.C., and Mohanakumar, T. 
(2003). Xenoreactive anti-Galalpha(1,3)Gal antibodies prevent porcine 
endogenous retrovirus infection of human in vivo. Hum Immunol 64, 708-717. 
McNatt, M.W., Zang, T., Hatziioannou, T., Bartlett, M., Fofana, I.B., Johnson, 
W.E., Neil, S.J., and Bieniasz, P.D. (2009). Species-specific activity of HIV-1 
Vpu and positive selection of tetherin transmembrane domain variants. PLoS 
Pathog 5, e1000300. 
Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. 
(2004). Vif overcomes the innate antiviral activity of APOBEC3G by 
promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 
279, 7792-7798. 
Mendoza, R., Anderson, M.M., and Overbaugh, J. (2006). A putative 
thiamine transport protein is a receptor for feline leukemia virus subgroup A. 
J Virol 80, 3378-3385. 
Meng, X.J., Halbur, P.G., Shapiro, M.S., Govindarajan, S., Bruna, J.D., 
Mushahwar, I.K., Purcell, R.H., and Emerson, S.U. (1998). Genetic and 
experimental evidence for cross-species infection by swine hepatitis E virus. 
J Virol 72, 9714-9721. 
Meng, X.J., Purcell, R.H., Halbur, P.G., Lehman, J.R., Webb, D.M., Tsareva, 
T.S., Haynes, J.S., Thacker, B.J., and Emerson, S.U. (1997). A novel virus in 
swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U 
S A 94, 9860-9865. 
Mengeling, W.L., and Cutlip, R.C. (1976). Reproductive disease 
experimentally induced by exposing pregnant gilts to porcine parvovirus. Am 
J Vet Res 37, 1393-1400. 246 
 
Meric, C., and Goff, S.P. (1989). Characterization of Moloney murine 
leukemia virus mutants with single-amino-acid substitutions in the Cys-His 
box of the nucleocapsid protein. J Virol 63, 1558-1568. 
Mertz, J.A., Simper, M.S., Lozano, M.M., Payne, S.M., and Dudley, J.P. 
(2005). Mouse mammary tumor virus encodes a self-regulatory RNA export 
protein and is a complex retrovirus. J Virol 79, 14737-14747. 
Mi, S., Lee, X., Li, X., Veldman, G.M., Finnerty, H., Racie, L., LaVallie, E., 
Tang, X.Y., Edouard, P., Howes, S., et al. (2000). Syncytin is a captive 
retroviral envelope protein involved in human placental morphogenesis. 
Nature 403, 785-789. 
Miller, A.D., Bergholz, U., Ziegler, M., and Stocking, C. (2008). Identification 
of the myelin protein plasmolipin as the cell entry receptor for Mus caroli 
endogenous retrovirus. J Virol 82, 6862-6868. 
Miller, A.D., and Wolgamot, G. (1997). Murine retroviruses use at least six 
different receptors for entry into Mus dunni cells. J Virol 71, 4531-4535. 
Miller, D.G., Edwards, R.H., and Miller, A.D. (1994). Cloning of the cellular 
receptor for amphotropic murine retroviruses reveals homology to that for 
gibbon ape leukemia virus. Proc Natl Acad Sci U S A 91, 78-82. 
Miller, D.G., and Miller, A.D. (1992). Tunicamycin treatment of CHO cells 
abrogates multiple blocks to retrovirus infection, one of which is due to a 
secreted inhibitor. J Virol 66, 78-84. 
Miller, D.G., and Miller, A.D. (1993). Inhibitors of retrovirus infection are 
secreted by several hamster cell lines and are also present in hamster sera. 
J Virol 67, 5346-5352. 
Miller, D.G., and Miller, A.D. (1994). A family of retroviruses that utilize 
related phosphate transporters for cell entry. J Virol 68, 8270-8276. 
Mitchell, R.S., Katsura, C., Skasko, M.A., Fitzpatrick, K., Lau, D., Ruiz, A., 
Stephens, E.B., Margottin-Goguet, F., Benarous, R., and Guatelli, J.C. 247 
 
(2009). Vpu antagonizes BST-2-mediated restriction of HIV-1 release via 
beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5, e1000450. 
Miyagawa, S., Nakatsu, S., Hazama, K., Nakagawa, T., Kondo, A., 
Matsunami, K., Yamamoto, A., Yamada, J., Miyazawa, T., and Shirakura, R. 
(2006). A novel strategy for preventing PERV transmission to human cells by 
remodeling the viral envelope glycoprotein. Xenotransplantation 13, 258-263. 
Miyagawa, S., Nakatsu, S., Nakagawa, T., Kondo, A., Matsunami, K., 
Hazama, K., Yamada, J., Tomonaga, K., Miyazawa, T., and Shirakura, R. 
(2005). Prevention of PERV infections in pig to human xenotransplantation 
by the RNA interference silences gene. J Biochem 137, 503-508. 
Mizuo, H., Yazaki, Y., Sugawara, K., Tsuda, F., Takahashi, M., Nishizawa, 
T., and Okamoto, H. (2005). Possible risk factors for the transmission of 
hepatitis E virus and for the severe form of hepatitis E acquired locally in 
Hokkaido, Japan. J Med Virol 76, 341-349. 
Moalic, Y., Blanchard, Y., Felix, H., and Jestin, A. (2006). Porcine 
endogenous retrovirus integration sites in the human genome: features in 
common with those of murine leukemia virus. J Virol 80, 10980-10988. 
Montelaro, R., Ball, L., and Rushlow, K. (1993). Equine retroviruses. In The 
Retroviridae, J. Levy, ed. (New York, Plenum Press), pp. 257-360. 
Morikawa, S., Saijo, M., and Kurane, I. (2007). Current knowledge on lower 
virulence of Reston Ebola virus (in French: Connaissances actuelles sur la 
moindre virulence du virus Ebola Reston). Comp Immunol Microbiol Infect 
Dis 30, 391-398. 
Moscoso, I., Hermida-Prieto, M., Manez, R., Lopez-Pelaez, E., Centeno, A., 
Diaz, T.M., and Domenech, N. (2005). Lack of cross-species transmission of 
porcine endogenous retrovirus in pig-to-baboon xenotransplantation with 
sustained depletion of anti-alphagal antibodies. Transplantation 79, 777-782. 
Mueller, N.J., Kuwaki, K., Dor, F.J., Knosalla, C., Gollackner, B., Wilkinson, 
R.A., Sachs, D.H., Cooper, D.K., and Fishman, J.A. (2004). Reduction of 248 
 
consumptive coagulopathy using porcine cytomegalovirus-free cardiac 
porcine grafts in pig-to-primate xenotransplantation. Transplantation 78, 
1449-1453. 
Mueller, N.J., Kuwaki, K., Knosalla, C., Dor, F.J., Gollackner, B., Wilkinson, 
R.A., Arn, S., Sachs, D.H., Cooper, D.K., and Fishman, J.A. (2005). Early 
weaning of piglets fails to exclude porcine lymphotropic herpesvirus. 
Xenotransplantation 12, 59-62. 
Muller, S., Moller, P., Bick, M.J., Wurr, S., Becker, S., Gunther, S., and 
Kummerer, B.M. (2007). Inhibition of filovirus replication by the zinc finger 
antiviral protein. J Virol 81, 2391-2400. 
Munk, C., Brandt, S.M., Lucero, G., and Landau, N.R. (2002). A dominant 
block to HIV-1 replication at reverse transcription in simian cells. Proc Natl 
Acad Sci U S A 99, 13843-13848. 
Mura, M., Murcia, P., Caporale, M., Spencer, T.E., Nagashima, K., Rein, A., 
and Palmarini, M. (2004). Late viral interference induced by transdominant 
Gag of an endogenous retrovirus. Proc Natl Acad Sci U S A 101, 11117-
11122. 
Mushahwar, I.K. (2008). Hepatitis E virus: molecular virology, clinical 
features, diagnosis, transmission, epidemiology, and prevention. J Med Virol 
80, 646-658. 
Nakayama, E.E., Miyoshi, H., Nagai, Y., and Shioda, T. (2005). A specific 
region of 37 amino acid residues in the SPRY (B30.2) domain of African 
green monkey TRIM5alpha determines species-specific restriction of simian 
immunodeficiency virus SIVmac infection. J Virol 79, 8870-8877. 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, 
I.M., and Trono, D. (1996). In vivo gene delivery and stable transduction of 
nondividing cells by a lentiviral vector. Science 272, 263-267. 
Neel, B.G., Hayward, W.S., Robinson, H.L., Fang, J., and Astrin, S.M. 
(1981). Avian leukosis virus-induced tumors have common proviral 249 
 
integration sites and synthesize discrete new RNAs: oncogenesis by 
promoter insertion. Cell 23, 323-334. 
Neil, S.J., Eastman, S.W., Jouvenet, N., and Bieniasz, P.D. (2006). HIV-1 
Vpu promotes release and prevents endocytosis of nascent retrovirus 
particles from the plasma membrane. PLoS Pathog 2, e39. 
Neil, S.J., Sandrin, V., Sundquist, W.I., and Bieniasz, P.D. (2007). An 
interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus 
particle release but is counteracted by the HIV-1 Vpu protein. Cell Host 
Microbe 2, 193-203. 
Neil, S.J., Zang, T., and Bieniasz, P.D. (2008). Tetherin inhibits retrovirus 
release and is antagonized by HIV-1 Vpu. Nature 451, 425-430. 
Newman, E.N., Holmes, R.K., Craig, H.M., Klein, K.C., Lingappa, J.R., 
Malim, M.H., and Sheehy, A.M. (2005). Antiviral function of APOBEC3G can 
be dissociated from cytidine deaminase activity. Curr Biol 15, 166-170. 
Newman, R.M., Hall, L., Kirmaier, A., Pozzi, L.A., Pery, E., Farzan, M., 
O'Neil, S.P., and Johnson, W. (2008). Evolution of a TRIM5-CypA splice 
isoform in old world monkeys. PLoS Pathog 4, e1000003. 
Nguyen, D.H., and Hildreth, J.E. (2000). Evidence for budding of human 
immunodeficiency virus type 1 selectively from glycolipid-enriched membrane 
lipid rafts. J Virol 74, 3264-3272. 
Niebert, M., Rogel-Gaillard, C., Chardon, P., and Tonjes, R.R. (2002). 
Characterization of chromosomally assigned replication-competent gamma 
porcine endogenous retroviruses derived from a large white pig and 
expression in human cells. J Virol 76, 2714-2720. 
Nishitai, R., Ikai, I., Shiotani, T., Katsura, N., Matsushita, T., Yamanokuchi, 
S., Matsuo, K., Sugimoto, S., and Yamaoka, Y. (2005). Absence of PERV 
infection in baboons after transgenic porcine liver perfusion. J Surg Res 124, 
45-51. 250 
 
Nisole, S., Stoye, J.P., and Saib, A. (2005). TRIM family proteins: retroviral 
restriction and antiviral defence. Nat Rev Microbiol 3, 799-808. 
Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-
expression transfectants with a novel eukaryotic vector. Gene 108, 193-199. 
Niwa, O., Yokota, Y., Ishida, H., and Sugahara, T. (1983). Independent 
mechanisms involved in suppression of the Moloney leukemia virus genome 
during differentiation of murine teratocarcinoma cells. Cell 32, 1105-1113. 
Noguchi, C., Ishino, H., Tsuge, M., Fujimoto, Y., Imamura, M., Takahashi, S., 
and Chayama, K. (2005). G to A hypermutation of hepatitis B virus. 
Hepatology 41, 626-633. 
O'Hara, B., Johann, S.V., Klinger, H.P., Blair, D.G., Rubinson, H., Dunn, K.J., 
Sass, P., Vitek, S.M., and Robins, T. (1990). Characterization of a human 
gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell 
Growth Differ 1, 119-127. 
Odaka, T., and Matsukura, M. (1969). Inheritance of Susceptibility to Friend 
Mouse Leukemia Virus: VI. Reciprocal Alteration of Innate Resistance or 
Susceptibility by Bone Marrow Transplantation Between Congenic Strains. J 
Virol 4, 837-843. 
Ogert, R.A., Lee, L.H., and Beemon, K.L. (1996). Avian retroviral RNA 
element promotes unspliced RNA accumulation in the cytoplasm. J Virol 70, 
3834-3843. 
Ohtomo, T., Sugamata, Y., Ozaki, Y., Ono, K., Yoshimura, Y., Kawai, S., 
Koishihara, Y., Ozaki, S., Kosaka, M., Hirano, T., et al. (1999). Molecular 
cloning and characterization of a surface antigen preferentially 
overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 
258, 583-591. 
Okura, E., Ishimaru, A., Yamamoto, A., Nakatsu, S., Shirakura, R., Okabe, 
M., Sawa, Y., Fukuzawa, M., Okumura, M., and Miyagawa, S. (2008). 251 
 
Differential human serum-mediated neutralization of PERV released from pig 
cells transfected with variants of hDAF. Xenotransplantation 15, 365-373. 
Olah, Z., Lehel, C., Anderson, W.B., Eiden, M.V., and Wilson, C.A. (1994). 
The cellular receptor for gibbon ape leukemia virus is a novel high affinity 
sodium-dependent phosphate transporter. J Biol Chem 269, 25426-25431. 
Oldmixon, B.A., Wood, J.C., Ericsson, T.A., Wilson, C.A., White-Scharf, M.E., 
Andersson, G., Greenstein, J.L., Schuurman, H.J., and Patience, C. (2002). 
Porcine endogenous retrovirus transmission characteristics of an inbred herd 
of miniature swine. J Virol 76, 3045-3048. 
Oliveira, N.M., Farrell, K.B., and Eiden, M.V. (2006). In vitro characterization 
of a koala retrovirus. J Virol 80, 3104-3107. 
Oliveira, N.M., Satija, H., Kouwenhoven, I.A., and Eiden, M.V. (2007). 
Changes in viral protein function that accompany retroviral endogenization. 
Proc Natl Acad Sci U S A 104, 17506-17511. 
Ono, A., and Freed, E.O. (2001). Plasma membrane rafts play a critical role 
in HIV-1 assembly and release. Proc Natl Acad Sci U S A 98, 13925-13930. 
Ono, A., and Freed, E.O. (2005). Role of lipid rafts in virus replication. Adv 
Virus Res 64, 311-358. 
Overbaugh, J., Miller, A.D., and Eiden, M.V. (2001). Receptors and entry 
cofactors for retroviruses include single and multiple transmembrane-
spanning proteins as well as newly described glycophosphatidylinositol-
anchored and secreted proteins. Microbiol Mol Biol Rev 65, 371-389, table of 
contents. 
Palacios, G., Druce, J., Du, L., Tran, T., Birch, C., Briese, T., Conlan, S., 
Quan, P.L., Hui, J., Marshall, J., et al. (2008). A new arenavirus in a cluster of 
fatal transplant-associated diseases. N Engl J Med 358, 991-998. 
Palacios, G., Quan, P.L., Jabado, O.J., Conlan, S., Hirschberg, D.L., Liu, Y., 
Zhai, J., Renwick, N., Hui, J., Hegyi, H., et al. (2007). Panmicrobial 252 
 
oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis 
13, 73-81. 
Panda, S.K., Thakral, D., and Rehman, S. (2007). Hepatitis E virus. Rev Med 
Virol 17, 151-180. 
Paradis, K., Langford, G., Long, Z., Heneine, W., Sandstrom, P., Switzer, 
W.M., Chapman, L.E., Lockey, C., Onions, D., and Otto, E. (1999). Search 
for cross-species transmission of porcine endogenous retrovirus in patients 
treated with living pig tissue. The XEN 111 Study Group. Science 285, 1236-
1241. 
Parashar, U.D., Sunn, L.M., Ong, F., Mounts, A.W., Arif, M.T., Ksiazek, T.G., 
Kamaluddin, M.A., Mustafa, A.N., Kaur, H., Ding, L.M., et al. (2000). Case-
control study of risk factors for human infection with a new zoonotic 
paramyxovirus, Nipah virus, during a 1998-1999 outbreak of severe 
encephalitis in Malaysia. J Infect Dis 181, 1755-1759. 
Patience, C., Patton, G.S., Takeuchi, Y., Weiss, R.A., McClure, M.O., 
Rydberg, L., and Breimer, M.E. (1998). No evidence of pig DNA or retroviral 
infection in patients with short-term extracorporeal connection to pig kidneys. 
Lancet 352, 699-701. 
Patience, C., Switzer, W.M., Takeuchi, Y., Griffiths, D.J., Goward, M.E., 
Heneine, W., Stoye, J.P., and Weiss, R.A. (2001). Multiple groups of novel 
retroviral genomes in pigs and related species. J Virol 75, 2771-2775. 
Patience, C., Takeuchi, Y., and Weiss, R.A. (1997). Infection of human cells 
by an endogenous retrovirus of pigs. Nat Med 3, 282-286. 
Paton, N.I., Leo, Y.S., Zaki, S.R., Auchus, A.P., Lee, K.E., Ling, A.E., Chew, 
S.K., Ang, B., Rollin, P.E., Umapathi, T., et al. (1999). Outbreak of Nipah-
virus infection among abattoir workers in Singapore. Lancet 354, 1253-1256. 
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., 
Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P.P., et al. (2000). PML 253 
 
regulates p53 acetylation and premature senescence induced by oncogenic 
Ras. Nature 406, 207-210. 
Pedersen, N.C., Ho, E.W., Brown, M.L., and Yamamoto, J.K. (1987). 
Isolation of a T-lymphotropic virus from domestic cats with an 
immunodeficiency-like syndrome. Science 235, 790-793. 
Perez-Caballero, D., Hatziioannou, T., Yang, A., Cowan, S., and Bieniasz, 
P.D. (2005). Human tripartite motif 5alpha domains responsible for retrovirus 
restriction activity and specificity. J Virol 79, 8969-8978. 
Perl, A., Colombo, E., Dai, H., Agarwal, R., Mark, K.A., Banki, K., Poiesz, 
B.J., Phillips, P.E., Hoch, S.O., Reveille, J.D., et al. (1995). Antibody 
reactivity to the HRES-1 endogenous retroviral element identifies a subset of 
patients with systemic lupus erythematosus and overlap syndromes. 
Correlation with antinuclear antibodies and HLA class II alleles. Arthritis 
Rheum 38, 1660-1671. 
Perron, H., Garson, J.A., Bedin, F., Beseme, F., Paranhos-Baccala, G., 
Komurian-Pradel, F., Mallet, F., Tuke, P.W., Voisset, C., Blond, J.L., et al. 
(1997). Molecular identification of a novel retrovirus repeatedly isolated from 
patients with multiple sclerosis. The Collaborative Research Group on 
Multiple Sclerosis. Proc Natl Acad Sci U S A 94, 7583-7588. 
Perron, M.J., Stremlau, M., Song, B., Ulm, W., Mulligan, R.C., and Sodroski, 
J. (2004). TRIM5alpha mediates the postentry block to N-tropic murine 
leukemia viruses in human cells. Proc Natl Acad Sci U S A 101, 11827-
11832. 
Perry, R.D., and Fetherston, J.D. (1997). Yersinia pestis--etiologic agent of 
plague. Clin Microbiol Rev 10, 35-66. 
Petersen, R., Kempler, G., and Barklis, E. (1991). A stem cell-specific 
silencer in the primer-binding site of a retrovirus. Mol Cell Biol 11, 1214-1221. 
Phelps, C.J., Koike, C., Vaught, T.D., Boone, J., Wells, K.D., Chen, S.H., 
Ball, S., Specht, S.M., Polejaeva, I.A., Monahan, J.A., et al. (2003). 254 
 
Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 299, 
411-414. 
Phillips, T.R., Lamont, C., Konings, D.A., Shacklett, B.L., Hamson, C.A., 
Luciw, P.A., and Elder, J.H. (1992). Identification of the Rev transactivation 
and Rev-responsive elements of feline immunodeficiency virus. J Virol 66, 
5464-5471. 
Picard-Maureau, M., Jarmy, G., Berg, A., Rethwilm, A., and Lindemann, D. 
(2003). Foamy virus envelope glycoprotein-mediated entry involves a pH-
dependent fusion process. J Virol 77, 4722-4730. 
Pincus, T., Rowe, W.P., and Lilly, F. (1971). A major genetic locus affecting 
resistance to infection with murine leukemia viruses. II. Apparent identity to a 
major locus described for resistance to friend murine leukemia virus. J Exp 
Med 133, 1234-1241. 
Pohlmann, S., Soilleux, E.J., Baribaud, F., Leslie, G.J., Morris, L.S., 
Trowsdale, J., Lee, B., Coleman, N., and Doms, R.W. (2001). DC-SIGNR, a 
DC-SIGN homologue expressed in endothelial cells, binds to human and 
simian immunodeficiency viruses and activates infection in trans. Proc Natl 
Acad Sci U S A 98, 2670-2675. 
Pollard, V.W., and Malim, M.H. (1998). The HIV-1 Rev protein. Annu Rev 
Microbiol 52, 491-532. 
Polonoff, E., Machida, C.A., and Kabat, D. (1982). Glycosylation and 
intracellular transport of membrane glycoproteins encoded by murine 
leukemia viruses. Inhibition by amino acid analogues and by tunicamycin. J 
Biol Chem 257, 14023-14028. 
Pothlichet, J., Heidmann, T., and Mangeney, M. (2006a). A recombinant 
endogenous retrovirus amplified in a mouse neuroblastoma is involved in 
tumor growth in vivo. Int J Cancer 119, 815-822. 255 
 
Pothlichet, J., Mangeney, M., and Heidmann, T. (2006b). Mobility and 
integration sites of a murine C57BL/6 melanoma endogenous retrovirus 
involved in tumor progression in vivo. Int J Cancer 119, 1869-1877. 
Poulet, H., Brunet, S., Boularand, C., Guiot, A.L., Leroy, V., Tartaglia, J., 
Minke, J., Audonnet, J.C., and Desmettre, P. (2003). Efficacy of a canarypox 
virus-vectored vaccine against feline leukaemia. Vet Rec 153, 141-145. 
Powell, S.K., Gates, M.E., Langford, G., Gu, M.L., Lockey, C., Long, Z., and 
Otto, E. (2000). Antiretroviral agents inhibit infection of human cells by 
porcine endogenous retroviruses. Antimicrob Agents Chemother 44, 3432-
3433. 
Prats, A.C., Sarih, L., Gabus, C., Litvak, S., Keith, G., and Darlix, J.L. (1988). 
Small finger protein of avian and murine retroviruses has nucleic acid 
annealing activity and positions the replication primer tRNA onto genomic 
RNA. EMBO J 7, 1777-1783. 
Qari, S.H., Magre, S., Garcia-Lerma, J.G., Hussain, A.I., Takeuchi, Y., 
Patience, C., Weiss, R.A., and Heneine, W. (2001). Susceptibility of the 
porcine endogenous retrovirus to reverse transcriptase and protease 
inhibitors. J Virol 75, 1048-1053. 
Quigley, J.G., Burns, C.C., Anderson, M.M., Lynch, E.D., Sabo, K.M., 
Overbaugh, J., and Abkowitz, J.L. (2000). Cloning of the cellular receptor for 
feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell 
aplasia. Blood 95, 1093-1099. 
Quigley, J.G., Yang, Z., Worthington, M.T., Phillips, J.D., Sabo, K.M., Sabath, 
D.E., Berg, C.L., Sassa, S., Wood, B.L., and Abkowitz, J.L. (2004). 
Identification of a human heme exporter that is essential for erythropoiesis. 
Cell 118, 757-766. 
Quigley, J.P., Rifkin, D.B., and Reich, E. (1971). Phospholipid composition of 
Rous sarcoma virus, host cell membranes and other enveloped RNA viruses. 
Virology 46, 106-116. 256 
 
Quinn, G., Wood, J.C., Ryan, D.J., Suling, K.M., Moran, K.M., Kolber-
Simonds, D.L., Greenstein, J.L., Schuurman, H.J., Hawley, R.J., and 
Patience, C. (2004). Porcine endogenous retrovirus transmission 
characteristics of galactose alpha1-3 galactose-deficient pig cells. J Virol 78, 
5805-5811. 
Rabson, A.B., and Graves, B.J. (1997). Synthesis and Processing of viral 
RNA. In Retroviruses, J.M. Coffin, S.H. Hughes, and H.E. Varmus, eds. (Cold 
Spring Harbor Laboratory Press), pp. 241-245. 
Ramig, R.F. (1997). Genetics of the rotaviruses. Annu Rev Microbiol 51, 225-
255. 
Ramsoondar, J., Vaught, T., Ball, S., Mendicino, M., Monahan, J., Jobst, P., 
Vance, A., Duncan, J., Wells, K., and Ayares, D. (2009). Production of 
transgenic pigs that express porcine endogenous retrovirus small interfering 
RNAs. Xenotransplantation 16, 164-180. 
Rasko, J.E., Battini, J.L., Gottschalk, R.J., Mazo, I., and Miller, A.D. (1999). 
The RD114/simian type D retrovirus receptor is a neutral amino acid 
transporter. Proc Natl Acad Sci U S A 96, 2129-2134. 
Reddy, B.A., Etkin, L.D., and Freemont, P.S. (1992). A novel zinc finger 
coiled-coil domain in a family of nuclear proteins. Trends Biochem Sci 17, 
344-345. 
Reemtsma, K., McCracken, B.H., Schlegel, J.U., Pearl, M.A., Pearce, C.W., 
Dewitt, C.W., Smith, P.E., Hewitt, R.L., Flinner, R.L., and Creech, O., Jr. 
(1964). Renal Heterotransplantation in Man. Ann Surg 160, 384-410. 
Regad, T., Saib, A., Lallemand-Breitenbach, V., Pandolfi, P.P., de The, H., 
and Chelbi-Alix, M.K. (2001). PML mediates the interferon-induced antiviral 
state against a complex retrovirus via its association with the viral 
transactivator. EMBO J 20, 3495-3505. 
Reichenbacher, F.W. (1975). Use of porcine skin in burn treatment. Aorn J 
21, 652, 654. 257 
 
Reid, A.H., Taubenberger, J.K., and Fanning, T.G. (2004). Evidence of an 
absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev 
Microbiol 2, 909-914. 
Rein, A. (1982). Interference grouping of murine leukemia viruses: a distinct 
receptor for the MCF-recombinant viruses in mouse cells. Virology 120, 251-
257. 
Rein, A., McClure, M.R., Rice, N.R., Luftig, R.B., and Schultz, A.M. (1986). 
Myristylation site in Pr65gag is essential for virus particle formation by 
Moloney murine leukemia virus. Proc Natl Acad Sci U S A 83, 7246-7250. 
Rein, A., and Schultz, A. (1984). Different recombinant murine leukemia 
viruses use different cell surface receptors. Virology 136, 144-152. 
Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., 
Riganelli, D., Zanaria, E., Messali, S., Cainarca, S., et al. (2001). The 
tripartite motif family identifies cell compartments. EMBO J 20, 2140-2151. 
Reynes, J.M., Counor, D., Ong, S., Faure, C., Seng, V., Molia, S., Walston, 
J., Georges-Courbot, M.C., Deubel, V., and Sarthou, J.L. (2005). Nipah virus 
in Lyle's flying foxes, Cambodia. Emerg Infect Dis 11, 1042-1047. 
Rima, B., Alexander, D.J., Billeter, M.A., Collins, P.L., Kingsbury, D.W., 
Lipkind, M.A., Nagai, Y., Örvell, C., Pringle, C.R., and ter Meulen, V.A. 
(2004). 01.048. Paramyxoviridae. In ICTVdB - The Universal Virus Database, 
version 3, C. Büchen-Osmond, ed. (New York, USA, ICTVdB Management, 
Columbia University). 
Rimsky, L., Hauber, J., Dukovich, M., Malim, M.H., Langlois, A., Cullen, B.R., 
and Greene, W.C. (1988). Functional replacement of the HIV-1 rev protein by 
the HTLV-1 rex protein. Nature 335, 738-740. 
Ritter, G.D., Jr., Yamshchikov, G., Cohen, S.J., and Mulligan, M.J. (1996). 
Human immunodeficiency virus type 2 glycoprotein enhancement of particle 
budding: role of the cytoplasmic domain. J Virol 70, 2669-2673. 258 
 
Ritzhaupt, A., Van Der Laan, L.J., Salomon, D.R., and Wilson, C.A. (2002). 
Porcine endogenous retrovirus infects but does not replicate in nonhuman 
primate primary cells and cell lines. J Virol 76, 11312-11320. 
Rogel-Gaillard, C., Bourgeaux, N., Billault, A., Vaiman, M., and Chardon, P. 
(1999). Construction of a swine BAC library: application to the 
characterization and mapping of porcine type C endoviral elements. 
Cytogenet Cell Genet 85, 205-211. 
Rollason, R., Korolchuk, V., Hamilton, C., Jepson, M., and Banting, G. 
(2009). A CD317/tetherin-RICH2 complex plays a critical role in the 
organization of the subapical actin cytoskeleton in polarized epithelial cells. J 
Cell Biol 184, 721-736. 
Rong, L., Zhang, J., Lu, J., Pan, Q., Lorgeoux, R.P., Aloysius, C., Guo, F., 
Liu, S.L., Wainberg, M.A., and Liang, C. (2009). The transmembrane domain 
of BST-2 determines its sensitivity to down-modulation by human 
immunodeficiency virus type 1 Vpu. J Virol 83, 7536-7546. 
Rosenberg, N., and Jolicoeur, P. (1997). Retroviral Pathogenesis. In 
Retroviruses, J.M. Coffin, S.H. Hughes, and H.E. Varmus, eds. (Cold Spring 
Harbor Laboratory Press), pp. 478-485. 
Rother, R.P., Fodor, W.L., Springhorn, J.P., Birks, C.W., Setter, E., Sandrin, 
M.S., Squinto, S.P., and Rollins, S.A. (1995). A novel mechanism of 
retrovirus inactivation in human serum mediated by anti-alpha-galactosyl 
natural antibody. J Exp Med 182, 1345-1355. 
Ruprecht, K., Mayer, J., Sauter, M., Roemer, K., and Mueller-Lantzsch, N. 
(2008). Endogenous retroviruses and cancer. Cell Mol Life Sci 65, 3366-
3382. 
Russell, R.A., Wiegand, H.L., Moore, M.D., Schafer, A., McClure, M.O., and 
Cullen, B.R. (2005). Foamy virus Bet proteins function as novel inhibitors of 
the APOBEC3 family of innate antiretroviral defense factors. J Virol 79, 8724-
8731. 259 
 
Sakai, H., Shibata, R., Sakuragi, J., Sakuragi, S., Kawamura, M., and Adachi, 
A. (1993). Cell-dependent requirement of human immunodeficiency virus 
type 1 Vif protein for maturation of virus particles. J Virol 67, 1663-1666. 
Sakuma, T., Noda, T., Urata, S., Kawaoka, Y., and Yasuda, J. (2009). 
Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83, 2382-
2385. 
Salaun, C., Marechal, V., and Heard, J.M. (2004). Transport-deficient Pit2 
phosphate transporters still modify cell surface oligomers structure in 
response to inorganic phosphate. J Mol Biol 340, 39-47. 
Salaun, C., Rodrigues, P., and Heard, J.M. (2001). Transmembrane topology 
of PiT-2, a phosphate transporter-retrovirus receptor. J Virol 75, 5584-5592. 
Sandrin, V., Boson, B., Salmon, P., Gay, W., Negre, D., Le Grand, R., Trono, 
D., and Cosset, F.L. (2002). Lentiviral vectors pseudotyped with a modified 
RD114 envelope glycoprotein show increased stability in sera and 
augmented transduction of primary lymphocytes and CD34+ cells derived 
from human and nonhuman primates. Blood 100, 823-832. 
Santiago, M.L., Montano, M., Benitez, R., Messer, R.J., Yonemoto, W., 
Chesebro, B., Hasenkrug, K.J., and Greene, W.C. (2008). Apobec3 encodes 
Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. 
Science 321, 1343-1346. 
Santoni, F., Lindner, I., Caselli, E., Goltz, M., Di Luca, D., and Ehlers, B. 
(2006). Molecular interactions between porcine and human 
gammaherpesviruses: implications for xenografts? Xenotransplantation 13, 
308-317. 
Saphire, A.C., Bobardt, M.D., and Gallay, P.A. (1999). Host cyclophilin A 
mediates HIV-1 attachment to target cells via heparans. Embo J 18, 6771-
6785. 260 
 
Sayah, D.M., Sokolskaja, E., Berthoux, L., and Luban, J. (2004). Cyclophilin 
A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. 
Nature 430, 569-573. 
Schroder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., and Bushman, F. 
(2002). HIV-1 integration in the human genome favors active genes and local 
hotspots. Cell 110, 521-529. 
Schrofelbauer, B., Chen, D., and Landau, N.R. (2004). A single amino acid of 
APOBEC3G controls its species-specific interaction with virion infectivity 
factor (Vif). Proc Natl Acad Sci U S A 101, 3927-3932. 
Schultz, D.C., Ayyanathan, K., Negorev, D., Maul, G.G., and Rauscher, F.J., 
3rd (2002). SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific 
methyltransferase that contributes to HP1-mediated silencing of euchromatic 
genes by KRAB zinc-finger proteins. Genes Dev 16, 919-932. 
Schultz, D.C., Friedman, J.R., and Rauscher, F.J., 3rd (2001). Targeting 
histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and 
bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform 
of the Mi-2alpha subunit of NuRD. Genes Dev 15, 428-443. 
Schwartz, D.E., Tizard, R., and Gilbert, W. (1983). Nucleotide sequence of 
Rous sarcoma virus. Cell 32, 853-869. 
Schwartz, O., Marechal, V., Friguet, B., Arenzana-Seisdedos, F., and Heard, 
J.M. (1998). Antiviral activity of the proteasome on incoming human 
immunodeficiency virus type 1. J Virol 72, 3845-3850. 
Scobie, L., Taylor, S., Wood, J.C., Suling, K.M., Quinn, G., Meikle, S., 
Patience, C., Schuurman, H.J., and Onions, D.E. (2004). Absence of 
replication-competent human-tropic porcine endogenous retroviruses in the 
germ line DNA of inbred miniature Swine. J Virol 78, 2502-2509. 
Sebastian, S., and Luban, J. (2005). TRIM5alpha selectively binds a 
restriction-sensitive retroviral capsid. Retrovirology 2, 40. 261 
 
Sendow, I., Field, H.E., Curran, J., Darminto, Morrissy, C., Meehan, G., 
Buick, T., and Daniels, P. (2006). Henipavirus in Pteropus vampyrus bats, 
Indonesia. Emerg Infect Dis 12, 711-712. 
Shah, C.A., Boni, J., Bisset, L.R., Seebach, J.D., and Schupbach, J. (2003). 
Ultra-sensitive and specific detection of porcine endogenous retrovirus 
(PERV) using a sequence-capture real-time PCR approach. J Virol Methods 
109, 209-216. 
Shalev, Z., Duffy, S.P., Adema, K.W., Prasad, R., Hussain, N., Willett, B.J., 
and Tailor, C.S. (2009). Identification of a feline leukemia virus variant that 
can use THTR1, FLVCR1, and FLVCR2 for infection. J Virol 83, 6706-6716. 
Sheehy, A.M., Gaddis, N.C., Choi, J.D., and Malim, M.H. (2002). Isolation of 
a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif 
protein. Nature 418, 646-650. 
Sheehy, A.M., Gaddis, N.C., and Malim, M.H. (2003). The antiretroviral 
enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 
Vif. Nat Med 9, 1404-1407. 
Shi, M., Wang, X., De Clercq, E., Takao, S., and Baba, M. (2007). Selective 
inhibition of porcine endogenous retrovirus replication in human cells by 
acyclic nucleoside phosphonates. Antimicrob Agents Chemother 51, 2600-
2604. 
Simon, A.R., Templin, C., Schroder, C., Laaff, G., Tessmann, R., Winkler, 
M.E., Tacke, S., Denner, J., Lapin, B., Chikobava, M., et al. (2003). No 
evidence for productive PERV infection of baboon cells in in vivo infection 
model. Ann Transplant 8, 24-34. 
Smagulova, F., Maurel, S., Morichaud, Z., Devaux, C., Mougel, M., and 
Houzet, L. (2005). The highly structured encapsidation signal of MuLV RNA 
is involved in the nuclear export of its unspliced RNA. J Mol Biol 354, 1118-
1128. 262 
 
Smith, G.J., Vijaykrishna, D., Bahl, J., Lycett, S.J., Worobey, M., Pybus, 
O.G., Ma, S.K., Cheung, C.L., Raghwani, J., Bhatt, S., et al. (2009). Origins 
and evolutionary genomics of the 2009 swine-origin H1N1 influenza A 
epidemic. Nature 459, 1122-1125. 
Smith, J.A., and Daniel, R. (2006). Following the path of the virus: the 
exploitation of host DNA repair mechanisms by retroviruses. ACS Chem Biol 
1, 217-226. 
Smith, T.F., Burgert, E.O., Jr., Dowdle, W.R., Noble, G.R., Campbell, R.J., 
and Van Scoy, R.E. (1976). Isolation of swine influenza virus from autopsy 
lung tissue of man. N Engl J Med 294, 708-710. 
Soin, B., Smith, K.G., Zaidi, A., Cozzi, E., Bradley, J.R., Ostlie, D.J., 
Lockhart, A., White, D.J., and Friend, P.J. (2001). Physiological aspects of 
pig-to-primate renal xenotransplantation. Kidney Int 60, 1592-1597. 
Soneoka, Y., Cannon, P.M., Ramsdale, E.E., Griffiths, J.C., Romano, G., 
Kingsman, S.M., and Kingsman, A.J. (1995). A transient three-plasmid 
expression system for the production of high titer retroviral vectors. Nucleic 
Acids Res 23, 628-633. 
Sparkes, A.H. (2003). Feline leukaemia virus and vaccination. J Feline Med 
Surg 5, 97-100. 
Speck, N.A., and Baltimore, D. (1987). Six distinct nuclear factors interact 
with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. 
Mol Cell Biol 7, 1101-1110. 
Specke, V., Plesker, R., Wood, J., Coulibaly, C., Suling, K., Patience, C., 
Kurth, R., Schuurman, H.J., and Denner, J. (2009). No in vivo infection of 
triple immunosuppressed non-human primates after inoculation with high 
titers of porcine endogenous retroviruses. Xenotransplantation 16, 34-44. 
Specke, V., Tacke, S.J., Boller, K., Schwendemann, J., and Denner, J. 
(2001). Porcine endogenous retroviruses: in vitro host range and attempts to 
establish small animal models. J Gen Virol 82, 837-844. 263 
 
Stehelin, D., Varmus, H.E., Bishop, J.M., and Vogt, P.K. (1976). DNA related 
to the transforming gene(s) of avian sarcoma viruses is present in normal 
avian DNA. Nature 260, 170-173. 
Stephan, O., Schwendemann, J., Specke, V., Tacke, S.J., Boller, K., and 
Denner, J. (2001). Porcine endogenous retroviruses (PERVs): generation of 
specific antibodies, development of an immunoperoxidase assay (IPA) and 
inhibition by AZT. Xenotransplantation 8, 310-316. 
Strebel, K., Klimkait, T., and Martin, M.A. (1988). A novel gene of HIV-1, vpu, 
and its 16-kilodalton product. Science 241, 1221-1223. 
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and 
Sodroski, J. (2004). The cytoplasmic body component TRIM5alpha restricts 
HIV-1 infection in Old World monkeys. Nature 427, 848-853. 
Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., Diaz-
Griffero, F., Anderson, D.J., Sundquist, W.I., and Sodroski, J. (2006). Specific 
recognition and accelerated uncoating of retroviral capsids by the 
TRIM5alpha restriction factor. Proc Natl Acad Sci U S A 103, 5514-5519. 
Stremlau, M., Perron, M., Welikala, S., and Sodroski, J. (2005). Species-
specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the 
potency of human immunodeficiency virus restriction. J Virol 79, 3139-3145. 
Suling, K., Quinn, G., Wood, J., and Patience, C. (2003). Packaging of 
human endogenous retrovirus sequences is undetectable in porcine 
endogenous retrovirus particles produced from human cells. Virology 312, 
330-336. 
Suspene, R., Guetard, D., Henry, M., Sommer, P., Wain-Hobson, S., and 
Vartanian, J.P. (2005). Extensive editing of both hepatitis B virus DNA 
strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl 
Acad Sci U S A 102, 8321-8326. 
Suzuki, Y., and Gojobori, T. (1997). The origin and evolution of Ebola and 
Marburg viruses. Mol Biol Evol 14, 800-806. 264 
 
Swanstrom, R., and Willis, J.W. (1997). Synthesis, Assembly and Viral 
Proteins. In Retroviruses, J.M. Coffin, S.H. Hughes, and H.E. Varmus, eds. 
(Cold Spring Harbor Laboratory Press), pp. 265-268. 
Swarz, J.R., Brooks, B.R., and Johnson, R.T. (1981). Spongiform 
polioencephalomyelopathy caused by a murine retrovirus. II. Ultrastructural 
localization of virus replication and spongiform changes in the central 
nervous system. Neuropathol Appl Neurobiol 7, 365-380. 
Switzer, W.M., Michler, R.E., Shanmugam, V., Matthews, A., Hussain, A.I., 
Wright, A., Sandstrom, P., Chapman, L.E., Weber, C., Safley, S., et al. 
(2001). Lack of cross-species transmission of porcine endogenous retrovirus 
infection to nonhuman primate recipients of porcine cells, tissues, or organs. 
Transplantation 71, 959-965. 
Switzer, W.M., Shanmugam, V., Chapman, L., and Heneine, W. (1999). 
Polymerase chain reaction assays for the diagnosis of infection with the 
porcine endogenous retrovirus and the detection of pig cells in human and 
nonhuman recipients of pig xenografts. Transplantation 68, 183-188. 
Sykes, M. (2008). 2007 IXA Presidential Address. Progress toward an ideal 
source animal: opportunities and challenges in a changing world. 
Xenotransplantation 15, 7-13. 
Tacke, S.J., Bodusch, K., Berg, A., and Denner, J. (2001). Sensitive and 
specific immunological detection methods for porcine endogenous 
retroviruses applicable to experimental and clinical xenotransplantation. 
Xenotransplantation 8, 125-135. 
Tailor, C.S., and Kabat, D. (1997). Variable regions A and B in the envelope 
glycoproteins of feline leukemia virus subgroup B and amphotropic murine 
leukemia virus interact with discrete receptor domains. J Virol 71, 9383-9391. 
Tailor, C.S., Lavillette, D., Marin, M., and Kabat, D. (2003). Cell surface 
receptors for gammaretroviruses. Curr Top Microbiol Immunol 281, 29-106. 265 
 
Tailor, C.S., Marin, M., Nouri, A., Kavanaugh, M.P., and Kabat, D. (2001). 
Truncated forms of the dual function human ASCT2 neutral amino acid 
transporter/retroviral receptor are translationally initiated at multiple 
alternative CUG and GUG codons. J Biol Chem 276, 27221-27230. 
Tailor, C.S., Nouri, A., and Kabat, D. (2000). Cellular and species resistance 
to murine amphotropic, gibbon ape, and feline subgroup C leukemia viruses 
is strongly influenced by receptor expression levels and by receptor masking 
mechanisms. J Virol 74, 9797-9801. 
Tailor, C.S., Nouri, A., Lee, C.G., Kozak, C., and Kabat, D. (1999a). Cloning 
and characterization of a cell surface receptor for xenotropic and polytropic 
murine leukemia viruses. Proc Natl Acad Sci U S A 96, 927-932. 
Tailor, C.S., Nouri, A., Zhao, Y., Takeuchi, Y., and Kabat, D. (1999b). A 
sodium-dependent neutral-amino-acid transporter mediates infections of 
feline and baboon endogenous retroviruses and simian type D retroviruses. J 
Virol 73, 4470-4474. 
Tailor, C.S., Takeuchi, Y., O'Hara, B., Johann, S.V., Weiss, R.A., and Collins, 
M.K. (1993). Mutation of amino acids within the gibbon ape leukemia virus 
(GALV) receptor differentially affects feline leukemia virus subgroup B, 
simian sarcoma-associated virus, and GALV infections. J Virol 67, 6737-
6741. 
Tailor, C.S., Willett, B.J., and Kabat, D. (1999c). A putative cell surface 
receptor for anemia-inducing feline leukemia virus subgroup C is a member 
of a transporter superfamily. J Virol 73, 6500-6505. 
Takefman, D.M., Spear, G.T., Saifuddin, M., and Wilson, C.A. (2002). Human 
CD59 incorporation into porcine endogenous retrovirus particles: implications 
for the use of transgenic pigs for xenotransplantation. J Virol 76, 1999-2002. 
Takeuchi, Y., Liong, S.H., Bieniasz, P.D., Jager, U., Porter, C.D., Friedman, 
T., McClure, M.O., and Weiss, R.A. (1997). Sensitization of rhabdo-, lenti-, 266 
 
and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J 
Virol 71, 6174-6178. 
Takeuchi, Y., Patience, C., Magre, S., Weiss, R.A., Banerjee, P.T., Le 
Tissier, P., and Stoye, J.P. (1998). Host range and interference studies of 
three classes of pig endogenous retrovirus. J Virol 72, 9986-9991. 
Takeuchi, Y., Porter, C.D., Strahan, K.M., Preece, A.F., Gustafsson, K., 
Cosset, F.L., Weiss, R.A., and Collins, M.K. (1996). Sensitization of cells and 
retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 
379, 85-88. 
Takeuchi, Y., Vile, R.G., Simpson, G., O'Hara, B., Collins, M.K., and Weiss, 
R.A. (1992). Feline leukemia virus subgroup B uses the same cell surface 
receptor as gibbon ape leukemia virus. J Virol 66, 1219-1222. 
Taniguchi, S., and Cooper, D.K. (1997). Clinical xenotransplantation: past, 
present and future. Ann R Coll Surg Engl 79, 13-19. 
Tarlinton, R., Meers, J., Hanger, J., and Young, P. (2005). Real-time reverse 
transcriptase PCR for the endogenous koala retrovirus reveals an 
association between plasma viral load and neoplastic disease in koalas. J 
Gen Virol 86, 783-787. 
Tarlinton, R.E., Meers, J., and Young, P.R. (2006). Retroviral invasion of the 
koala genome. Nature 442, 79-81. 
Tartaglia, J., Jarrett, O., Neil, J.C., Desmettre, P., and Paoletti, E. (1993). 
Protection of cats against feline leukemia virus by vaccination with a 
canarypox virus recombinant, ALVAC-FL. J Virol 67, 2370-2375. 
Taubenberger, J.K., Reid, A.H., Krafft, A.E., Bijwaard, K.E., and Fanning, 
T.G. (1997). Initial genetic characterization of the 1918 "Spanish" influenza 
virus. Science 275, 1793-1796. 
Teich, N.M., Weiss, R.A., Martin, G.R., and Lowy, D.R. (1977). Virus infection 
of murine teratocarcinoma stem cell lines. Cell 12, 973-982. 267 
 
Telesnitsky, A., and Goff, S.P. (1997). Reverse Transcriptase and the 
Generation of Retroviral DNA. In Retroviruses, J.M. Coffin, S.H. Hughes, and 
H.E. Varmus, eds. (Cold Spring Harbor Laboratory Press), pp. 125-126. 
Templin, C., Schroder, C., Simon, A.R., Laaff, G., Kohl, J., Chikobava, M., 
Lapin, B., Steinhoff, G., and Martin, U. (2000). Analysis of potential porcine 
endogenous retrovirus transmission to baboon in vitro and in vivo. Transplant 
Proc 32, 1163-1164. 
Teng, B., Burant, C.F., and Davidson, N.O. (1993). Molecular cloning of an 
apolipoprotein B messenger RNA editing protein. Science 260, 1816-1819. 
Tissot, C., and Mechti, N. (1995). Molecular cloning of a new interferon-
induced factor that represses human immunodeficiency virus type 1 long 
terminal repeat expression. J Biol Chem 270, 14891-14898. 
Tizard, I., and Bass, E.P. (1991). Evaluation of a killed, whole virion feline 
leukemia virus vaccine. J Am Vet Med Assoc 199, 1410-1413. 
Todaro, G.J., Benveniste, R.E., Lieber, M.M., and Sherr, C.J. (1974). 
Characterization of a type C virus released from the porcine cell line PK(15). 
Virology 58, 65-74. 
Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J.P., and Danos, O. 
(2000). A conserved mechanism of retrovirus restriction in mammals. Proc 
Natl Acad Sci U S A 97, 12295-12299. 
Towers, G., Collins, M., and Takeuchi, Y. (2002). Abrogation of Ref1 
retrovirus restriction in human cells. J Virol 76, 2548-2550. 
Tseng, Y.L., Kuwaki, K., Dor, F.J., Shimizu, A., Houser, S., Hisashi, Y., 
Yamada, K., Robson, S.C., Awwad, M., Schuurman, H.J., et al. (2005). 
alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in 
baboons with survival approaching 6 months. Transplantation 80, 1493-1500. 268 
 
Tsukiyama, T., Niwa, O., and Yokoro, K. (1989). Mechanism of suppression 
of the long terminal repeat of Moloney leukemia virus in mouse embryonal 
carcinoma cells. Mol Cell Biol 9, 4670-4676. 
Turelli, P., Doucas, V., Craig, E., Mangeat, B., Klages, N., Evans, R., 
Kalpana, G., and Trono, D. (2001). Cytoplasmic recruitment of INI1 and PML 
on incoming HIV preintegration complexes: interference with early steps of 
viral replication. Mol Cell 7, 1245-1254. 
Van Damme, N., Goff, D., Katsura, C., Jorgenson, R.L., Mitchell, R., 
Johnson, M.C., Stephens, E.B., and Guatelli, J. (2008). The interferon-
induced protein BST-2 restricts HIV-1 release and is downregulated from the 
cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252. 
van der Laan, L.J., Lockey, C., Griffeth, B.C., Frasier, F.S., Wilson, C.A., 
Onions, D.E., Hering, B.J., Long, Z., Otto, E., Torbett, B.E., et al. (2000). 
Infection by porcine endogenous retrovirus after islet xenotransplantation in 
SCID mice. Nature 407, 90-94. 
Van Hoeven, N.S., and Miller, A.D. (2005). Use of different but overlapping 
determinants in a retrovirus receptor accounts for non-reciprocal interference 
between xenotropic and polytropic murine leukemia viruses. Retrovirology 2, 
76. 
van Zeijl, M., Johann, S.V., Closs, E., Cunningham, J., Eddy, R., Shows, 
T.B., and O'Hara, B. (1994). A human amphotropic retrovirus receptor is a 
second member of the gibbon ape leukemia virus receptor family. Proc Natl 
Acad Sci U S A 91, 1168-1172. 
Varthakavi, V., Smith, R.M., Bour, S.P., Strebel, K., and Spearman, P. 
(2003). Viral protein U counteracts a human host cell restriction that inhibits 
HIV-1 particle production. Proc Natl Acad Sci U S A 100, 15154-15159. 
Vogt, P. (1997). Retroviral virions and genomes. In Retroviruses, J.M. Coffin, 
S.H. Hughes, and H.E. Varmus, eds. (Cold Spring Harbor Laboratory Press), 
pp. 33-41. 269 
 
Voisset, C., Weiss, R.A., and Griffiths, D.J. (2008). Human RNA "rumor" 
viruses: the search for novel human retroviruses in chronic disease. Microbiol 
Mol Biol Rev 72, 157-196, table of contents. 
von Schwedler, U., Kornbluth, R.S., and Trono, D. (1994). The nuclear 
localization signal of the matrix protein of human immunodeficiency virus type 
1 allows the establishment of infection in macrophages and quiescent T 
lymphocytes. Proc Natl Acad Sci U S A 91, 6992-6996. 
Wang, D., Coscoy, L., Zylberberg, M., Avila, P.C., Boushey, H.A., Ganem, 
D., and DeRisi, J.L. (2002). Microarray-based detection and genotyping of 
viral pathogens. Proc Natl Acad Sci U S A 99, 15687-15692. 
Wang, D., Urisman, A., Liu, Y.T., Springer, M., Ksiazek, T.G., Erdman, D.D., 
Mardis, E.R., Hickenbotham, M., Magrini, V., Eldred, J., et al. (2003). Viral 
discovery and sequence recovery using DNA microarrays. PLoS Biol 1, E2. 
Wang, H., Dechant, E., Kavanaugh, M., North, R.A., and Kabat, D. (1992). 
Effects of ecotropic murine retroviruses on the dual-function cell surface 
receptor/basic amino acid transporter. J Biol Chem 267, 23617-23624. 
Wang, H., Kavanaugh, M.P., and Kabat, D. (1994). A critical site in the cell 
surface receptor for ecotropic murine retroviruses required for amino acid 
transport but not for viral reception. Virology 202, 1058-1060. 
Wang, Y., Li, Y., Qi, X., Yuan, W., Ai, J., Zhu, C., Cao, L., Yang, H., Liu, F., 
Wu, X., et al. (2004). TRIM45, a novel human RBCC/TRIM protein, inhibits 
transcriptional activities of ElK-1 and AP-1. Biochem Biophys Res Commun 
323, 9-16. 
Wang, Z.G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R., and 
Pandolfi, P.P. (1998). PML is essential for multiple apoptotic pathways. Nat 
Genet 20, 266-272. 
Ward, L.A., Yuan, L., Rosen, B.I., To, T.L., and Saif, L.J. (1996). 
Development of mucosal and systemic lymphoproliferative responses and 270 
 
protective immunity to human group A rotaviruses in a gnotobiotic pig model. 
Clin Diagn Lab Immunol 3, 342-350. 
Watanabe, R., Miyazawa, T., and Matsuura, Y. (2005). Cell-binding 
properties of the envelope proteins of porcine endogenous retroviruses. 
Microbes Infect 7, 658-665. 
Webster, R.G., Sharp, G.B., and Claas, E.C. (1995). Interspecies 
transmission of influenza viruses. Am J Respir Crit Care Med 152, S25-30. 
Weijer, K., Pfauth, A., van Herwijnen, R., Jarrett, O., Meloen, R.H., Tomee, 
C., and Osterhaus, A.D. (1993). Induction of feline leukaemia virus-
neutralizing antibodies by immunization with synthetic peptides derived from 
the FeLV env gene. Vaccine 11, 946-956. 
Weimin Wu, B., Cannon, P.M., Gordon, E.M., Hall, F.L., and Anderson, W.F. 
(1998). Characterization of the proline-rich region of murine leukemia virus 
envelope protein. J Virol 72, 5383-5391. 
Weiss, R.A. (2006). The discovery of endogenous retroviruses. Retrovirology 
3, 67. 
Wilhelm, M., Fishman, J.A., Pontikis, R., Aubertin, A.M., and Wilhelm, F.X. 
(2002). Susceptibility of recombinant porcine endogenous retrovirus reverse 
transcriptase to nucleoside and non-nucleoside inhibitors. Cell Mol Life Sci 
59, 2184-2190. 
Will, R.G., Ironside, J.W., Zeidler, M., Cousens, S.N., Estibeiro, K., 
Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A., and Smith, P.G. (1996). 
A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925. 
Wilson, C.A., Eiden, M.V., Anderson, W.B., Lehel, C., and Olah, Z. (1995). 
The dual-function hamster receptor for amphotropic murine leukemia virus 
(MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate 
symporter. J Virol 69, 534-537. 271 
 
Wilson, C.A., Laeeq, S., Ritzhaupt, A., Colon-Moran, W., and Yoshimura, 
F.K. (2003). Sequence analysis of porcine endogenous retrovirus long 
terminal repeats and identification of transcriptional regulatory regions. J Virol 
77, 142-149. 
Wilson, C.A., Wong, S., Muller, J., Davidson, C.E., Rose, T.M., and Burd, P. 
(1998). Type C retrovirus released from porcine primary peripheral blood 
mononuclear cells infects human cells. J Virol 72, 3082-3087. 
Wilson, C.A., Wong, S., VanBrocklin, M., and Federspiel, M.J. (2000). 
Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J 
Virol 74, 49-56. 
Wilson, S.J., Webb, B.L., Ylinen, L.M., Verschoor, E., Heeney, J.L., and 
Towers, G.J. (2008). Independent evolution of an antiviral TRIMCyp in 
rhesus macaques. Proc Natl Acad Sci U S A 105, 3557-3562. 
Wolf, D., and Goff, S.P. (2007). TRIM28 mediates primer binding site-
targeted silencing of murine leukemia virus in embryonic cells. Cell 131, 46-
57. 
Wolf, D., and Goff, S.P. (2008). Host restriction factors blocking retroviral 
replication. Annu Rev Genet 42, 143-163. 
Wolf, D., and Goff, S.P. (2009). Embryonic stem cells use ZFP809 to silence 
retroviral DNAs. Nature 458, 1201-1204. 
Wood, A., Webb, B.L., Bartosch, B., Schaller, T., Takeuchi, Y., and Towers, 
G.J. (2009). Porcine endogenous retroviruses PERV A and A/C recombinant 
are insensitive to a range of divergent mammalian TRIM5alpha proteins 
including human TRIM5alpha. J Gen Virol 90, 702-709. 
Wood, J.C., Quinn, G., Suling, K.M., Oldmixon, B.A., Van Tine, B.A., Cina, 
R., Arn, S., Huang, C.A., Scobie, L., Onions, D.E., et al. (2004). Identification 
of exogenous forms of human-tropic porcine endogenous retrovirus in 
miniature Swine. J Virol 78, 2494-2501. 272 
 
Woolhouse, M.E., and Gowtage-Sequeria, S. (2005). Host range and 
emerging and reemerging pathogens. Emerg Infect Dis 11, 1842-1847. 
Wu, T., Yan, Y., and Kozak, C.A. (2005). Rmcf2, a xenotropic provirus in the 
Asian mouse species Mus castaneus, blocks infection by polytropic mouse 
gammaretroviruses. J Virol 79, 9677-9684. 
Wu, X., Anderson, J.L., Campbell, E.M., Joseph, A.M., and Hope, T.J. 
(2006). Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of 
HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A 103, 
7465-7470. 
Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003). Transcription start 
regions in the human genome are favored targets for MLV integration. 
Science 300, 1749-1751. 
Wyatt, R., and Sodroski, J. (1998). The HIV-1 envelope glycoproteins: 
fusogens, antigens, and immunogens. Science 280, 1884-1888. 
Xu, H., Sharma, A., Okabe, J., Cui, C., Huang, L., Wei, Y.Y., Wan, H., Lei, Y., 
Logan, J.S., Levy, M.F., et al. (2003). Serologic analysis of anti-porcine 
endogenous retroviruses immune responses in humans after ex vivo 
transgenic pig liver perfusion. ASAIO J 49, 407-416. 
Xu, H., Svarovskaia, E.S., Barr, R., Zhang, Y., Khan, M.A., Strebel, K., and 
Pathak, V.K. (2004). A single amino acid substitution in human APOBEC3G 
antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-
induced depletion. Proc Natl Acad Sci U S A 101, 5652-5657. 
Yamada, K., Yazawa, K., Shimizu, A., Iwanaga, T., Hisashi, Y., Nuhn, M., 
O'Malley, P., Nobori, S., Vagefi, P.A., Patience, C., et al. (2005). Marked 
prolongation of porcine renal xenograft survival in baboons through the use 
of alpha1,3-galactosyltransferase gene-knockout donors and the 
cotransplantation of vascularized thymic tissue. Nat Med 11, 32-34. 
Yamamoto, H., Li, T.C., Koshimoto, C., Ito, K., Kita, M., Miyashita, N., 
Arikawa, J., Yagami, K., Asano, M., Tezuka, H., et al. (2008). Serological 273 
 
evidence for hepatitis e virus infection in laboratory monkeys and pigs in 
animal facilities in Japan. Exp Anim 57, 367-376. 
Yan, Y., Buckler-White, A., Wollenberg, K., and Kozak, C.A. (2009). Origin, 
antiviral function and evidence for positive selection of the gammaretrovirus 
restriction gene Fv1 in the genus Mus. Proc Natl Acad Sci U S A 106, 3259-
3263. 
Yan, Y., Jung, Y.T., Wu, T., and Kozak, C.A. (2008). Role of receptor 
polymorphism and glycosylation in syncytium induction and host range 
variation of ecotropic mouse gammaretroviruses. Retrovirology 5, 2. 
Yang, Y.G., and Sykes, M. (2007). Xenotransplantation: current status and a 
perspective on the future. Nat Rev Immunol 7, 519-531. 
Yang, Y.G., Wood, J.C., Lan, P., Wilkinson, R.A., Sykes, M., Fishman, J.A., 
and Patience, C. (2004). Mouse retrovirus mediates porcine endogenous 
retrovirus transmission into human cells in long-term human-porcine chimeric 
mice. J Clin Invest 114, 695-700. 
Yang, Y.L., Guo, L., Xu, S., Holland, C.A., Kitamura, T., Hunter, K., and 
Cunningham, J.M. (1999). Receptors for polytropic and xenotropic mouse 
leukaemia viruses encoded by a single gene at Rmc1. Nat Genet 21, 216-
219. 
Yap, M.W., Nisole, S., Lynch, C., and Stoye, J.P. (2004). Trim5alpha protein 
restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 
101, 10786-10791. 
Yap, M.W., Nisole, S., and Stoye, J.P. (2005). A single amino acid change in 
the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 
15, 73-78. 
Yazaki, Y., Mizuo, H., Takahashi, M., Nishizawa, T., Sasaki, N., Gotanda, Y., 
and Okamoto, H. (2003). Sporadic acute or fulminant hepatitis E in Hokkaido, 
Japan, may be food-borne, as suggested by the presence of hepatitis E virus 
in pig liver as food. J Gen Virol 84, 2351-2357. 274 
 
Ylinen, L.M., Keckesova, Z., Wilson, S.J., Ranasinghe, S., and Towers, G.J. 
(2005). Differential restriction of human immunodeficiency virus type 2 and 
simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol 79, 
11580-11587. 
Yonezawa, A., Masuda, S., Katsura, T., and Inui, K. (2008). Identification and 
functional characterization of a novel human and rat riboflavin transporter, 
RFT1. Am J Physiol Cell Physiol 295, C632-641. 
York, S.M., and York, C.J. (1991). Development of a whole killed feline 
leukemia virus vaccine. J Am Vet Med Assoc 199, 1419-1422. 
Yoshii, H., Kamiyama, H., Amanuma, H., Oishi, K., Yamamoto, N., and Kubo, 
Y. (2008). Mechanisms underlying glycosylation-mediated loss of ecotropic 
receptor function in murine MDTF cells and implications for receptor 
evolution. J Gen Virol 89, 297-305. 
Yoshimoto, T., Yoshimoto, E., and Meruelo, D. (1991). Molecular cloning and 
characterization of a novel human gene homologous to the murine ecotropic 
retroviral receptor. Virology 185, 10-17. 
Yoshimoto, T., Yoshimoto, E., and Meruelo, D. (1993). Identification of amino 
acid residues critical for infection with ecotropic murine leukemia retrovirus. J 
Virol 67, 1310-1314. 
Yoshinaka, Y., Katoh, I., Copeland, T.D., and Oroszlan, S. (1985). Murine 
leukemia virus protease is encoded by the gag-pol gene and is synthesized 
through suppression of an amber termination codon. Proc Natl Acad Sci U S 
A 82, 1618-1622. 
Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D., and Landau, N.R. 
(2004a). APOBEC3B and APOBEC3C are potent inhibitors of simian 
immunodeficiency virus replication. J Biol Chem 279, 53379-53386. 
Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., 
Coffin, J.M., and Landau, N.R. (2004b). Single-strand specificity of 275 
 
APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat 
Struct Mol Biol 11, 435-442. 
Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X.F. (2003). 
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-
Cul5-SCF complex. Science 302, 1056-1060. 
Yu, X., Yuan, X., Matsuda, Z., Lee, T.H., and Essex, M. (1992). The matrix 
protein of human immunodeficiency virus type 1 is required for incorporation 
of viral envelope protein into mature virions. J Virol 66, 4966-4971. 
Yuan, B., Fassati, A., Yueh, A., and Goff, S.P. (2002). Characterization of 
Moloney murine leukemia virus p12 mutants blocked during early events of 
infection. J Virol 76, 10801-10810. 
Yuan, B., Li, X., and Goff, S.P. (1999). Mutations altering the moloney murine 
leukemia virus p12 Gag protein affect virion production and early events of 
the virus life cycle. EMBO J 18, 4700-4710. 
Zachary, J.F., Knupp, C.J., and Wong, P.K. (1986). Noninflammatory 
spongiform polioencephalomyelopathy caused by a neurotropic temperature-
sensitive mutant of Moloney murine leukemia virus TB. Am J Pathol 124, 
457-468. 
Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P. (2000). RNAi: double-
stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 
nucleotide intervals. Cell 101, 25-33. 
Zhang, F., Wilson, S.J., Landford, W.C., Virgen, B., Gregory, D., Johnson, 
M.C., Munch, J., Kirchhoff, F., Bieniasz, P.D., and Hatziioannou, T. (2009). 
Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin 
Antagonists. Cell Host Microbe. 
Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam, S.C., and 
Gao, L. (2003). The cytidine deaminase CEM15 induces hypermutation in 
newly synthesized HIV-1 DNA. Nature 424, 94-98. 276 
 
Zhang, L., Yu, P., Bu, H., Li, S., Li, Y., and Cheng, J. (2005). Porcine 
endogenus retrovirus transmission from pig cell line to mouse tissues but not 
human cells in nude mice. Transplant Proc 37, 493-495. 
Zolotukhin, A.S., Valentin, A., Pavlakis, G.N., and Felber, B.K. (1994). 
Continuous propagation of RRE(-) and Rev(-)RRE(-) human 
immunodeficiency virus type 1 molecular clones containing a cis-acting 
element of simian retrovirus type 1 in human peripheral blood lymphocytes. J 
Virol 68, 7944-7952. 
Zufferey, R., Nagy, D., Mandel, R.J., Naldini, L., and Trono, D. (1997). 
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. 
Nat Biotechnol 15, 871-875. 
 
 